
<html lang="en"     class="pb-page"  data-request-id="0027c970-95f3-474d-b101-b0cdc8aefdea"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b00964;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2020.63.issue-1;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases" /></meta><meta name="dc.Creator" content="Janina  Niggenaber" /></meta><meta name="dc.Creator" content="Julia  Hardick" /></meta><meta name="dc.Creator" content="Jonas  Lategahn" /></meta><meta name="dc.Creator" content="Daniel  Rauh" /></meta><meta name="dc.Description" content="The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their impo..." /></meta><meta name="Description" content="The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their impo..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 15, 2019" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00964" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00964" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00964" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00964" /></link>
        
    
    

<title>Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00964" /></meta><meta property="og:title" content="Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0006.jpeg" /></meta><meta property="og:description" content="The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their importance in proliferation, apoptosis, and cell death ultimately renders them hot targets in cancer therapy. Small-molecule tyrosine kinase inhibitors seem well suited to be tailor-made therapeutics for EGFR mutant NSCLC; however, drug resistance mutations limit their success. Against this background, the elucidation and visualization of the three-dimensional structure of cancer-related kinases provide valuable insights into their molecular functions. This field has undergone a revolution because X-ray crystal structure determinations aided structure-based drug design approaches and clarified the effect of activating and resistance-conferring mutations. Here, we present an overview of important mutations affecting EGFR and Her2 and highlight their influence on the kinase domain conformations and active site accessibility." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00964"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00964">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00964&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00964&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00964&amp;href=/doi/10.1021/acs.jmedchem.9b00964" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 40-51</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00924" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.9b01180" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Janina Niggenaber</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Janina Niggenaber</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</div><div class="loa-info-affiliations-info">Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Janina++Niggenaber">Janina Niggenaber</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2942-263X" title="Orcid link">http://orcid.org/0000-0003-2942-263X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Julia Hardick</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Julia Hardick</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</div><div class="loa-info-affiliations-info">Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Julia++Hardick">Julia Hardick</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Jonas Lategahn</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Jonas Lategahn</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</div><div class="loa-info-affiliations-info">Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</div></div><span class="conrtib-corresp"><strong>*</strong>For J.L.: E-mail: <a href="/cdn-cgi/l/email-protection#aac0c5c4cbd984c6cbdecfcdcbc2c4eadedf87cec5d8dec7dfc4ce84cecf"><span class="__cf_email__" data-cfemail="85efeaebe4f6abe9e4f1e0e2e4edebc5f1f0a8e1eaf7f1e8f0ebe1abe1e0">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Jonas++Lategahn">Jonas Lategahn</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5993-7082" title="Orcid link">http://orcid.org/0000-0001-5993-7082</a></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Daniel Rauh</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Daniel Rauh</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Faculty of Chemistry and Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</div><div class="loa-info-affiliations-info">Drug Discovery Hub Dortmund (DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</div></div><span class="conrtib-corresp"><strong>*</strong>For D.R.: phone, +49 (0)231/755-7080; E-mail, <a href="/cdn-cgi/l/email-protection#1470757a7d71783a6675617c54606139707b666079617a703a7071"><span class="__cf_email__" data-cfemail="1470757a7d71783a6675617c54606139707b666079617a703a7071">[email protected]</span></a>; Twitter, @DDHDortmund; website, DDHDortmund.de.</span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Daniel++Rauh">Daniel Rauh</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath4">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00964&amp;href=/doi/10.1021%2Facs.jmedchem.9b00964" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 40–51</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 15, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>17 June 2019</li><li><span class="item_label"><b>Published</b> online</span>15 August 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 9 January 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D40%26pageCount%3D12%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DJanina%2BNiggenaber%252C%2BJulia%2BHardick%252C%2BJonas%2BLategahn%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D1%26contentID%3Dacs.jmedchem.9b00964%26title%3DStructure%2BDefines%2BFunction%253A%2BClinically%2BRelevant%2BMutations%2Bin%2BErbB%2BKinases%26numPages%3D12%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D51%26publicationDate%3DJanuary%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00964"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2125</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">3</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00964" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Janina&quot;,&quot;last_name&quot;:&quot;Niggenaber&quot;},{&quot;first_name&quot;:&quot;Julia&quot;,&quot;last_name&quot;:&quot;Hardick&quot;},{&quot;first_name&quot;:&quot;Jonas&quot;,&quot;last_name&quot;:&quot;Lategahn&quot;},{&quot;first_name&quot;:&quot;Daniel&quot;,&quot;last_name&quot;:&quot;Rauh&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;15&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;40-51&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00964&quot;},&quot;abstract&quot;:&quot;The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their importance in proliferation, apoptosis, and cell death ultimately renders them hot targets in cancer therapy. Small-molecule tyrosine kinase inhibitors seem well suited to be tailor-made therapeutics for EGFR mutant NSCLC; however, drug resistance mutations limit their success. Against this background, the elucidation and visualization of the three-dimensional structure of cancer-related kinases provide valuable insights into their molecular functions. This field has undergone a revolution because X-ray crystal structure determinations aided structure-based drug design approaches and clarified the effect of activating and resistance-conferring mutations. Here, we present an overview of important mutations affecting EGFR and Her2 and highlight their influence on the kinase domain conformations and active site accessibili&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00964&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00964" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00964&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00964" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00964&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00964" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00964&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00964&amp;href=/doi/10.1021/acs.jmedchem.9b00964" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00964" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00964" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26pmid%3D31414802%26genre%3Darticle%26aulast%3DNiggenaber%26date%3D2020%26atitle%3DStructure%2BDefines%2BFunction%253A%2BClinically%2BRelevant%2BMutations%2Bin%2BErbB%2BKinases%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=291880" title="Crystal structure">Crystal structure</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291026" title="Conformation">Conformation</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/jmcmar.2020.63.issue-1/20200109/jmcmar.2020.63.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">The ErbB receptor tyrosine kinase family members EGFR (epidermal growth factor receptor) and Her2 are among the prominent mutated oncogenic drivers of non-small cell lung cancer (NSCLC). Their importance in proliferation, apoptosis, and cell death ultimately renders them hot targets in cancer therapy. Small-molecule tyrosine kinase inhibitors seem well suited to be tailor-made therapeutics for EGFR mutant NSCLC; however, drug resistance mutations limit their success. Against this background, the elucidation and visualization of the three-dimensional structure of cancer-related kinases provide valuable insights into their molecular functions. This field has undergone a revolution because X-ray crystal structure determinations aided structure-based drug design approaches and clarified the effect of activating and resistance-conferring mutations. Here, we present an overview of important mutations affecting EGFR and Her2 and highlight their influence on the kinase domain conformations and active site accessibility.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_23875" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_23875" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Lung cancer has the highest cancer incidence and mortality worldwide.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> The identification of predictive biomarkers and a detailed understanding of drug resistance recently led to a substantial boost in the development of selective small-molecule inhibitors to specifically inhibit oncogenic targets. To selected patient populations, this precision medicine offers an alternative to platinum-based chemotherapy with improved survival and enhanced quality of life.<a onclick="showRef(event, 'ref2 ref3'); return false;" href="javascript:void(0);" class="ref ref2 ref3">(2,3)</a></div><div class="NLM_p">Genetic mutations affecting the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and Her2, members of the ErbB receptor tyrosine kinase family, result in the onset and progression of non-small cell lung cancer (NSCLC) or drug resistance to targeted small-molecule inhibitors. These targets comprise an extracellular ligand-binding domain, a transmembrane segment, and an intracellular tyrosine kinase domain.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a> Upon ligand binding, EGFR undergoes homo- or heterodimerization with Her2, for example.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Autophosphorylation of tyrosine residues within the intracellular kinase domain leads to complete activation.<a onclick="showRef(event, 'ref5 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref7">(5,7)</a> Activated EGFR is part of important signal transduction pathways, such as RAS–RAF–MEK–ERK or PI3K–AKT–mTOR, regulating proliferation, apoptosis, and cell death, among others. Dysregulation of EGFR or Her2 signaling therefore ultimately leads to tumorigenesis.<a onclick="showRef(event, 'ref4 ref5 ref8'); return false;" href="javascript:void(0);" class="ref ref4 ref5 ref8">(4,5,8)</a></div><div class="NLM_p">For the treatment of aberrant ErbB signaling, three generations of targeted inhibitors are readily available and currently in clinical use (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>C and Supporting Information, <a href="/doi/suppl/10.1021/acs.jmedchem.9b00964/suppl_file/jm9b00964_si_001.pdf" class="ext-link">Figure S1</a>). First-generation tyrosine kinase inhibitors (TKIs) comprise ATP-competitive inhibitors such as gefitinib<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> and erlotinib.<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> Afatinib<a onclick="showRef(event, 'ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref12 ref13">(12,13)</a> and dacomitinib<a onclick="showRef(event, 'ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref14 ref15">(14,15)</a> are second-generation inhibitors with an acrylamide that covalently reacts with a reactive cysteine in EGFR and Her2. In this way, competition with the cofactor for the binding site is offset, the drug–target residence time is maximized, and selectivity within the kinome is increased.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> Although similar to first-generation inhibitors, this warhead is the only distinctive feature. Therefore, adverse events related to wild-type inhibition which are observed with first-generation TKIs are similarly observed with second-generation EGFR inhibitors. Lapatinib<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> and neratinib<a onclick="showRef(event, 'ref18 ref19 ref20'); return false;" href="javascript:void(0);" class="ref ref18 ref19 ref20">(18−20)</a> are first- and second-generation inhibitors, respectively, that bind to inactive EGFR, as outlined below. Inhibitors in the third generation are best exemplified by osimertinib,<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> rociletinib,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> and olmutinib,<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> which also incorporate an acrylamide but are based on different scaffolds that allow for a high degree of mutant selectivity. To be precise, these inhibitors are specifically designed to target mutant variants of EGFR while sparing wild-type.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inactive and active kinase domain conformations. (A) The inactive conformation (bound with lapatinib, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) exhibits an outward rotated helix αC (red) and a small helical turn within the activation loop (orange). It is in an equilibrium with the active conformation (bound with erlotinib, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>), which exhibits an inward rotated helix αC (green) that allows for a salt bridge between the catalytic lysine Lys745 and Glu762. Moreover, it is characterized by an extended activation loop (blue). (B) The side chain of Leu858 within the helical turn (orange) plays a crucial role in stabilizing the inactive conformation by packing into a hydrophobic cavity between helix αC (red) and glycine-rich loop (gray). Mutation of this amino acid to the polar Arg858 therefore results in an equilibrium shift toward the active conformation (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITT">2ITT</a>). The QR code provides an augmented reality view of a corresponding 3D model.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (C) Chemical structures of representative examples of the three EGFR TKI-generations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">In the quest to optimize patient selection or develop a fourth generation of inhibitors targeting (multi)mutated EGFR, a detailed understanding of how mutations influence its activity and drug susceptibility is required.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> Against this background, structure determination methodologies are key to gaining detailed insights into the receptor’s molecular features at the atomic level. Among these methods, protein X-ray crystallography has yielded several data sets that allow for dissecting the effect of distinct mutations on the kinase domain of EGFR and Her2. Here, we review from a structural perspective the relevant activating and drug-resistant mutations affecting the ErbB kinases and their influence on conformation and active site texture.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_32786" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_32786" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4"> EGFR Kinase Domain Conformations Predict the Activation State</h3><div class="NLM_p last">The kinase domain of EGFR is subject to an equilibrium between inactive and active conformations (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). It is tightly regulated by extracellular ligand binding,<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(27,28)</a> dimerization,<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> internalization,<a onclick="showRef(event, 'ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref30 ref31">(30,31)</a> and degradation.<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> Upon a ligand-binding event, receptor dimerization is initiated, resulting in asymmetric dimer formation of the intracellular kinase units. This formation allows interaction of the C-terminus of the activator kinase with the N-terminal portion of the receiver kinase. The inactive receiver kinase is characterized by an outward rotated helix αC (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A, red), which allows the activation loop (orange) to form a short helical segment next to the helix αC.<a onclick="showRef(event, 'ref27 ref34'); return false;" href="javascript:void(0);" class="ref ref27 ref34">(27,34)</a> This kinase conformation facilitates binding of inhibitors, such as lapatinib or neratinib,<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> which can be assessed by a direct binding assay utilizing a fluorescent labeled activation loop.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> The interaction with the activator kinase forces a rearrangement of the receiver kinase, resulting in its active state. The activated conformation exhibits an extended activation loop (blue), stabilized by a short antiparallel β-segment, to allow inward rotation of helix C (green), which creates the interaction surface with the activator kinase. In addition, Glu762 forms a characteristic salt bridge with the catalytic Lys745 side chain. This partially active dimer becomes fully activated following trans-autophosphorylation, as mentioned above.<a onclick="showRef(event, 'ref27 ref34 ref37'); return false;" href="javascript:void(0);" class="ref ref27 ref34 ref37">(27,34,37)</a> Of note, crystallographic studies have revealed different conformational states with respect to the DFG triad (DFG-<i>in</i> active,<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Src-like (DFG-<i>in</i>/helix C-<i>out</i>) inactive,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and DFG-<i>out</i> inactive<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a>).</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Point Mutations within the Activation Loop Destabilize the Inactive Helix αC-<i>Out</i> State</h3><div class="NLM_p">Given the importance of the regulatory helix C, it is conceivable that mutations affecting its conformational freedom occur in cancer. Because of their shift in kinase conformation equilibrium in favor of the active state, these aberrations are termed “activating mutations”.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> One of the most prevalent EGFR activating mutations found in NSCLC patients is the substitution L858R in exon 21, occurring in around 38% of cases.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> It is located within the activation loop, central to the crucial helical turn structure (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, orange). A polar interaction between the main chain carbonyl of Leu858 and the main chain nitrogen of Leu862 contributes to stabilization of the inactive helical turn motif. Through packing into a hydrophobic cavity between the helix αC and the glycine-rich loop (shown in red and gray, respectively), the Leu858 side chain takes a pivotal role in stabilizing the inactive state. Specifically, the residues Leu858, Leu861, and Leu862 (activation loop), Leu788, Leu777, Met766, Ile759, and Leu747 (helix C and adjacent regions), and Phe723 (G-rich loop) are involved. Within this arrangement, the mutated, much larger, and charged Arg858 side chain would disrupt the hydrophobic assembly and is incompatible with the inactive state. Therefore, it shifts the kinase domain toward the active conformation by resolving the important helical turn structure and providing space for the helix C to rotate inward. In addition, Arg858 further stabilizes the active state of the mutant kinase, forming a network of polar interactions with Arg836 and Tyr891 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, blue).<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> The mutation L861Q was also observed in cancer patients,<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> and as being located within the helical turn motif next to Leu858 and participating in the hydrophobic cluster (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B, orange), is proposed to activate EGFR via a similar mechanism.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p last">Together, the point mutations L858R and L861Q trigger a shift in the equilibrium to a constitutive active kinase conformation, which can be clearly assessed through crystal structures obtained from wild-type and L858R mutant kinases. These findings are directly relevant because affected cancer patients respond well to treatment with approved small-molecule inhibitors.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Deletion Mutations in Exon 19 Restrict the Flexibility of the Regulatory Helix αC</h3><div class="NLM_p">Another subgroup of TKI-responsive tumors exhibits exon 19 deletion mutations affecting the β3−αC protein strand adjacent to the helix αC. These mutations are observed in 46% of patients and are the most prevalent and clinically important mutations beside the point mutation L858R. The deletion mutations, as well as the activating point mutation, cause the constitutive activation of the kinase by destabilizing the inactive conformation, which is maintained absent of ligand stimulation.<a onclick="showRef(event, 'ref42 ref44 ref45 ref47'); return false;" href="javascript:void(0);" class="ref ref42 ref44 ref45 ref47">(42,44,45,47)</a></div><div class="NLM_p">Foster et al. analyzed public available data sets and reported the clinically most frequent deletion mutation of the ELREA motif (delE746_A750), followed by a lower prevalence of delREAT and delLRE.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Homologous short in-frame deletions within the Her2 kinase domain (delLRENT) are reported in Her2 nonamplified breast cancer at a low frequency.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> In this context, attempts to gain crystal structures of respective mutants have been unsuccessful to date. Therefore, insights were attained by means of in silico molecular dynamics (MD) simulations, which add up to the repertoire of structure elucidation methodologies. The ELREA motif plays an important role in the transition between the active and inactive conformations of the regulatory helix αC and promotes the required flexibility of the region.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Modeling studies suggest that the deletion induces partial loss of helicity within the N-terminal portion of helix C, which is repositioned to form a tight β3−αC loop while retaining the characteristic Glu762–Lys745 salt bridge (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>). It is therefore inferred that the reduced length and flexibility of this strand locks the helix αC-<i>in</i> state and prohibits transition to the inactive conformation to promote an active kinase domain.<a onclick="showRef(event, 'ref48 ref51'); return false;" href="javascript:void(0);" class="ref ref48 ref51">(48,51)</a> This assumption is underlined by the different sensitivities of the EGFR mutants to the inhibitors erlotinib and lapatinib. Erlotinib binds to the active helix αC-<i>in</i> conformation. Accordingly, the mutants show a significant sensitivity relative to wild-type EGFR. In contrast, lapatinib binds to the helix C-<i>out</i> conformation, and resistance is associated with deletion mutants of EGFR.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> Similarly, the recently reported allosteric EGFR TKIs failed to target deletion mutations in EGFR.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> In agreement, further studies have emphasized that reducing the length of the β3−αC loop shifts most low-energy conformations accessible to the αC helix from the <i>out</i>-conformation toward the <i>in</i>-conformation. The deletion of five amino acids leads to the optimal helix αC orientation for catalytic activity, while deletion of six or more amino acids leads to structural perturbations that diminish kinase activity. Of interest, the deletion of six residues can trigger an active kinase if a serine replaces a rigid proline side chain N-terminal at the beginning of the helix αC (P753S, <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>) to allow for a more extended conformation. Conversely, shorter deletion-length mutations promote an active kinase domain if accompanied by substitution of a remaining loop residue to a proline.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Deletion mutation of the ELREA motif in exon 19. MD simulations (blue) suggest that these mutations lock the kinase in its active conformation (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) by restricting the flexibility of helix αC, which is crucial for adopting the inactive conformation (black outlined, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Taken together, these data illustrate that EGFR β3−αC deletions in exon 19 shift the equilibrium to the active helix αC conformation, which remains inhibitor-sensitive. However, it is incompatible with TKIs which bind to helix C-<i>out</i> kinase conformations.</div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Insertion Mutations in Exon 20 Heterogeneously Respond to TKIs</h3><div class="NLM_p">A small subset of patients (9%) diagnosed with lung adenocarcinoma presented with in-frame insertion mutations within exon 20 of EGFR.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Contrasting with exon 19 deletions and L858R-bearing tumors, most mutations of this type are considered primary resistant because current treatment options are limited to chemotherapy and clinically effective small-molecule TKIs are lacking.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Clinically relevant insertion mutations primarily occur adjacent to the helix αC within the αC−β4 loop. The mutations D770_N771insSVD and V769_D770insASV together account for 36% of EGFR exon 20 insertions, resulting in duplication of codon 768–770 or 767–769, respectively (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A).<a onclick="showRef(event, 'ref42 ref54'); return false;" href="javascript:void(0);" class="ref ref42 ref54">(42,54)</a> The understanding of the molecular features of this type of mutation is limited; moreover, crystallographic studies have yielded only one crystal structure so far. The only cocrystal structure reported revealed EGFR-D770_N771insNPG bound with the covalent quinazoline-based second-generation inhibitor PD168393<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> at a poor resolution of 3.5 Å.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> The insertion mutation lies at the C-terminal end of the helix αC immediately following Asp770, which forms a tight turn together with the three inserted residues. In this assembly, a hydrogen bond formed between the main chain carbonyl of Asp770 and the amide of the inserted glycine locks the kinase in its active conformation by keeping the helix αC in its inward rotated position (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> After the insertion, the protein chain is quite similar to active EGFR kinase domains.<a onclick="showRef(event, 'ref53 ref54'); return false;" href="javascript:void(0);" class="ref ref53 ref54">(53,54)</a> On the basis of inspection of this crystal structure, Kosaka et al. proposed that the residue Asp770 plays a key role because of its localization in a region that is rearranged in the translocation between the active and inactive conformation. During transition to the inactive conformation, the side chain of Arg776 is repositioned to form hydrogen bonds with the backbone carbonyl groups of Ala767 at the end of the helix αC and Leu703. Although this position is available in wild-type EGFR, the inserted residues reposition Asp770, sterically blocking Arg776 from accessing the end of the helix αC (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B). In accordance with this idea, exon 20 insertions that replace Arg770 with a flexible glycine (D770delinsGY; <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A) are sensitive to afatinib because of restored access of Arg776.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> The inserted residues are not directly in contact with the ATP binding site, however, it has been speculated that drug resistance may arise from a narrow binding site that is incompatible with third-generation TKI binding.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Insertion mutations in exon 20. (A) Overview of the clinically most prevalent EGFR insertion mutations in exon 20 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>). (B) A crystal structure of EGFR-D770_N771insNPG (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM">4LRM</a>) revealed a small wedge that locks the kinase in its active conformation by hindering Arg776 to stabilize the inactive conformation (red, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>). (C) Overview of the clinically most prevalent Her2 insertion mutations in exon 20 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PP0">3PP0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Yasuda et al. analyzed a homology model of A763_Y764insFQEA-mutated EGFR. Contrasting with previously described exon 20 mutations, which affect the αC−β4 loop or the beginning of helix αC, these four amino acids are inserted central to the regulatory helix C (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A). Moreover, patients harboring this insertion mutation remain sensitive to TKI treatment. The FQEA sequence is expected to form one additional helical turn and shift the register of the adjacent residues toward the N-terminus. In this way, the catalytically important Glu762 is displaced by one turn and effectively replaced with the glutamic acid residue introduced by the insertion. More important, the mutation places a smaller alanine side chain in the former position of Ile759. Again, the amino acid at this position is involved in a hydrophobic interplay around Leu858 (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B), which is indispensable to stabilizing the inactive state. Here, a weakened interaction accounts for sensitivity toward small-molecule inhibitors. Moreover, it can be speculated that a I759A mutation might occur, eliciting a similar effect.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></div><div class="NLM_p">Hirano et al. conducted further studies of the mutation Y764_V765insHH (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A), using homology modeling. They assumed that the catalytically essential Glu762 retains its position while shifting the inserted residues toward the C-terminus. In this way, two histidine residues are inserted in a distinct position, one directly interfering with the binding of anilinoquinazoline-based inhibitors and the second interrupting the hydrophobic cavity with Leu858. As outlined above, Leu858 takes a prominent role in stabilizing the inactive state and is prone to mutations, preserving its active conformation. However, third-generation TKIs remain resistant to this type of exon 20 insertion mutation. This finding is not explained by the model presented, highlighting the need for further structural characterizations.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></div><div class="NLM_p">Of note, mutations in Her2 show structural similarity to EGFR exon 20 insertion mutations. However, the observed Her2 insertion mutations are less homogeneous, with A775_G776insYVMA (resulting in duplication of codons 772–775) accounting for 80% of mutations found in Her2 mutant NSCLC (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>C).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Data suggesting success of treating Her2 mutant tumors with TKIs are limited to date.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Crystallographic studies of Her2 focus on the extracellular domain and their targeting with antibodies or related approaches. Two crystal structures of the wild-type Her2 kinase domain are deposited in the Protein Data Bank (PDB) and show a flexible GVG motif adjacent to the regulatory helix.<a onclick="showRef(event, 'ref58 ref59'); return false;" href="javascript:void(0);" class="ref ref58 ref59">(58,59)</a> This structure contrasts with other ErbB kinases, which exhibit an SVD sequence in the homologous position (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>A,C). Her2 insertion mutations are located next to this flexible motif, leading Aertgeerts et al. to propose their role in stabilizing the loop region, resulting in reduced flexibility of the helix αC.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></div><div class="NLM_p last">Taken together, considerations on the structural level imply an effectiveness in treating a subset of tumors in the clinical setting with appropriate EGFR-targeted TKIs. Although most exon 20 insertion mutations remain resistant and their treatment challenging, D770delinsGY and A763_Y764insFQEA are sensitive to approved inhibitors as predicted by 3D models. The latter one exhibits sensitivity because it interferes with the hydrophobic assembly, similar to the L858R mutation. Further structural characterizations will certainly unravel the features of elusive exon 20 mutants in EGFR and Her2.</div></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8"> Point Mutations within the Glycine-Rich Loop Influence Its Crucial Dynamics</h3><div class="NLM_p">Among the structural elements comprising the kinase domain, the glycine-rich loop (homologous to the P-loop in phosphatases) plays a crucial role during ATP or ligand binding. This highly conserved and flexible element forms like a lid over the active site and is characterized by a canonical GxGxxG sequence pattern, in which x represents any amino acid. In EGFR, this sequence is located in exon 18 as GSGAFG (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>). Because of its vital influence on the active site, it has a major effect on the affinity of TKIs. Thus, it is not surprising that point mutations in this region affect ligand-binding events.<a onclick="showRef(event, 'ref60 ref61'); return false;" href="javascript:void(0);" class="ref ref60 ref61">(60,61)</a></div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mutations within the flexible glycine-rich loop (GSGAFG motif) that is involved in ligand recognition. G719S or G724S mutations are thought to affect its dynamics, resulting in steric repulsion or loss of crucial interactions, involving Leu718 or Phe723, for example, with the binding of distinct inhibitors (gray surfaces). Alignment of EGFR crystal structures harboring an exon 20 insertion mutation (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM">4LRM</a>) and G719S (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITO">2ITO</a>) as well as an MD simulation of EGFR-G724S (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Accordingly, mutations in Gly719, which is the first glycine within the G-rich loop, are found in about 2% of NSCLC patients.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Mutations replacing the glycine at codon 719 by Ser, Cys, or Ala side chains are most frequently detected<a onclick="showRef(event, 'ref38 ref62 ref63 ref64'); return false;" href="javascript:void(0);" class="ref ref38 ref62 ref63 ref64">(38,62−64)</a> and exhibit sensitivity toward first- and second-generation TKI treatment.<a onclick="showRef(event, 'ref44 ref45'); return false;" href="javascript:void(0);" class="ref ref44 ref45">(44,45)</a> Although the mutation G719S was characterized by means of X-ray structure determinations and yielded several PDB entries (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), its effect is not yet understood in detail. In line with reports by Yun et al., Yoshikawa et al. revealed a slight upward shift of the Gly-rich loop, which was proposed to account for observed reduced affinity toward ATP and gefitinib.<a onclick="showRef(event, 'ref38 ref65'); return false;" href="javascript:void(0);" class="ref ref38 ref65">(38,65)</a> Because the cofactor and ligand compete for the binding site and their loss in affinity is not equally high, gefitinib binds 6-fold more effectively to the binding site, as compared to wild-type EGFR. In addition, a stabilizing effect of G719S on the active kinase domain conformation has been assumed because the adjacent Phe723 is part of important interaction networks contributing to a stabilized inactive conformation, as mentioned above.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Accordingly, the influence of this central phenylalanine was assessed by analysis of the F723A mutation, which showed a higher gefitinib sensitivity compared to wild-type or the G719S mutation.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> These considerations are in line with an increased kinase activity observed for this mutant variant and point to a possible explanation for its clinical sensitivity toward first-generation TKIs.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Of interest, Gly719 mutations have been described as exhibiting resistance toward osimertinib,<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> probably because of the neighboring Leu718 side chain,<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> which makes important contributions for third-generation inhibitor binding.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Osimertinib might be incompatible with an opened binding cleft upon G719S/A, acting similar to the L718V mutation, as outlined below.</div><div class="NLM_p">A mutation of the last glycine within the G-rich loop, G724S, is increasingly frequently observed.<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">(69,70)</a> Fassunke et al. revisited a cluster of 30 patients who were treated with third-generation inhibitors and observed the emergence of G724S in conjunction with deletion mutations in exon 19 in four patients.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> It was speculated that similar to the EGFR crystal structure harboring the exon 20 insertion mutation,<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> substitution with serine within the glycine-rich loop could induce a conformation, resulting in a narrower binding site. In this way, third-generation inhibitors might experience steric repulsion, hindering their efficient binding. A similar effect of these mutations was assumed because the glycine-rich loop, ELREA motif, and helix C compose a network of regulatory elements, as outlined previously. This hypothesis was supported in MD simulations (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>), which verified an enhanced flexibility of this network despite the strain introduced by deleting the ELREA sequence. Another valid conclusion might therefore include a loss of crucial interactions with third-generation TKIs, similar to G719S/C/A or L718V mutations. However, the study comprised a comprehensive profiling of 32 described inhibitors, including EGFR inhibitors of all three generations. In line with the findings from structural analyses, second-generation inhibitors, such as afatinib, are well tolerated because their quinazoline core avoids potential steric conflicts and their covalent mode of action provides sustained binding.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> These findings were validated and further elaborated by Brown et al., who found a G724S-induced conformation of the G-rich loop, provoking a loss of interaction with osimertinib. Here, the observed resistance was attributed to disruption of the ligand’s interaction with Phe723, whereas second-generation inhibitors do not depend on this interaction and remained sensitive. Of interest, the study revealed the co-occurring exon 19 deletion mutation to be essential for osimertinib drug resistance, while the double mutation G724S+L858R was potently inhibited.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></div><div class="NLM_p last">Although insights into the structure of mutations within the glycine-rich loop were gained and sensitive inhibitors could be identified, further analyses are required to gain a deep understanding of the distinct effects. Particularly, a crystal structure of G724S-mutated EGFR is desired for clarification.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Point Mutations Affecting the Binding Site Mediate Acquired Drug Resistance</h3><div class="NLM_p">The efficacy of first- and second-generation TKIs such as gefitinib or afatinib is limited by the emergence of a drug resistance mutation of the gatekeeper residue Thr790 in exon 20.<a onclick="showRef(event, 'ref72 ref73'); return false;" href="javascript:void(0);" class="ref ref72 ref73">(72,73)</a> The threonine in the back of the ATP-binding cleft is substituted with a sterically more demanding methionine side chain (T790M), which results in steric repulsion with the aniline moieties of quinazoline-based inhibitors (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>A).<a onclick="showRef(event, 'ref74 ref75'); return false;" href="javascript:void(0);" class="ref ref74 ref75">(74,75)</a> In addition, it was reported that the point mutation L858R activates the kinase accompanied by a decrease in affinity for the cofactor ATP. This fact allows for more efficient inhibition of this mutant with TKIs as compared to wild-type EGFR. The T790M mutation, on the other hand, restores the ATP affinity to a similar level as observed with WT-EGFR and thus mediates drug resistance.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Point mutations in the binding site directly interfere with ligand binding. (A) The T790M mutation hinders first- and second-generation EGFR inhibitor binding through increased steric demand. Afatinib binding to wild-type EGFR (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>) aligned with T790M mutant apo-EGFR (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UG1">3UG1</a>). (B) The C797S mutation hinders third-generation covalent inhibitor binding through reduced reactivity of the Ser797 side chain. Binding mode of the reversible analogue WZ4003 (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X2K">5X2K</a>) aligned with C797S-mutated EGFR (blue, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>) as compared to the binding mode of covalent WZ4002 (black outlined, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (C) G796R and L792H mutations interfere with third-generation inhibitor binding, illustrated using the crystal structure of rociletinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK">5XDK</a>). (D) The L718Q mutation interferes with third-generation inhibitor binding (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK">5XDK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">To overcome this type of drug resistance, a third generation of TKIs was developed. These TKIs have novel scaffolds, avoid steric interference with Met790, and take advantage of alkylating Cys797 while being selective over EGFR wild-type.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> The development of a novel point mutation C797S is therefore inevitable and again limits the success of these inhibitors. Substitution of the reactive cysteine by a less nucleophilic serine side chain prevents covalent bond formation, resulting in a loss of efficacy.<a onclick="showRef(event, 'ref76 ref77'); return false;" href="javascript:void(0);" class="ref ref76 ref77">(76,77)</a> The effect of the gatekeeper mutation was clearly resolved through several available crystal structures of inhibitors based on quinazoline and related scaffolds. Furthermore, a 3D model of C797S-mediated resistance can be assessed through an existing cocrystal structure of WZ4003, the reversible counterpart of the third-generation inhibitor WZ4002,<a onclick="showRef(event, 'ref78 ref79'); return false;" href="javascript:void(0);" class="ref ref78 ref79">(78,79)</a> and a crystal structure of C797S-mutated EGFR bound with a derivative of staurosporine,<a onclick="showRef(event, 'ref80 ref81'); return false;" href="javascript:void(0);" class="ref ref80 ref81">(80,81)</a> Gö6976.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> It is believed that WZ4003 somehow resembles the binding mode of covalent pyrimidine-based inhibitors upon mutation of the reactive cysteine (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>B).<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></div><div class="NLM_p">The knowledge gained about the binding mode of TKIs within the EGFR binding site could be easily applied to additional point mutations affecting the binding site and that mediate drug resistance toward small-molecule inhibitors. Recent reports have identified mutations replacing the glycine at codon 796 in the EGFR with polar and sterically more demanding amino acids (G796S/R/D).<a onclick="showRef(event, 'ref66 ref83 ref84 ref85'); return false;" href="javascript:void(0);" class="ref ref66 ref83 ref84 ref85">(66,83−85)</a> Revision of available crystal structures revealed a tremendous impact on ligand binding. Because Gly796 is located at the lip of the active site, an enlarged side chain was found to cause steric interference with the solubilizing groups and core structures of available TKIs (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Another point mutation was observed in NSCLC patients. It affects the binding site at the hinge region, connecting the N- and C-lobes of the kinase domain. In this way, Leu792 is replaced by different side chains, with case reports mentioning mutations to His, Tyr, Phe, Arg, Pro, and Val.<a onclick="showRef(event, 'ref66 ref83'); return false;" href="javascript:void(0);" class="ref ref66 ref83">(66,83)</a> Leu792 has important interactions with a methoxy group included in third-generation inhibitors rociletinib or osimertinib, which thus exhibits resistance toward replacement of the important amino acid (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>C). Given these structural considerations, inhibitors that do not interact with Leu792 are believed to show a markedly reduced degree of resistance upon this type of mutation. A similar effect was observed for mutations in Leu718.<a onclick="showRef(event, 'ref66 ref86 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref66 ref86 ref87 ref88">(66,86−88)</a> This particular side chain is part of a hydrophobic clamp motif that has important hydrophobic interactions with third-generation TKIs.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Therefore, L718V results in a loss of ligand contacts, while L718Q results in steric conflict with rociletinib or osimertinib (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>D). In addition, both substitutions found in lung cancer patients lead to a loss of hydrophobicity in close proximity to TKIs. However, the L718V mutation was found to retain sensitivity toward afatinib.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></div><div class="NLM_p last">Altogether, a detailed understanding of the distinct effects of mutations within the binding site has been established and will stimulate rational drug design approaches for developing novel chemical entities that can overcome drug resistance in cancer patients with EGFR mutations.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i10">Summary and Outlook</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40573" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40573" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The field of protein structure determination has undergone a massive expansion over the past decade. Tools for the determination of high-resolution protein structures via X-ray crystallography have become more powerful and provide insights into the functions of numerous biological processes.<a onclick="showRef(event, 'ref89 ref90'); return false;" href="javascript:void(0);" class="ref ref89 ref90">(89,90)</a> The ability to gain cocrystal structures of the target protein and small-molecule ligands supports the development of new drugs by promoting detailed understanding of the structure–activity relationship. However, successful structure determination by X-ray crystallography requires overcoming critical bottlenecks, which include gene design, protein expression and purification, crystallization, X-ray diffraction pattern acquisition, and finally, data set processing to yield the desired 3D model according to the electron density maps. Specifically, kinases often require more complex expression systems, such as insect cells, and successful crystallization is likely to depend on the protein sequence, taking intensive and time-consuming optimization cycles. Moreover, access to highly sophisticated equipment is required, essentially a high-energy synchrotron light source.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Of note, the resulting structure typically provides a static snapshot of the protein, which is not necessarily the predominant state in biological systems.<a onclick="showRef(event, 'ref91 ref92'); return false;" href="javascript:void(0);" class="ref ref91 ref92">(91,92)</a> Despite these and other limitations, protein crystallography is the method of choice for structure determination and accounted for 90% of the structures deposited in the PDB in 2016.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> The remaining 10% were solved by nuclear magnetic resonance (NMR) spectroscopy, which offers structure elucidation in solution and provides an alternative for proteins that are unlikely to crystallize. Moreover, real-time NMR provides information about the protein dynamics over a long period using exchange spectroscopy or relaxation measurements. An important feature during drug discovery is the mapping of chemical shifts, resulting in information about detailed protein–ligand interaction patterns. NMR studies have been limited to small proteins or fragments, but thanks to technical advances in the field, it can now be successfully applied to larger proteins.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a></div><div class="NLM_p">Because these methodologies are experimentally intensive, time-consuming, and have limitations, in silico modeling provides additional tools for accessing structural information. Among these, homology modeling has gained increasing interest because of the gap between the number of available protein sequences and disclosed protein structures. The method is based on the conditional evolutionary similarity of protein sequences, which results in similar three-dimensional architectures within a protein family. Therefore, the known structure of one member allows a structural description of another family member by mapping the sequence of the target protein onto the resolved structure. Although homology modeling is less accurate than experimental methods, it is useful for hypotheses regarding overall protein folding or localization of ligand binding sites.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Another method for investigating dynamic structural changes of side chains or even domain movements within the proteins is offered by MD simulations. With this approach, protein conformation transitions that are relevant to molecular function can be visualized. These investigations are based on crystal structures, which in turn illustrates the importance of the protein crystallography methodology.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a></div><div class="NLM_p">The technology of cryogenic electron microscopy (cryo-EM) was recognized with the 2017 Nobel Prize in Chemistry, −which represents the impact to the field, and constitutes another method for high-resolution structure determination applied to large proteins and protein complexes (>500 kDa).<a onclick="showRef(event, 'ref91 ref97'); return false;" href="javascript:void(0);" class="ref ref91 ref97">(91,97)</a> It provides access to structures in solution or to membrane-spanning proteins that cannot be clarified by NMR or X-ray crystallography.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Cryo-EM is currently not suited for high-throughput application because of intensive sample preparation, image capturing, and processing that require deep experience. However, the method allows for exact fitting of side chains and exact positioning of small molecules. It will thus certainly take a key role in drug discovery soon.<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a></div><div class="NLM_p last">In summary, the repertoire of 3D structure determination methodologies facilitates medicinal chemistry approaches, for example, in the field of kinase-targeted therapy of NSCLC, which we reviewed here. Specifically, we presented important activating and drug-resistant mutations of EGFR and Her2 and their effect on protein structures. We highlighted (i) a common mechanism of drug sensitivity upon mutations destabilizing a hydrophobic cluster, which is crucial for maintaining an inactive helix C-<i>out</i> conformation, (ii) the effect of deletion mutations in exon 19, which influence the regulatory helix C’s flexibility, and (iii) mutations within the glycine-rich loop, which affect ligand binding affinity by steric repulsion or loss of crucial interactions but are not yet fully understood. Moreover, we pointed out that (iv) the field lacks detailed insights into drug-resistant exon 20 insertion mutations in EGFR and Her2, but that (v) drug resistance arising from steric interference with active site-directed small-molecule inhibitors can be easily assessed using existing crystal structures. We are therefore certain that elusive mutants of EGFR and Her2 will be pinned down through further structural characterizations in the future. These findings will be directly relevant to structure-based drug design approaches and improve the efficiency of precision medicines. Ultimately, protein structure elucidations will push us further along the path to improved survival and quality of life for patients suffering from lung cancer.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i11"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00964" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65813" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65813" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00964" class="ext-link">10.1021/acs.jmedchem.9b00964</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Chemical structures of representative examples of the three TKI-generations of EGFR (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00964/suppl_file/jm9b00964_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00964/suppl_file/jm9b00964_si_001.pdf">jm9b00964_si_001.pdf (46.32 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00964" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_50327" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_50327" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonas Lategahn</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and
Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</span>; 
    <span class="hlFld-Affiliation affiliation">Drug Discovery Hub Dortmund
(DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</span>; 
    <span>Present Address:
                        For J.L.: PearlRiver Bio GmbH, Otto-Hahn-Strasse 15, 44227 Dortmund, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-5993-7082" title="Orcid link">http://orcid.org/0000-0001-5993-7082</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e8828786899bc684899c8d8f898086a89c9dc58c879a9c859d868cc68c8d"><span class="__cf_email__" data-cfemail="83e9ecede2f0adefe2f7e6e4e2ebedc3f7f6aee7ecf1f7eef6ede7ade7e6">[email protected]</span></a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Daniel Rauh</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and
Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</span>; 
    <span class="hlFld-Affiliation affiliation">Drug Discovery Hub Dortmund
(DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-1970-7642" title="Orcid link">http://orcid.org/0000-0002-1970-7642</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#5135303f38343d7f233024391125247c353e23253c243f357f3534"><span class="__cf_email__" data-cfemail="7216131c1b171e5c0013071a3206075f161d00061f071c165c1617">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Janina Niggenaber</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and
Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</span>; 
    <span class="hlFld-Affiliation affiliation">Drug Discovery Hub Dortmund
(DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0003-2942-263X" title="Orcid link">http://orcid.org/0000-0003-2942-263X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Julia Hardick</span> - <span class="hlFld-Affiliation affiliation">Faculty of Chemistry and
Chemical Biology, TU Dortmund University, Otto-Hahn-Strasse 4a, 44227 Dortmund, (Germany)</span>; 
    <span class="hlFld-Affiliation affiliation">Drug Discovery Hub Dortmund
(DDHD) am Zentrum für Integrierte Wirkstoffforschung (ZIW), TU Dortmund University, 44227 Dortmund (Germany)</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>J.N. and J.H. contributed equally. The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare the following competing financial interest(s): J.L. is shareholder and full-time employee of PearlRiver Bio GmbH; D.R. is shareholder and consultant of PearlRiver Bio GmbH.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77524" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77524" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Janina Niggenaber</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=BIO-d7e841-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Janina Niggenaber</b> studied Chemical Biology at TU Dortmund University (Germany). She joined the group of Daniel Rauh for her Bachelor studies on the biochemical evaluation of the detoxification enzyme Keap1. During her Master’s thesis and following Ph.D. studies, she has been engaged in the optimization of the expression and purification of clinically relevant mutants of the ErbB family with a strong focus on the crystallization of these mutants. Moreover, she is responsible for the cellular evaluation of inhibitors developed in the work group.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Julia Hardick</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=BIO-d7e846-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Julia Hardick</b> studied Chemical Biology at TU Dortmund University (Germany). She joined the group of Daniel Rauh for her Bachelor and Master studies dealing with structure-based design, synthesis, and biochemical evaluation of p38α kinase inhibitors. In her current Ph.D. studies, she focuses on the development of covalent inhibitors to target cancer-related drug targets such as members of the ErbB-family as well as the in vitro pharmacokinetic properties evaluation of these inhibitors.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Jonas Lategahn</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=BIO-d7e851-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Jonas Lategahn</b> studied Chemical Biology at TU Dortmund University (Germany) and performed his Bachelor studies at the Max Planck Institute of Molecular Physiology in the group of Andrey Antonchick. He joined the group of Daniel Rauh for his Master’s thesis followed by Ph.D. studies in the field of Medicinal Chemistry with ErbB-driven non-small cell lung cancer as a key subject. During his post-doctoral research at the Drug Discovery Hub Dortmund (DDHD), he focused on the development of inhibitors of aberrant kinase signaling and acquired drug resistance.</p></figure></div><div class="bio" rid="ath4"><figure id="ath4" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Daniel Rauh</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=BIO-d7e856-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Daniel Rauh</b> is a pharmacist by training and completed his Ph.D. in the group of Gerhard Klebe in Marburg in 2003. After postdoctoral stays with Milton Stubbs in Halle and Kevan Shokat in San Francisco, he started his independent career at the Chemical Genomics Centre of the Max Planck Society in Dortmund. Since 2013, he serves as Professor and Chair of Chemical Biology and Medicinal Chemistry at TU Dortmund University. His research interests focus on the structure-based design and synthesis of small molecules for the modulation of biological systems. He is a cofounder of the Zentrum für Integrierte Wirkstoffforschung (ZIW) at TU Dortmund University and coordinates the Drug Discovery Hub Dortmund (DDHD), which aim at translating basic academic research into pharmaceutical application.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">cryo-EM</td><td class="NLM_def"><p class="first last">cryogenic electron microscopy</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">NMR</td><td class="NLM_def"><p class="first last">nuclear magnetic resonance</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">PDB</td><td class="NLM_def"><p class="first last">Protein Data Bank</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_25185" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_25185" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 97 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-424&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2eYYuJ5LATidQLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%25202018%253A%2520GLOBOCAN%2520estimates%2520of%2520incidence%2520and%2520mortality%2520worldwide%2520for%252036%2520cancers%2520in%2520185%2520countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D424%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolly, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of molecularly targeted agents in non-small-cell lung cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0732-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-017-0732-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28378229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1ynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=813-827&author=S.+O.+Dollyauthor=D.+C.+Collinsauthor=R.+Sundarauthor=S.+Popatauthor=T.+A.+Yap&title=Advances+in+the+development+of+molecularly+targeted+agents+in+non-small-cell+lung+cancer&doi=10.1007%2Fs40265-017-0732-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Dolly, Saoirse O.; Collins, Dearbhaile C.; Sundar, Raghav; Popat, Sanjay; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">813-827</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality.  The traditional 'one-size-fits-all' treatment approach has now evolved into one that involves personalized strategies based on histol. and mol. subtypes.  The mol. era has revolutionized the treatment of patients harboring epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS1 gene aberrations.  In the appropriately selected population, anti-tumor agents against these mol. targets can significantly improve progression-free survival.  However, the emergence of acquired resistance is inevitable.  Novel potent compds. with much improved and rational selectivity profiles, such as third-generation EGFR T790M resistance mutation-specific inhibitors, have been developed and added to the NSCLC armamentarium.  To date, attempts to overcome resistance bypass pathways through downstream signaling blockade has had limited success.  Furthermore, the majority of patients still do not harbor known driver genetic or epigenetic alterations and/or have no new available treatment options, with chemotherapy remaining their std. of care.  Several potentially actionable driver aberrations have recently been identified, with the early clin. development of multiple inhibitors against these promising targets currently in progress.  The advent of immune checkpoint inhibitors has led to significant benefit for advanced NSCLC patients with durable responses obsd.  Further interrogation of the underlying biol. of NSCLC, coupled with modern clin. trial designs, is now required to develop novel targeted therapeutics rationally matched with predictive biomarkers of response, so as to further advance NSCLC therapeutics through the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVGMcn1PkzYrVg90H21EOLACvtfcHk0lj8OLzA7Xml2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1ynt7o%253D&md5=e446c6b4a40e3c4e9f5a2b6f1f623c06</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0732-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0732-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolly%26aufirst%3DS.%2BO.%26aulast%3DCollins%26aufirst%3DD.%2BC.%26aulast%3DSundar%26aufirst%3DR.%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520molecularly%2520targeted%2520agents%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D813%26epage%3D827%26doi%3D10.1007%2Fs40265-017-0732-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">Refining the treatment of NSCLC according to histological and molecular subtypes</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnrclinonc.2015.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=25963091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=511-526&author=A.+Thomasauthor=S.+V.+Liuauthor=D.+S.+Subramaniamauthor=G.+Giaccone&title=Refining+the+treatment+of+NSCLC+according+to+histological+and+molecular+subtypes&doi=10.1038%2Fnrclinonc.2015.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the treatment of NSCLC according to histological and molecular subtypes</span></div><div class="casAuthors">Thomas, Anish; Liu, Stephen V.; Subramaniam, Deepa S.; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">511-526</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into subtypes based on genotype and histol. has resulted in dramatic improvements in disease outcome in select patient subgroups.  In particular, molecularly targeted agents that inhibit EGFR or ALK are approved for the treatment of NSCLC harboring genetic alterations in the genes encoding these proteins.  Although acquired resistance usually limits the duration of response to these therapies, a no. of new agents have proven effective at tackling specific resistance mechanisms to first-generation inhibitors.  Large initiatives are starting to address the role of biomarker-driven targeted therapy in squamous lung cancers, and in the adjuvant setting.  Immunotherapy undeniably holds great promise and our understanding of subsets of NSCLC based on patterns of immune response is continuing to evolve.  In addn., efforts are underway to identify rare genomic subsets through genomic screening, functional studies, and mol. characterization of exceptional responders.  This Review provides an overview of the key developments in the treatment of NSCLC, and discusses potential strategies to further optimize therapy by targeting disease subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkYdEvAhD-ALVg90H21EOLACvtfcHk0lj8OLzA7Xml2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7%252FN&md5=ac3985abb9bf2d0b9d43231ebe0b5def</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.90%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DSubramaniam%26aufirst%3DD.%2BS.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DRefining%2520the%2520treatment%2520of%2520NSCLC%2520according%2520to%2520histological%2520and%2520molecular%2520subtypes%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D511%26epage%3D526%26doi%3D10.1038%2Fnrclinonc.2015.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lj8OLzA7Xml2Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The EGF receptor family as targets for cancer therapy</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6550</span>– <span class="NLM_lpage">6565</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fsj.onc.1204082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=11426640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6550-6565&author=J.+Mendelsohnauthor=J.+Baselga&title=The+EGF+receptor+family+as+targets+for+cancer+therapy&doi=10.1038%2Fsj.onc.1204082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The EGF receptor family as targets for cancer therapy</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6550-6565</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with many refs.  Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been assocd. with a more aggressive clin. behavior.  Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype.  For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments.  In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed.  These MAbs have shown promising preclin. activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions.  Clin. activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy.  In addn. to antibodies, compds. that directly inhibit receptor tyrosine kinases have shown preclin. activity and early clin. activity has been reported.  A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq686yufIuCk7Vg90H21EOLACvtfcHk0libENnywCPvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2ku7k%253D&md5=a268fb11a31755e161176780ac37e015</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204082%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520EGF%2520receptor%2520family%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6550%26epage%3D6565%26doi%3D10.1038%2Fsj.onc.1204082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy-Chowdhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4910</span>– <span class="NLM_lpage">4918</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-12-0912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22761469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4910-4918&author=M.+E.+Arcilaauthor=J.+E.+Chaftauthor=K.+Nafaauthor=S.+Roy-Chowdhuriauthor=C.+Lauauthor=M.+Zaidinskiauthor=P.+K.+Paikauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=Prevalence%2C+clinicopathologic+associations%2C+and+molecular+spectrum+of+ERBB2+%28HER2%29+tyrosine+kinase+mutations+in+lung+adenocarcinomas&doi=10.1158%2F1078-0432.CCR-12-0912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas</span></div><div class="casAuthors">Arcila, Maria E.; Chaft, Jamie E.; Nafa, Khedoudja; Roy-Chowdhuri, Sinchita; Lau, Christopher; Zaidinski, Michael; Paik, Paul K.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4910-4918</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations.  The prevalence, clinicopathol. characteristics, prognostic implications, and mol. heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients.  Exptl. Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and neg. cases were then assessed for HER2 mutations (exons 19-20) using a sizing assay and mass spectrometry.  Testing for addnl. recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry.  ALK rearrangements and HER2 amplification were assessed by FISH.  Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-neg. specimens.  Small insertions in exon 20 accounted for 96% (24/25) of the cases.  Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775.  Morphol., 92% (23/25) were moderately or poorly differentiated ADC.  HER2 mutation was not assocd. with concurrent HER2 amplification in 11 cases tested for both.  HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no assocns. with sex, race, or stage.  Conclusions: HER2 mutations identify a distinct subset of lung ADCs.  Given the high prevalence of lung cancer worldwide and the availability of std. and investigational therapies targeting HER2, routine clin. genotyping of lung ADC should include HER2.  Clin Cancer Res; 18(18); 4910-8. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2xQKmrAL7bVg90H21EOLACvtfcHk0libENnywCPvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7%252FM&md5=683086d6c06b3fb76b94f7c4d8bfed40</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0912%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DRoy-Chowdhuri%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DZaidinski%26aufirst%3DM.%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DPrevalence%252C%2520clinicopathologic%2520associations%252C%2520and%2520molecular%2520spectrum%2520of%2520ERBB2%2520%2528HER2%2529%2520tyrosine%2520kinase%2520mutations%2520in%2520lung%2520adenocarcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4910%26epage%3D4918%26doi%3D10.1158%2F1078-0432.CCR-12-0912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alroy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(97)00412-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2FS0014-5793%2897%2900412-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9247128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Shu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=1997&pages=83-86&author=I.+Alroyauthor=Y.+Yarden&title=The+ErbB+signaling+network+in+embryogenesis+and+oncogenesis%3A+signal+diversification+through+combinatorial+ligand-receptor+interactions&doi=10.1016%2FS0014-5793%2897%2900412-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions</span></div><div class="casAuthors">Alroy, Iris; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-86</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 47 refs.  Ligand-induced activation of receptor tyrosine kinases (RTK) results in the initiation of diverse cellular pathways, including proliferation, differentiation and cell migration.  The ErbB family of RTKs represents a model for signal diversification through the formation of homo- and heterodimeric receptor complexes.  Each dimeric receptor complex will initiate a distinct signaling pathway by recruiting a different set of Src homol. 2- (SH2-) contg. effector proteins.  Further complexity is added due to the existence of an oncogenic receptor that enhances and stabilizes dimerization but has no ligand (ErbB-2), and a receptor that can recruit novel SH-2-contg. proteins, but is itself devoid of kinase activity (ErbB-3).  The resulting signaling network has important implications for embryonic development and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe8I6zWoDu4LVg90H21EOLACvtfcHk0libENnywCPvIA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Shu70%253D&md5=0d5a27cf91dedbe113e6e061fdd17ee5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2897%2900412-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252897%252900412-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlroy%26aufirst%3DI.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DThe%2520ErbB%2520signaling%2520network%2520in%2520embryogenesis%2520and%2520oncogenesis%253A%2520signal%2520diversification%2520through%2520combinatorial%2520ligand-receptor%2520interactions%26jtitle%3DFEBS%2520Lett.%26date%3D1997%26volume%3D410%26spage%3D83%26epage%3D86%26doi%3D10.1016%2FS0014-5793%2897%2900412-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons to be learned: the molecular basis of kinase-targeted therapies and drug resistance in non-small cell lung cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+to+be+learned%3A+the+molecular+basis+of+kinase-targeted+therapies+and+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0lg_MkQfZFYd7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520to%2520be%2520learned%253A%2520the%2520molecular%2520basis%2520of%2520kinase-targeted%2520therapies%2520and%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodburn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henthorn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, L.</span></span> <span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lg_MkQfZFYd7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodburn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. H.</span></span> <span> </span><span class="NLM_article-title">ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5749</span>– <span class="NLM_lpage">5754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=12384534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gibson&title=ZD1839+%28Iressa%29%3A+an+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span></div><div class="casAuthors">Wakeling, Alan E.; Guy, Simon P.; Woodburn, Jim R.; Ashton, Susan E.; Curry, Brenda J.; Barker, Andrew J.; Gibson, Keith H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5749-5754</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy.  We have developed a low-mol.-wt. EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa).  ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC50 = 0.033 μM) that selectively inhibits EGF-stimulated tumor cell growth (IC50 = 0.054 μM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells.  In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner.  The level of expression of EGFR did not det. xenograft tumor sensitivity to ZD1839.  Long-term ZD1839 (>3 mo) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors.  No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal.  These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkoHZ9zL06abVg90H21EOLACvtfcHk0lg_MkQfZFYd7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D&md5=f5f86c652786db476a2d23b5bbd1a9e9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacci, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiOrio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pustilnik, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4838</span>– <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+DiOrioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnikauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0li4aBVVf3fKCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDiOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4702</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0li4aBVVf3fKCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0li4aBVVf3fKCA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettiere, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1880</span>– <span class="NLM_lpage">1889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.+M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0lhSlSPYryYXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0lhSlSPYryYXiQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0lhPjdMqItGFJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6255</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fsj.onc.1205794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=12214266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1yrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=W.+Xiaauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW572016%3A+a+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways&doi=10.1038%2Fsj.onc.1205794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span></div><div class="casAuthors">Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6255-6263</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals.  Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.  GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp.  Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls.  EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016.  These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.  Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016.  Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYPkZ4sa88irVg90H21EOLACvtfcHk0lhPjdMqItGFJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1yrs7w%253D&md5=38d6e25a7cfa1fdfe77fa2fea2c0aa0c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205794%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW572016%253A%2520a%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263%26doi%3D10.1038%2Fsj.onc.1205794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosfjord, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3965</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-2868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase&doi=10.1158%2F0008-5472.CAN-03-2868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0lhPjdMqItGFJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965%26doi%3D10.1158%2F0008-5472.CAN-03-2868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0ljLxIoyR68How"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosfjord, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+F.+Wangauthor=L.+M.+Greenbergerauthor=H.+R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)</span></div><div class="casAuthors">Wissner, Allan; Overbeek, Elsebe; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Mamuya, Nellie; Rosfjord, Edward C.; Discafani, Carolyn; Davis, Rachel; Shi, Xiaoqing; Rabindran, Sridhar K.; Gruber, Brian C.; Ye, Fei; Hallett, William A.; Nilakantan, Ramaswamy; Shen, Ru; Wang, Yu-Fen; Greenberger, Lee M.; Tsou, Hwei-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles, e.g., I, that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepd.  These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles, e.g., II, with unsatd. acid chlorides or mixed anhydrides.  Competitive reactivity studies were performed, showing that attaching a dialkylamino group onto the end of the Michael acceptor results in compds. with greater reactivity due to intramol. catalysis of the Michael addn.  This, along with improved water-soly. results in compds. with enhanced biol. properties.  Mol. modeling results consistent with the proposed mechanism of inhibition are presented.  One compd., I (EKB-569), which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq317fAvBYUW7Vg90H21EOLACvtfcHk0ljLxIoyR68How"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D&md5=db70c2f78c62824810854295d06ef6a4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0ljLxIoyR68How"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lgscImP5xp-Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0lgscImP5xp-Dw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0lj_uG2XZWXfQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lj_uG2XZWXfQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lj_uG2XZWXfQQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wemmer, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2009.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19563760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvlt1Kqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=1293-1307&author=N.+Juraauthor=N.+F.+Endresauthor=K.+Engelauthor=S.+Deindlauthor=R.+Dasauthor=M.+H.+Lamersauthor=D.+E.+Wemmerauthor=X.+Zhangauthor=J.+Kuriyan&title=Mechanism+for+activation+of+the+EGF+receptor+catalytic+domain+by+the+juxtamembrane+segment&doi=10.1016%2Fj.cell.2009.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment</span></div><div class="casAuthors">Jura Natalia; Endres Nicholas F; Engel Kate; Deindl Sebastian; Das Rahul; Lamers Meindert H; Wemmer David E; Zhang Xuewu; Kuriyan John</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1293-307</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signaling by the epidermal growth factor receptor requires an allosteric interaction between the kinase domains of two receptors, whereby one activates the other.  We show that the intracellular juxtamembrane segment of the receptor, known to potentiate kinase activity, is able to dimerize the kinase domains.  The C-terminal half of the juxtamembrane segment latches the activated kinase domain to the activator, and the N-terminal half of this segment further potentiates dimerization, most likely by forming an antiparallel helical dimer that engages the transmembrane helices of the activated receptor.  Our data are consistent with a mechanism in which the extracellular domains block the intrinsic ability of the transmembrane and cytoplasmic domains to dimerize and activate, with ligand binding releasing this block.  The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTynNJaIAyrIFEOhA_Im3cfW6udTcc2eaQoD6lukquJrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvlt1Kqsw%253D%253D&md5=6b47587025fd347e72fd240097a0b311</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DJura%26aufirst%3DN.%26aulast%3DEndres%26aufirst%3DN.%2BF.%26aulast%3DEngel%26aufirst%3DK.%26aulast%3DDeindl%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DLamers%26aufirst%3DM.%2BH.%26aulast%3DWemmer%26aufirst%3DD.%2BE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DMechanism%2520for%2520activation%2520of%2520the%2520EGF%2520receptor%2520catalytic%2520domain%2520by%2520the%2520juxtamembrane%2520segment%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D1293%26epage%3D1307%26doi%3D10.1016%2Fj.cell.2009.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced ErbB receptor dimerization</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2008.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.yexcr.2008.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19038249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1alurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2009&pages=638-648&author=M.+A.+Lemmon&title=Ligand-induced+ErbB+receptor+dimerization&doi=10.1016%2Fj.yexcr.2008.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-induced ErbB receptor dimerization</span></div><div class="casAuthors">Lemmon, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family of receptor tyrosine kinases.  These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell transformation (and tumorigenesis) by simple overexpression.  In parallel with these advances, studies of the EGF receptor at the cell surface increasingly argue that the structural studies are missing key mechanistic components.  This is particularly evident in the structural prediction that EGF binding linked to receptor dimerization should be pos. cooperative, whereas cell-surface EGF-binding studies suggest neg. cooperativity.  In this review, I summarize studies of ErbB receptor extracellular regions in soln. and of intact receptors at the cell surface, and attempt to reconcile the differences suggested by the two approaches.  By combining results obtained with receptor 'parts', it is qual. possible to explain some models for the properties of the whole receptor.  These considerations underline the need to consider the intact ErbB receptors as intact allosterically regulated enzymes, and to combine cellular and structural studies into a complete picture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYKrRiZAe2bVg90H21EOLACvtfcHk0ljF6U0rVAszbA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1alurs%253D&md5=62a7a424e192dbd493da47db3bb03ea0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2008.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2008.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26atitle%3DLigand-induced%2520ErbB%2520receptor%2520dimerization%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2009%26volume%3D315%26spage%3D638%26epage%3D648%26doi%3D10.1016%2Fj.yexcr.2008.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Spatial control of EGF receptor activation by reversible dimerization on living cells</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nature08827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature08827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20208517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=783-787&author=I.+Chungauthor=R.+Akitaauthor=R.+Vandlenauthor=D.+Toomreauthor=J.+Schlessingerauthor=I.+Mellman&title=Spatial+control+of+EGF+receptor+activation+by+reversible+dimerization+on+living+cells&doi=10.1038%2Fnature08827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial control of EGF receptor activation by reversible dimerization on living cells</span></div><div class="casAuthors">Chung, Inhee; Akita, Robert; Vandlen, Richard; Toomre, Derek; Schlessinger, Joseph; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7289</span>),
    <span class="NLM_cas:pages">783-787</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase, the deregulation of which has been implicated in a variety of human carcinomas.  EGFR signaling is preceded by receptor dimerization, typically thought to result from a ligand-induced conformational change in the ectodomain that exposes a loop (dimerization arm) required for receptor assocn.  Ligand binding may also trigger allosteric changes in the cytoplasmic domain of the receptor that is crucial for signaling.  Despite these insights, ensemble-averaging approaches have not detd. the precise mechanism of receptor activation in situ.  Using quantum-dot-based optical tracking of single mols. combined with a novel time-dependent diffusivity anal., here we present the dimerization dynamics of individual EGFRs on living cells.  Before ligand addn., EGFRs spontaneously formed finite-lifetime dimers kinetically stabilized by their dimerization arms.  The dimers were primed both for ligand binding and for signaling, such that after EGF addn. they rapidly showed a very slow diffusivity state that correlated with activation.  Although the kinetic stability of unliganded dimers was in principle sufficient for EGF-independent activation, ligand binding was still required for signaling.  Interestingly, dimers were enriched in the cell periphery in an actin- and receptor-expression-dependent fashion, resulting in a peripheral enhancement of EGF-induced signaling that may enable polarized responses to growth factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYh4yyD5mS7Vg90H21EOLACvtfcHk0lgR0vV-2aigHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVCitL8%253D&md5=c6d3437ece792063efd06017d917ae0b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature08827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08827%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DI.%26aulast%3DAkita%26aufirst%3DR.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DToomre%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DSpatial%2520control%2520of%2520EGF%2520receptor%2520activation%2520by%2520reversible%2520dimerization%2520on%2520living%2520cells%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D783%26epage%3D787%26doi%3D10.1038%2Fnature08827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madshus, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, E.</span></span> <span> </span><span class="NLM_article-title">Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3433</span>– <span class="NLM_lpage">3439</span>, <span class="refDoi"> DOI: 10.1242/jcs.050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1242%2Fjcs.050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19759283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3433-3439&author=I.+H.+Madshusauthor=E.+Stang&title=Internalization+and+intracellular+sorting+of+the+EGF+receptor%3A+a+model+for+understanding+the+mechanisms+of+receptor+trafficking&doi=10.1242%2Fjcs.050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking</span></div><div class="casAuthors">Madshus, Inger Helene; Stang, Espen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3433-3439</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR; also known as ErbB1) is 1 of 4 related receptor tyrosine kinases.  These receptors (EGFR, ErbB2, ErbB3, and ErbB4) are frequently overexpressed in cancer and such overexpression is assocd. with poor clin. outcome.  Understanding the mechanisms involved in growth-factor-receptor downregulation is medically important, as several drugs that interfere with the function and trafficking of ErbB proteins are currently being developed or are already in clin. trials.  EGFR has become a model protein for understanding the biol. and endocytosis of related growth-factor receptors, and the mechanisms involved in its endocytosis and degrdn. have been scrutinized for several decades.  Nevertheless, the details and principles of these processes are still poorly understood and often controversial.  In particular, the literature describing how the ubiquitylation and recruitment of EGFR to clathrin-coated pits are connected is inconsistent and confusing.  We discuss the impact of signaling motifs, kinase activity, and ubiquitylation on clathrin-dependent endocytosis and lysosomal sorting of EGFR.  In addn., we discuss potential explanations for contradicting reports, and propose models for the recruitment of ligand-activated EGFR to clathrin-coated pits as well as for lysosomal sorting of ligand-activated EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrii2kZPG0_hrVg90H21EOLACvtfcHk0lgR0vV-2aigHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurjF&md5=81b4646afcd6fb43600ef6bd5c8d2bf6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1242%2Fjcs.050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.050260%26sid%3Dliteratum%253Aachs%26aulast%3DMadshus%26aufirst%3DI.%2BH.%26aulast%3DStang%26aufirst%3DE.%26atitle%3DInternalization%2520and%2520intracellular%2520sorting%2520of%2520the%2520EGF%2520receptor%253A%2520a%2520model%2520for%2520understanding%2520the%2520mechanisms%2520of%2520receptor%2520trafficking%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3433%26epage%3D3439%26doi%3D10.1242%2Fjcs.050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, E. R.</span></span> <span> </span><span class="NLM_article-title">EGF receptor trafficking: consequences for signaling and cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.tcb.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24295852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=26-34&author=A.+Tomasauthor=C.+E.+Futterauthor=E.+R.+Eden&title=EGF+receptor+trafficking%3A+consequences+for+signaling+and+cancer&doi=10.1016%2Fj.tcb.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor trafficking: consequences for signaling and cancer</span></div><div class="casAuthors">Tomas, Alejandra; Futter, Clare E.; Eden, Emily R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the anal. of mol. mechanisms regulating endocytic traffic and the role of that traffic in signal transduction.  Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy.  Here we review recent advances in our understanding of mol. mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting.  The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed.  Finally, we speculate on the relationship between EGFR traffic and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDLWxypVYs-bVg90H21EOLACvtfcHk0lgR0vV-2aigHQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP&md5=850921a0c652f9401704f4152db482a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFutter%26aufirst%3DC.%2BE.%26aulast%3DEden%26aufirst%3DE.%2BR.%26atitle%3DEGF%2520receptor%2520trafficking%253A%2520consequences%2520for%2520signaling%2520and%2520cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.tcb.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okizono, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, H.</span></span> <span> </span><span class="NLM_article-title">Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.811299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.M117.811299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29255092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVCktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=2288-2301&author=T.+Tanakaauthor=Y.+Zhouauthor=T.+Ozawaauthor=R.+Okizonoauthor=A.+Banbaauthor=T.+Yamamuraauthor=E.+Ogaauthor=A.+Muraguchiauthor=H.+Sakurai&title=Ligand-activated+epidermal+growth+factor+receptor+%28EGFR%29+signaling+governs+endocytic+trafficking+of+unliganded+receptor+monomers+by+non-canonical+phosphorylation&doi=10.1074%2Fjbc.M117.811299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation</span></div><div class="casAuthors">Tanaka, Tomohiro; Zhou, Yue; Ozawa, Tatsuhiko; Okizono, Ryuya; Banba, Ayako; Yamamura, Tomohiro; Oga, Eiji; Muraguchi, Atsushi; Sakurai, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2288-2301</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The canonical description of transmembrane receptor function is initial binding of ligand, followed by initiation of intracellular signaling and then internalization en route to degrdn. or recycling to the cell surface.  It is known that low concns. of extracellular ligand lead to a higher proportion of receptor that is recycled and that non-canonical mechanisms of receptor activation, including phosphorylation by the kinase p38, can induce internalization and recycling.  However, no connections have been made between these pathways; i.e. it has yet to be established what happens to unbound receptors following stimulation with ligand.  Here we demonstrate that a minimal level of activation of epidermal growth factor receptor (EGFR) tyrosine kinase by low levels of ligand is sufficient to fully activate downstream mitogen-activated protein kinase (MAPK) pathways, with most of the remaining unbound EGFR mols. being efficiently phosphorylated at intracellular serine/threonine residues by activated mitogen-activated protein kinase.  This non-canonical, p38-mediated phosphorylation of the C-tail of EGFR, near Ser-1015, induces the clathrin-mediated endocytosis of the unliganded EGFR monomers, which occurs slightly later than the canonical endocytosis of ligand-bound EGFR dimers via tyrosine autophosphorylation.  EGFR endocytosis via the non-canonical pathway is largely recycled back to the plasma membrane as functional receptors, whereas p38-independent populations are mainly sorted for lysosomal degrdn.  Moreover, ligand concns. balance these endocytic trafficking pathways.  These results demonstrate that ligand-activated EGFR signaling controls unliganded receptors through feedback phosphorylation, identifying a dual-mode regulation of the endocytic trafficking dynamics of EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUZPggAmsqrVg90H21EOLACvtfcHk0liFzhf8osQ1Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVCktrY%253D&md5=8fdbb32e1e5f14330bd31938c6e1669d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.811299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.811299%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DOkizono%26aufirst%3DR.%26aulast%3DBanba%26aufirst%3DA.%26aulast%3DYamamura%26aufirst%3DT.%26aulast%3DOga%26aufirst%3DE.%26aulast%3DMuraguchi%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DH.%26atitle%3DLigand-activated%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520governs%2520endocytic%2520trafficking%2520of%2520unliganded%2520receptor%2520monomers%2520by%2520non-canonical%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D2288%26epage%3D2301%26doi%3D10.1074%2Fjbc.M117.811299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirisits, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pils, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.biocel.2007.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17855153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWgsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=2173-2182&author=A.+Kirisitsauthor=D.+Pilsauthor=M.+Krainer&title=Epidermal+growth+factor+receptor+degradation%3A+an+alternative+view+of+oncogenic+pathways&doi=10.1016%2Fj.biocel.2007.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor degradation: An alternative view of oncogenic pathways</span></div><div class="casAuthors">Kirisits, Andreas; Pils, Dietmar; Krainer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2173-2182</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Pos. regulation of epidermal growth factor receptor signaling is related to many human malignancies.  Besides overexpression and gain of function mutations, the escape from neg. regulation through an increase in epidermal growth factor receptor stability has evolved as yet another key factor contributing to enhanced receptor activity.  Intensive research over the past years has provided considerable evidence concerning the mol. mechanisms which provide epidermal growth factor receptor degrdn. c-Cbl mediated ubiquitination, endocytosis via clathrin-coated pits, endosomal sorting and lysosomal degrdn. have become well-investigated cornerstones.  Recent findings on the interdependency of the endosomal sorting complexes required for transport in multivesicular body sorting, stress the topicality of receptor tyrosine kinase downregulation.  Here, we review the degrdn. pathway of the epidermal growth factor receptor, following the receptor from ligand binding to the lysosome and illustrating different modes of oncogenic deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmbYOt2CM-7Vg90H21EOLACvtfcHk0liFzhf8osQ1Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWgsL%252FE&md5=217d7eca5e246a18927e5a94ca476897</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DKirisits%26aufirst%3DA.%26aulast%3DPils%26aufirst%3DD.%26aulast%3DKrainer%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520degradation%253A%2520an%2520alternative%2520view%2520of%2520oncogenic%2520pathways%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D2173%26epage%3D2182%26doi%3D10.1016%2Fj.biocel.2007.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0liFzhf8osQ1Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0liFzhf8osQ1Fg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Monitoring conformational changes in the receptor tyrosine kinase EGFR</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1002/cbic.201600115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fcbic.201600115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=26991964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=990-994&author=C.+Beckerauthor=S.+Ocalauthor=H.+D.+Nguyenauthor=T.+Phanauthor=M.+Keulauthor=J.+R.+Simardauthor=D.+Rauh&title=Monitoring+conformational+changes+in+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fcbic.201600115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Becker, Christian; Oecal, Sinan; Nguyen, Hoang D.; Phan, Trang; Keul, Marina; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer.  Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding.  Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity.  We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdR7Fh5FHtLVg90H21EOLACvtfcHk0lhl_DMxQf9xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVGgu74%253D&md5=2380ac96f4e43ce19a95eca1e0d81f46</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201600115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201600115%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DOcal%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%2BD.%26aulast%3DPhan%26aufirst%3DT.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DMonitoring%2520conformational%2520changes%2520in%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D990%26epage%3D994%26doi%3D10.1002%2Fcbic.201600115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckmantel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Proteus in the world of proteins: conformational changes in protein kinases</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+Tuckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+conformational+changes+in+protein+kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0lhl_DMxQf9xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DTuckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhl_DMxQf9xKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2250</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmc.2013.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23490150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2250-2261&author=Y.+Kawakitaauthor=M.+Setoauthor=T.+Ohashiauthor=T.+Tamuraauthor=T.+Yusaauthor=H.+Mikiauthor=H.+Iwataauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=S.+Sogabeauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+pyrimido%5B4%2C5-b%5Dazepine+derivatives+as+HER2%2FEGFR+dual+inhibitors&doi=10.1016%2Fj.bmc.2013.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors</span></div><div class="casAuthors">Kawakita, Youichi; Seto, Masaki; Ohashi, Tomohiro; Tamura, Toshiya; Yusa, Tadashi; Miki, Hiroshi; Iwata, Hidehisa; Kamiguchi, Hidenori; Tanaka, Toshimasa; Sogabe, Satoshi; Ohta, Yoshikazu; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2250-2261</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel 7,6 fused bicyclic scaffold, pyrimido[4,5-b]azepine was designed to fit into the ATP binding site of the HER2/EGFR proteins.  The synthesis of this scaffold was accomplished by an intramol. Claisen-type condensation.  As the results of optimization lead us to 4-anilino and 6-functional groups, we discovered 6-substituted amide deriv. 19b, which has a 1-benzothiophen-4-yloxy group attached to the 4-anilino group.  An x-ray co-crystal structure of 19b with EGFR demonstrated that the N-1 and N-3 nitrogens of the pyrimido[4,5-b]azepine scaffold make hydrogen-bonding interactions with the main chain NH of Met793 and the side chain of Thr854 via a water-mediated hydrogen bond network, resp.  In addn., the NH proton at the 9-position makes an addnl. hydrogen bond with the carbonyl group of Met793, as we expected.  Compd. 19b revealed potent HER2/EGFR kinase (IC50: 24/36 nM) and BT474 cell growth (GI50: 18 nM) inhibitory activities based on its pseudo-irreversible (PI) profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZnx0wBvJ2bVg90H21EOLACvtfcHk0lj7iSlr_YHayA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOjur4%253D&md5=956974cbdbe39b00edb70587ca97af22</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DYusa%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimido%255B4%252C5-b%255Dazepine%2520derivatives%2520as%2520HER2%252FEGFR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2250%26epage%3D2261%26doi%3D10.1016%2Fj.bmc.2013.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span> <span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23273428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0lj7iSlr_YHayA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1167</span>, <span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0lj7iSlr_YHayA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-12-0620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23371856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=220-229&author=M.+E.+Arcilaauthor=K.+Nafaauthor=J.+E.+Chaftauthor=N.+Rekhtmanauthor=C.+Lauauthor=B.+A.+Revaauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=EGFR+exon+20+insertion+mutations+in+lung+adenocarcinomas%3A+prevalence%2C+molecular+heterogeneity%2C+and+clinicopathologic+characteristics&doi=10.1158%2F1535-7163.MCT-12-0620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics</span></div><div class="casAuthors">Arcila, Maria E.; Nafa, Khedoudja; Chaft, Jamie E.; Rekhtman, Natasha; Lau, Christopher; Reva, Boris A.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-229</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally assocd. with resistance to EGFR-tyrosine kinase inhibitors.  Their mol. spectrum, clinicopathol. characteristics, and prevalence are not well established.  Tumors harboring EGFR exon 20 insertions were identified through an algorithmic screen of 1,500 lung adenocarcinomas.  Cases were first tested for common mutations in EGFR (exons 19 and 21) and KRAS (exon 2) and, if neg., further analyzed for EGFR exon 20 insertions.  All samples underwent extended genotyping for other driver mutations in EGFR, KRAS, BRAF, ERBB2/HER2, NRAS, PIK3CA, MEK1, and AKT by mass spectrometry; a subset was evaluated for ALK rearrangements.  We identified 33 EGFR exon 20 insertion cases [2.2%, 95% confidence interval (CI), 1.6-3.1], all mutually exclusive with mutations in the other genes tested (except PIK3CA).  They were more common among never-smokers (P < 0.0001).  There was no assocn. with age, sex, race, or stage.  Morphol., tumors were similar to those with common EGFR mutations but with frequent solid histol.  Insertions were highly variable in position and size, ranging from 3 to 12 bp, resulting in 13 different insertions, which, by mol. modeling, are predicted to have potentially different effects on erlotinib binding.  EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.  Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1GpDUzx3KLVg90H21EOLACvtfcHk0lim4M_m1F2ehA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D&md5=5f9c4df38f65a6948af8572c5dbfd222</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0620%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DReva%26aufirst%3DB.%2BA.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DEGFR%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520adenocarcinomas%253A%2520prevalence%252C%2520molecular%2520heterogeneity%252C%2520and%2520clinicopathologic%2520characteristics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D220%26epage%3D229%26doi%3D10.1158%2F1535-7163.MCT-12-0620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlio, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debieuvre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringuier, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouquette, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraboulet-Moreau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouessel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaylet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlais, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beau-Faller, M.</span></span> <span> </span><span class="NLM_article-title">Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2715</span>– <span class="NLM_lpage">2724</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1093%2Fannonc%2Fmdx404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28945865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FitV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2715-2724&author=C.+Leducauthor=J.+P.+Merlioauthor=B.+Besseauthor=H.+Blonsauthor=D.+Debieuvreauthor=P.+P.+Bringuierauthor=I.+Monnetauthor=I.+Rouquetteauthor=S.+Fraboulet-Moreauauthor=A.+Lemoineauthor=D.+Pouesselauthor=J.+Mosserauthor=F.+Vayletauthor=A.+Langlaisauthor=P.+Missyauthor=F.+Morinauthor=D.+Moro-Sibilotauthor=J.+Cadranelauthor=F.+Barlesiauthor=M.+Beau-Faller&title=Clinical+and+molecular+characteristics+of+non-small-cell+lung+cancer+%28NSCLC%29+harboring+EGFR+mutation%3A+results+of+the+nationwide+French+Cooperative+Thoracic+Intergroup+%28IFCT%29+program&doi=10.1093%2Fannonc%2Fmdx404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</span></div><div class="casAuthors">Leduc C; Merlio J P; Merlio J P; Besse B; Blons H; Blons H; Debieuvre D; Bringuier P P; Bringuier P P; Monnet I; Rouquette I; Fraboulet-Moreau S; Lemoine A; Lemoine A; Pouessel D; Mosser J; Vaylet F; Langlais A; Missy P; Morin F; Moro-Sibilot D; Cadranel J; Cadranel J; Barlesi F; Beau-Faller M; Beau-Faller M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2715-2724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI).  To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database.  Patients and methods:  Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics.  Results were correlated with survival and treatment response for the 848 stage IV patients.  Results:  EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively.  Over 50% of exon 18 and 20 mutated patients were smokers.  The median follow-up was 51.7 months.  EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}.  EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07].  First-line treatment choice did not influence OS in multivariate analysis.  First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001].  OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q.  TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients.  Conclusion:  EGFR mutation type can inform the most appropriate treatment.  Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBxG_Z3jiSUcKL0FlyGHDofW6udTcc2eYembHtLlngi7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FitV2rsw%253D%253D&md5=96f76c23b8d2b0ae5cc743f6fcce53a2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx404%26sid%3Dliteratum%253Aachs%26aulast%3DLeduc%26aufirst%3DC.%26aulast%3DMerlio%26aufirst%3DJ.%2BP.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBlons%26aufirst%3DH.%26aulast%3DDebieuvre%26aufirst%3DD.%26aulast%3DBringuier%26aufirst%3DP.%2BP.%26aulast%3DMonnet%26aufirst%3DI.%26aulast%3DRouquette%26aufirst%3DI.%26aulast%3DFraboulet-Moreau%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DPouessel%26aufirst%3DD.%26aulast%3DMosser%26aufirst%3DJ.%26aulast%3DVaylet%26aufirst%3DF.%26aulast%3DLanglais%26aufirst%3DA.%26aulast%3DMissy%26aufirst%3DP.%26aulast%3DMorin%26aufirst%3DF.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DBeau-Faller%26aufirst%3DM.%26atitle%3DClinical%2520and%2520molecular%2520characteristics%2520of%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520harboring%2520EGFR%2520mutation%253A%2520results%2520of%2520the%2520nationwide%2520French%2520Cooperative%2520Thoracic%2520Intergroup%2520%2528IFCT%2529%2520program%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D2715%26epage%3D2724%26doi%3D10.1093%2Fannonc%2Fmdx404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupfer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ″never smokers″ and are associated with sensitivity of tumors to gefitinib and erlotinib</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">13306</span>– <span class="NLM_lpage">13311</span>, <span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%B3never+smokers%E2%80%B3+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0ljhfPSitDwDMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%25B3never%2520smokers%25E2%2580%25B3%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0ljhfPSitDwDMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Augmented reality in scientific publications-taking the visualization of 3D structures to the next level</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=496-499&author=P.+Wolleauthor=M.+P.+M%C3%BCllerauthor=D.+Rauh&title=Augmented+reality+in+scientific+publications-taking+the+visualization+of+3D+structures+to+the+next+level&doi=10.1021%2Facschembio.8b00153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level</span></div><div class="casAuthors">Wolle, Patrik; Mueller, Matthias P.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">496-499</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The examn. of three-dimensional structural models in scientific publications allows the reader to validate or invalidate conclusions drawn by the authors.  However, either due to a (temporary) lack of access to proper visualization software or a lack of proficiency, this information is not necessarily available to every reader.  As the digital revolution is quickly progressing, technologies have become widely available that overcome the limitations and offer to all the opportunity to appreciate models not only in 2D, but also in 3D.  Addnl., mobile devices such as smartphones and tablets allow access to this information almost anywhere, at any time.  Since access to such information has only recently become std. practice, we want to outline straightforward ways to incorporate 3D models in augmented reality into scientific publications, books, posters, and presentations and suggest that this should become general practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChR9HXFg1QrVg90H21EOLACvtfcHk0ljsPFCtpSEffQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOlu78%253D&md5=43b9e304629aea6e073f00a76e10f928</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00153%26sid%3Dliteratum%253Aachs%26aulast%3DWolle%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DAugmented%2520reality%2520in%2520scientific%2520publications-taking%2520the%2520visualization%2520of%25203D%2520structures%2520to%2520the%2520next%2520level%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D496%26epage%3D499%26doi%3D10.1021%2Facschembio.8b00153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0ljsPFCtpSEffQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ccell.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=26996308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=477-493&author=S.+A.+Fosterauthor=D.+M.+Whalenauthor=A.+Ozenauthor=M.+J.+Wongchenkoauthor=J.+Yinauthor=I.+Yenauthor=G.+Schaeferauthor=J.+D.+Mayfieldauthor=J.+Chmieleckiauthor=P.+J.+Stephensauthor=L.+A.+Albackerauthor=Y.+Yanauthor=K.+Songauthor=G.+Hatzivassiliouauthor=C.+Eigenbrotauthor=C.+Yuauthor=A.+S.+Shawauthor=G.+Manningauthor=N.+J.+Skeltonauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Activation+mechanism+of+oncogenic+deletion+mutations+in+BRAF%2C+EGFR%2C+and+HER2&doi=10.1016%2Fj.ccell.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span></div><div class="casAuthors">Foster, Scott A.; Whalen, Daniel M.; Ozen, Aysegul; Wongchenko, Matthew J.; Yin, Jian Ping; Yen, Ivana; Schaefer, Gabriele; Mayfield, John D.; Chmielecki, Juliann; Stephens, Philip J.; Albacker, Lee A.; Yan, Yibing; Song, Kyung; Hatzivassiliou, Georgia; Eigenbrot, Charles; Yu, Christine; Shaw, Andrey S.; Manning, Gerard; Skelton, Nicholas J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-493</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in protein kinases drive many cancers.  While how recurring point mutations affect kinase activity has been described, the effect of in-frame deletions is not well understood.  We show that oncogenic deletions within the β3-αC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19 deletions.  We identify pancreatic carcinomas with BRAF deletions mutually exclusive with KRAS mutations.  Crystal structures of BRAF deletions reveal the truncated loop restrains αC in an active "in" conformation, imparting resistance to inhibitors like vemurafenib that bind the αC "out" conformation.  Characterization of loop length explains the prevalence of five amino acid deletions in BRAF, EGFR, and HER2 and highlights the importance of this region for kinase activity and inhibitor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObiwE2cwFlbVg90H21EOLACvtfcHk0lhg0iZwQ5H67Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D&md5=7aad1cea6f17f2b74c42fbc3c1c9b0fd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DWhalen%26aufirst%3DD.%2BM.%26aulast%3DOzen%26aufirst%3DA.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMayfield%26aufirst%3DJ.%2BD.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DAlbacker%26aufirst%3DL.%2BA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DManning%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DActivation%2520mechanism%2520of%2520oncogenic%2520deletion%2520mutations%2520in%2520BRAF%252C%2520EGFR%252C%2520and%2520HER2%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D477%26epage%3D493%26doi%3D10.1016%2Fj.ccell.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searleman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activating HER2 mutations in HER2 gene amplification negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-12-0349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23220880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=224-237&author=R.+Boseauthor=S.+M.+Kavuriauthor=A.+C.+Searlemanauthor=W.+Shenauthor=D.+Shenauthor=D.+C.+Koboldtauthor=J.+Monseyauthor=N.+Goelauthor=A.+B.+Aronsonauthor=S.+Liauthor=C.+X.+Maauthor=L.+Dingauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Activating+HER2+mutations+in+HER2+gene+amplification+negative+breast+cancer&doi=10.1158%2F2159-8290.CD-12-0349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer</span></div><div class="casAuthors">Bose, Ron; Kavuri, Shyam M.; Searleman, Adam C.; Shen, Wei; Shen, Dong; Koboldt, Daniel C.; Monsey, John; Goel, Nicholas; Aronson, Adam B.; Li, Shunqiang; Ma, Cynthia X.; Ding, Li; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-237</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification.  To det. the phenotype of these mutations, we functionally characterized 13 HER2 mutations using in vitro kinase assays, protein structure anal., cell culture, and xenograft expts.  Seven of these mutations are activating mutations, including G309A, D769H, D769Y, V777L, P780ins, V842I, and R896C. HER2 in-frame deletion 755-759, which is homologous to EGF receptor (EGFR) exon 19 in-frame deletions, had a neomorphic phenotype with increased phosphorylation of EGFR or HER3.  L755S produced lapatinib resistance, but was not an activating mutation in our exptl. systems.  All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.  These findings show that HER2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer and they validate HER2 somatic mutations as drug targets for breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpInHiFiSDrrVg90H21EOLACvtfcHk0ljB_Ti-nyR-PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrg%253D&md5=4b271e961ad4a68862e4a3ba80e88972</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0349%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%26aulast%3DKavuri%26aufirst%3DS.%2BM.%26aulast%3DSearleman%26aufirst%3DA.%2BC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DMonsey%26aufirst%3DJ.%26aulast%3DGoel%26aufirst%3DN.%26aulast%3DAronson%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivating%2520HER2%2520mutations%2520in%2520HER2%2520gene%2520amplification%2520negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D224%26epage%3D237%26doi%3D10.1158%2F2159-8290.CD-12-0349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">860</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2012.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22579287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=860-780&author=Y.+Shanauthor=M.+P.+Eastwoodauthor=X.+Zhangauthor=E.+T.+Kimauthor=A.+Arkhipovauthor=R.+O.+Drorauthor=J.+Jumperauthor=J.+Kuriyanauthor=D.+E.+Shaw&title=Oncogenic+mutations+counteract+intrinsic+disorder+in+the+EGFR+kinase+and+promote+receptor+dimerization&doi=10.1016%2Fj.cell.2012.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span></div><div class="casAuthors">Shan, Yibing; Eastwood, Michael P.; Zhang, Xuewu; Kim, Eric T.; Arkhipov, Anton; Dror, Ron O.; Jumper, John; Kuriyan, John; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">860-870</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mutation and overexpression of the epidermal growth factor receptor (EGFR) are assocd. with the development of a variety of cancers, making this prototypical dimerization-activated receptor tyrosine kinase a prominent target of cancer drugs.  Using long-timescale mol. dynamics simulations, we find that the N lobe dimerization interface of the wild-type EGFR kinase domain is intrinsically disordered and that it becomes ordered only upon dimerization.  Our simulations suggest, moreover, that some cancer-linked mutations distal to the dimerization interface, particularly the widespread L834R mutation (also referred to as L858R), facilitate EGFR dimerization by suppressing this local disorder.  Corroborating these findings, our biophys. expts. and kinase enzymic assays indicate that the L834R mutation causes abnormally high activity primarily by promoting EGFR dimerization rather than by allowing activation without dimerization.  We also find that phosphorylation of EGFR kinase domain at Tyr845 may suppress the intrinsic disorder, suggesting a mol. mechanism for autonomous EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhEY912uUTrVg90H21EOLACvtfcHk0ljB_Ti-nyR-PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D&md5=8ab973e5a5626ac495d176322f30d2b7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJumper%26aufirst%3DJ.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DOncogenic%2520mutations%2520counteract%2520intrinsic%2520disorder%2520in%2520the%2520EGFR%2520kinase%2520and%2520promote%2520receptor%2520dimerization%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D860%26epage%3D780%26doi%3D10.1016%2Fj.cell.2012.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimsoeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priesner, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4655</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fs41467-018-07078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30405134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4655&author=J.+Fassunkeauthor=F.+M%C3%BCllerauthor=M.+Keulauthor=S.+Michelsauthor=M.+A.+Dammertauthor=A.+Schmittauthor=D.+Plenkerauthor=J.+Lategahnauthor=C.+Heydtauthor=J.+Bragelmannauthor=H.+L.+Tumbrinkauthor=Y.+Alberauthor=S.+Kleinauthor=A.+Heimsoethauthor=I.+Dahmenauthor=R.+N.+Fischerauthor=M.+Schefflerauthor=M.+A.+Ihleauthor=V.+Priesnerauthor=A.+H.+Scheelauthor=S.+Wagenerauthor=A.+Kronauthor=K.+Frankauthor=K.+Garbertauthor=T.+Persigehlauthor=M.+Puskenauthor=S.+Hanederauthor=B.+Schaafauthor=E.+Rodermannauthor=W.+Engel-Riedelauthor=E.+Felipauthor=E.+F.+Smitauthor=S.+Merkelbach-Bruseauthor=H.+C.+Reinhardtauthor=S.+M.+Kastauthor=J.+Wolfauthor=D.+Rauhauthor=R.+Buttnerauthor=M.+L.+Sos&title=Overcoming+EGFR%28G724S%29-mediated+osimertinib+resistance+through+unique+binding+characteristics+of+second-generation+EGFR+inhibitors&doi=10.1038%2Fs41467-018-07078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span></div><div class="casAuthors">Fassunke Jana; Heydt Carina; Klein Sebastian; Ihle Michaela A; Scheel Andreas H; Wagener Svenja; Merkelbach-Bruse Sabine; Buttner Reinhard; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Garbert Katia; Sos Martin L; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Dahmen Ilona; Garbert Katia; Buttner Reinhard; Sos Martin L; Keul Marina; Lategahn Jonas; Alber Yannic; Kast Stefan M; Rauh Daniel; Michels Sebastian; Fischer Rieke N; Scheffler Matthias; Priesner Vanessa; Kron Anna; Wolf Jurgen; Buttner Reinhard; Schmitt Anna; Reinhardt H Christian; Sos Martin L; Schmitt Anna; Reinhardt H Christian; Schmitt Anna; Reinhardt H Christian; Klein Sebastian; Frank Konrad; Persigehl Thorsten; Pusken Michael; Haneder Stefan; Schaaf Bernhard; Rodermann Ernst; Engel-Riedel Walburga; Felip Enriqueta; Smit Egbert F</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients.  In a subgroup of these patients we identified an association between selection of EGFR(T790M)-negative but EGFR(G724S)-positive subclones and osimertinib resistance.  We demonstrate that EGFR(G724S) limits the activity of third-generation EGFR inhibitors both in vitro and in vivo.  Structural analyses and computational modeling indicate that EGFR(G724S) mutations may induce a conformation of the glycine-rich loop, which is incompatible with the binding of third-generation TKIs.  Systematic inhibitor screening and in-depth kinetic profiling validate these findings and show that second-generation EGFR inhibitors retain kinase affinity and overcome EGFR(G724S)-mediated resistance.  In the case of afatinib this profile translates into a robust reduction of colony formation and tumor growth of EGFR(G724S)-driven cells.  Our data provide a mechanistic basis for the osimertinib-induced selection of EGFR(G724S)-mutant clones and a rationale to treat these patients with clinically approved second-generation EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbrRUzliurTsve_zCu79I8fW6udTcc2ealYBxbPrNCDrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D&md5=a09a4c84fb50fd456dcab005d2d9366a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07078-0%26sid%3Dliteratum%253Aachs%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DF.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBragelmann%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DAlber%26aufirst%3DY.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DHeimsoeth%26aufirst%3DA.%26aulast%3DDahmen%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DR.%2BN.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPriesner%26aufirst%3DV.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DWagener%26aufirst%3DS.%26aulast%3DKron%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DGarbert%26aufirst%3DK.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DPusken%26aufirst%3DM.%26aulast%3DHaneder%26aufirst%3DS.%26aulast%3DSchaaf%26aufirst%3DB.%26aulast%3DRodermann%26aufirst%3DE.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DButtner%26aufirst%3DR.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DOvercoming%2520EGFR%2528G724S%2529-mediated%2520osimertinib%2520resistance%2520through%2520unique%2520binding%2520characteristics%2520of%2520second-generation%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4655%26doi%3D10.1038%2Fs41467-018-07078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lgNlNAeNz72mg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sng, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena-Araujo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">216ra177</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3007205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscitranslmed.3007205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24353160" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=216ra177&author=H.+Yasudaauthor=E.+Parkauthor=C.+H.+Yunauthor=N.+J.+Sngauthor=A.+R.+Lucena-Araujoauthor=W.+L.+Yeoauthor=M.+S.+Hubermanauthor=D.+W.+Cohenauthor=S.+Nakayamaauthor=K.+Ishiokaauthor=N.+Yamaguchiauthor=M.+Hannaauthor=G.+R.+Oxnardauthor=C.+S.+Lathanauthor=T.+Moranauthor=L.+V.+Sequistauthor=J.+E.+Chaftauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=R.+A.+Sooauthor=M.+Meyersonauthor=M.+J.+Eckauthor=S.+S.+Kobayashiauthor=D.+B.+Costa&title=Structural%2C+biochemical%2C+and+clinical+characterization+of+epidermal+growth+factor+receptor+%28EGFR%29+exon+20+insertion+mutations+in+lung+cancer&doi=10.1126%2Fscitranslmed.3007205"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3007205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3007205%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DSng%26aufirst%3DN.%2BJ.%26aulast%3DLucena-Araujo%26aufirst%3DA.%2BR.%26aulast%3DYeo%26aufirst%3DW.%2BL.%26aulast%3DHuberman%26aufirst%3DM.%2BS.%26aulast%3DCohen%26aufirst%3DD.%2BW.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DIshioka%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DLathan%26aufirst%3DC.%2BS.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520clinical%2520characterization%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D216ra177%26doi%3D10.1126%2Fscitranslmed.3007205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repellin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2712</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-16-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28363995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Skt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2712-2721&author=T.+Kosakaauthor=J.+Tanizakiauthor=R.+M.+Paranalauthor=H.+Endohauthor=C.+Lydonauthor=M.+Capellettiauthor=C.+E.+Repellinauthor=J.+Choiauthor=A.+Oginoauthor=A.+Callesauthor=D.+Ercanauthor=A.+J.+Redigauthor=M.+Bahcallauthor=G.+R.+Oxnardauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=Response+heterogeneity+of+EGFR+and+HER2+exon+20+insertions+to+covalent+EGFR+and+HER2+inhibitors&doi=10.1158%2F0008-5472.CAN-16-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors</span></div><div class="casAuthors">Kosaka, Takayuki; Tanizaki, Junko; Paranal, Raymond M.; Endoh, Hideki; Lydon, Christine; Capelletti, Marzia; Repellin, Claire E.; Choi, Jihyun; Ogino, Atsuko; Calles, Antonio; Ercan, Dalia; Redig, Amanda J.; Bahcall, Magda; Oxnard, Geoffrey R.; Eck, Michael J.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2712-2721</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20.  Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clin. responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, resp.  In this study, we investigated the effects of specific EGFR and HER2 exon 20 insertion mutations from NSCLC patients that had clin. achieved a partial response after dacomitinib treatment.  We identified Gly770 as a common feature among the drug-sensitive mutations.  Structural modeling suggested that this mutation may facilitate inhibitor binding to EGFR.  Introduction of Gly770 into two dacomitinib-resistant EGFR exon 20 insertion mutants restored sensitivity to dacomitinib.  Based on these findings, we used afatinib to treat an NSCLC patient whose tumor harbored the HER2 V777_G778insGSP mutation and achieved a durable partial response.  We further identified secondary mutations in EGFR (T790M or C797S) and HER2 (C805S) that mediated acquired drug resistance in drug-sensitive EGFR or HER2 exon 20 insertion models.  Overall, our findings identified a subset of EGFR and HER2 exon 20 insertion mutations that are sensitive to existing covalent quinazoline-based EGFR/HER2 inhibitors, with implications for current clin. treatment and next-generation small-mol. inhibitors.  Cancer Res; 77(10); 2712-21. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon3qnueNbKabVg90H21EOLACvtfcHk0liCHvyxJq6gGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Skt74%253D&md5=fec24919ffcaef20ab9046f93727e81d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3404%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DLydon%26aufirst%3DC.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRepellin%26aufirst%3DC.%2BE.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DCalles%26aufirst%3DA.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DResponse%2520heterogeneity%2520of%2520EGFR%2520and%2520HER2%2520exon%252020%2520insertions%2520to%2520covalent%2520EGFR%2520and%2520HER2%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D2712%26epage%3D2721%26doi%3D10.1158%2F0008-5472.CAN-16-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trumpp-Kallmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span> <span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">12022</span>– <span class="NLM_lpage">12027</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0liCHvyxJq6gGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poteete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fs41591-018-0007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29686424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=638-646&author=J.+P.+Robichauxauthor=Y.+Y.+Elaminauthor=Z.+Tanauthor=B.+W.+Carterauthor=S.+Zhangauthor=S.+Liuauthor=S.+Liauthor=T.+Chenauthor=A.+Poteeteauthor=A.+Estrada-Bernalauthor=A.+T.+Leauthor=A.+Truiniauthor=M.+B.+Nilssonauthor=H.+Sunauthor=E.+Roartyauthor=S.+B.+Goldbergauthor=J.+R.+Brahmerauthor=M.+Altanauthor=C.+Luauthor=V.+Papadimitrakopoulouauthor=K.+Politiauthor=R.+C.+Doebeleauthor=K.+K.+Wongauthor=J.+V.+Heymach&title=Mechanisms+and+clinical+activity+of+an+EGFR+and+HER2+exon+20-selective+kinase+inhibitor+in+non-small+cell+lung+cancer&doi=10.1038%2Fs41591-018-0007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span></div><div class="casAuthors">Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie R.; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok-Kin; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">638-646</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy.  We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors.  We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants.  Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC.  In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%.  These data identify poziotinib as a potent, clin. active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the mol. features of TKIs that may circumvent steric changes induced by these mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6UyVpv0h47Vg90H21EOLACvtfcHk0lgc_TwQUlCf7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D&md5=316a0a0765ebc9eec9b6460d27b28bb5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaux%26aufirst%3DJ.%2BP.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DCarter%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPoteete%26aufirst%3DA.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTruini%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DMechanisms%2520and%2520clinical%2520activity%2520of%2520an%2520EGFR%2520and%2520HER2%2520exon%252020-selective%2520kinase%2520inhibitor%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D638%26epage%3D646%26doi%3D10.1038%2Fs41591-018-0007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betsuyaku, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-17-1033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29467275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1ejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=740-750&author=T.+Hiranoauthor=H.+Yasudaauthor=J.+Hamamotoauthor=S.+Nukagaauthor=K.+Masuzawaauthor=I.+Kawadaauthor=K.+Naokiauthor=T.+Niimiauthor=S.+Mimasuauthor=H.+Sakagamiauthor=K.+Soejimaauthor=T.+Betsuyaku&title=Pharmacological+and+structural+characterizations+of+naquotinib%2C+a+novel+third-generation+EGFR+tyrosine+kinase+inhibitor%2C+in+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1158%2F1535-7163.MCT-17-1033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hirano, Toshiyuki; Yasuda, Hiroyuki; Hamamoto, Junko; Nukaga, Shigenari; Masuzawa, Keita; Kawada, Ichiro; Naoki, Katsuhiko; Niimi, Tatsuya; Mimasu, Shinya; Sakagami, Hideki; Soejima, Kenzo; Betsuyaku, Tomoko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-750</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non-small cell lung cancer (NSCLC).  In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clin. relevant EGFR mutations, including L858R, exon 19 deletion, L858R+T790M, exon 19 deletion+T790M with or without a C797S mutation, and several exon 20 insertion mutations.  Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations.  The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletion+T790M was comparable with that of osimertinib.  Interestingly, naquotinib was more potent than osimertinib for L858R+T790M.  Addnl., naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions.  Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH.  In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations.  Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biol. of EGFR exon 20 insertion mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM7fXCcishlLVg90H21EOLACvtfcHk0lgc_TwQUlCf7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1ejt7o%253D&md5=a654bd8355c631ecf63ecb51c13b8ac2</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1033%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DHamamoto%26aufirst%3DJ.%26aulast%3DNukaga%26aufirst%3DS.%26aulast%3DMasuzawa%26aufirst%3DK.%26aulast%3DKawada%26aufirst%3DI.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DMimasu%26aufirst%3DS.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DSoejima%26aufirst%3DK.%26aulast%3DBetsuyaku%26aufirst%3DT.%26atitle%3DPharmacological%2520and%2520structural%2520characterizations%2520of%2520naquotinib%252C%2520a%2520novel%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D740%26epage%3D750%26doi%3D10.1158%2F1535-7163.MCT-17-1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirokawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span> <span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">18756</span>– <span class="NLM_lpage">18765</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.206193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.M110.206193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=21454582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+C.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein&doi=10.1074%2Fjbc.M110.206193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein</span></div><div class="casAuthors">Aertgeerts, Kathleen; Skene, Robert; Yano, Jason; Sang, Bi-Ching; Zou, Hua; Snell, Gyorgy; Jennings, Andy; Iwamoto, Keiji; Habuka, Noriyuki; Hirokawa, Aki; Ishikawa, Tomoyasu; Tanaka, Toshimasa; Miki, Hiroshi; Ohta, Yoshikazu; Sogabe, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18756-18765</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis.  Small mol. kinase inhibitors of EGFR and of both HER2 and EGFR have received approval for the treatment of cancer.  We present the first high resoln. crystal structure of the kinase domain of HER2 in complex with a selective inhibitor to understand protein activation, inhibition, and function at the mol. level.  HER2 kinase domain crystallizes as a dimer and suggests evidence for an allosteric mechanism of activation comparable with previously reported activation mechanisms for EGFR and HER4.  A unique Gly-rich region in HER2 following the α-helix C is responsible for increased conformational flexibility within the active site and could explain the low intrinsic catalytic activity previously reported for HER2.  In addn., we solved the crystal structure of the kinase domain of EGFR in complex with a HER2/EGFR dual inhibitor (TAK-285).  Comparison with previously reported inactive and active EGFR kinase domain structures gave insight into the mechanism of HER2 and EGFR inhibition and may help guide the design and development of new cancer drugs with improved potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtAlJ0FGUX7Vg90H21EOLACvtfcHk0lgF0JfdFSo3KA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D&md5=c7897f5363d6452f7b60a8ced0f2bc30</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206193%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765%26doi%3D10.1074%2Fjbc.M110.206193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oorui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8030</span>– <span class="NLM_lpage">8050</span>, <span class="refDoi"> DOI: 10.1021/jm2008634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold&doi=10.1021%2Fjm2008634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0liI6LRd76rpHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050%26doi%3D10.1021%2Fjm2008634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsigelny, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">16946</span>– <span class="NLM_lpage">16954</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.27.16946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.272.27.16946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9202006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXksVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=16946-16954&author=W.+Hemmerauthor=M.+McGloneauthor=I.+Tsigelnyauthor=S.+S.+Taylor&title=Role+of+the+glycine+triad+in+the+ATP-binding+site+of+cAMP-dependent+protein+kinase&doi=10.1074%2Fjbc.272.27.16946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase</span></div><div class="casAuthors">Hemmer, Wolfram; McGlones, Maria; Tsigelny, Igor; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">16946-16954</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A Gly-rich loop in the ATP-binding site is one of the most highly conserved sequence motifs in protein kinases.  Each conserved Gly residue (Gly-50, Gly-52, and Gly-55) in the catalytic (C) subunit of cAMP-dependent protein kinase (protein kinase A; PKA) was replaced with Ser and/or Ala.  Active mutant proteins were expressed in Escherichia coli, purified to apparent homogeneity, sepd. into phosphoisoforms, and characterized.  Replacing Gly-55 had minimal effects on steady-state kinetic parameters, whereas replacement of either Gly-50 or Gly-52 had major effects on both Km and kcat values consistent with the prediction of the importance of the tip of the Gly-rich loop for catalysis.  Substitution of Gly-50 caused a 5-8 fold redn. in Km(ATP), an 8-12-fold increase in Km(peptide), and a 3-5-fold drop in the kcat.  The Km(ATP) and Km(peptide) values of the C(G52S) were increased 8- and 18-fold, resp., and the kcat was decreased 6-fold.  In contrast to catalytic efficiency, the ATPase rates of C(G50S) and C(G52S) were increased by more than an order of magnitude.  The thermostability of each mutant was slightly increased.  Unphosphorylated C(G52S) was characterized as well as several isoforms phosphorylated at a single site, Ser-338.  All of these phosphorylation-defective mutants displayed a substantial decrease in both enzymic activity and thermal stability that correlated with the missing phosphate at Thr-197.  These results were correlated with the crystal structure, models of the resp. mutant proteins, and conservation of the Gly residues within the protein kinase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNlWdiG-3RhrVg90H21EOLACvtfcHk0liI6LRd76rpHg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVemtr4%253D&md5=c443c26a926a5ccbfef213947186423d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.27.16946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.27.16946%26sid%3Dliteratum%253Aachs%26aulast%3DHemmer%26aufirst%3DW.%26aulast%3DMcGlone%26aufirst%3DM.%26aulast%3DTsigelny%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DRole%2520of%2520the%2520glycine%2520triad%2520in%2520the%2520ATP-binding%2520site%2520of%2520cAMP-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D16946%26epage%3D16954%26doi%3D10.1074%2Fjbc.272.27.16946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">4152</span>– <span class="NLM_lpage">4160</span>, <span class="refDoi"> DOI: 10.1021/ja908083e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja908083e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislKit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=4152-4160&author=J.+R.+Simardauthor=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=R.+Schneiderauthor=S.+Wulfertauthor=D.+Rauh&title=Fluorophore+labeling+of+the+glycine-rich+loop+as+a+method+of+identifying+inhibitors+that+bind+to+active+and+inactive+kinase+conformations&doi=10.1021%2Fja908083e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations</span></div><div class="casAuthors">Simard, Jeffrey R.; Getlik, Matthaeus; Gruetter, Christian; Schneider, Ralf; Wulfert, Sabine; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4152-4160</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein kinases with small org. mols. is a promising strategy to regulate unwanted kinase activity in both chem. biol. and medicinal chem. research.  Traditionally, kinase inhibitors are identified in activity-based screening assays using enzymically active kinase prepns. to measure the perturbation of substrate phosphorylation, often resulting in the enrichment of classical ATP competitive (Type I) inhibitors.  However, addressing enzymically incompetent kinase conformations offers new opportunities for targeted therapies and is moving to the forefront of kinase inhibitor research.  Here we report the development of a new FLiK (Fluorescent Labels in Kinases) binding assay to detect small mols. that induce changes in the conformation of the glycine-rich loop.  Due to cross-talk between the glycine-rich loop and the activation loop in kinases, this alternative labeling approach can also detect ligands that stabilize inactive kinase conformations, including slow-binding Type II and Type III kinase inhibitors.  Protein x-ray crystallog. validated the assay results and identified a novel DFG-out binding mode for a quinazoline-based inhibitor in p38α kinase.  We also detected the high-affinity binding of a clin. relevant and specific VEGFR2 inhibitor, and we provide structural details of its binding mode in p38α, in which it stabilizes the DFG-out conformation.  Last, we demonstrate the power of this new FLiK labeling strategy to detect the binding of Type I ligands that induce conformational changes in the glycine-rich loop as a means of gaining affinity for the target kinase.  This approach may be a useful alternative to develop direct binding assays for kinases that do not adopt the DFG-out conformation while also avoiding the use of expensive kits, detection reagents, or radioactivity frequently employed with activity-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNWnX2gIfS7Vg90H21EOLACvtfcHk0ljrSPAhSJUOWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislKit7c%253D&md5=ec40d16fa19b59beeb10ebbae6f4aaf1</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fja908083e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja908083e%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DWulfert%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DFluorophore%2520labeling%2520of%2520the%2520glycine-rich%2520loop%2520as%2520a%2520method%2520of%2520identifying%2520inhibitors%2520that%2520bind%2520to%2520active%2520and%2520inactive%2520kinase%2520conformations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D4152%26epage%3D4160%26doi%3D10.1021%2Fja908083e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">8968</span>– <span class="NLM_lpage">8974</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-1829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-05-1829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16204070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8968-8974&author=J.+Jiangauthor=H.+Greulichauthor=P.+A.+J%C3%A4nneauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=J.+D.+Griffin&title=Epidermal+growth+factor-independent+transformation+of+Ba%2FF3+cells+with+cancer-derived+epidermal+growth+factor+receptor+mutants+induces+gefitinib-sensitive+cell+cycle+progression&doi=10.1158%2F0008-5472.CAN-05-1829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces Gefitinib-sensitive cell cycle progression</span></div><div class="casAuthors">Jiang, Jingrui; Greulich, Heidi; Jaenne, Pasi A.; Sellers, William R.; Meyerson, Matthew; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8968-8974</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) plays crit. roles in many biol. processes and in tumorigenesis.  Here, we show that two mutated EGFRs found in lung and other malignancies, EGFR-G719S and EGFR-L858R, could transform Ba/F3 cells to interleukin-3 (IL-3)-independent growth, in a ligand-independent manner, an activity assocd. with the transforming function of other mutated tyrosine kinases.  The mutated receptors are autophosphorylated in the absence of IL-3 without EGF stimulation, and their expression led to the constitutive activation of signal transducers and activators of transcription 5, extracellular signal-regulated kinase 1/2 (ERK1/2), ERK5, and Akt.  In wild-type EGFR-expressing Ba/F3 cells, the major EGF-mediated signaling pathways were still intact.  Gefitinib inhibited the growth of mutant EGFR-transformed Ba/F3 cells.  Strikingly, the gefitinib sensitivity of cells expressing the L858R mutant was significantly greater than that of cells expressing the G719S mutant form, suggesting that distinct EGFR mutations may be differentially sensitive to small-mol. inhibitors.  Furthermore, our data showed an antiproliferative effect of gefitinib on the EGFR-transformed Ba/F3 cells.  Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacol. EGFR inhibition on the distinct mutant forms of this tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpgPE3k7sNbVg90H21EOLACvtfcHk0ljrSPAhSJUOWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rO&md5=d0f02ce379ff724245967f833e39507f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1829%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DEpidermal%2520growth%2520factor-independent%2520transformation%2520of%2520Ba%252FF3%2520cells%2520with%2520cancer-derived%2520epidermal%2520growth%2520factor%2520receptor%2520mutants%2520induces%2520gefitinib-sensitive%2520cell%2520cycle%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8968%26epage%3D8974%26doi%3D10.1158%2F0008-5472.CAN-05-1829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ejca.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16364841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer+-+search+and+destroy&doi=10.1016%2Fj.ejca.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy</span></div><div class="casAuthors">Chan, S. K.; Gullick, W. J.; Hill, M. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small mol. drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer.  However, it is now apparent that only a subset of patients responds to such treatment.  Two publications in early 2004 reported the presence of activating mutations in the EGFR tyrosine kinase gene conferring exquisite sensitivity to these drugs.  Several publications have since reported prospective data consistent with this finding.  This brief review summarizes the mutation data from 15 such studies in terms of mutation frequency by clinicopathol. features and correlation with response to tyrosine kinase inhibition.  A new paradigm for the routine detection of such mutations is needed to facilitate patient selection for treatment and further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2iKbYyg0gqbVg90H21EOLACvtfcHk0lgyz03xwgUlJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL&md5=01e38085f3beed6636d5e3979d4b9c5a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%2520-%2520search%2520and%2520destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shigematsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A. F.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1002/ijc.21496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fijc.21496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16231326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD2Mngs1Ojug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=257-262&author=H.+Shigematsuauthor=A.+F.+Gazdar&title=Somatic+mutations+of+epidermal+growth+factor+receptor+signaling+pathway+in+lung+cancers&doi=10.1002%2Fijc.21496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers</span></div><div class="casAuthors">Shigematsu Hisayuki; Gazdar Adi F</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-62</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers have generated enormous interest, because they predict for sensitivity to TK inhibitors (TKIs).  While mutational status is of great importance in determining response to TKIs, it is not the sole factor, and evidence is accumulating that EGFR gene amplification, other members of the EGFR family (HER2, HER3) and genes downstream of EGFR signaling (KRAS, BRAF), may be involved in cancer pathogenesis and the response of TKIs.  EGFR mutations occur in highly selected subpopulations of lung cancer patients: adenocarcinoma histology, never-smoker status, East Asian ethnicity and female gender.  The recent finding of "a resistance associated" mutation for TKIs also provides new insights into this complicated mechanism.  Thus, molecular-based studies to analyze the biological functions and to assess TKI sensitivity depending on the type of mutations are required.  Epidemiological studies to identify possible carcinogenic factor(s) affecting different subpopulations are also of interest.  In addition, for optimal therapeutic approach a comprehensive understanding of the genes related to EGFR signaling pathway, including RAS/RAF/MAPK and PI3K-AKT pathways, are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSKJs50Ui3ehWfpMXQLRstfW6udTcc2ebD4WY2ty8V1Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mngs1Ojug%253D%253D&md5=14c1c3ef842ca5817275870c9667ec10</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fijc.21496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21496%26sid%3Dliteratum%253Aachs%26aulast%3DShigematsu%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DSomatic%2520mutations%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%2520pathway%2520in%2520lung%2520cancers%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D257%26epage%3D262%26doi%3D10.1002%2Fijc.21496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukimoto-Niino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terazawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fonc.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22349823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFKl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=27-38&author=S.+Yoshikawaauthor=M.+Kukimoto-Niinoauthor=L.+Parkerauthor=N.+Handaauthor=T.+Teradaauthor=T.+Fujimotoauthor=Y.+Terazawaauthor=M.+Wakiyamaauthor=M.+Satoauthor=S.+Sanoauthor=T.+Kobayashiauthor=T.+Tanakaauthor=L.+Chenauthor=Z.+J.+Liuauthor=B.+C.+Wangauthor=M.+Shirouzuauthor=S.+Kawaauthor=K.+Sembaauthor=T.+Yamamotoauthor=S.+Yokoyama&title=Structural+basis+for+the+altered+drug+sensitivities+of+non-small+cell+lung+cancer-associated+mutants+of+human+epidermal+growth+factor+receptor&doi=10.1038%2Fonc.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span></div><div class="casAuthors">Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z.-J.; Wang, B.-C.; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain.  The non-small cell lung cancer (NSCLC)-assocd. EGFR mutants, L858R and G719S, are constitutively active and oncogenic.  They display sensitivity to TK inhibitors, including gefitinib and erlotinib.  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants.  In this study, our biochem. analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant.  The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity.  The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant.  Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation.  The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.  In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop.  Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.  Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-assocd. EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr7hEqvdS5i7Vg90H21EOLACvtfcHk0lh-ELejCYfc-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFKl&md5=f9b29aac7bcb52cc0605f157f7f14809</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DL.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DTerazawa%26aufirst%3DY.%26aulast%3DWakiyama%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSano%26aufirst%3DS.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26aulast%3DWang%26aufirst%3DB.%2BC.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKawa%26aufirst%3DS.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520for%2520the%2520altered%2520drug%2520sensitivities%2520of%2520non-small%2520cell%2520lung%2520cancer-associated%2520mutants%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D27%26epage%3D38%26doi%3D10.1038%2Fonc.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0lh-ELejCYfc-A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2018.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29571986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktlyrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=1-5&author=Y.+Liuauthor=Y.+Liauthor=Q.+Ouauthor=X.+Wuauthor=X.+Wangauthor=Y.+W.+Shaoauthor=J.+Ying&title=Acquired+EGFR+L718V+mutation+mediates+resistance+to+osimertinib+in+non-small+cell+lung+cancer+but+retains+sensitivity+to+afatinib&doi=10.1016%2Fj.lungcan.2018.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib</span></div><div class="casAuthors">Liu Yutao; Li Yan; Ou Qiuxiang; Wu Xue; Wang Xiaonan; Shao Yang W; Ying Jianming</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) patients.  However, acquired resistance inevitably develops.  Comprehensive and dynamic companion genomic diagnosis can gain insights into underlying resistance mechanisms, thereby help oncologists and patients to make informed decision on the potential benefit of the treatment.  MATERIALS AND METHODS:  A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery.  The EGFR mutational status of individual metastatic lesion was determined by genetic testing of the tumor tissue biopsies using next generation sequencing (NGS) throughout the patient's clinical course.  An acquired potentially drug-resistant EGFR mutation was functionally validated in vitro and its sensitivity to different EGFR TKIs was assessed simultaneously.  RESULTS:  We have identified distinct resistance mechanisms to EGFR blockade in different metastatic lung lesions.  Acquired EGFR T790M was first detected that leads to the resistance to the gefitinib treatment.  Consequently, osimertinib was administrated and the response lasted until disease progressed.  We identified a newly acquired EGFR L718V mutation in one lesion in conjunction with L858R, but not T790M, which showed stable disease on the following erlotinib treatment, while EGFR C797S together with L858R/T790M was detected in the other lesion that continuously progressed.  In vitro functional studies demonstrated that EGFR-L858R/L718V confers resistance to osimertinib, but retains sensitivity to the second generation TKI afatinib.  CONCLUSION:  We reported that distinct resistance mechanisms could arise in different metastases within the same patient in response to EGFR blockade.  We also demonstrated in vitro that EGFR L718V mutation mediates resistance to osimertinib, but retains sensitivity to afatinib.  We evidenced that dynamic companion genomic diagnosis offers valuable information to help define the mechanisms of drug resistance and to guide the selection of subsequent treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgt4Gd6-WlAL5XHngOXiV_fW6udTcc2ea6Rq2WCGNfSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktlyrtQ%253D%253D&md5=d4501279f5b5faa7d8a099e608e17e47</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DYing%26aufirst%3DJ.%26atitle%3DAcquired%2520EGFR%2520L718V%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520but%2520retains%2520sensitivity%2520to%2520afatinib%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D1%26epage%3D5%26doi%3D10.1016%2Fj.lungcan.2018.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural insights into drug development strategy targeting EGFR T790M/C797S</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">13652</span>– <span class="NLM_lpage">13665</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.18632%2Foncotarget.24113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29568384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=13652-13665&author=S.+J.+Zhuauthor=P.+Zhaoauthor=J.+Yangauthor=R.+Maauthor=X.+E.+Yanauthor=S.+Y.+Yangauthor=J.+W.+Yangauthor=C.+H.+Yun&title=Structural+insights+into+drug+development+strategy+targeting+EGFR+T790M%2FC797S&doi=10.18632%2Foncotarget.24113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into drug development strategy targeting EGFR T790M/C797S</span></div><div class="casAuthors">Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Yang Jiao; Yang Sheng-Yong; Yang Jing-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">13652-13665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.  Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation.  New agents effectively inhibiting EGFR T790M without covalent linkage through Cys 797 may solve this problem.  We presented here crystal structures of EGFR activating/drug-resistant mutants in complex with a panel of reversible inhibitors along with mutagenesis and enzyme kinetic data.  These data revealed a previously un-described hydrophobic clamp structure in the EGFR kinase which may be exploited to facilitate development of next generation drugs targeting EGFR T790M with or without concomitant C797S.  Interestingly, mutations in the hydrophobic clamp that hinder drug binding often also weaken ATP binding and/or abolish kinase activity, thus do not readily result in resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRatiF0vPAX33ELvajU9pjPfW6udTcc2ea6Rq2WCGNfSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D&md5=7502a50efce99f712a54003680a95bde</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24113%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520insights%2520into%2520drug%2520development%2520strategy%2520targeting%2520EGFR%2520T790M%252FC797S%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D13652%26epage%3D13665%26doi%3D10.18632%2Foncotarget.24113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oztan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span> <span> </span><span class="NLM_article-title">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28838405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2017&pages=84-87&author=A.+Oztanauthor=S.+Fischerauthor=A.+B.+Schrockauthor=R.+L.+Erlichauthor=C.+M.+Lovlyauthor=P.+J.+Stephensauthor=J.+S.+Rossauthor=V.+Millerauthor=S.+M.+Aliauthor=S.+I.+Ouauthor=L.+E.+Raez&title=Emergence+of+EGFR+G724S+mutation+in+EGFR-mutant+lung+adenocarcinoma+post+progression+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span></div><div class="casAuthors">Oztan A; Fischer S; Schrock A B; Erlich R L; Stephens P J; Ross J S; Miller V; Ali S M; Lovly C M; Ou S-H I; Raez L E</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers.  Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined.  The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment.  This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsycCvNkMcjjToTC3aBaesfW6udTcc2eaRZiHQkoezALntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D&md5=c7173dc6b94f44f48532bebb352e345f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DOztan%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DErlich%26aufirst%3DR.%2BL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26atitle%3DEmergence%2520of%2520EGFR%2520G724S%2520mutation%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520post%2520progression%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D111%26spage%3D84%26epage%3D87%26doi%3D10.1016%2Fj.lungcan.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span> <span> </span><span class="NLM_article-title">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.2147/OTT.S188612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2147%2FOTT.S188612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30588029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=51-56&author=Y.+Zhangauthor=B.+Heauthor=D.+Zhouauthor=M.+Liauthor=C.+Hu&title=Newly+emergent+acquired+EGFR+exon+18+G724S+mutation+after+resistance+of+a+T790M+specific+EGFR+inhibitor+osimertinib+in+non-small-cell+lung+cancer%3A+a+case+report&doi=10.2147%2FOTT.S188612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span></div><div class="casAuthors">Zhang, Yan; He, Bixiu; Zhou, Dongbo; Li, Min; Hu, Chengping</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer.  Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored.  Case presentation: A non-smoking 58-yr-old female patient was initially diagnosed with lung adenocarcinoma harboring EGFR exon 19 deletion and clin. responded to initial gefitinib treatment.  The patient progressed on gefitinib after > 1 yr and a T790M mutation was detected in tissue biopsy by next-generation sequencing (NGS).  Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance.  Conclusion: The specific mechanisms of acquiring drug resistance for EGFR-TKIs have not been fully explored.  EGFR G724S mutation might be assocd. with osimertinib resistance but more studies about the mechanism should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGCPcRDGUQb7Vg90H21EOLACvtfcHk0lh25iDIgc_dFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K&md5=87e7c138506ba5973a82cf7715aacff5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FOTT.S188612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S188612%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.%26atitle%3DNewly%2520emergent%2520acquired%2520EGFR%2520exon%252018%2520G724S%2520mutation%2520after%2520resistance%2520of%2520a%2520T790M%2520specific%2520EGFR%2520inhibitor%2520osimertinib%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D51%26epage%3D56%26doi%3D10.2147%2FOTT.S188612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3351</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-18-3829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30796031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=3341-3351&author=B.+P.+Brownauthor=Y.+K.+Zhangauthor=D.+Westoverauthor=Y.+Yanauthor=H.+Qiaoauthor=V.+Huangauthor=Z.+Duauthor=J.+A.+Smithauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+Aliauthor=L.+Bazhenovaauthor=A.+B.+Schrockauthor=J.+Meilerauthor=C.+M.+Lovly&title=On-target+resistance+to+the+mutant-selective+EGFR+inhibitor+osimertinib+can+develop+in+an+allele-specific+manner+dependent+on+the+original+EGFR-activating+mutation&doi=10.1158%2F1078-0432.CCR-18-3829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span></div><div class="casAuthors">Brown, Benjamin P.; Zhang, Yun-Kai; Westover, David; Yan, Yingjun; Qiao, Huan; Huang, Vincent; Du, Zhenfang; Smith, Jarrod A.; Ross, Jeffrey S.; Miller, Vincent A.; Ali, Siraj; Bazhenova, Lyudmila; Schrock, Alexa B.; Meiler, Jens; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3341-3351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer.  Here, we investigate how G724S confers resistance to osimertinib.  We combine structure-based predictive modeling of G724S in combination with the 2 most common EGFR-activating mutations, exon 19 deletion (Ex19Del) and L858R, with in vitro drug-response models and patient genomic profiling.  Our simulations suggest that the G724S mutation selectively reduces osimertinib-binding affinity in the context of Ex19Del.  Consistent with our simulations, cell lines transduced with Ex19Del/G724S demonstrate resistance to osimertinib, whereas cells transduced with L858R/G724S are sensitive to osimertinib.  Subsequent clin. genomic profiling data further suggest G724S occurs with Ex19Del but not L858R.  Furthermore, we demonstrate that Ex19Del/G724S retains sensitivity to afatinib, but not to erlotinib, suggesting a possible therapy for patients at the time of disease relapse.  Altogether, these data suggest that G724S is an allele-specific resistance mutation emerging in the context of Ex19Del but not L858R.  Our results fundamentally reframe the problem of targeted therapy resistance from one focused on the drug-resistance mutation pair to one focused on activating mutation-drug-resistance mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKneM5OFx3BrVg90H21EOLACvtfcHk0lh25iDIgc_dFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO&md5=5ea6914733351fabdf1c59c19a66e49e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3829%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DB.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DOn-target%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520osimertinib%2520can%2520develop%2520in%2520an%2520allele-specific%2520manner%2520dependent%2520on%2520the%2520original%2520EGFR-activating%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D3341%26epage%3D3351%26doi%3D10.1158%2F1078-0432.CCR-18-3829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e73</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYNqHlW95MoYbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0lhvOhH7-SZplw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michalczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3482</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18316192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR&doi=10.1016%2Fj.bmc.2008.02.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span></div><div class="casAuthors">Michalczyk, Anja; Klueter, Sabine; Rode, Haridas B.; Simard, Jeffrey R.; Gruetter, Christian; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3482-3488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Resistance to kinase-targeted cancer drugs has recently been linked to a single point mutation in the ATP binding site of the kinase.  In EGFR, the crucial Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP competitive inhibitors from binding.  Irreversible 4-(phenylamino)quinazolines have been shown to overcome this drug resistance and are currently in clin. trials.  In order to obtain a detailed structural understanding of how irreversible inhibitors overcome drug resistance, the authors used Src kinase as a model system for drug resistant EGFR-T790M.  The authors report the first crystal structure of a drug resistant kinase in complex with an irreversible inhibitor.  This 4-(phenylamino)quinazoline inhibits wild type and drug resistant EGFR in vitro at low nM concns.  The cocrystal structure of drug resistant cSrc-T338M kinase domain provides the structural basis of this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp52JtORqsX7Vg90H21EOLACvtfcHk0lhvOhH7-SZplw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D&md5=b9fc704067e495279bad4913e9c703ab</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488%26doi%3D10.1016%2Fj.bmc.2008.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddigkeit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0liqcq6jTca9tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">ORAL17.07</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=ORAL17.07&issue=Suppl.+2&author=G.+R.+Oxnardauthor=K.+Thressauthor=C.+Paweletzauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=E.+Felipauthor=A.+Vivancosauthor=Y.+Kuangauthor=L.+Shollauthor=A.+J.+Redigauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=R.+N.+Pillaiauthor=B.+C.+Choauthor=L.+Lacroixauthor=D.+Planchardauthor=J.+C.+Soriaauthor=P.+A.+J%C3%A4nne&title=Mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M+positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DSholl%26aufirst%3DL.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DPillai%26aufirst%3DR.%2BN.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M%2520positive%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSuppl.%25202%26spage%3DORAL17.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0liqcq6jTca9tg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lhNjz1P-xEAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lhNjz1P-xEAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuma, R.</span></span> <span> </span><span class="NLM_article-title">A new alkaloid AM-2282 of streptomyces origin. taxonomy, fermentation, isolation and preliminary characterization</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.30.275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.7164%2Fantibiotics.30.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=612708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1977&pages=275-282&author=S.+Omuraauthor=Y.+Iwaiauthor=A.+Hiranoauthor=A.+Nakagawaauthor=J.+Awayaauthor=H.+Tsuchiyaauthor=Y.+Takahashiauthor=R.+Asuma&title=A+new+alkaloid+AM-2282+of+streptomyces+origin.+taxonomy%2C+fermentation%2C+isolation+and+preliminary+characterization&doi=10.7164%2Fantibiotics.30.275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A new alkaloid AM-2282 of Streptomyces origin.  Taxonomy, fermentation, isolation and preliminary characterization</span></div><div class="casAuthors">Omura, Satoshi; Iwai, Yuzuru; Hirano, Atsushi; Nakagawa, Akira; Awaya, Juichi; Tsuchiya, Hisae; Takahashi, Yoko; Masuma, Rokurou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-82</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel alkaloid, AM-2282 [62996-74-1], with high hypotensive activity, was isolated from Streptomyces strain AM-2282, for which the name S. staurosporens is proposed.  The substance was active against fungi and yeast but had no activity against bacteria.  The mol. formula is C28H26N4O3, and the i.p. LD50 of its hydrochloride in mice was 6.6 mg/kg.  Taxonomic features of the strain AM-2282, together with the fermn. isolation, and physicochem. and biol. properties of the new alkaloid are presented.  UV, IR, and 1H-NMR spectra are also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjO4pjDwMWLrVg90H21EOLACvtfcHk0lhNjz1P-xEAfw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D&md5=4f52ee08da1cba35345c971c313c7fc6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.30.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.30.275%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DAwaya%26aufirst%3DJ.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DAsuma%26aufirst%3DR.%26atitle%3DA%2520new%2520alkaloid%2520AM-2282%2520of%2520streptomyces%2520origin.%2520taxonomy%252C%2520fermentation%252C%2520isolation%2520and%2520preliminary%2520characterization%26jtitle%3DJ.%2520Antibiot.%26date%3D1977%26volume%3D30%26spage%3D275%26epage%3D282%26doi%3D10.7164%2Fantibiotics.30.275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0liGvKmUho0AWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yauch, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirazzoli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-12-0357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23229345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+J.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M&doi=10.1158%2F2159-8290.CD-12-0357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M</span></div><div class="casAuthors">Lee, Ho-June; Schaefer, Gabriele; Heffron, Timothy P.; Shao, Lily; Ye, Xiaofen; Sideris, Steve; Malek, Shiva; Chan, Emily; Merchant, Mark; La, Hank; Ubhayakar, Savita; Yauch, Robert L.; Pirazzoli, Valentina; Politi, Katerina; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Approx. half of EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with small-mol. EGFR kinase inhibitors develop drug resistance assocd. with the EGF receptor (EGFR)T790M "gatekeeper" substitution, prompting efforts to develop covalent EGFR inhibitors, which can effectively suppress EGFR T790M in preclin. models.  However, these inhibitors have yet to prove clin. efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo.  While profiling sensitivity to various kinase inhibi.tors across a large cancer cell line panel, we identified indolocarbazole compds., including a clin. well-tolerated FLTB inhibitor, as potent and reversible inhibitors of EGFR T790M that spare wild-type EGFR.  These findings show the use of broad cancer cell profiling of kinase inhibitor efficacy to identify unanticipated novel applications, and they identify indolocarbazole compds. as potentially effective EGFR inhibitors in the context of T790M-mediated drug resistance in N5CLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5m_cmYkDYrVg90H21EOLACvtfcHk0liGvKmUho0AWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrw%253D&md5=fe34e9532c254baa0e834a801fd361bd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0357%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181%26doi%3D10.1158%2F2159-8290.CD-12-0357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2eZ08nO323Z3irntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2ebg_EChREMfL7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S147129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2147%2FLCTT.S147129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFKmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=241-247&author=S.+J.+Klempnerauthor=P.+Mehtaauthor=A.+B.+Schrockauthor=S.+M.+Aliauthor=S.+I.+Ou&title=Cis-oriented+solvent-front+EGFR+G796S+mutation+in+tissue+and+ctDNA+in+a+patient+progressing+on+osimertinib%3A+a+case+report+and+review+of+the+literature&doi=10.2147%2FLCTT.S147129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature</span></div><div class="casAuthors">Klempner, Samuel J.; Mehta, Pareen; Schrock, Alexa B.; Ali, Siraj M.; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-247</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clin. efficacy.  The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M pos. non-small-cell lung cancer.  Mechanisms of acquired resistance are emerging, and here we describe a cis-oriented solvent-front EGFR G796S mutation as the resistance mechanism obsd. in a progression biopsy and circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib.  This is one of the earliest reports of a sole solvent-front tertiary EGFR mutation as a resistance mechanism to osimertinib.  Our case suggests a monoclonal resistance mechanism.  We review the importance of the solvent-front residues across TKIs and describe known osimertinib resistance mechanisms.  We observe that nearly all clin. osimertinib-resistant tertiary EGFR mutations are oriented in cis with EGFR T790M.  This case highlights the importance of mutations affecting EGFR kinase domains and supports the feasibility of broad panel ctDNA assays for detection of novel acquired resistance and tumor heterogeneity in routine clin. care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm4B6qa-qgibVg90H21EOLACvtfcHk0lisTAjClRtrfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFKmtrg%253D&md5=5115bf357ae144230739b72520908815</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S147129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S147129%26sid%3Dliteratum%253Aachs%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DCis-oriented%2520solvent-front%2520EGFR%2520G796S%2520mutation%2520in%2520tissue%2520and%2520ctDNA%2520in%2520a%2520patient%2520progressing%2520on%2520osimertinib%253A%2520a%2520case%2520report%2520and%2520review%2520of%2520the%2520literature%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D241%26epage%3D247%26doi%3D10.2147%2FLCTT.S147129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">e123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-e123&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De121%26epage%3De123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovinger, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinsurongkawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glisson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6203</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-18-1542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30228210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3czgtV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6195-6203&author=X.+Leauthor=S.+Puriauthor=M.+V.+Negraoauthor=M.+B.+Nilssonauthor=J.+Robichauxauthor=T.+Boyleauthor=J.+K.+Hicksauthor=K.+L.+Lovingerauthor=E.+Roartyauthor=W.+Rinsurongkawongauthor=M.+Tangauthor=H.+Sunauthor=Y.+Elaminauthor=L.+C.+Lacerdaauthor=J.+Lewisauthor=J.+A.+Rothauthor=S.+G.+Swisherauthor=J.+J.+Leeauthor=W.+N.+Williamauthor=B.+S.+Glissonauthor=J.+Zhangauthor=V.+A.+Papadimitrakopoulouauthor=J.+E.+Grayauthor=J.+V.+Heymach&title=Landscape+of+EGFR-dependent+and+-independent+resistance+mechanisms+to+osimertinib+and+continuation+therapy+beyond+progression+in+EGFR-Mutant+NSCLC&doi=10.1158%2F1078-0432.CCR-18-1542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC</span></div><div class="casAuthors">Le Xiuning; Negrao Marcelo V; Nilsson Monique B; Robichaux Jacqulyne; Roarty Emily; Rinsurongkawong Waree; Tang Ming; Sun Huiying; Elamin Yasir; Lacerda Lara C; William William N Jr; Glisson Bonnie S; Zhang Jianjun; Papadimitrakopoulou Vassiliki A; Heymach John V; Puri Sonam; Gray Jhanelle E; Boyle Theresa; Hicks J Kevin; Lovinger Katherine L; Lewis Jeff; Lee J Jack; Roth Jack A; Swisher Stephen G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6195-6203</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC.  However, resistance mechanisms to osimertinib have been incompletely described.  EXPERIMENTAL DESIGN:  Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib.  Molecular profiling analysis was performed at the time of progression in a subset of the patients.  RESULTS:  In the 118 patients treated with osimertinib, 42 had molecular profiling at progression.  T790M was preserved in 21 (50%) patients and lost in 21 (50%).  EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases.  MET amplification was the second most common alteration (14%).  Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET.  Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers.  Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01).  In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months.  Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02).  CONCLUSIONS:  Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations.  Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients.See related commentary by Devarakonda and Govindan, p. 6112.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdipwLPXO73z69zv1FsJFMfW6udTcc2ebumtKMiyTxB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czgtV2qtw%253D%253D&md5=7228ac68946b3d2f0a26ec4158c71655</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1542%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DS.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DJ.%2BK.%26aulast%3DLovinger%26aufirst%3DK.%2BL.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DRinsurongkawong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElamin%26aufirst%3DY.%26aulast%3DLacerda%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DLandscape%2520of%2520EGFR-dependent%2520and%2520-independent%2520resistance%2520mechanisms%2520to%2520osimertinib%2520and%2520continuation%2520therapy%2520beyond%2520progression%2520in%2520EGFR-Mutant%2520NSCLC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6195%26epage%3D6203%26doi%3D10.1158%2F1078-0432.CCR-18-1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Rare mechanism of acquired resistance to osimertinib in Korean patients with EGFR-mutated non-small cell lung cancer</span>. <i>Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.4143/crt.2018.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.4143%2Fcrt.2018.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29807405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MfnvVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=408-412&author=J.+Leeauthor=J.+H.+Shimauthor=W.+Y.+Parkauthor=H.+K.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=M.+J.+Ahn&title=Rare+mechanism+of+acquired+resistance+to+osimertinib+in+Korean+patients+with+EGFR-mutated+non-small+cell+lung+cancer&doi=10.4143%2Fcrt.2018.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer</span></div><div class="casAuthors">Lee Jiyun; Kim Hee Kyung; Sun Jong-Mu; Lee Se-Hoon; Ahn Jin Seok; Park Keunchil; Ahn Myung-Ju; Shim Joon Ho; Park Woong-Yang; Shim Joon Ho; Park Woong-Yang; Park Woong-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">408-412</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC).  Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations.  However, the vast majority of patients acquire resistance following successful treatment.  A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib.  CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%).  Another 53-year-old female patient developed systemic progression after 10 months of osimertinib.  CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation.  The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkG4XPud7IksKL0FlyGHDofW6udTcc2ebumtKMiyTxB7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfnvVehtw%253D%253D&md5=c5c21a7076c96e86592fc2b7f93cddfc</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2018.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2018.138%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DW.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DRare%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520osimertinib%2520in%2520Korean%2520patients%2520with%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D51%26spage%3D408%26epage%3D412%26doi%3D10.4143%2Fcrt.2018.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span> <span> </span><span class="NLM_article-title">Protein structure from x-ray diffraction</span>. <i>J. Biol. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1023/A:1027310719146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1023%2FA%3A1027310719146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23345855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1amtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2003&pages=341-362&author=M.+W.+Parker&title=Protein+structure+from+x-ray+diffraction&doi=10.1023%2FA%3A1027310719146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Structure from X-Ray Diffraction</span></div><div class="casAuthors">Parker, M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Physics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-362</span>CODEN:
                <span class="NLM_cas:coden">JBPHBZ</span>;
        ISSN:<span class="NLM_cas:issn">0092-0606</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Protein crystallog. is the study of the three-dimensional structures of proteins at near at. resoln.  It has provided a tremendous insight into the workings of numerous biol. processes over the last few decades.  The field has undergone a massive worldwide expansion over the last ten years, not only in academic labs., but also in the pharmaceutical industry.  The main driving force for this expansion has been the promise of using three-dimensional at. structures of proteins and other macromols. to design lead drugs and to improve the action of existing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol2Lb4Niz6zbVg90H21EOLACvtfcHk0li5x3G6hI6YSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1amtrw%253D&md5=7edbffbbd98d19a2967bb4bd6c4ae3d1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1027310719146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1027310719146%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DProtein%2520structure%2520from%2520x-ray%2520diffraction%26jtitle%3DJ.%2520Biol.%2520Phys.%26date%3D2003%26volume%3D29%26spage%3D341%26epage%3D362%26doi%3D10.1023%2FA%3A1027310719146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sayers, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avsar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmous, I.</span></span> <span> </span><span class="NLM_article-title">Application of advanced X-ray methods in life sciences</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1861</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3685</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2016.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bbagen.2016.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27156488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslansL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1861&publication_year=2017&pages=3671-3685&author=Z.+Sayersauthor=B.+Avsarauthor=E.+Cholakauthor=I.+Karmous&title=Application+of+advanced+X-ray+methods+in+life+sciences&doi=10.1016%2Fj.bbagen.2016.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Application of advanced X-ray methods in life sciences</span></div><div class="casAuthors">Sayers, Zehra; Avsar, Bihter; Cholak, Ersoy; Karmous, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1861</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">3671-3685</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synchrotron radiation (SR) sources provide diverse X-ray methods for the investigation of structure-function relationships in biol. macromols.  Recent developments in SR sources and in the X-ray tools they offer for life sciences are reviewed.  Specifically, advances in macromol. crystallog., small angle X-ray soln. scattering, X-ray absorption and fluorescence spectroscopy, and imaging are discussed with examples.  SR sources offer a range of X-ray techniques that can be used in a complementary fashion in studies of biol. systems at a wide range of resolns. from at. to cellular scale.  Emerging applications of X-ray techniques include the characterization of disordered proteins, noncryst. and nonequil. systems, elemental imaging of tissues, cells and organs, and detection of time-resolved changes in mol. structures.  X-ray techniques are in the center of hybrid approaches that are used to gain insight into complex problems relating to biomol. mechanisms, disease and possible therapeutic solns.  This article is part of a Special Issue entitled "Science for Life". Guest Editors: Dr. Austen Angell, Dr. Salvatore Magaz´u and Dr. Federica Migliardo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOzYI_kZg_NrVg90H21EOLACvtfcHk0lhoiKOXqgb6vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslansL0%253D&md5=8edd9f24140c85d7b2b0f0d0499e97e6</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2016.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2016.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DSayers%26aufirst%3DZ.%26aulast%3DAvsar%26aufirst%3DB.%26aulast%3DCholak%26aufirst%3DE.%26aulast%3DKarmous%26aufirst%3DI.%26atitle%3DApplication%2520of%2520advanced%2520X-ray%2520methods%2520in%2520life%2520sciences%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2017%26volume%3D1861%26spage%3D3671%26epage%3D3685%26doi%3D10.1016%2Fj.bbagen.2016.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venien-Bryan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J. A.</span></span> <span> </span><span class="NLM_article-title">Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1107/S2053230X17003740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1107%2FS2053230X17003740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28368275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFSiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=174-183&author=C.+Venien-Bryanauthor=Z.+Liauthor=L.+Vuillardauthor=J.+A.+Boutin&title=Cryo-electron+microscopy+and+X-ray+crystallography%3A+complementary+approaches+to+structural+biology+and+drug+discovery&doi=10.1107%2FS2053230X17003740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery</span></div><div class="casAuthors">Venien-Bryan, Catherine; Li, Zhuolun; Vuillard, Laurent; Boutin, Jean Albert</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The invention of the electron microscope has greatly enhanced the view scientists have of small structural details.  Since its implementation, this technol. has undergone considerable evolution and the resoln. that can be obtained for biol. objects has been extended.  In addn., the latest generation of cryo-electron microscopes equipped with direct electron detectors and software for the automated collection of images, in combination with the use of advanced image-anal. methods, has dramatically improved the performance of this technique in terms of resoln.  While calcg. a sub-10 Å resoln. structure was an accomplishment less than a decade ago, it is now common to generate structures at sub-5 Å resoln. and even better.  It is becoming possible to relatively quickly obtain high-resoln. structures of biol. mols., in particular large ones (>500 kDa) which, in some cases, have resisted more conventional methods such as X-ray crystallog. or NMR (NMR).  Such newly resolved structures may, for the first time, shed light on the precise mechanisms that are essential for cellular physiol. processes.  The ability to attain at. resoln. may support the development of new drugs that target these proteins, allowing medicinal chemists to understand the intimacy of the relationship between their mols. and targets.  In addn., recent developments in cryo-electron microscopy combined with image anal. can provide unique information on the conformational variability of macromol. complexes.  Conformational flexibility of macromol. complexes can be investigated using cryo-electron microscopy and multiconformation reconstruction methods.  However, the biochem. quality of the sample remains the major bottleneck to routine cryo-electron microscopy-based detn. of structures at very high resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIUueQxXP1bVg90H21EOLACvtfcHk0lhoiKOXqgb6vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFSiu78%253D&md5=38ce13849f7695231022821f5bcea946</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1107%2FS2053230X17003740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X17003740%26sid%3Dliteratum%253Aachs%26aulast%3DVenien-Bryan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVuillard%26aufirst%3DL.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26atitle%3DCryo-electron%2520microscopy%2520and%2520X-ray%2520crystallography%253A%2520complementary%2520approaches%2520to%2520structural%2520biology%2520and%2520drug%2520discovery%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2017%26volume%3D73%26spage%3D174%26epage%3D183%26doi%3D10.1107%2FS2053230X17003740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radmer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Improving structure-based function prediction using molecular dynamics</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.str.2009.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.str.2009.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19604472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosV2gsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=919-929&author=D.+S.+Glazerauthor=R.+J.+Radmerauthor=R.+B.+Altman&title=Improving+structure-based+function+prediction+using+molecular+dynamics&doi=10.1016%2Fj.str.2009.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Structure-Based Function Prediction Using Molecular Dynamics</span></div><div class="casAuthors">Glazer, Dariya S.; Radmer, Randall J.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-929</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The no. of mols. with solved three-dimensional structure but unknown function is increasing rapidly.  Particularly problematic are novel folds with little detectable similarity to mols. of known function.  Exptl. assays can det. the functions of such mols., but are time-consuming and expensive.  Computational approaches can identify potential functional sites; however, these approaches generally rely on single static structures and do not use information about dynamics.  In fact, structural dynamics can enhance function prediction: the authors coupled mol. dynamics simulations with structure-based function prediction algorithms that identify Ca2+ binding sites.  When applied to 11 challenging proteins, both methods showed substantial improvement in performance, revealing 22 more sites in one case and 12 more in the other, with a modest increase in apparent false positives.  Thus, the authors show that treating mols. as dynamic entities improves the performance of structure-based function prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX8TYjzyrgD7Vg90H21EOLACvtfcHk0lhoiKOXqgb6vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosV2gsrw%253D&md5=f3bc60f2400bf2ec4d2d7634ef6a6663</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2009.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2009.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlazer%26aufirst%3DD.%2BS.%26aulast%3DRadmer%26aufirst%3DR.%2BJ.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DImproving%2520structure-based%2520function%2520prediction%2520using%2520molecular%2520dynamics%26jtitle%3DStructure%26date%3D2009%26volume%3D17%26spage%3D919%26epage%3D929%26doi%3D10.1016%2Fj.str.2009.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faraggi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloczkowski, A.</span></span> <span> </span><span class="NLM_article-title">Comparing NMR and X-ray protein structure: Lindemann-like parameters and NMR disorder</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2341</span>, <span class="refDoi"> DOI: 10.1080/07391102.2017.1352539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1080%2F07391102.2017.1352539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28714803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht12ltL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2331-2341&author=E.+Faraggiauthor=A.+K.+Dunkerauthor=J.+L.+Sussmanauthor=A.+Kloczkowski&title=Comparing+NMR+and+X-ray+protein+structure%3A+Lindemann-like+parameters+and+NMR+disorder&doi=10.1080%2F07391102.2017.1352539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing NMR and X-ray protein structure: Lindemann-like parameters and NMR disorder</span></div><div class="casAuthors">Faraggi, Eshel; Dunker, A. Keith; Sussman, Joel L.; Kloczkowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2331-2341</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Disordered protein chains and segments are fast becoming a major pathway for our understanding of biol. function, esp. in more evolved species.  However, the std. definition of disordered residues: the inability to constrain them in X-ray derived structures, is not easily applied to NMR derived structures.  We carry out a statistical comparison between proteins whose structure was resolved using NMR and using X-ray protocols.  We start by establishing a connection between these two protocols for obtaining protein structure.  We find a close statistical correspondence between NMR and X-ray structures if fluctuations inherent to the NMR protocol are taken into account.  Intuitively this tends to lend support to the validity of both NMR and X-ray protocols in deriving biomol. models that correspond to in vivo conditions.  We then establish Lindemann-like parameters for NMR derived structures and examine what order/disorder cutoffs for these parameters are most consistent with X-ray data and how consistent are they.  Finally, we find crit. value of for the best correspondence between X-ray and NMR derived order/disorder assignment, judged by maximizing the Matthews correlation, and a crit. value if a balance between false pos. and false neg. prediction is sought.  We examine a few non-conforming cases, and examine the origin of the structure derived in X-ray.  This study could help in assigning meaningful disorder from NMR expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql_4jZYodT4bVg90H21EOLACvtfcHk0lhoiKOXqgb6vQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht12ltL3M&md5=a9d1aba4bc60bd89c19d03a980eeef5f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1080%2F07391102.2017.1352539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2017.1352539%26sid%3Dliteratum%253Aachs%26aulast%3DFaraggi%26aufirst%3DE.%26aulast%3DDunker%26aufirst%3DA.%2BK.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26aulast%3DKloczkowski%26aufirst%3DA.%26atitle%3DComparing%2520NMR%2520and%2520X-ray%2520protein%2520structure%253A%2520Lindemann-like%2520parameters%2520and%2520NMR%2520disorder%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2018%26volume%3D36%26spage%3D2331%26epage%3D2341%26doi%3D10.1080%2F07391102.2017.1352539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marion, D.</span></span> <span> </span><span class="NLM_article-title">An introduction to biological NMR spectroscopy</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3025</span>, <span class="refDoi"> DOI: 10.1074/mcp.O113.030239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fmcp.O113.030239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23831612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3006-3025&author=D.+Marion&title=An+introduction+to+biological+NMR+spectroscopy&doi=10.1074%2Fmcp.O113.030239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">An Introduction to Biological NMR Spectroscopy</span></div><div class="casAuthors">Marion, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3006-3025</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  NMR spectroscopy is a powerful tool for biologists interested in the structure, dynamics, and interactions of biol. macromols.  This review aims at presenting in an accessible manner the requirements and limitations of this technique.  As an introduction, the history of NMR will highlight how the method evolved from physics to chem. and finally to biol. over several decades.  We then introduce the NMR spectral parameters used in structural biol., namely the chem. shift, the J-coupling, nuclear Overhauser effects, and residual dipolar couplings.  Resonance assignment, the required step for any further NMR study, bears a resemblance to jigsaw puzzle strategy.  The NMR spectral parameters are then converted into angle and distances and used as input using restrained mol. dynamics to compute a bundle of structures.  When interpreting a NMR-derived structure, the biologist has to judge its quality on the basis of the statistics provided.  When the 3D structure is a priori known by other means, the mol. interaction with a partner can be mapped by NMR: information on the binding interface as well as on kinetic and thermodn. consts. can be gathered.  NMR is suitable to monitor, over a wide range of frequencies, protein fluctuations that play a crucial role in their biol. function.  In the last section of this review, intrinsically disordered proteins, which have escaped the attention of classical structural biol., are discussed in the perspective of NMR, one of the rare available techniques able to describe structural ensembles.  This Tutorial is part of the International Proteomics Tutorial Program (IPTP 16 MCP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2WDfR3dKc4bVg90H21EOLACvtfcHk0lglXxsSVCjaQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrrJ&md5=2825e9c538ac6d594f853a0895fd7207</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fmcp.O113.030239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.O113.030239%26sid%3Dliteratum%253Aachs%26aulast%3DMarion%26aufirst%3DD.%26atitle%3DAn%2520introduction%2520to%2520biological%2520NMR%2520spectroscopy%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2013%26volume%3D12%26spage%3D3006%26epage%3D3025%26doi%3D10.1074%2Fmcp.O113.030239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Religa, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprangers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, B.</span></span> <span> </span><span class="NLM_article-title">NMR spectroscopy of soluble protein complexes at one mega-dalton and beyond</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8746</span>– <span class="NLM_lpage">8751</span>, <span class="refDoi"> DOI: 10.1002/anie.201301215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201301215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8746-8751&author=A.+Mainzauthor=T.+L.+Religaauthor=R.+Sprangersauthor=R.+Linserauthor=L.+E.+Kayauthor=B.+Reif&title=NMR+spectroscopy+of+soluble+protein+complexes+at+one+mega-dalton+and+beyond&doi=10.1002%2Fanie.201301215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">NMR Spectroscopy of Soluble Protein Complexes at One Mega-Dalton and Beyond</span></div><div class="casAuthors">Mainz, Andi; Religa, Tomasz L.; Sprangers, Remco; Linser, Rasmus; Kay, Lewis E.; Reif, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">8746-8751</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sequential backbone assignments are obtained by NMR spectroscopy for a 1 MDa proteasome complex.  The method relies on immobilization of a sol. protein complex by magic-angle spinning.  Deuteration and proton detection of exchangeable sites and paramagnetic relaxation enhancement enables exploration of structural and dynamic properties of supramol. assemblies at at. resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPETi3UNlWr7Vg90H21EOLACvtfcHk0lglXxsSVCjaQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL%252FN&md5=e40812180583d71b01a05439ab1be1a8</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301215%26sid%3Dliteratum%253Aachs%26aulast%3DMainz%26aufirst%3DA.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DLinser%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DReif%26aufirst%3DB.%26atitle%3DNMR%2520spectroscopy%2520of%2520soluble%2520protein%2520complexes%2520at%2520one%2520mega-dalton%2520and%2520beyond%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8746%26epage%3D8751%26doi%3D10.1002%2Fanie.201301215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in homology protein structure modeling</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.2174/138920306777452312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2174%2F138920306777452312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16787261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1emtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=217-227&author=Z.+Xiang&title=Advances+in+homology+protein+structure+modeling&doi=10.2174%2F138920306777452312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in homology protein structure modeling</span></div><div class="casAuthors">Xiang, Zhexin</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Homol. modeling plays a central role in detg. protein structure in the structural genomics project.  The importance of homol. modeling has been steadily increasing because of the large gap that exists between the overwhelming no. of available protein sequences and exptl. solved protein structures, and also, more importantly, because of the increasing reliability and accuracy of the method.  In fact, a protein sequence with over 30% identity to a known structure can often be predicted with an accuracy equiv. to a low-resoln. x-ray structure.  The recent advances in homol. modeling, esp. in detecting distant homologs, aligning sequences with template structures, modeling of loops and side chains, as well as detecting errors in a model, have contributed to reliable prediction of protein structure, which was not possible even several years ago.  The ongoing efforts in solving protein structures, which can be time-consuming and often difficult, will continue to spur the development of a host of new computational methods that can fill in the gap and further contribute to understanding the relationship between protein structure and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQdunnMscg7Vg90H21EOLACvtfcHk0lglXxsSVCjaQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1emtLc%253D&md5=46bb5be04bc0e85cebbfb71b0a3040a1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F138920306777452312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920306777452312%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520homology%2520protein%2520structure%2520modeling%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2006%26volume%3D7%26spage%3D217%26epage%3D227%26doi%3D10.2174%2F138920306777452312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raunser, S.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM revolutionizes the structure determination of biomolecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">16450</span>– <span class="NLM_lpage">16452</span>, <span class="refDoi"> DOI: 10.1002/anie.201710679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201710679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFegt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=16450-16452&author=S.+Raunser&title=Cryo-EM+revolutionizes+the+structure+determination+of+biomolecules&doi=10.1002%2Fanie.201710679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM Revolutionizes the Structure Determination of Biomolecules</span></div><div class="casAuthors">Raunser, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">16450-16452</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review, discussing cryo-electron microscopy, which has now become a major technique in structural biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkYhmLo9aQLVg90H21EOLACvtfcHk0lglXxsSVCjaQw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFegt7nJ&md5=032af61f396e08f9e835df5818d24e2d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710679%26sid%3Dliteratum%253Aachs%26aulast%3DRaunser%26aufirst%3DS.%26atitle%3DCryo-EM%2520revolutionizes%2520the%2520structure%2520determination%2520of%2520biomolecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D16450%26epage%3D16452%26doi%3D10.1002%2Fanie.201710679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 3 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Jonas Lategahn, Julia Hardick, Tobias Grabe, Janina Niggenaber, Kirujan Jeyakumar, Marina Keul, Hannah L. Tumbrink, Christian Becker, Luke Hodson, Tonia Kirschner, Philip Klövekorn, Julia Ketzer, Matthias Baumann, Susanne Terheyden, Anke Unger, Jörn Weisner, Matthias P. Müller, Willem A. L. van Otterlo, Sebastian Bauer, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Her2-insYVMA with Covalent Inhibitors—A Focused Compound Screening and Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11725-11755. <a href="https://doi.org/10.1021/acs.jmedchem.0c00870" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00870</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00870&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00870%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BHer2-insYVMA%252Bwith%252BCovalent%252BInhibitors%2525E2%252580%252594A%252BFocused%252BCompound%252BScreening%252Band%252BStructure-Based%252BDesign%252BApproach%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D22052020%26date%3D30092020%26date%3D15092020%26volume%3D63%26issue%3D20%26spage%3D11725%26epage%3D11755" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiang Zhai, Richard A. Ward, Peter Doig, <span class="NLM_string-name hlFld-ContribAuthor">Argyrides Argyrou</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2020,</strong> <em>59 </em>
                                    (14)
                                     , 1428-1441. <a href="https://doi.org/10.1021/acs.biochem.0c00104" title="DOI URL">https://doi.org/10.1021/acs.biochem.0c00104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.0c00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.0c00104%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DInsight%252Binto%252Bthe%252BTherapeutic%252BSelectivity%252Bof%252Bthe%252BIrreversible%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%252BOsimertinib%252Bthrough%252BEnzyme%252BKinetic%252BStudies%26aulast%3DZhai%26aufirst%3DXiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05022020%26date%3D20032020%26date%3D31032020%26date%3D24032020%26volume%3D59%26issue%3D14%26spage%3D1428%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kenji  Kashima</span>, <span class="hlFld-ContribAuthor ">Hiroki  Kawauchi</span>, <span class="hlFld-ContribAuthor ">Hiromi  Tanimura</span>, <span class="hlFld-ContribAuthor ">Yukako  Tachibana</span>, <span class="hlFld-ContribAuthor ">Takashi  Chiba</span>, <span class="hlFld-ContribAuthor ">Takuya  Torizawa</span>, <span class="hlFld-ContribAuthor ">Hiroshi  Sakamoto</span>. </span><span class="cited-content_cbyCitation_article-title">CH7233163 Overcomes Osimertinib-Resistant EGFR-Del19/T790M/C797S Mutation. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Therapeutics</span><span> <strong>2020,</strong> <em>19 </em>
                                    (11)
                                     , 2288-2297. <a href="https://doi.org/10.1158/1535-7163.MCT-20-0229" title="DOI URL">https://doi.org/10.1158/1535-7163.MCT-20-0229</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1535-7163.MCT-20-0229&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1535-7163.MCT-20-0229%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Therapeutics%26atitle%3DCH7233163%252BOvercomes%252BOsimertinib-Resistant%252BEGFR-Del19%25252FT790M%25252FC797S%252BMutation%26aulast%3DKashima%26aufirst%3DKenji%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D11%26spage%3D2288%26epage%3D2297" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0006.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Inactive and active kinase domain conformations. (A) The inactive conformation (bound with lapatinib, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>) exhibits an outward rotated helix αC (red) and a small helical turn within the activation loop (orange). It is in an equilibrium with the active conformation (bound with erlotinib, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>), which exhibits an inward rotated helix αC (green) that allows for a salt bridge between the catalytic lysine Lys745 and Glu762. Moreover, it is characterized by an extended activation loop (blue). (B) The side chain of Leu858 within the helical turn (orange) plays a crucial role in stabilizing the inactive conformation by packing into a hydrophobic cavity between helix αC (red) and glycine-rich loop (gray). Mutation of this amino acid to the polar Arg858 therefore results in an equilibrium shift toward the active conformation (<a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITT">2ITT</a>). The QR code provides an augmented reality view of a corresponding 3D model.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> (C) Chemical structures of representative examples of the three EGFR TKI-generations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Deletion mutation of the ELREA motif in exon 19. MD simulations (blue) suggest that these mutations lock the kinase in its active conformation (green, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>) by restricting the flexibility of helix αC, which is crucial for adopting the inactive conformation (black outlined, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV">2JIV</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Insertion mutations in exon 20. (A) Overview of the clinically most prevalent EGFR insertion mutations in exon 20 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17">1M17</a>). (B) A crystal structure of EGFR-D770_N771insNPG (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM">4LRM</a>) revealed a small wedge that locks the kinase in its active conformation by hindering Arg776 to stabilize the inactive conformation (red, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK">1XKK</a>). (C) Overview of the clinically most prevalent Her2 insertion mutations in exon 20 (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PP0">3PP0</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mutations within the flexible glycine-rich loop (GSGAFG motif) that is involved in ligand recognition. G719S or G724S mutations are thought to affect its dynamics, resulting in steric repulsion or loss of crucial interactions, involving Leu718 or Phe723, for example, with the binding of distinct inhibitors (gray surfaces). Alignment of EGFR crystal structures harboring an exon 20 insertion mutation (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM">4LRM</a>) and G719S (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITO">2ITO</a>) as well as an MD simulation of EGFR-G724S (green).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/medium/jm9b00964_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Point mutations in the binding site directly interfere with ligand binding. (A) The T790M mutation hinders first- and second-generation EGFR inhibitor binding through increased steric demand. Afatinib binding to wild-type EGFR (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J">4G5J</a>) aligned with T790M mutant apo-EGFR (blue, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UG1">3UG1</a>). (B) The C797S mutation hinders third-generation covalent inhibitor binding through reduced reactivity of the Ser797 side chain. Binding mode of the reversible analogue WZ4003 (gray, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X2K">5X2K</a>) aligned with C797S-mutated EGFR (blue, PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN">5XGN</a>) as compared to the binding mode of covalent WZ4002 (black outlined, PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA">3IKA</a>). (C) G796R and L792H mutations interfere with third-generation inhibitor binding, illustrated using the crystal structure of rociletinib (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK">5XDK</a>). (D) The L718Q mutation interferes with third-generation inhibitor binding (PDB <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK">5XDK</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-1/acs.jmedchem.9b00964/20200106/images/large/jm9b00964_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00964&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i19">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15414" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15414" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 97 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bray, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferlay, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soerjomataram, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siegel, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Torre, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jemal, A.</span></span> <span> </span><span class="NLM_article-title">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span>. <i>Ca-Cancer J. Clin.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>68</i></span>,  <span class="NLM_fpage">394</span>– <span class="NLM_lpage">424</span>, <span class="refDoi"> DOI: 10.3322/caac.21492</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.3322%2Fcaac.21492" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30207593" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2018&pages=394-424&author=F.+Brayauthor=J.+Ferlayauthor=I.+Soerjomataramauthor=R.+L.+Siegelauthor=L.+A.+Torreauthor=A.+Jemal&title=Global+cancer+statistics+2018%3A+GLOBOCAN+estimates+of+incidence+and+mortality+worldwide+for+36+cancers+in+185+countries&doi=10.3322%2Fcaac.21492"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries</span></div><div class="casAuthors">Bray Freddie; Ferlay Jacques; Soerjomataram Isabelle; Siegel Rebecca L; Torre Lindsey A; Jemal Ahmedin</div><div class="citationInfo"><span class="NLM_cas:title">CA: a cancer journal for clinicians</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">394-424</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">This article provides a status report on the global burden of cancer worldwide using the GLOBOCAN 2018 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer, with a focus on geographic variability across 20 world regions.  There will be an estimated 18.1 million new cancer cases (17.0 million excluding nonmelanoma skin cancer) and 9.6 million cancer deaths (9.5 million excluding nonmelanoma skin cancer) in 2018.  In both sexes combined, lung cancer is the most commonly diagnosed cancer (11.6% of the total cases) and the leading cause of cancer death (18.4% of the total cancer deaths), closely followed by female breast cancer (11.6%), prostate cancer (7.1%), and colorectal cancer (6.1%) for incidence and colorectal cancer (9.2%), stomach cancer (8.2%), and liver cancer (8.2%) for mortality.  Lung cancer is the most frequent cancer and the leading cause of cancer death among males, followed by prostate and colorectal cancer (for incidence) and liver and stomach cancer (for mortality).  Among females, breast cancer is the most commonly diagnosed cancer and the leading cause of cancer death, followed by colorectal and lung cancer (for incidence), and vice versa (for mortality); cervical cancer ranks fourth for both incidence and mortality.  The most frequently diagnosed cancer and the leading cause of cancer death, however, substantially vary across countries and within each country depending on the degree of economic development and associated social and life style factors.  It is noteworthy that high-quality cancer registry data, the basis for planning and implementing evidence-based cancer control programs, are not available in most low- and middle-income countries.  The Global Initiative for Cancer Registry Development is an international partnership that supports better estimation, as well as the collection and use of local data, to prioritize and evaluate national cancer control efforts.  CA: A Cancer Journal for Clinicians 2018;0:1-31. © 2018 American Cancer Society.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQaW5wv8ocuhLxanA7vODO6fW6udTcc2eaxACQt2k1Gjrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otVGlsg%253D%253D&md5=48529f8f794092779d70a27eec5c9017</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.3322%2Fcaac.21492&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3322%252Fcaac.21492%26sid%3Dliteratum%253Aachs%26aulast%3DBray%26aufirst%3DF.%26aulast%3DFerlay%26aufirst%3DJ.%26aulast%3DSoerjomataram%26aufirst%3DI.%26aulast%3DSiegel%26aufirst%3DR.%2BL.%26aulast%3DTorre%26aufirst%3DL.%2BA.%26aulast%3DJemal%26aufirst%3DA.%26atitle%3DGlobal%2520cancer%2520statistics%25202018%253A%2520GLOBOCAN%2520estimates%2520of%2520incidence%2520and%2520mortality%2520worldwide%2520for%252036%2520cancers%2520in%2520185%2520countries%26jtitle%3DCa-Cancer%2520J.%2520Clin.%26date%3D2018%26volume%3D68%26spage%3D394%26epage%3D424%26doi%3D10.3322%2Fcaac.21492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolly, S. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Collins, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sundar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yap, T. A.</span></span> <span> </span><span class="NLM_article-title">Advances in the development of molecularly targeted agents in non-small-cell lung cancer</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">813</span>– <span class="NLM_lpage">827</span>, <span class="refDoi"> DOI: 10.1007/s40265-017-0732-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-017-0732-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28378229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXls1ynt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=813-827&author=S.+O.+Dollyauthor=D.+C.+Collinsauthor=R.+Sundarauthor=S.+Popatauthor=T.+A.+Yap&title=Advances+in+the+development+of+molecularly+targeted+agents+in+non-small-cell+lung+cancer&doi=10.1007%2Fs40265-017-0732-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer</span></div><div class="casAuthors">Dolly, Saoirse O.; Collins, Dearbhaile C.; Sundar, Raghav; Popat, Sanjay; Yap, Timothy A.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">813-827</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer (NSCLC) remains a significant global health challenge and the leading cause of cancer-related mortality.  The traditional 'one-size-fits-all' treatment approach has now evolved into one that involves personalized strategies based on histol. and mol. subtypes.  The mol. era has revolutionized the treatment of patients harboring epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK) and ROS1 gene aberrations.  In the appropriately selected population, anti-tumor agents against these mol. targets can significantly improve progression-free survival.  However, the emergence of acquired resistance is inevitable.  Novel potent compds. with much improved and rational selectivity profiles, such as third-generation EGFR T790M resistance mutation-specific inhibitors, have been developed and added to the NSCLC armamentarium.  To date, attempts to overcome resistance bypass pathways through downstream signaling blockade has had limited success.  Furthermore, the majority of patients still do not harbor known driver genetic or epigenetic alterations and/or have no new available treatment options, with chemotherapy remaining their std. of care.  Several potentially actionable driver aberrations have recently been identified, with the early clin. development of multiple inhibitors against these promising targets currently in progress.  The advent of immune checkpoint inhibitors has led to significant benefit for advanced NSCLC patients with durable responses obsd.  Further interrogation of the underlying biol. of NSCLC, coupled with modern clin. trial designs, is now required to develop novel targeted therapeutics rationally matched with predictive biomarkers of response, so as to further advance NSCLC therapeutics through the next decade.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqVGMcn1PkzYrVg90H21EOLACvtfcHk0liXkiXAiDQHvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXls1ynt7o%253D&md5=e446c6b4a40e3c4e9f5a2b6f1f623c06</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1007%2Fs40265-017-0732-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-017-0732-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolly%26aufirst%3DS.%2BO.%26aulast%3DCollins%26aufirst%3DD.%2BC.%26aulast%3DSundar%26aufirst%3DR.%26aulast%3DPopat%26aufirst%3DS.%26aulast%3DYap%26aufirst%3DT.%2BA.%26atitle%3DAdvances%2520in%2520the%2520development%2520of%2520molecularly%2520targeted%2520agents%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DDrugs%26date%3D2017%26volume%3D77%26spage%3D813%26epage%3D827%26doi%3D10.1007%2Fs40265-017-0732-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Subramaniam, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giaccone, G.</span></span> <span> </span><span class="NLM_article-title">Refining the treatment of NSCLC according to histological and molecular subtypes</span>. <i>Nat. Rev. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">511</span>– <span class="NLM_lpage">526</span>, <span class="refDoi"> DOI: 10.1038/nrclinonc.2015.90</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnrclinonc.2015.90" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=25963091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2015&pages=511-526&author=A.+Thomasauthor=S.+V.+Liuauthor=D.+S.+Subramaniamauthor=G.+Giaccone&title=Refining+the+treatment+of+NSCLC+according+to+histological+and+molecular+subtypes&doi=10.1038%2Fnrclinonc.2015.90"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Refining the treatment of NSCLC according to histological and molecular subtypes</span></div><div class="casAuthors">Thomas, Anish; Liu, Stephen V.; Subramaniam, Deepa S.; Giaccone, Giuseppe</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">511-526</span>CODEN:
                <span class="NLM_cas:coden">NRCOAA</span>;
        ISSN:<span class="NLM_cas:issn">1759-4774</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into subtypes based on genotype and histol. has resulted in dramatic improvements in disease outcome in select patient subgroups.  In particular, molecularly targeted agents that inhibit EGFR or ALK are approved for the treatment of NSCLC harboring genetic alterations in the genes encoding these proteins.  Although acquired resistance usually limits the duration of response to these therapies, a no. of new agents have proven effective at tackling specific resistance mechanisms to first-generation inhibitors.  Large initiatives are starting to address the role of biomarker-driven targeted therapy in squamous lung cancers, and in the adjuvant setting.  Immunotherapy undeniably holds great promise and our understanding of subsets of NSCLC based on patterns of immune response is continuing to evolve.  In addn., efforts are underway to identify rare genomic subsets through genomic screening, functional studies, and mol. characterization of exceptional responders.  This Review provides an overview of the key developments in the treatment of NSCLC, and discusses potential strategies to further optimize therapy by targeting disease subtypes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkYdEvAhD-ALVg90H21EOLACvtfcHk0liXkiXAiDQHvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFOju7%252FN&md5=ac3985abb9bf2d0b9d43231ebe0b5def</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrclinonc.2015.90&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrclinonc.2015.90%26sid%3Dliteratum%253Aachs%26aulast%3DThomas%26aufirst%3DA.%26aulast%3DLiu%26aufirst%3DS.%2BV.%26aulast%3DSubramaniam%26aufirst%3DD.%2BS.%26aulast%3DGiaccone%26aufirst%3DG.%26atitle%3DRefining%2520the%2520treatment%2520of%2520NSCLC%2520according%2520to%2520histological%2520and%2520molecular%2520subtypes%26jtitle%3DNat.%2520Rev.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D12%26spage%3D511%26epage%3D526%26doi%3D10.1038%2Fnrclinonc.2015.90" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span>. <i>Nat. Rev. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1038/nrc2088</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer&doi=10.1038%2Fnrc2088"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0liXkiXAiDQHvQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181%26doi%3D10.1038%2Fnrc2088" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mendelsohn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baselga, J.</span></span> <span> </span><span class="NLM_article-title">The EGF receptor family as targets for cancer therapy</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">6550</span>– <span class="NLM_lpage">6565</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1204082</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fsj.onc.1204082" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=11426640" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3MXhsF2ku7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=6550-6565&author=J.+Mendelsohnauthor=J.+Baselga&title=The+EGF+receptor+family+as+targets+for+cancer+therapy&doi=10.1038%2Fsj.onc.1204082"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">The EGF receptor family as targets for cancer therapy</span></div><div class="casAuthors">Mendelsohn, John; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">56</span>),
    <span class="NLM_cas:pages">6550-6565</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review with many refs.  Human carcinomas frequently express high levels of receptors in the EGF receptor family, and overexpression of at least two of these receptors, the EGF receptor (EGFr) and closely related ErbB2, has been assocd. with a more aggressive clin. behavior.  Further, transfection or activation of high levels of these two receptors in nonmalignant cell lines can lead to a transformed phenotype.  For these reasons therapies directed at preventing the function of these receptors have the potential to be useful anti-cancer treatments.  In the last two decades monoclonal antibodies (MAbs) which block activation of the EGFr and ErbB2 have been developed.  These MAbs have shown promising preclin. activity and "chimeric" and "humanized" MAbs have been produced in order to obviate the problem of host immune reactions.  Clin. activity with these antibodies has been documented: trastuzumab, a humanized anti-ErbB2 MAb, is active and was recently approved in combination with paclitaxel for the therapy of patients with metastatic ErbB2-overexpressing breast cancer; IMC-C225, a chimeric anti-EGFr MAb, has shown impressive activity when combined with radiation therapy and reverses resistance to chemotherapy.  In addn. to antibodies, compds. that directly inhibit receptor tyrosine kinases have shown preclin. activity and early clin. activity has been reported.  A series of phase III studies with these antibodies and direct tyrosine kinase inhibitors are ongoing or planned, and will further address the role of these active anti-receptor agents in the treatment of patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq686yufIuCk7Vg90H21EOLACvtfcHk0lj2e98bARiZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXhsF2ku7k%253D&md5=a268fb11a31755e161176780ac37e015</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1204082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1204082%26sid%3Dliteratum%253Aachs%26aulast%3DMendelsohn%26aufirst%3DJ.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DThe%2520EGF%2520receptor%2520family%2520as%2520targets%2520for%2520cancer%2520therapy%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D6550%26epage%3D6565%26doi%3D10.1038%2Fsj.onc.1204082" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roy-Chowdhuri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zaidinski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paik, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">4910</span>– <span class="NLM_lpage">4918</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-0912</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-12-0912" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22761469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=4910-4918&author=M.+E.+Arcilaauthor=J.+E.+Chaftauthor=K.+Nafaauthor=S.+Roy-Chowdhuriauthor=C.+Lauauthor=M.+Zaidinskiauthor=P.+K.+Paikauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=Prevalence%2C+clinicopathologic+associations%2C+and+molecular+spectrum+of+ERBB2+%28HER2%29+tyrosine+kinase+mutations+in+lung+adenocarcinomas&doi=10.1158%2F1078-0432.CCR-12-0912"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas</span></div><div class="casAuthors">Arcila, Maria E.; Chaft, Jamie E.; Nafa, Khedoudja; Roy-Chowdhuri, Sinchita; Lau, Christopher; Zaidinski, Michael; Paik, Paul K.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">4910-4918</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Activating mutations in the tyrosine kinase domain of HER2 (ERBB2) have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR and KRAS mutations.  The prevalence, clinicopathol. characteristics, prognostic implications, and mol. heterogeneity of HER2-mutated lung ADCs are not well established in U.S. patients.  Exptl. Design: Lung ADC samples (N = 1,478) were first screened for mutations in EGFR (exons 19 and 21) and KRAS (exon 2), and neg. cases were then assessed for HER2 mutations (exons 19-20) using a sizing assay and mass spectrometry.  Testing for addnl. recurrent point mutations in EGFR, KRAS, BRAF, NRAS, PIK3CA, MEK1, and AKT was conducted by mass spectrometry.  ALK rearrangements and HER2 amplification were assessed by FISH.  Results: We identified 25 cases with HER2 mutations, representing 6% of EGFR/KRAS/ALK-neg. specimens.  Small insertions in exon 20 accounted for 96% (24/25) of the cases.  Compared with insertions in EGFR exon 20, there was less variability, with 83% (20/24) being a 12 bp insertion causing duplication of amino acids YVMA at codon 775.  Morphol., 92% (23/25) were moderately or poorly differentiated ADC.  HER2 mutation was not assocd. with concurrent HER2 amplification in 11 cases tested for both.  HER2 mutations were more frequent among never-smokers (P < 0.0001) but there were no assocns. with sex, race, or stage.  Conclusions: HER2 mutations identify a distinct subset of lung ADCs.  Given the high prevalence of lung cancer worldwide and the availability of std. and investigational therapies targeting HER2, routine clin. genotyping of lung ADC should include HER2.  Clin Cancer Res; 18(18); 4910-8. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql2xQKmrAL7bVg90H21EOLACvtfcHk0lj2e98bARiZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhtl2lt7%252FM&md5=683086d6c06b3fb76b94f7c4d8bfed40</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-0912&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-0912%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DRoy-Chowdhuri%26aufirst%3DS.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DZaidinski%26aufirst%3DM.%26aulast%3DPaik%26aufirst%3DP.%2BK.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DPrevalence%252C%2520clinicopathologic%2520associations%252C%2520and%2520molecular%2520spectrum%2520of%2520ERBB2%2520%2528HER2%2529%2520tyrosine%2520kinase%2520mutations%2520in%2520lung%2520adenocarcinomas%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2012%26volume%3D18%26spage%3D4910%26epage%3D4918%26doi%3D10.1158%2F1078-0432.CCR-12-0912" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alroy, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yarden, Y.</span></span> <span> </span><span class="NLM_article-title">The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions</span>. <i>FEBS Lett.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>410</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">86</span>, <span class="refDoi"> DOI: 10.1016/S0014-5793(97)00412-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2FS0014-5793%2897%2900412-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9247128" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXkt1Shu70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=410&publication_year=1997&pages=83-86&author=I.+Alroyauthor=Y.+Yarden&title=The+ErbB+signaling+network+in+embryogenesis+and+oncogenesis%3A+signal+diversification+through+combinatorial+ligand-receptor+interactions&doi=10.1016%2FS0014-5793%2897%2900412-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions</span></div><div class="casAuthors">Alroy, Iris; Yarden, Yosef</div><div class="citationInfo"><span class="NLM_cas:title">FEBS Letters</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">410</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">83-86</span>CODEN:
                <span class="NLM_cas:coden">FEBLAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-5793</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">A review with 47 refs.  Ligand-induced activation of receptor tyrosine kinases (RTK) results in the initiation of diverse cellular pathways, including proliferation, differentiation and cell migration.  The ErbB family of RTKs represents a model for signal diversification through the formation of homo- and heterodimeric receptor complexes.  Each dimeric receptor complex will initiate a distinct signaling pathway by recruiting a different set of Src homol. 2- (SH2-) contg. effector proteins.  Further complexity is added due to the existence of an oncogenic receptor that enhances and stabilizes dimerization but has no ligand (ErbB-2), and a receptor that can recruit novel SH-2-contg. proteins, but is itself devoid of kinase activity (ErbB-3).  The resulting signaling network has important implications for embryonic development and malignant transformation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoe8I6zWoDu4LVg90H21EOLACvtfcHk0lj2e98bARiZZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXkt1Shu70%253D&md5=0d5a27cf91dedbe113e6e061fdd17ee5</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2FS0014-5793%2897%2900412-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0014-5793%252897%252900412-2%26sid%3Dliteratum%253Aachs%26aulast%3DAlroy%26aufirst%3DI.%26aulast%3DYarden%26aufirst%3DY.%26atitle%3DThe%2520ErbB%2520signaling%2520network%2520in%2520embryogenesis%2520and%2520oncogenesis%253A%2520signal%2520diversification%2520through%2520combinatorial%2520ligand-receptor%2520interactions%26jtitle%3DFEBS%2520Lett.%26date%3D1997%26volume%3D410%26spage%3D83%26epage%3D86%26doi%3D10.1016%2FS0014-5793%2897%2900412-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Lessons to be learned: the molecular basis of kinase-targeted therapies and drug resistance in non-small cell lung cancer</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">2307</span>– <span class="NLM_lpage">2313</span>, <span class="refDoi"> DOI: 10.1002/anie.201710398</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201710398" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2018&pages=2307-2313&author=J.+Lategahnauthor=M.+Keulauthor=D.+Rauh&title=Lessons+to+be+learned%3A+the+molecular+basis+of+kinase-targeted+therapies+and+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1002%2Fanie.201710398"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Lessons to be Learned: The Molecular Basis of Kinase-Targeted Therapies and Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Lategahn, Jonas; Keul, Marina; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2307-2313</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The treatment of non-small cell lung cancer (NSCLC) is currently experiencing a revolution.  Over the last decade, the knowledge gained about the biochem. features of biomarkers and their predictive abilities has led to the development of targeted small-mol. inhibitors that present an alternative to harsh chemotherapy.  The use of these new therapies has improved the quality of life and increased the survival of patients.  The occurrence of inevitable drug resistance requires the const. development of precision medicine.  The detailed understanding of the target biol. and the search for innovative chem. approaches has encouraged investigations in this field.  Herein, the authors review selected aspects of the mol. targets and present an overview of current topics and challenges in the rational development of small mols. to target NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowadpmmNyvGbVg90H21EOLACvtfcHk0lgYEJZ8TZDCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXoslygtw%253D%253D&md5=78d3ce523d076c820cb7fcbf9a321e63</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710398&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710398%26sid%3Dliteratum%253Aachs%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DLessons%2520to%2520be%2520learned%253A%2520the%2520molecular%2520basis%2520of%2520kinase-targeted%2520therapies%2520and%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2018%26volume%3D57%26spage%3D2307%26epage%3D2313%26doi%3D10.1002%2Fanie.201710398" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grundy, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godfrey, A. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlow, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Healy, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodburn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scarlett, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Henthorn, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richards, L.</span></span> <span> </span><span class="NLM_article-title">Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1911</span>– <span class="NLM_lpage">1914</span>, <span class="refDoi"> DOI: 10.1016/S0960-894X(01)00344-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2FS0960-894X%2801%2900344-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=11459659" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2001&pages=1911-1914&author=A.+J.+Barkerauthor=K.+H.+Gibsonauthor=W.+Grundyauthor=A.+A.+Godfreyauthor=J.+J.+Barlowauthor=M.+P.+Healyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=L.+Scarlettauthor=L.+Henthornauthor=L.+Richards&title=Studies+leading+to+the+identification+of+ZD1839+%28IRESSA%29%3A+an+orally+active%2C+selective+epidermal+growth+factor+receptor+tyrosine+kinase+inhibitor+targeted+to+the+treatment+of+cancer&doi=10.1016%2FS0960-894X%2801%2900344-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Studies leading to the identification of ZD1839 (iressa): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer</span></div><div class="casAuthors">Barker, A. J.; Gibson, K. H.; Grundy, W.; Godfrey, A. A.; Barlow, J. J.; Healy, M. P.; Woodburn, J. R.; Ashton, S. E.; Curry, B. J.; Scarlett, L.; Henthorn, L.; Richards, L.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">1911-1914</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">This paper describes the development of the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 from a lead series of 4-anilinoquinazoline compds.  ZD1839 has suitable properties for use as a clin. effective drug and shows activity against human tumors.  In particular, the use of pharmacokinetic data in the development of ZD1839 is discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpvsJ1FTqEwvbVg90H21EOLACvtfcHk0lgYEJZ8TZDCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXltFylsLo%253D&md5=ebb210453ade246e43de9fd07ae1d581</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2FS0960-894X%2801%2900344-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0960-894X%252801%252900344-4%26sid%3Dliteratum%253Aachs%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26aulast%3DGrundy%26aufirst%3DW.%26aulast%3DGodfrey%26aufirst%3DA.%2BA.%26aulast%3DBarlow%26aufirst%3DJ.%2BJ.%26aulast%3DHealy%26aufirst%3DM.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DScarlett%26aufirst%3DL.%26aulast%3DHenthorn%26aufirst%3DL.%26aulast%3DRichards%26aufirst%3DL.%26atitle%3DStudies%2520leading%2520to%2520the%2520identification%2520of%2520ZD1839%2520%2528IRESSA%2529%253A%2520an%2520orally%2520active%252C%2520selective%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%2520inhibitor%2520targeted%2520to%2520the%2520treatment%2520of%2520cancer%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2001%26volume%3D11%26spage%3D1911%26epage%3D1914%26doi%3D10.1016%2FS0960-894X%2801%2900344-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wakeling, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guy, S. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woodburn, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Curry, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barker, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gibson, K. H.</span></span> <span> </span><span class="NLM_article-title">ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">5749</span>– <span class="NLM_lpage">5754</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=12384534" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2002&pages=5749-5754&author=A.+E.+Wakelingauthor=S.+P.+Guyauthor=J.+R.+Woodburnauthor=S.+E.+Ashtonauthor=B.+J.+Curryauthor=A.+J.+Barkerauthor=K.+H.+Gibson&title=ZD1839+%28Iressa%29%3A+an+orally+active+inhibitor+of+epidermal+growth+factor+signaling+with+potential+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy</span></div><div class="casAuthors">Wakeling, Alan E.; Guy, Simon P.; Woodburn, Jim R.; Ashton, Susan E.; Curry, Brenda J.; Barker, Andrew J.; Gibson, Keith H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5749-5754</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is a promising target for anticancer therapy because of its role in tumor growth, metastasis and angiogenesis, and tumor resistance to chemotherapy and radiotherapy.  We have developed a low-mol.-wt. EGFR tyrosine kinase inhibitor (EGFR-TKI), ZD1839 (Iressa).  ZD1839, a substituted anilinoquinazoline, is a potent EGFR-TKI (IC50 = 0.033 μM) that selectively inhibits EGF-stimulated tumor cell growth (IC50 = 0.054 μM) and that blocks EGF-stimulated EGFR autophosphorylation in tumor cells.  In studies with mice bearing a range of human tumor-derived xenografts, ZD1839 given p.o. once a day inhibited tumor growth in a dose-dependent manner.  The level of expression of EGFR did not det. xenograft tumor sensitivity to ZD1839.  Long-term ZD1839 (>3 mo) treatment of mice bearing A431 xenografts was well tolerated, and ZD1839 completely inhibited tumor growth and induced regression of established tumors.  No drug-resistant tumors appeared during ZD1839 treatment, but some tumors regrew after drug withdrawal.  These studies indicate the potential utility of ZD1839 in the treatment of many human tumors and indicate that continuous once-a-day p.o. dosing might be a suitable therapeutic regimen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqkoHZ9zL06abVg90H21EOLACvtfcHk0lgYEJZ8TZDCrw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XotFyktr8%253D&md5=f5f86c652786db476a2d23b5bbd1a9e9</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWakeling%26aufirst%3DA.%2BE.%26aulast%3DGuy%26aufirst%3DS.%2BP.%26aulast%3DWoodburn%26aufirst%3DJ.%2BR.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DCurry%26aufirst%3DB.%2BJ.%26aulast%3DBarker%26aufirst%3DA.%2BJ.%26aulast%3DGibson%26aufirst%3DK.%2BH.%26atitle%3DZD1839%2520%2528Iressa%2529%253A%2520an%2520orally%2520active%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520signaling%2520with%2520potential%2520for%2520cancer%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2002%26volume%3D62%26spage%3D5749%26epage%3D5754" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacci, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arnold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boman, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cunningham, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiOrio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moyer, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Neveu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pollack, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pustilnik, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reynolds, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sloan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Theleman, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, P.</span></span> <span> </span><span class="NLM_article-title">Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">4838</span>– <span class="NLM_lpage">4848</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9354447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=1997&pages=4838-4848&author=J.+D.+Moyerauthor=E.+G.+Barbacciauthor=K.+K.+Iwataauthor=L.+Arnoldauthor=B.+Bomanauthor=A.+Cunninghamauthor=C.+DiOrioauthor=J.+Dotyauthor=M.+J.+Morinauthor=M.+P.+Moyerauthor=M.+Neveuauthor=V.+A.+Pollackauthor=L.+R.+Pustilnikauthor=M.+M.+Reynoldsauthor=D.+Sloanauthor=A.+Thelemanauthor=P.+Miller&title=Induction+of+apoptosis+and+cell+cycle+arrest+by+CP-358%2C774%2C+an+inhibitor+of+epidermal+growth+factor+receptor+tyrosine+kinase"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Induction of apoptosis and cell cycle arrest by CP-358774, an inhibitor of epidermal growth factor receptor tyrosine kinase</span></div><div class="casAuthors">Moyer, James D.; Barbacci, Elsa G.; Iwata, Kenneth K.; Arnold, Lee; Boman, Bruce; Cunningham, Ann; Diorio, Catherine; Doty, Jonathan; Morin, Michael J.; Moyer, Mikel P.; Neveu, Mark; Pollack, Vincent A.; Pustilnik, Leslie R.; Reynolds, Margaret M.; Sloan, Don; Theleman, April; Miller, Penny</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">4838-4848</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) is overexpressed in a significant percentage of carcinomas and contributes to the malignant phenotype.  CP-358774 is a directly acting inhibitor of human EGFR tyrosine kinase with an IC50 of 2 nM and reduces EGFR autophosphorylation in intact tumor cells with an IC50 of 20 nM.  This inhibition is selective for EGFR tyrosine kinase relative to other tyrosine kinases we have examd., both in assays of isolated kinases and whole cells.  At doses of 100 mg/kg, CP-358774 completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice.  CP-358774 inhibits the proliferation of DiFi human colon tumor cells at submicromolar concns. in cell culture and blocks cell cycle progression at the G1 phase.  This inhibitor produces a marked accumulation of retinoblastoma protein in its underphosphorylated form and accumulation of p27KIP1 in DiFi cells, which may contribute to the cell cycle block.  Inhibition of the EGFR also triggers apoptosis in these cells as detd. by formation of DNA fragments and other criteria.  These results indicate that CP-358774 has potential for the treatment of tumors that are dependent on the EGFR pathway for proliferation or survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpghArQOnGlkbVg90H21EOLACvtfcHk0li6KRLKeGuztQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXnt12nsr4%253D&md5=0a6e9697bf290d8e7c44cbe2a125e0b1</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMoyer%26aufirst%3DJ.%2BD.%26aulast%3DBarbacci%26aufirst%3DE.%2BG.%26aulast%3DIwata%26aufirst%3DK.%2BK.%26aulast%3DArnold%26aufirst%3DL.%26aulast%3DBoman%26aufirst%3DB.%26aulast%3DCunningham%26aufirst%3DA.%26aulast%3DDiOrio%26aufirst%3DC.%26aulast%3DDoty%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DM.%2BJ.%26aulast%3DMoyer%26aufirst%3DM.%2BP.%26aulast%3DNeveu%26aufirst%3DM.%26aulast%3DPollack%26aufirst%3DV.%2BA.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DReynolds%26aufirst%3DM.%2BM.%26aulast%3DSloan%26aufirst%3DD.%26aulast%3DTheleman%26aufirst%3DA.%26aulast%3DMiller%26aufirst%3DP.%26atitle%3DInduction%2520of%2520apoptosis%2520and%2520cell%2520cycle%2520arrest%2520by%2520CP-358%252C774%252C%2520an%2520inhibitor%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D1997%26volume%3D57%26spage%3D4838%26epage%3D4848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambrogio, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kubo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Himmelsbach, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rettig, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Solca, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">4702</span>– <span class="NLM_lpage">4711</span>, <span class="refDoi"> DOI: 10.1038/onc.2008.109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fonc.2008.109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18408761" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2008&pages=4702-4711&author=D.+Liauthor=L.+Ambrogioauthor=T.+Shimamuraauthor=S.+Kuboauthor=M.+Takahashiauthor=L.+R.+Chirieacauthor=R.+F.+Paderaauthor=G.+I.+Shapiroauthor=A.+Baumauthor=F.+Himmelsbachauthor=W.+J.+Rettigauthor=M.+Meyersonauthor=F.+Solcaauthor=H.+Greulichauthor=K.+K.+Wong&title=BIBW2992%2C+an+irreversible+EGFR%2FHER2+inhibitor+highly+effective+in+preclinical+lung+cancer+models&doi=10.1038%2Fonc.2008.109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models</span></div><div class="casAuthors">Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">34</span>),
    <span class="NLM_cas:pages">4702-4711</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are assocd. with sensitivity to treatment with small mol. tyrosine kinase inhibitors.  Although first-generation reversible, ATP-competitive inhibitors showed encouraging clin. responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time.  Such resistance to first-generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3.  Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen.  Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms.  Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib.  These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.  Oncogene (2008) 27, 4702-4711; doi:10.1038/onc.2008.109; published online 14 Apr. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo5PQdKep-Sp7Vg90H21EOLACvtfcHk0li6KRLKeGuztQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXptlKnsbk%253D&md5=24945893e83b4e3d01c267100fdaf57c</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1038%2Fonc.2008.109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2008.109%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DD.%26aulast%3DAmbrogio%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DKubo%26aufirst%3DS.%26aulast%3DTakahashi%26aufirst%3DM.%26aulast%3DChirieac%26aufirst%3DL.%2BR.%26aulast%3DPadera%26aufirst%3DR.%2BF.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DBaum%26aufirst%3DA.%26aulast%3DHimmelsbach%26aufirst%3DF.%26aulast%3DRettig%26aufirst%3DW.%2BJ.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DSolca%26aufirst%3DF.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DBIBW2992%252C%2520an%2520irreversible%2520EGFR%252FHER2%2520inhibitor%2520highly%2520effective%2520in%2520preclinical%2520lung%2520cancer%2520models%26jtitle%3DOncogene%26date%3D2008%26volume%3D27%26spage%3D4702%26epage%3D4711%26doi%3D10.1038%2Fonc.2008.109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dungo, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keating, G. M.</span></span> <span> </span><span class="NLM_article-title">Afatinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">1503</span>– <span class="NLM_lpage">1515</span>, <span class="refDoi"> DOI: 10.1007/s40265-013-0111-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-013-0111-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23982599" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=1503-1515&author=R.+T.+Dungoauthor=G.+M.+Keating&title=Afatinib%3A+first+global+approval&doi=10.1007%2Fs40265-013-0111-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib: First Global Approval</span></div><div class="casAuthors">Dungo, Rosselle T.; Keating, Gillian M.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">1503-1515</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">A review.  Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer.  Afatinib downregulates ErbB signalling by covalently binding to epidermal growth factor receptor (EGFR), human epidermal growth factor receptor (HER) 2 and HER4, irreversibly inhibiting tyrosine kinase autophosphorylation.  It also inhibits transphosphorylation of HER3.  Oral afatinib (Gilotrif®) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumors with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.  Afatinib has also been approved in Taiwan for the first-line treatment of patients with EGFR mutation-pos. NSCLC.  In addn., the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of afatinib (Giotrif) for the treatment of patients with locally advanced or metastatic NSCLC with activating EGFR mutations who are EGFR tyrosine kinase inhibitor naive.  Afatinib is also under regulatory review in Canada, Japan and other Asian countries.  This article summarizes the milestones in the development of afatinib, leading to this first approval in patients with metastatic NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrdPcU5aIqrY7Vg90H21EOLACvtfcHk0ljcPhlQBkEJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVWmurnM&md5=21851cbfac56e2fffcba6c731f123cff</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1007%2Fs40265-013-0111-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-013-0111-6%26sid%3Dliteratum%253Aachs%26aulast%3DDungo%26aufirst%3DR.%2BT.%26aulast%3DKeating%26aufirst%3DG.%2BM.%26atitle%3DAfatinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2013%26volume%3D73%26spage%3D1503%26epage%3D1515%26doi%3D10.1007%2Fs40265-013-0111-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lettiere, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baker, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vincent, P. W.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1880</span>– <span class="NLM_lpage">1889</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-07-2232</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-07-2232" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18606718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2008&pages=1880-1889&author=A.+J.+Gonzalesauthor=K.+E.+Hookauthor=I.+W.+Althausauthor=P.+A.+Ellisauthor=E.+Trachetauthor=A.+M.+Delaneyauthor=P.+J.+Harveyauthor=T.+A.+Ellisauthor=D.+M.+Amatoauthor=J.+M.+Nelsonauthor=D.+W.+Fryauthor=T.+Zhuauthor=C.+M.+Loiauthor=S.+A.+Fakhouryauthor=K.+M.+Schlosserauthor=K.+E.+Sextonauthor=R.+T.+Wintersauthor=J.+E.+Reedauthor=A.+J.+Bridgesauthor=D.+J.+Lettiereauthor=D.+A.+Bakerauthor=J.+Yangauthor=H.+T.+Leeauthor=H.+Tecleauthor=P.+W.+Vincent&title=Antitumor+activity+and+pharmacokinetic+properties+of+PF-00299804%2C+a+second-generation+irreversible+pan-erbB+receptor+tyrosine+kinase+inhibitor&doi=10.1158%2F1535-7163.MCT-07-2232"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor</span></div><div class="casAuthors">Gonzales, Andrea J.; Hook, Kenneth E.; Althaus, Irene W.; Ellis, Paul A.; Trachet, Erin; Delaney, Amy M.; Harvey, Patricia J.; Ellis, Teresa A.; Amato, Danielle M.; Nelson, James M.; Fry, David W.; Zhu, Tong; Loi, Cho-Ming; Fakhoury, Stephen A.; Schlosser, Kevin M.; Sexton, Karen E.; Winters, R. Thomas; Reed, Jessica E.; Bridges, Alex J.; Lettiere, Daniel J.; Baker, Deborah A.; Yang, Jianxin; Lee, Helen T.; Tecle, Haile; Vincent, Patrick W.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1880-1889</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types.  Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments.  PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clin. trials.  PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members.  Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) assocd. with resistance to gefitinib and erlotinib.  Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species. [Mol Cancer Ther 2008;7(7):1880-9].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbL0hP8K2G37Vg90H21EOLACvtfcHk0ljcPhlQBkEJTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCgtb0%253D&md5=3392275d1e4f4d5d70e3b22d4893e3c8</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-07-2232&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-07-2232%26sid%3Dliteratum%253Aachs%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DDelaney%26aufirst%3DA.%2BM.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DEllis%26aufirst%3DT.%2BA.%26aulast%3DAmato%26aufirst%3DD.%2BM.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DLoi%26aufirst%3DC.%2BM.%26aulast%3DFakhoury%26aufirst%3DS.%2BA.%26aulast%3DSchlosser%26aufirst%3DK.%2BM.%26aulast%3DSexton%26aufirst%3DK.%2BE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DLettiere%26aufirst%3DD.%2BJ.%26aulast%3DBaker%26aufirst%3DD.%2BA.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DH.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DVincent%26aufirst%3DP.%2BW.%26atitle%3DAntitumor%2520activity%2520and%2520pharmacokinetic%2520properties%2520of%2520PF-00299804%252C%2520a%2520second-generation%2520irreversible%2520pan-erbB%2520receptor%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2008%26volume%3D7%26spage%3D1880%26epage%3D1889%26doi%3D10.1158%2F1535-7163.MCT-07-2232" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gonzales, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spicer, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reed, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sexton, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Althaus, I. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blaser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fakhoury, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harvey, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCarthy, F. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palmer, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rivault, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlosser, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trachet, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winters, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tecle, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A.</span></span> <span> </span><span class="NLM_article-title">Tyrosine kinase inhibitors. 20. Optimization of substituted quinazoline and pyrido[3,4-d]pyrimidine derivatives as orally active, irreversible inhibitors of the epidermal growth factor receptor family</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">8103</span>– <span class="NLM_lpage">8124</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00883</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00883" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=8103-8124&author=J.+B.+Smaillauthor=A.+J.+Gonzalesauthor=J.+A.+Spicerauthor=H.+Leeauthor=J.+E.+Reedauthor=K.+Sextonauthor=I.+W.+Althausauthor=T.+Zhuauthor=S.+L.+Blackauthor=A.+Blaserauthor=W.+A.+Dennyauthor=P.+A.+Ellisauthor=S.+Fakhouryauthor=P.+J.+Harveyauthor=K.+Hookauthor=F.+O.+McCarthyauthor=B.+D.+Palmerauthor=F.+Rivaultauthor=K.+Schlosserauthor=T.+Ellisauthor=A.+M.+Thompsonauthor=E.+Trachetauthor=R.+T.+Wintersauthor=H.+Tecleauthor=A.+Bridges&title=Tyrosine+kinase+inhibitors.+20.+Optimization+of+substituted+quinazoline+and+pyrido%5B3%2C4-d%5Dpyrimidine+derivatives+as+orally+active%2C+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+family&doi=10.1021%2Facs.jmedchem.6b00883"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4-d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family</span></div><div class="casAuthors">Smaill, Jeff B.; Gonzales, Andrea J.; Spicer, Julie A.; Lee, Helen; Reed, Jessica E.; Sexton, Karen; Althaus, Irene W.; Zhu, Tong; Black, Shannon L.; Blaser, Adrian; Denny, William A.; Ellis, Paul A.; Fakhoury, Stephen; Harvey, Patricia J.; Hook, Ken; McCarthy, Florence O. J.; Palmer, Brian D.; Rivault, Freddy; Schlosser, Kevin; Ellis, Teresa; Thompson, Andrew M.; Trachet, Erin; Winters, R. Thomas; Tecle, Haile; Bridges, Alexander</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">8103-8124</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Structure-activity relationships for inhibition of erbB1, erbB2 and erbB4 were detd. for a series of quinazoline- and pyrido[3,4-d]pyrimidine-based analogs of the irreversible pan-erbB inhibitor, canertinib.  Cyclic amine bearing crotonamides were detd. to provide rapid inhibition of cellular erbB1 autophosphorylation and good metabolic stability in liver microsome and hepatocyte assays.  The influence of 4-anilino substitution on pan-erbB inhibitory potency was investigated.  Several anilines were identified as providing potent, reversible pan-erbB inhibition.  Optimum 4- and 6-substituents with known 7-substituents provided preferred irreversible inhibitors for pharmacodynamic testing in vivo.  Quinazoline I and pyrido[3,4-d]pyrimidine II were identified as clearly superior to canertinib.  Both compds. possess a piperidinyl crotonamide Michael acceptor and a 3-chloro-4-fluoroaniline, indicating these as optimized 6- and 4-substituents resp.  Pharmacokinetic comparison of compds. I and II across three species selected compd. I as the preferred candidate.  Compd. I (PF-00299804) has been assigned the nomenclature of dacomitinib and is currently under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo0-NpOmVq10bVg90H21EOLACvtfcHk0liDGDyDlGiU4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht12gtbvM&md5=442afda669a5c1b7a190cd82b77bee33</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00883&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00883%26sid%3Dliteratum%253Aachs%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DGonzales%26aufirst%3DA.%2BJ.%26aulast%3DSpicer%26aufirst%3DJ.%2BA.%26aulast%3DLee%26aufirst%3DH.%26aulast%3DReed%26aufirst%3DJ.%2BE.%26aulast%3DSexton%26aufirst%3DK.%26aulast%3DAlthaus%26aufirst%3DI.%2BW.%26aulast%3DZhu%26aufirst%3DT.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DBlaser%26aufirst%3DA.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DEllis%26aufirst%3DP.%2BA.%26aulast%3DFakhoury%26aufirst%3DS.%26aulast%3DHarvey%26aufirst%3DP.%2BJ.%26aulast%3DHook%26aufirst%3DK.%26aulast%3DMcCarthy%26aufirst%3DF.%2BO.%26aulast%3DPalmer%26aufirst%3DB.%2BD.%26aulast%3DRivault%26aufirst%3DF.%26aulast%3DSchlosser%26aufirst%3DK.%26aulast%3DEllis%26aufirst%3DT.%26aulast%3DThompson%26aufirst%3DA.%2BM.%26aulast%3DTrachet%26aufirst%3DE.%26aulast%3DWinters%26aufirst%3DR.%2BT.%26aulast%3DTecle%26aufirst%3DH.%26aulast%3DBridges%26aufirst%3DA.%26atitle%3DTyrosine%2520kinase%2520inhibitors.%252020.%2520Optimization%2520of%2520substituted%2520quinazoline%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidine%2520derivatives%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520family%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D8103%26epage%3D8124%26doi%3D10.1021%2Facs.jmedchem.6b00883" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barf, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaptein, A.</span></span> <span> </span><span class="NLM_article-title">Irreversible protein kinase inhibitors: balancing the benefits and risks</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">6243</span>– <span class="NLM_lpage">6262</span>, <span class="refDoi"> DOI: 10.1021/jm3003203</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm3003203" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6243-6262&author=T.+Barfauthor=A.+Kaptein&title=Irreversible+protein+kinase+inhibitors%3A+balancing+the+benefits+and+risks&doi=10.1021%2Fjm3003203"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks</span></div><div class="casAuthors">Barf, Tjeerd; Kaptein, Allard</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">6243-6262</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Not applicable for a Perspective.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo4PLlisO0OVbVg90H21EOLACvtfcHk0liDGDyDlGiU4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVerur8%253D&md5=5d87850857d37faab02e6037ef8140a4</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm3003203&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm3003203%26sid%3Dliteratum%253Aachs%26aulast%3DBarf%26aufirst%3DT.%26aulast%3DKaptein%26aufirst%3DA.%26atitle%3DIrreversible%2520protein%2520kinase%2520inhibitors%253A%2520balancing%2520the%2520benefits%2520and%2520risks%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6243%26epage%3D6262%26doi%3D10.1021%2Fjm3003203" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xia, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mullin, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keith, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Owens, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spector, N. L.</span></span> <span> </span><span class="NLM_article-title">Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">6255</span>– <span class="NLM_lpage">6263</span>, <span class="refDoi"> DOI: 10.1038/sj.onc.1205794</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fsj.onc.1205794" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=12214266" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38Xms1yrs7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2002&pages=6255-6263&author=W.+Xiaauthor=R.+J.+Mullinauthor=B.+R.+Keithauthor=L.+H.+Liuauthor=H.+Maauthor=D.+W.+Rusnakauthor=G.+Owensauthor=K.+J.+Alligoodauthor=N.+L.+Spector&title=Anti-tumor+activity+of+GW572016%3A+a+dual+tyrosine+kinase+inhibitor+blocks+EGF+activation+of+EGFR%2FerbB2+and+downstream+Erk1%2F2+and+AKT+pathways&doi=10.1038%2Fsj.onc.1205794"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways</span></div><div class="casAuthors">Xia, Wenle; Mullin, Robert J.; Keith, Barry R.; Liu, Lei-Hua; Ma, Hong; Rusnak, David W.; Owens, Gary; Alligood, Krystal J.; Spector, Neil L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">41</span>),
    <span class="NLM_cas:pages">6255-6263</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Dual EGFR/erbB2 inhibition is an attractive therapeutic strategy for epithelial tumors, as ligand-induced erbB2/EGFR heterodimerization triggers potent proliferative and survival signals.  Here we show that a small mol., GW572016, potently inhibits both EGFR and erbB2 tyrosine kinases leading to growth arrest and/or apoptosis in EGFR and erbB2-dependent tumor cell lines.  GW572016 markedly reduced tyrosine phosphorylation of EGFR and erbB2, and inhibited activation of Erk1/2 and AKT, downstream effectors of proliferation and cell survival, resp.  Complete inhibition of activated AKT in erbB2 overexpressing cells correlated with a 23-fold increase in apoptosis compared with vehicle controls.  EGF, often elevated in cancer patients, did not reverse the inhibitory effects of GW572016.  These observations were reproduced in vivo, where GW572016 treatment inhibited activation of EGFR, erbB2, Erk1/2 and AKT in human tumor xenografts.  Erk1/2 and AKT represent potential biomarkers to assess the clin. activity of GW572016.  Inhibition of activated AKT in EGFR or erbB2-dependent tumors by GW572016 may lead to tumor regressions when used as a monotherapy, or may enhance the anti-tumor activity of chemotherapeutics, since constitutive activation of AKT has been linked to chemo-resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqYPkZ4sa88irVg90H21EOLACvtfcHk0liDGDyDlGiU4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xms1yrs7w%253D&md5=38d6e25a7cfa1fdfe77fa2fea2c0aa0c</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1205794&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1205794%26sid%3Dliteratum%253Aachs%26aulast%3DXia%26aufirst%3DW.%26aulast%3DMullin%26aufirst%3DR.%2BJ.%26aulast%3DKeith%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DL.%2BH.%26aulast%3DMa%26aufirst%3DH.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DOwens%26aufirst%3DG.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DSpector%26aufirst%3DN.%2BL.%26atitle%3DAnti-tumor%2520activity%2520of%2520GW572016%253A%2520a%2520dual%2520tyrosine%2520kinase%2520inhibitor%2520blocks%2520EGF%2520activation%2520of%2520EGFR%252FerbB2%2520and%2520downstream%2520Erk1%252F2%2520and%2520AKT%2520pathways%26jtitle%3DOncogene%26date%3D2002%26volume%3D21%26spage%3D6255%26epage%3D6263%26doi%3D10.1038%2Fsj.onc.1205794" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosfjord, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baxter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">3958</span>– <span class="NLM_lpage">3965</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-03-2868</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-03-2868" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15173008" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=3958-3965&author=S.+K.+Rabindranauthor=C.+M.+Discafaniauthor=E.+C.+Rosfjordauthor=M.+Baxterauthor=M.+B.+Floydauthor=J.+Golasauthor=W.+A.+Hallettauthor=B.+D.+Johnsonauthor=R.+Nilakantanauthor=E.+Overbeekauthor=M.+F.+Reichauthor=R.+Shenauthor=X.+Shiauthor=H.+R.+Tsouauthor=Y.+F.+Wangauthor=A.+Wissner&title=Antitumor+activity+of+HKI-272%2C+an+orally+active%2C+irreversible+inhibitor+of+the+HER-2+tyrosine+kinase&doi=10.1158%2F0008-5472.CAN-03-2868"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase</span></div><div class="casAuthors">Rabindran, Sridhar K.; Discafani, Carolyn M.; Rosfjord, Edward C.; Baxter, Michelle; Floyd, M. Brawner; Golas, Jonathan; Hallett, William A.; Johnson, Bernard D.; Nilakantan, Ramaswamy; Overbeek, Elsebe; Reich, Marvin F.; Shen, Ru; Shi, Xiaoqing; Tsou, Hwei-Ru; Wang, Yu-Fen; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3958-3965</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">HER-2 belongs to the ErbB family of receptor tyrosine kinases, which has been implicated in a variety of cancers.  Overexpression of HER-2 is seen in 25-30% of breast cancer patients and predicts a poor outcome in patients with primary disease.  Trastuzumab (Herceptin), a monoclonal antibody to HER-2, is specifically approved for HER-2-pos. breast cancer but is active only in a subset of these tumors.  Blocking HER-2 function by a small mol. kinase inhibitor, therefore, represents an attractive alternate strategy to inhibit the growth of HER-2-pos. tumors.  HKI-272 is a potent inhibitor of HER-2 and is highly active against HER-2-overexpressing human breast cancer cell lines in vitro.  It also inhibits the epidermal growth factor receptor (EGFR) kinase and the proliferation of EGFR-dependent cells.  HKI-272 reduces HER-2 receptor autophosphorylation in cells at doses consistent with inhibition of cell proliferation and functions as an irreversible binding inhibitor, most likely by targeting a cysteine residue in the ATP-binding pocket of the receptor.  In agreement with the predicted effects of HER-2 inactivation, HKI-272 treatment of cells results in inhibition of downstream signal transduction events and cell cycle regulatory pathways.  This leads to arrest at the G1-S (Gap 1/DNA synthesis)-phase transition of the cell division cycle, ultimately resulting in decreased cell proliferation.  In vivo, HKI-272 is active in HER-2- and EGFR-dependent tumor xenograft models when dosed orally on a once daily schedule.  On the basis of its favorable preclin. pharmacol. profile, HKI-272 has been selected as a candidate for addnl. development as an antitumor agent in breast and other HER-2-dependent cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2xeLXlAwWvbVg90H21EOLACvtfcHk0ljsqFATZDxwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVKns7o%253D&md5=60accd0599b7c489e4c3753d4f39cab4</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-03-2868&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-03-2868%26sid%3Dliteratum%253Aachs%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DDiscafani%26aufirst%3DC.%2BM.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DBaxter%26aufirst%3DM.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DAntitumor%2520activity%2520of%2520HKI-272%252C%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520HER-2%2520tyrosine%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D3958%26epage%3D3965%26doi%3D10.1158%2F0008-5472.CAN-03-2868" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek-Klumpers, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michalak, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Golas, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Upeslacis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span> <span> </span><span class="NLM_article-title">Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1107</span>– <span class="NLM_lpage">1131</span>, <span class="refDoi"> DOI: 10.1021/jm040159c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040159c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1107-1131&author=H.+R.+Tsouauthor=E.+G.+Overbeek-Klumpersauthor=W.+A.+Hallettauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=R.+S.+Michalakauthor=R.+Nilakantanauthor=C.+Discafaniauthor=J.+Golasauthor=S.+K.+Rabindranauthor=R.+Shenauthor=X.+Shiauthor=Y.+F.+Wangauthor=J.+Upeslacisauthor=A.+Wissner&title=Optimization+of+6%2C7-disubstituted-4-%28arylamino%29quinoline-3-carbonitriles+as+orally+active%2C+irreversible+inhibitors+of+human+epidermal+growth+factor+receptor-2+kinase+activity&doi=10.1021%2Fjm040159c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Optimization of 6,7-Disubstituted-4-(arylamino)quinoline-3-carbonitriles as Orally Active, Irreversible Inhibitors of Human Epidermal Growth Factor Receptor-2 Kinase Activity</span></div><div class="casAuthors">Tsou, Hwei-Ru; Overbeek-Klumpers, Elsebe G.; Hallett, William A.; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Michalak, Ronald S.; Nilakantan, Ramaswamy; Discafani, Carolyn; Golas, Jonathan; Rabindran, Sridhar K.; Shen, Ru; Shi, Xiaoqing; Wang, Yu-Fen; Upeslacis, Janis; Wissner, Allan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1107-1131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles, e.g. I (R1 = H, Cl; R2 = PhCH2O, 1-imidazolyl, 2-furylmethoxy, etc.; R3 = Cl, CN, PhCH2O; R4 = Me, Et; R5 = Me, R6 = Me, HOCH2CH2; R5R6N = azetidinyl, piperidinyl, thiomorpholinyl, etc.) that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepd.  These compds. demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 pos. cells compared to the EGFR kinase inhibitor I [R1 = H; R2 = F; R3 = Cl; R4 = Et; R5 = R6 = Me; (EKB-569)].  Three synthetic routes were used to prep. these compds.  They were prepd. mostly by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles with unsatd. acid chlorides or by amination of 4-chloro-6-(crotonamido)quinoline-3-carbonitriles with monocyclic or bicyclic anilines.  The third route was developed to prep. a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step.  It was shown that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase.  The importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramol. catalysis of the Michael addn. has also been demonstrated.  This, along with improved water soly., resulted in compds. with enhanced biol. properties.  The mol. modeling results consistent with the proposed mechanism of inhibition are presented.  Binding studies of one compd., I [R1 = H; R2 = 2-pyridylmethoxy; R3 = Cl; R4 = Et; R5 = R6 = Me; (HKI-272)] (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells.  Furthermore, it demonstrated excellent oral activity, esp. in HER-2 overexpressing xenografts.  Compd. HKI-272 was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqD0QL4-qQZCbVg90H21EOLACvtfcHk0ljsqFATZDxwyg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXntFKjsA%253D%253D&md5=55f77e41bf920f738ae2750e7ca0eb22</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1021%2Fjm040159c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040159c%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%2BR.%26aulast%3DOverbeek-Klumpers%26aufirst%3DE.%2BG.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMichalak%26aufirst%3DR.%2BS.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DGolas%26aufirst%3DJ.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DUpeslacis%26aufirst%3DJ.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3DOptimization%2520of%25206%252C7-disubstituted-4-%2528arylamino%2529quinoline-3-carbonitriles%2520as%2520orally%2520active%252C%2520irreversible%2520inhibitors%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520kinase%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1107%26epage%3D1131%26doi%3D10.1021%2Fjm040159c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wissner, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Overbeek, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reich, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamuya, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosfjord, E. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Discafani, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabindran, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gruber, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hallett, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilakantan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenberger, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsou, H. R.</span></span> <span> </span><span class="NLM_article-title">Synthesis and structure-activity relationships of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles. The design of an orally active, irreversible inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor (EGFR) and the human epidermal growth factor receptor-2 (HER-2)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>46</i></span>,  <span class="NLM_fpage">49</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1021/jm020241c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm020241c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=46&publication_year=2003&pages=49-63&author=A.+Wissnerauthor=E.+Overbeekauthor=M.+F.+Reichauthor=M.+B.+Floydauthor=B.+D.+Johnsonauthor=N.+Mamuyaauthor=E.+C.+Rosfjordauthor=C.+Discafaniauthor=R.+Davisauthor=X.+Shiauthor=S.+K.+Rabindranauthor=B.+C.+Gruberauthor=F.+Yeauthor=W.+A.+Hallettauthor=R.+Nilakantanauthor=R.+Shenauthor=Y.+F.+Wangauthor=L.+M.+Greenbergerauthor=H.+R.+Tsou&title=Synthesis+and+structure-activity+relationships+of+6%2C7-disubstituted+4-anilinoquinoline-3-carbonitriles.+The+design+of+an+orally+active%2C+irreversible+inhibitor+of+the+tyrosine+kinase+activity+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+the+human+epidermal+growth+factor+receptor-2+%28HER-2%29&doi=10.1021%2Fjm020241c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2)</span></div><div class="casAuthors">Wissner, Allan; Overbeek, Elsebe; Reich, Marvin F.; Floyd, M. Brawner; Johnson, Bernard D.; Mamuya, Nellie; Rosfjord, Edward C.; Discafani, Carolyn; Davis, Rachel; Shi, Xiaoqing; Rabindran, Sridhar K.; Gruber, Brian C.; Ye, Fei; Hallett, William A.; Nilakantan, Ramaswamy; Shen, Ru; Wang, Yu-Fen; Greenberger, Lee M.; Tsou, Hwei-Ru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">46</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">49-63</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A series of 6,7-disubstituted 4-anilinoquinoline-3-carbonitriles, e.g., I, that function as irreversible inhibitors of EGFR and HER-2 kinases have been prepd.  These inhibitors have, at the 6-position, butynamide, crotonamide, and methacrylamide Michael acceptors bearing water-solubilizing substituents.  These compds. were prepd. by acylation of 6-amino-4-(arylamino)quinoline-3-carbonitriles, e.g., II, with unsatd. acid chlorides or mixed anhydrides.  Competitive reactivity studies were performed, showing that attaching a dialkylamino group onto the end of the Michael acceptor results in compds. with greater reactivity due to intramol. catalysis of the Michael addn.  This, along with improved water-soly. results in compds. with enhanced biol. properties.  Mol. modeling results consistent with the proposed mechanism of inhibition are presented.  One compd., I (EKB-569), which shows excellent oral in vivo activity, was selected for further studies and is currently in phase I clin. trials for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq317fAvBYUW7Vg90H21EOLACvtfcHk0lg37gyfxF4Www"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XptFOlsbk%253D&md5=db70c2f78c62824810854295d06ef6a4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fjm020241c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm020241c%26sid%3Dliteratum%253Aachs%26aulast%3DWissner%26aufirst%3DA.%26aulast%3DOverbeek%26aufirst%3DE.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DFloyd%26aufirst%3DM.%2BB.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DRosfjord%26aufirst%3DE.%2BC.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DShi%26aufirst%3DX.%26aulast%3DRabindran%26aufirst%3DS.%2BK.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DHallett%26aufirst%3DW.%2BA.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%2BF.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DTsou%26aufirst%3DH.%2BR.%26atitle%3DSynthesis%2520and%2520structure-activity%2520relationships%2520of%25206%252C7-disubstituted%25204-anilinoquinoline-3-carbonitriles.%2520The%2520design%2520of%2520an%2520orally%2520active%252C%2520irreversible%2520inhibitor%2520of%2520the%2520tyrosine%2520kinase%2520activity%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520the%2520human%2520epidermal%2520growth%2520factor%2520receptor-2%2520%2528HER-2%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2003%26volume%3D46%26spage%3D49%26epage%3D63%26doi%3D10.1021%2Fjm020241c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ghiorghiu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nebhan, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spitzler, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hughes, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jacobs, V. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brewer, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ichihara, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Kadhimi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rowlinson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ranson, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span> <span> </span><span class="NLM_article-title">AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">1046</span>– <span class="NLM_lpage">1061</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-14-0337</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-14-0337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24893891" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=1046-1061&author=D.+A.+Crossauthor=S.+E.+Ashtonauthor=S.+Ghiorghiuauthor=C.+Eberleinauthor=C.+A.+Nebhanauthor=P.+J.+Spitzlerauthor=J.+P.+Ormeauthor=M.+R.+Finlayauthor=R.+A.+Wardauthor=M.+J.+Mellorauthor=G.+Hughesauthor=A.+Rahiauthor=V.+N.+Jacobsauthor=M.+R.+Brewerauthor=E.+Ichiharaauthor=J.+Sunauthor=H.+Jinauthor=P.+Ballardauthor=K.+Al-Kadhimiauthor=R.+Rowlinsonauthor=T.+Klinowskaauthor=G.+H.+Richmondauthor=M.+Cantariniauthor=D.+W.+Kimauthor=M.+R.+Ransonauthor=W.+Pao&title=AZD9291%2C+an+irreversible+EGFR+TKI%2C+overcomes+T790M-mediated+resistance+to+EGFR+inhibitors+in+lung+cancer&doi=10.1158%2F2159-8290.CD-14-0337"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer</span></div><div class="casAuthors">Cross, Darren A. E.; Ashton, Susan E.; Ghiorghiu, Serban; Eberlein, Cath; Nebhan, Caroline A.; Spitzler, Paula J.; Orme, Jonathon P.; Finlay, M. Raymond V.; Ward, Richard A.; Mellor, Martine J.; Hughes, Gareth; Rahi, Amar; Jacobs, Vivien N.; Brewer, Monica Red; Ichihara, Eiki; Sun, Jing; Jin, Hailing; Ballard, Peter; Al-Kadhimi, Katherine; Rowlinson, Rachel; Klinowska, Teresa; Richmond, Graham H. P.; Cantarini, Mireille; Kim, Dong-Wan; Ranson, Malcolm R.; Pao, William</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1046-1061</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A third-generation EGFR inhibitor selectively targets EGFR mutants, including T790M, but not wild-type EGFR, and induces durable antitumor responses in preclin. models and patients with NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDo3e2pAh8YbVg90H21EOLACvtfcHk0lg37gyfxF4Www"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVykur%252FP&md5=f72e56f9463236ddc89eef32a4ab61b3</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-14-0337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-14-0337%26sid%3Dliteratum%253Aachs%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DAshton%26aufirst%3DS.%2BE.%26aulast%3DGhiorghiu%26aufirst%3DS.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DNebhan%26aufirst%3DC.%2BA.%26aulast%3DSpitzler%26aufirst%3DP.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DHughes%26aufirst%3DG.%26aulast%3DRahi%26aufirst%3DA.%26aulast%3DJacobs%26aufirst%3DV.%2BN.%26aulast%3DBrewer%26aufirst%3DM.%2BR.%26aulast%3DIchihara%26aufirst%3DE.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DAl-Kadhimi%26aufirst%3DK.%26aulast%3DRowlinson%26aufirst%3DR.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DRichmond%26aufirst%3DG.%2BH.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DRanson%26aufirst%3DM.%2BR.%26aulast%3DPao%26aufirst%3DW.%26atitle%3DAZD9291%252C%2520an%2520irreversible%2520EGFR%2520TKI%252C%2520overcomes%2520T790M-mediated%2520resistance%2520to%2520EGFR%2520inhibitors%2520in%2520lung%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2014%26volume%3D4%26spage%3D1046%26epage%3D1061%26doi%3D10.1158%2F2159-8290.CD-14-0337" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradbury, R. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Currie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassall, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">James, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kemmitt, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamont, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McFarland, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellor, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perkins, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richmond, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wells, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wrigley, G. L.</span></span> <span> </span><span class="NLM_article-title">Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>57</i></span>,  <span class="NLM_fpage">8249</span>– <span class="NLM_lpage">8267</span>, <span class="refDoi"> DOI: 10.1021/jm500973a</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500973a" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8249-8267&author=M.+R.+Finlayauthor=M.+Andertonauthor=S.+Ashtonauthor=P.+Ballardauthor=P.+A.+Bethelauthor=M.+R.+Boxauthor=R.+H.+Bradburyauthor=S.+J.+Brownauthor=S.+Butterworthauthor=A.+Campbellauthor=C.+Chorleyauthor=N.+Colcloughauthor=D.+A.+Crossauthor=G.+S.+Currieauthor=M.+Gristauthor=L.+Hassallauthor=G.+B.+Hillauthor=D.+Jamesauthor=M.+Jamesauthor=P.+Kemmittauthor=T.+Klinowskaauthor=G.+Lamontauthor=S.+G.+Lamontauthor=N.+Martinauthor=H.+L.+McFarlandauthor=M.+J.+Mellorauthor=J.+P.+Ormeauthor=D.+Perkinsauthor=P.+Perkinsauthor=G.+Richmondauthor=P.+Smithauthor=R.+A.+Wardauthor=M.+J.+Waringauthor=D.+Whittakerauthor=S.+Wellsauthor=G.+L.+Wrigley&title=Discovery+of+a+potent+and+selective+EGFR+inhibitor+%28AZD9291%29+of+both+sensitizing+and+T790M+resistance+mutations+that+spares+the+wild+type+form+of+the+receptor&doi=10.1021%2Fjm500973a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor</span></div><div class="casAuthors">Finlay, M. Raymond V.; Anderton, Mark; Ashton, Susan; Ballard, Peter; Bethel, Paul A.; Box, Matthew R.; Bradbury, Robert H.; Brown, Simon J.; Butterworth, Sam; Campbell, Andrew; Chorley, Christopher; Colclough, Nicola; Cross, Darren A. E.; Currie, Gordon S.; Grist, Matthew; Hassall, Lorraine; Hill, George B.; James, Daniel; James, Michael; Kemmitt, Paul; Klinowska, Teresa; Lamont, Gillian; Lamont, Scott G.; Martin, Nathaniel; McFarland, Heather L.; Mellor, Martine J.; Orme, Jonathon P.; Perkins, David; Perkins, Paula; Richmond, Graham; Smith, Peter; Ward, Richard A.; Waring, Michael J.; Whittaker, David; Wells, Stuart; Wrigley, Gail L.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8249-8267</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) inhibitors have been used clin. in the treatment of nonsmall-cell lung cancer (NSCLC) patients harboring sensitizing (or activating) mutations for a no. of years.  Despite encouraging clin. efficacy with these agents, in many patients resistance develops leading to disease progression.  In most cases, this resistance is in the form of the T790M mutation.  In addn., EGFR wild type receptor inhibition inherent with these agents can lead to dose limiting toxicities of rash and diarrhea.  The authors describe herein the evolution of an early, mutant selective lead to the clin. candidate AZD9291 I, an irreversible inhibitor of both EGFR sensitizing (EGFRm+) and T790M resistance mutations with selectivity over the wild type form of the receptor.  Following observations of significant tumor inhibition in preclin. models, the clin. candidate was administered clin. to patients with T790M pos. EGFR-TKI resistant NSCLC and early efficacy has been obsd., accompanied by an encouraging safety profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGouPAWG9N0Ro7Vg90H21EOLACvtfcHk0lgIUX6Pc-QTqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs1KhurrI&md5=db9db624bb4324c2e22b1ab12035263b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500973a%26sid%3Dliteratum%253Aachs%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DAnderton%26aufirst%3DM.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBallard%26aufirst%3DP.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%2BR.%26aulast%3DBradbury%26aufirst%3DR.%2BH.%26aulast%3DBrown%26aufirst%3DS.%2BJ.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DCampbell%26aufirst%3DA.%26aulast%3DChorley%26aufirst%3DC.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DCurrie%26aufirst%3DG.%2BS.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DHassall%26aufirst%3DL.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DJames%26aufirst%3DD.%26aulast%3DJames%26aufirst%3DM.%26aulast%3DKemmitt%26aufirst%3DP.%26aulast%3DKlinowska%26aufirst%3DT.%26aulast%3DLamont%26aufirst%3DG.%26aulast%3DLamont%26aufirst%3DS.%2BG.%26aulast%3DMartin%26aufirst%3DN.%26aulast%3DMcFarland%26aufirst%3DH.%2BL.%26aulast%3DMellor%26aufirst%3DM.%2BJ.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DPerkins%26aufirst%3DD.%26aulast%3DPerkins%26aufirst%3DP.%26aulast%3DRichmond%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26aulast%3DWhittaker%26aufirst%3DD.%26aulast%3DWells%26aufirst%3DS.%26aulast%3DWrigley%26aufirst%3DG.%2BL.%26atitle%3DDiscovery%2520of%2520a%2520potent%2520and%2520selective%2520EGFR%2520inhibitor%2520%2528AZD9291%2529%2520of%2520both%2520sensitizing%2520and%2520T790M%2520resistance%2520mutations%2520that%2520spares%2520the%2520wild%2520type%2520form%2520of%2520the%2520receptor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8249%26epage%3D8267%26doi%3D10.1021%2Fjm500973a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ward, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Anderton, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ashton, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bethel, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Box, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Butterworth, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Colclough, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chorley, C. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chuaqui, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cross, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dakin, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debreczeni, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eberlein, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finlay, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, G. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grist, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinowska, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lane, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orme, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Waring, M. J.</span></span> <span> </span><span class="NLM_article-title">Structure- and reactivity-based development of covalent inhibitors of the activating and gatekeeper mutant forms of the epidermal growth factor receptor (EGFR)</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">7025</span>– <span class="NLM_lpage">7048</span>, <span class="refDoi"> DOI: 10.1021/jm400822z</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm400822z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=7025-7048&author=R.+A.+Wardauthor=M.+J.+Andertonauthor=S.+Ashtonauthor=P.+A.+Bethelauthor=M.+Boxauthor=S.+Butterworthauthor=N.+Colcloughauthor=C.+G.+Chorleyauthor=C.+Chuaquiauthor=D.+A.+Crossauthor=L.+A.+Dakinauthor=J.+E.+Debreczeniauthor=C.+Eberleinauthor=M.+R.+Finlayauthor=G.+B.+Hillauthor=M.+Gristauthor=T.+C.+Klinowskaauthor=C.+Laneauthor=S.+Martinauthor=J.+P.+Ormeauthor=P.+Smithauthor=F.+Wangauthor=M.+J.+Waring&title=Structure-+and+reactivity-based+development+of+covalent+inhibitors+of+the+activating+and+gatekeeper+mutant+forms+of+the+epidermal+growth+factor+receptor+%28EGFR%29&doi=10.1021%2Fjm400822z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></div><div class="casAuthors">Ward, Richard A.; Anderton, Mark J.; Ashton, Susan; Bethel, Paul A.; Box, Matthew; Butterworth, Sam; Colclough, Nicola; Chorley, Christopher G.; Chuaqui, Claudio; Cross, Darren A. E.; Dakin, Les A.; Debreczeni, Judit E.; Eberlein, Cath; Finlay, M. Raymond V.; Hill, George B.; Grist, Matthew; Klinowska, Teresa C. M.; Lane, Clare; Martin, Scott; Orme, Jonathon P.; Smith, Peter; Wang, Fengjiang; Waring, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7025-7048</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A novel series of small-mol. inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib.  Our reported compds. also show selectivity over wild-type EGFR.  Guided by mol. modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR.  In addn., these compds. show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their obsd. clin. efficacy.  A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quant. structure-property relationship (QSPR) to support design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKi6oNvtQPEbVg90H21EOLACvtfcHk0li4ujTeefAQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXht1CltL%252FN&md5=59c86415d71ac2abe5c6d4486e5d2517</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1021%2Fjm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26aulast%3DWard%26aufirst%3DR.%2BA.%26aulast%3DAnderton%26aufirst%3DM.%2BJ.%26aulast%3DAshton%26aufirst%3DS.%26aulast%3DBethel%26aufirst%3DP.%2BA.%26aulast%3DBox%26aufirst%3DM.%26aulast%3DButterworth%26aufirst%3DS.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DChorley%26aufirst%3DC.%2BG.%26aulast%3DChuaqui%26aufirst%3DC.%26aulast%3DCross%26aufirst%3DD.%2BA.%26aulast%3DDakin%26aufirst%3DL.%2BA.%26aulast%3DDebreczeni%26aufirst%3DJ.%2BE.%26aulast%3DEberlein%26aufirst%3DC.%26aulast%3DFinlay%26aufirst%3DM.%2BR.%26aulast%3DHill%26aufirst%3DG.%2BB.%26aulast%3DGrist%26aufirst%3DM.%26aulast%3DKlinowska%26aufirst%3DT.%2BC.%26aulast%3DLane%26aufirst%3DC.%26aulast%3DMartin%26aufirst%3DS.%26aulast%3DOrme%26aufirst%3DJ.%2BP.%26aulast%3DSmith%26aufirst%3DP.%26aulast%3DWang%26aufirst%3DF.%26aulast%3DWaring%26aufirst%3DM.%2BJ.%26atitle%3DStructure-%2520and%2520reactivity-based%2520development%2520of%2520covalent%2520inhibitors%2520of%2520the%2520activating%2520and%2520gatekeeper%2520mutant%2520forms%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D7025%26epage%3D7048%26doi%3D10.1021%2Fjm400822z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Walter, A. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sjin, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haringsma, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubrovskiy, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labenski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sheets, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St Martin, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karp, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Kalken, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaturvedi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nacht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petter, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westlin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jaw-Tsai, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raponi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Dyke, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Etter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weaver, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simmons, A. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harding, T. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A.</span></span> <span> </span><span class="NLM_article-title">Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">1404</span>– <span class="NLM_lpage">1415</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-13-0314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-13-0314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24065731" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=1404-1415&author=A.+O.+Walterauthor=R.+T.+Sjinauthor=H.+J.+Haringsmaauthor=K.+Ohashiauthor=J.+Sunauthor=K.+Leeauthor=A.+Dubrovskiyauthor=M.+Labenskiauthor=Z.+Zhuauthor=Z.+Wangauthor=M.+Sheetsauthor=T.+St+Martinauthor=R.+Karpauthor=D.+van+Kalkenauthor=P.+Chaturvediauthor=D.+Niuauthor=M.+Nachtauthor=R.+C.+Petterauthor=W.+Westlinauthor=K.+Linauthor=S.+Jaw-Tsaiauthor=M.+Raponiauthor=T.+Van+Dykeauthor=J.+Etterauthor=Z.+Weaverauthor=W.+Paoauthor=J.+Singhauthor=A.+D.+Simmonsauthor=T.+C.+Hardingauthor=A.+Allen&title=Discovery+of+a+mutant-selective+covalent+inhibitor+of+EGFR+that+overcomes+T790M-mediated+resistance+in+NSCLC&doi=10.1158%2F2159-8290.CD-13-0314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC</span></div><div class="casAuthors">Walter, Annette O.; Sjin, Robert Tjin Tham; Haringsma, Henry J.; Ohashi, Kadoaki; Sun, Jing; Lee, Kwangho; Dubrovskiy, Aleksandr; Labenski, Matthew; Zhu, Zhendong; Wang, Zhigang; Sheets, Michael; St. Martin, Thia; Karp, Russell; van Kalken, Dan; Chaturvedi, Prasoon; Niu, Deqiang; Nacht, Mariana; Petter, Russell C.; Westlin, William; Lin, Kevin; Jaw-Tsai, Sarah; Raponi, Mitch; Van Dyke, Terry; Etter, Jeff; Weaver, Zoe; Pao, William; Singh, Juswinder; Simmons, Andrew D.; Harding, Thomas C.; Allen, Andrew</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1404-1415</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors.  However, clin. efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation.  CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor.  Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models.  Minimal activity of CO-1686 against the WT EGFR receptor was obsd.  In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of addnl. mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial-mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors.  These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoR0CDWQZ5wn7Vg90H21EOLACvtfcHk0li4ujTeefAQFQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2rtLvN&md5=3d111f4bf958f2fda6890fbc0e1d99f5</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-13-0314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-13-0314%26sid%3Dliteratum%253Aachs%26aulast%3DWalter%26aufirst%3DA.%2BO.%26aulast%3DSjin%26aufirst%3DR.%2BT.%26aulast%3DHaringsma%26aufirst%3DH.%2BJ.%26aulast%3DOhashi%26aufirst%3DK.%26aulast%3DSun%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DLabenski%26aufirst%3DM.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DSt%2BMartin%26aufirst%3DT.%26aulast%3DKarp%26aufirst%3DR.%26aulast%3Dvan%2BKalken%26aufirst%3DD.%26aulast%3DChaturvedi%26aufirst%3DP.%26aulast%3DNiu%26aufirst%3DD.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DLin%26aufirst%3DK.%26aulast%3DJaw-Tsai%26aufirst%3DS.%26aulast%3DRaponi%26aufirst%3DM.%26aulast%3DVan%2BDyke%26aufirst%3DT.%26aulast%3DEtter%26aufirst%3DJ.%26aulast%3DWeaver%26aufirst%3DZ.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DSimmons%26aufirst%3DA.%2BD.%26aulast%3DHarding%26aufirst%3DT.%2BC.%26aulast%3DAllen%26aufirst%3DA.%26atitle%3DDiscovery%2520of%2520a%2520mutant-selective%2520covalent%2520inhibitor%2520of%2520EGFR%2520that%2520overcomes%2520T790M-mediated%2520resistance%2520in%2520NSCLC%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D1404%26epage%3D1415%26doi%3D10.1158%2F2159-8290.CD-13-0314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. S.</span></span> <span> </span><span class="NLM_article-title">Olmutinib: first global approval</span>. <i>Drugs</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>76</i></span>,  <span class="NLM_fpage">1153</span>– <span class="NLM_lpage">1157</span>, <span class="refDoi"> DOI: 10.1007/s40265-016-0606-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1007%2Fs40265-016-0606-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27357069" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2016&pages=1153-1157&author=E.+S.+Kim&title=Olmutinib%3A+first+global+approval&doi=10.1007%2Fs40265-016-0606-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Olmutinib: First Global Approval</span></div><div class="casAuthors">Kim, Esther S.</div><div class="citationInfo"><span class="NLM_cas:title">Drugs</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1153-1157</span>CODEN:
                <span class="NLM_cas:coden">DRUGAY</span>;
        ISSN:<span class="NLM_cas:issn">0012-6667</span>.
    
            (<span class="NLM_cas:orgname">Springer International Publishing AG</span>)
        </div><div class="casAbstract">Olmutinib (OlitaTM) is an oral, third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) that is being developed by Boehringer Ingelheim and Hanmi Pharmaceutical Co.  Ltd for the treatment of non-small cell lung cancer (NSCLC).  Third-generation EGFR TKIs with covalent binding to the receptors demonstrate irreversible enzymic inhibition of activating EGFR mutations and T790M mutation (a common reason for acquired EGFR TKI resistance), while sparing wild-type EGFR.  In Dec. 2015, olmutinib was granted breakthrough therapy designation in NSCLC by the US FDA.  In May 2016, olmutinib received its first global approval in South Korea for the treatment of patients with locally advanced or metastatic EGFR T790M mutation-pos. NSCLC.  This article summarizes the milestones in the development of olmutinib leading to this first approval.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriY-HbqvpWrrVg90H21EOLACvtfcHk0lhIdkl_Q2c_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtFaitr%252FP&md5=749828b58c3a4ce11f607c2dcfef6b9c</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1007%2Fs40265-016-0606-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs40265-016-0606-z%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DE.%2BS.%26atitle%3DOlmutinib%253A%2520first%2520global%2520approval%26jtitle%3DDrugs%26date%3D2016%26volume%3D76%26spage%3D1153%26epage%3D1157%26doi%3D10.1007%2Fs40265-016-0606-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Engel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Hope and disappointment: covalent inhibitors to overcome drug resistance in non-small cell lung cancer</span>. <i>ACS Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">2</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1021/acsmedchemlett.5b00475</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acsmedchemlett.5b00475" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2016&pages=2-5&author=J.+Engelauthor=J.+Lategahnauthor=D.+Rauh&title=Hope+and+disappointment%3A+covalent+inhibitors+to+overcome+drug+resistance+in+non-small+cell+lung+cancer&doi=10.1021%2Facsmedchemlett.5b00475"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Hope and Disappointment: Covalent Inhibitors to Overcome Drug Resistance in Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Engel, Julian; Lategahn, Jonas; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-5</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the last five years, the detailed understanding of how to overcome T790M drug resistance in non-small cell lung cancer (NSCLC) has culminated in the development of a third-generation of covalent EGFR inhibitors with excellent clin. outcomes.  However, the emergence of a newly discovered acquired drug resistance challenges the concept of small mol. targeted cancer therapy in NSCLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcxNkfyBm4vrVg90H21EOLACvtfcHk0lhIdkl_Q2c_4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XktVOluw%253D%253D&md5=738e3286dd1b1d4110249e33cceec9ac</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Facsmedchemlett.5b00475&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facsmedchemlett.5b00475%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DJ.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DHope%2520and%2520disappointment%253A%2520covalent%2520inhibitors%2520to%2520overcome%2520drug%2520resistance%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2016%26volume%3D7%26spage%3D2%26epage%3D5%26doi%3D10.1021%2Facsmedchemlett.5b00475" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jura, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endres, N. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deindl, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Das, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamers, M. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wemmer, D. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>137</i></span>,  <span class="NLM_fpage">1293</span>– <span class="NLM_lpage">1307</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2009.04.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2009.04.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19563760" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD1Mvlt1Kqsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=137&publication_year=2009&pages=1293-1307&author=N.+Juraauthor=N.+F.+Endresauthor=K.+Engelauthor=S.+Deindlauthor=R.+Dasauthor=M.+H.+Lamersauthor=D.+E.+Wemmerauthor=X.+Zhangauthor=J.+Kuriyan&title=Mechanism+for+activation+of+the+EGF+receptor+catalytic+domain+by+the+juxtamembrane+segment&doi=10.1016%2Fj.cell.2009.04.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment</span></div><div class="casAuthors">Jura Natalia; Endres Nicholas F; Engel Kate; Deindl Sebastian; Das Rahul; Lamers Meindert H; Wemmer David E; Zhang Xuewu; Kuriyan John</div><div class="citationInfo"><span class="NLM_cas:title">Cell</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">137</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1293-307</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Signaling by the epidermal growth factor receptor requires an allosteric interaction between the kinase domains of two receptors, whereby one activates the other.  We show that the intracellular juxtamembrane segment of the receptor, known to potentiate kinase activity, is able to dimerize the kinase domains.  The C-terminal half of the juxtamembrane segment latches the activated kinase domain to the activator, and the N-terminal half of this segment further potentiates dimerization, most likely by forming an antiparallel helical dimer that engages the transmembrane helices of the activated receptor.  Our data are consistent with a mechanism in which the extracellular domains block the intrinsic ability of the transmembrane and cytoplasmic domains to dimerize and activate, with ligand binding releasing this block.  The formation of the activating juxtamembrane latch is prevented by the C-terminal tails in a structure of an inactive kinase domain dimer, suggesting how alternative dimers can prevent ligand-independent activation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTTynNJaIAyrIFEOhA_Im3cfW6udTcc2eaqxus8xxYD97ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1Mvlt1Kqsw%253D%253D&md5=6b47587025fd347e72fd240097a0b311</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2009.04.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2009.04.025%26sid%3Dliteratum%253Aachs%26aulast%3DJura%26aufirst%3DN.%26aulast%3DEndres%26aufirst%3DN.%2BF.%26aulast%3DEngel%26aufirst%3DK.%26aulast%3DDeindl%26aufirst%3DS.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DLamers%26aufirst%3DM.%2BH.%26aulast%3DWemmer%26aufirst%3DD.%2BE.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DMechanism%2520for%2520activation%2520of%2520the%2520EGF%2520receptor%2520catalytic%2520domain%2520by%2520the%2520juxtamembrane%2520segment%26jtitle%3DCell%26date%3D2009%26volume%3D137%26spage%3D1293%26epage%3D1307%26doi%3D10.1016%2Fj.cell.2009.04.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lemmon, M. A.</span></span> <span> </span><span class="NLM_article-title">Ligand-induced ErbB receptor dimerization</span>. <i>Exp. Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">648</span>, <span class="refDoi"> DOI: 10.1016/j.yexcr.2008.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.yexcr.2008.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19038249" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXis1alurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=2009&pages=638-648&author=M.+A.+Lemmon&title=Ligand-induced+ErbB+receptor+dimerization&doi=10.1016%2Fj.yexcr.2008.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-induced ErbB receptor dimerization</span></div><div class="casAuthors">Lemmon, Mark A.</div><div class="citationInfo"><span class="NLM_cas:title">Experimental Cell Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">638-648</span>CODEN:
                <span class="NLM_cas:coden">ECREAL</span>;
        ISSN:<span class="NLM_cas:issn">0014-4827</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Structural studies have provided important new insights into how ligand binding promotes homodimerization and activation of the EGF receptor and the other members of the ErbB family of receptor tyrosine kinases.  These structures have also suggested possible explanations for the unique properties of ErbB2, which has no known ligand and can cause cell transformation (and tumorigenesis) by simple overexpression.  In parallel with these advances, studies of the EGF receptor at the cell surface increasingly argue that the structural studies are missing key mechanistic components.  This is particularly evident in the structural prediction that EGF binding linked to receptor dimerization should be pos. cooperative, whereas cell-surface EGF-binding studies suggest neg. cooperativity.  In this review, I summarize studies of ErbB receptor extracellular regions in soln. and of intact receptors at the cell surface, and attempt to reconcile the differences suggested by the two approaches.  By combining results obtained with receptor 'parts', it is qual. possible to explain some models for the properties of the whole receptor.  These considerations underline the need to consider the intact ErbB receptors as intact allosterically regulated enzymes, and to combine cellular and structural studies into a complete picture.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRYKrRiZAe2bVg90H21EOLACvtfcHk0ljxbkW34a7lRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXis1alurs%253D&md5=62a7a424e192dbd493da47db3bb03ea0</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.yexcr.2008.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexcr.2008.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DLemmon%26aufirst%3DM.%2BA.%26atitle%3DLigand-induced%2520ErbB%2520receptor%2520dimerization%26jtitle%3DExp.%2520Cell%2520Res.%26date%3D2009%26volume%3D315%26spage%3D638%26epage%3D648%26doi%3D10.1016%2Fj.yexcr.2008.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chung, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akita, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vandlen, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toomre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schlessinger, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mellman, I.</span></span> <span> </span><span class="NLM_article-title">Spatial control of EGF receptor activation by reversible dimerization on living cells</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>464</i></span>,  <span class="NLM_fpage">783</span>– <span class="NLM_lpage">787</span>, <span class="refDoi"> DOI: 10.1038/nature08827</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature08827" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20208517" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXivVCitL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=464&publication_year=2010&pages=783-787&author=I.+Chungauthor=R.+Akitaauthor=R.+Vandlenauthor=D.+Toomreauthor=J.+Schlessingerauthor=I.+Mellman&title=Spatial+control+of+EGF+receptor+activation+by+reversible+dimerization+on+living+cells&doi=10.1038%2Fnature08827"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Spatial control of EGF receptor activation by reversible dimerization on living cells</span></div><div class="casAuthors">Chung, Inhee; Akita, Robert; Vandlen, Richard; Toomre, Derek; Schlessinger, Joseph; Mellman, Ira</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">464</span>
        (<span class="NLM_cas:issue">7289</span>),
    <span class="NLM_cas:pages">783-787</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) is a type I receptor tyrosine kinase, the deregulation of which has been implicated in a variety of human carcinomas.  EGFR signaling is preceded by receptor dimerization, typically thought to result from a ligand-induced conformational change in the ectodomain that exposes a loop (dimerization arm) required for receptor assocn.  Ligand binding may also trigger allosteric changes in the cytoplasmic domain of the receptor that is crucial for signaling.  Despite these insights, ensemble-averaging approaches have not detd. the precise mechanism of receptor activation in situ.  Using quantum-dot-based optical tracking of single mols. combined with a novel time-dependent diffusivity anal., here we present the dimerization dynamics of individual EGFRs on living cells.  Before ligand addn., EGFRs spontaneously formed finite-lifetime dimers kinetically stabilized by their dimerization arms.  The dimers were primed both for ligand binding and for signaling, such that after EGF addn. they rapidly showed a very slow diffusivity state that correlated with activation.  Although the kinetic stability of unliganded dimers was in principle sufficient for EGF-independent activation, ligand binding was still required for signaling.  Interestingly, dimers were enriched in the cell periphery in an actin- and receptor-expression-dependent fashion, resulting in a peripheral enhancement of EGF-induced signaling that may enable polarized responses to growth factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUYh4yyD5mS7Vg90H21EOLACvtfcHk0ljxbkW34a7lRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXivVCitL8%253D&md5=c6d3437ece792063efd06017d917ae0b</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1038%2Fnature08827&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08827%26sid%3Dliteratum%253Aachs%26aulast%3DChung%26aufirst%3DI.%26aulast%3DAkita%26aufirst%3DR.%26aulast%3DVandlen%26aufirst%3DR.%26aulast%3DToomre%26aufirst%3DD.%26aulast%3DSchlessinger%26aufirst%3DJ.%26aulast%3DMellman%26aufirst%3DI.%26atitle%3DSpatial%2520control%2520of%2520EGF%2520receptor%2520activation%2520by%2520reversible%2520dimerization%2520on%2520living%2520cells%26jtitle%3DNature%26date%3D2010%26volume%3D464%26spage%3D783%26epage%3D787%26doi%3D10.1038%2Fnature08827" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Madshus, I. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stang, E.</span></span> <span> </span><span class="NLM_article-title">Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking</span>. <i>J. Cell Sci.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>122</i></span>,  <span class="NLM_fpage">3433</span>– <span class="NLM_lpage">3439</span>, <span class="refDoi"> DOI: 10.1242/jcs.050260</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1242%2Fjcs.050260" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19759283" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurjF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2009&pages=3433-3439&author=I.+H.+Madshusauthor=E.+Stang&title=Internalization+and+intracellular+sorting+of+the+EGF+receptor%3A+a+model+for+understanding+the+mechanisms+of+receptor+trafficking&doi=10.1242%2Fjcs.050260"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Internalization and intracellular sorting of the EGF receptor: a model for understanding the mechanisms of receptor trafficking</span></div><div class="casAuthors">Madshus, Inger Helene; Stang, Espen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cell Science</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3433-3439</span>CODEN:
                <span class="NLM_cas:coden">JNCSAI</span>;
        ISSN:<span class="NLM_cas:issn">0021-9533</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR; also known as ErbB1) is 1 of 4 related receptor tyrosine kinases.  These receptors (EGFR, ErbB2, ErbB3, and ErbB4) are frequently overexpressed in cancer and such overexpression is assocd. with poor clin. outcome.  Understanding the mechanisms involved in growth-factor-receptor downregulation is medically important, as several drugs that interfere with the function and trafficking of ErbB proteins are currently being developed or are already in clin. trials.  EGFR has become a model protein for understanding the biol. and endocytosis of related growth-factor receptors, and the mechanisms involved in its endocytosis and degrdn. have been scrutinized for several decades.  Nevertheless, the details and principles of these processes are still poorly understood and often controversial.  In particular, the literature describing how the ubiquitylation and recruitment of EGFR to clathrin-coated pits are connected is inconsistent and confusing.  We discuss the impact of signaling motifs, kinase activity, and ubiquitylation on clathrin-dependent endocytosis and lysosomal sorting of EGFR.  In addn., we discuss potential explanations for contradicting reports, and propose models for the recruitment of ligand-activated EGFR to clathrin-coated pits as well as for lysosomal sorting of ligand-activated EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrii2kZPG0_hrVg90H21EOLACvtfcHk0ljxbkW34a7lRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhsVSkurjF&md5=81b4646afcd6fb43600ef6bd5c8d2bf6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1242%2Fjcs.050260&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fjcs.050260%26sid%3Dliteratum%253Aachs%26aulast%3DMadshus%26aufirst%3DI.%2BH.%26aulast%3DStang%26aufirst%3DE.%26atitle%3DInternalization%2520and%2520intracellular%2520sorting%2520of%2520the%2520EGF%2520receptor%253A%2520a%2520model%2520for%2520understanding%2520the%2520mechanisms%2520of%2520receptor%2520trafficking%26jtitle%3DJ.%2520Cell%2520Sci.%26date%3D2009%26volume%3D122%26spage%3D3433%26epage%3D3439%26doi%3D10.1242%2Fjcs.050260" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tomas, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Futter, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eden, E. R.</span></span> <span> </span><span class="NLM_article-title">EGF receptor trafficking: consequences for signaling and cancer</span>. <i>Trends Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">26</span>– <span class="NLM_lpage">34</span>, <span class="refDoi"> DOI: 10.1016/j.tcb.2013.11.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.tcb.2013.11.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24295852" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2014&pages=26-34&author=A.+Tomasauthor=C.+E.+Futterauthor=E.+R.+Eden&title=EGF+receptor+trafficking%3A+consequences+for+signaling+and+cancer&doi=10.1016%2Fj.tcb.2013.11.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor trafficking: consequences for signaling and cancer</span></div><div class="casAuthors">Tomas, Alejandra; Futter, Clare E.; Eden, Emily R.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Cell Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-34</span>CODEN:
                <span class="NLM_cas:coden">TCBIEK</span>;
        ISSN:<span class="NLM_cas:issn">0962-8924</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The ligand-stimulated epidermal growth factor receptor (EGFR) has been extensively studied in the anal. of mol. mechanisms regulating endocytic traffic and the role of that traffic in signal transduction.  Although such studies have largely focused on mitogenic signaling and dysregulated traffic in tumorigenesis, there is growing interest in the potential role of EGFR traffic in cell survival and the consequent response to cancer therapy.  Here we review recent advances in our understanding of mol. mechanisms regulating ligand-stimulated EGFR activation, internalization, and post-endocytic sorting.  The role of EGFR overexpression/mutation and new modulators of EGFR traffic in cancer and the response to cancer therapeutics are also discussed.  Finally, we speculate on the relationship between EGFR traffic and cell survival.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDLWxypVYs-bVg90H21EOLACvtfcHk0lhVAeL6U_HbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvV2gt7zP&md5=850921a0c652f9401704f4152db482a5</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.tcb.2013.11.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tcb.2013.11.002%26sid%3Dliteratum%253Aachs%26aulast%3DTomas%26aufirst%3DA.%26aulast%3DFutter%26aufirst%3DC.%2BE.%26aulast%3DEden%26aufirst%3DE.%2BR.%26atitle%3DEGF%2520receptor%2520trafficking%253A%2520consequences%2520for%2520signaling%2520and%2520cancer%26jtitle%3DTrends%2520Cell%2520Biol.%26date%3D2014%26volume%3D24%26spage%3D26%26epage%3D34%26doi%3D10.1016%2Fj.tcb.2013.11.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Okizono, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banba, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oga, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Muraguchi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakurai, H.</span></span> <span> </span><span class="NLM_article-title">Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>293</i></span>,  <span class="NLM_fpage">2288</span>– <span class="NLM_lpage">2301</span>, <span class="refDoi"> DOI: 10.1074/jbc.M117.811299</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.M117.811299" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29255092" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXivVCktrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2018&pages=2288-2301&author=T.+Tanakaauthor=Y.+Zhouauthor=T.+Ozawaauthor=R.+Okizonoauthor=A.+Banbaauthor=T.+Yamamuraauthor=E.+Ogaauthor=A.+Muraguchiauthor=H.+Sakurai&title=Ligand-activated+epidermal+growth+factor+receptor+%28EGFR%29+signaling+governs+endocytic+trafficking+of+unliganded+receptor+monomers+by+non-canonical+phosphorylation&doi=10.1074%2Fjbc.M117.811299"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Ligand-activated epidermal growth factor receptor (EGFR) signaling governs endocytic trafficking of unliganded receptor monomers by non-canonical phosphorylation</span></div><div class="casAuthors">Tanaka, Tomohiro; Zhou, Yue; Ozawa, Tatsuhiko; Okizono, Ryuya; Banba, Ayako; Yamamura, Tomohiro; Oga, Eiji; Muraguchi, Atsushi; Sakurai, Hiroaki</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2288-2301</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The canonical description of transmembrane receptor function is initial binding of ligand, followed by initiation of intracellular signaling and then internalization en route to degrdn. or recycling to the cell surface.  It is known that low concns. of extracellular ligand lead to a higher proportion of receptor that is recycled and that non-canonical mechanisms of receptor activation, including phosphorylation by the kinase p38, can induce internalization and recycling.  However, no connections have been made between these pathways; i.e. it has yet to be established what happens to unbound receptors following stimulation with ligand.  Here we demonstrate that a minimal level of activation of epidermal growth factor receptor (EGFR) tyrosine kinase by low levels of ligand is sufficient to fully activate downstream mitogen-activated protein kinase (MAPK) pathways, with most of the remaining unbound EGFR mols. being efficiently phosphorylated at intracellular serine/threonine residues by activated mitogen-activated protein kinase.  This non-canonical, p38-mediated phosphorylation of the C-tail of EGFR, near Ser-1015, induces the clathrin-mediated endocytosis of the unliganded EGFR monomers, which occurs slightly later than the canonical endocytosis of ligand-bound EGFR dimers via tyrosine autophosphorylation.  EGFR endocytosis via the non-canonical pathway is largely recycled back to the plasma membrane as functional receptors, whereas p38-independent populations are mainly sorted for lysosomal degrdn.  Moreover, ligand concns. balance these endocytic trafficking pathways.  These results demonstrate that ligand-activated EGFR signaling controls unliganded receptors through feedback phosphorylation, identifying a dual-mode regulation of the endocytic trafficking dynamics of EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeUZPggAmsqrVg90H21EOLACvtfcHk0lhVAeL6U_HbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXivVCktrY%253D&md5=8fdbb32e1e5f14330bd31938c6e1669d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M117.811299&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M117.811299%26sid%3Dliteratum%253Aachs%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DOzawa%26aufirst%3DT.%26aulast%3DOkizono%26aufirst%3DR.%26aulast%3DBanba%26aufirst%3DA.%26aulast%3DYamamura%26aufirst%3DT.%26aulast%3DOga%26aufirst%3DE.%26aulast%3DMuraguchi%26aufirst%3DA.%26aulast%3DSakurai%26aufirst%3DH.%26atitle%3DLigand-activated%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520governs%2520endocytic%2520trafficking%2520of%2520unliganded%2520receptor%2520monomers%2520by%2520non-canonical%2520phosphorylation%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2018%26volume%3D293%26spage%3D2288%26epage%3D2301%26doi%3D10.1074%2Fjbc.M117.811299" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kirisits, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pils, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krainer, M.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor receptor degradation: an alternative view of oncogenic pathways</span>. <i>Int. J. Biochem. Cell Biol.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">2173</span>– <span class="NLM_lpage">2182</span>, <span class="refDoi"> DOI: 10.1016/j.biocel.2007.07.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.biocel.2007.07.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17855153" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtFWgsL%252FE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2007&pages=2173-2182&author=A.+Kirisitsauthor=D.+Pilsauthor=M.+Krainer&title=Epidermal+growth+factor+receptor+degradation%3A+an+alternative+view+of+oncogenic+pathways&doi=10.1016%2Fj.biocel.2007.07.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor degradation: An alternative view of oncogenic pathways</span></div><div class="casAuthors">Kirisits, Andreas; Pils, Dietmar; Krainer, Michael</div><div class="citationInfo"><span class="NLM_cas:title">International Journal of Biochemistry & Cell Biology</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2173-2182</span>CODEN:
                <span class="NLM_cas:coden">IJBBFU</span>;
        ISSN:<span class="NLM_cas:issn">1357-2725</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Pos. regulation of epidermal growth factor receptor signaling is related to many human malignancies.  Besides overexpression and gain of function mutations, the escape from neg. regulation through an increase in epidermal growth factor receptor stability has evolved as yet another key factor contributing to enhanced receptor activity.  Intensive research over the past years has provided considerable evidence concerning the mol. mechanisms which provide epidermal growth factor receptor degrdn. c-Cbl mediated ubiquitination, endocytosis via clathrin-coated pits, endosomal sorting and lysosomal degrdn. have become well-investigated cornerstones.  Recent findings on the interdependency of the endosomal sorting complexes required for transport in multivesicular body sorting, stress the topicality of receptor tyrosine kinase downregulation.  Here, we review the degrdn. pathway of the epidermal growth factor receptor, following the receptor from ligand binding to the lysosome and illustrating different modes of oncogenic deregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFmbYOt2CM-7Vg90H21EOLACvtfcHk0lhVAeL6U_HbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtFWgsL%252FE&md5=217d7eca5e246a18927e5a94ca476897</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.biocel.2007.07.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.biocel.2007.07.012%26sid%3Dliteratum%253Aachs%26aulast%3DKirisits%26aufirst%3DA.%26aulast%3DPils%26aufirst%3DD.%26aulast%3DKrainer%26aufirst%3DM.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520degradation%253A%2520an%2520alternative%2520view%2520of%2520oncogenic%2520pathways%26jtitle%3DInt.%2520J.%2520Biochem.%2520Cell%2520Biol.%26date%3D2007%26volume%3D39%26spage%3D2173%26epage%3D2182%26doi%3D10.1016%2Fj.biocel.2007.07.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gureasko, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span> <span> </span><span class="NLM_article-title">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>125</i></span>,  <span class="NLM_fpage">1137</span>– <span class="NLM_lpage">1149</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2006.05.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2006.05.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16777603" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=125&publication_year=2006&pages=1137-1149&author=X.+Zhangauthor=J.+Gureaskoauthor=K.+Shenauthor=P.+A.+Coleauthor=J.+Kuriyan&title=An+allosteric+mechanism+for+activation+of+the+kinase+domain+of+epidermal+growth+factor+receptor&doi=10.1016%2Fj.cell.2006.05.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor</span></div><div class="casAuthors">Zhang, Xuewu; Gureasko, Jodi; Shen, Kui; Cole, Philip A.; Kuriyan, John</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">125</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1137-1149</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mechanism by which the epidermal growth factor receptor (EGFR) is activated upon dimerization has eluded definition.  We find that the EGFR kinase domain can be activated by increasing its local concn. or by mutating a leucine (L834R) in the activation loop, the phosphorylation of which is not required for activation.  This suggests that the kinase domain is intrinsically auto-inhibited, and an intermol. interaction promotes its activation.  Using further mutational anal. and crystallog. we demonstrate that the auto-inhibited conformation of the EGFR kinase domain resembles that of Src and cyclin-dependent kinases (CDKs).  EGFR activation results from the formation of an asym. dimer in which the C-terminal lobe of one kinase domain plays a role analogous to that of cyclin in activated CDK/cyclin complexes.  The CDK/cyclin-like complex formed by two kinase domains thus explains the activation of EGFR-family receptors by homo- or heterodimerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQsRAzLF-wK7Vg90H21EOLACvtfcHk0lhVAeL6U_HbDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmsVOms7g%253D&md5=f7b6795851425346f588cbd682125c93</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2006.05.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2006.05.013%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DGureasko%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DK.%26aulast%3DCole%26aufirst%3DP.%2BA.%26aulast%3DKuriyan%26aufirst%3DJ.%26atitle%3DAn%2520allosteric%2520mechanism%2520for%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DCell%26date%3D2006%26volume%3D125%26spage%3D1137%26epage%3D1149%26doi%3D10.1016%2Fj.cell.2006.05.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truesdale, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, O. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hassell, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dickerson, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pennisi, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Horne, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lackey, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alligood, K. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusnak, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilmer, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shewchuk, L.</span></span> <span> </span><span class="NLM_article-title">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">6652</span>– <span class="NLM_lpage">6659</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-04-1168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-04-1168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15374980" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2004&pages=6652-6659&author=E.+R.+Woodauthor=A.+T.+Truesdaleauthor=O.+B.+McDonaldauthor=D.+Yuanauthor=A.+Hassellauthor=S.+H.+Dickersonauthor=B.+Ellisauthor=C.+Pennisiauthor=E.+Horneauthor=K.+Lackeyauthor=K.+J.+Alligoodauthor=D.+W.+Rusnakauthor=T.+M.+Gilmerauthor=L.+Shewchuk&title=A+unique+structure+for+epidermal+growth+factor+receptor+bound+to+GW572016+%28Lapatinib%29%3A+relationships+among+protein+conformation%2C+inhibitor+off-rate%2C+and+receptor+activity+in+tumor+cells&doi=10.1158%2F0008-5472.CAN-04-1168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells</span></div><div class="casAuthors">Wood, Edgar R.; Truesdale, Anne T.; McDonald, Octerloney B.; Yuan, Derek; Hassell, Anne; Dickerson, Scott H.; Ellis, Byron; Pennisi, Christopher; Horne, Earnest; Lackey, Karen; Alligood, Krystal J.; Rusnak, David W.; Gilmer, Tona M.; Shewchuk, Lisa</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6652-6659</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">GW572016 (Lapatinib) is a tyrosine kinase inhibitor in clin. development for cancer that is a potent dual inhibitor of epidermal growth factor receptor (EGFR, ErbB-1) and ErbB-2.  The authors detd. the crystal structure of EGFR bound to GW572016.  The compd. is bound to an inactive-like conformation of EGFR that is very different from the active-like structure bound by the selective EGFR inhibitor OSI-774 (Tarceva) described previously.  Surprisingly, the authors found that GW572016 has a very slow off-rate from the purified intracellular domains of EGFR and ErbB-2 compared with OSI-774 and another EGFR selective inhibitor, ZD-1839 (Iressa).  Treatment of tumor cells with these inhibitors results in down-regulation of receptor tyrosine phosphorylation.  The authors evaluated the duration of the drug effect after washing away free compd. and found that the rate of recovery of receptor phosphorylation in the tumor cells reflected the inhibitor off-rate from the purified intracellular domain.  The slow off-rate of GW572016 correlates with a prolonged down-regulation of receptor tyrosine phosphorylation in tumor cells.  The differences in the off-rates of these drugs and the ability of GW572016 to inhibit ErbB-2 can be explained by the enzyme-inhibitor structures.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXjJPy6XYk4rVg90H21EOLACvtfcHk0liN5JGCErD2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnsFOlu7g%253D&md5=788d92fc5db9f1ecf9d3fbf3142e5c9f</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-04-1168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-04-1168%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DE.%2BR.%26aulast%3DTruesdale%26aufirst%3DA.%2BT.%26aulast%3DMcDonald%26aufirst%3DO.%2BB.%26aulast%3DYuan%26aufirst%3DD.%26aulast%3DHassell%26aufirst%3DA.%26aulast%3DDickerson%26aufirst%3DS.%2BH.%26aulast%3DEllis%26aufirst%3DB.%26aulast%3DPennisi%26aufirst%3DC.%26aulast%3DHorne%26aufirst%3DE.%26aulast%3DLackey%26aufirst%3DK.%26aulast%3DAlligood%26aufirst%3DK.%2BJ.%26aulast%3DRusnak%26aufirst%3DD.%2BW.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26aulast%3DShewchuk%26aufirst%3DL.%26atitle%3DA%2520unique%2520structure%2520for%2520epidermal%2520growth%2520factor%2520receptor%2520bound%2520to%2520GW572016%2520%2528Lapatinib%2529%253A%2520relationships%2520among%2520protein%2520conformation%252C%2520inhibitor%2520off-rate%252C%2520and%2520receptor%2520activity%2520in%2520tumor%2520cells%26jtitle%3DCancer%2520Res.%26date%3D2004%26volume%3D64%26spage%3D6652%26epage%3D6659%26doi%3D10.1158%2F0008-5472.CAN-04-1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Becker, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ocal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nguyen, H. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phan, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Monitoring conformational changes in the receptor tyrosine kinase EGFR</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">990</span>– <span class="NLM_lpage">994</span>, <span class="refDoi"> DOI: 10.1002/cbic.201600115</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fcbic.201600115" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=26991964" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XmsVGgu74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2016&pages=990-994&author=C.+Beckerauthor=S.+Ocalauthor=H.+D.+Nguyenauthor=T.+Phanauthor=M.+Keulauthor=J.+R.+Simardauthor=D.+Rauh&title=Monitoring+conformational+changes+in+the+receptor+tyrosine+kinase+EGFR&doi=10.1002%2Fcbic.201600115"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Monitoring Conformational Changes in the Receptor Tyrosine Kinase EGFR</span></div><div class="casAuthors">Becker, Christian; Oecal, Sinan; Nguyen, Hoang D.; Phan, Trang; Keul, Marina; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">990-994</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The receptor tyrosine kinase EGFR is regulated by complex conformational changes, and this conformational control is disturbed in certain types of cancer.  Many ligands are known to bind EGFR in its active conformation, thereby preventing ATP from binding.  Only a few ligands are known to stabilize EGFR in its inactive conformation, thus providing novel strategies for perturbing EGFR activity.  We report a direct binding assay that enables the identification of novel ligands that bind to and stabilize the inactive conformation of EGFR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMdR7Fh5FHtLVg90H21EOLACvtfcHk0liN5JGCErD2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XmsVGgu74%253D&md5=2380ac96f4e43ce19a95eca1e0d81f46</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fcbic.201600115&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.201600115%26sid%3Dliteratum%253Aachs%26aulast%3DBecker%26aufirst%3DC.%26aulast%3DOcal%26aufirst%3DS.%26aulast%3DNguyen%26aufirst%3DH.%2BD.%26aulast%3DPhan%26aufirst%3DT.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DMonitoring%2520conformational%2520changes%2520in%2520the%2520receptor%2520tyrosine%2520kinase%2520EGFR%26jtitle%3DChemBioChem%26date%3D2016%26volume%3D17%26spage%3D990%26epage%3D994%26doi%3D10.1002%2Fcbic.201600115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Richters, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tuckmantel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Proteus in the world of proteins: conformational changes in protein kinases</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>343</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">206</span>, <span class="refDoi"> DOI: 10.1002/ardp.201000028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fardp.201000028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20336692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=343&publication_year=2010&pages=193-206&author=M.+Rabillerauthor=M.+Getlikauthor=S.+Kl%C3%BCterauthor=A.+Richtersauthor=S.+Tuckmantelauthor=J.+R.+Simardauthor=D.+Rauh&title=Proteus+in+the+world+of+proteins%3A+conformational+changes+in+protein+kinases&doi=10.1002%2Fardp.201000028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Proteus in the world of proteins: Conformational changes in protein kinases</span></div><div class="casAuthors">Rabiller, Matthias; Getlik, Matthaeus; Klueter, Sabine; Richters, Andre; Tueckmantel, Sandra; Simard, Jeffrey R.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Archiv der Pharmazie (Weinheim, Germany)</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">343</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">193-206</span>CODEN:
                <span class="NLM_cas:coden">ARPMAS</span>;
        ISSN:<span class="NLM_cas:issn">0365-6233</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  The 512 protein kinases encoded by the human genome are a prime example of Nature's ability to create diversity by introducing variations to a highly conserved theme.  The activity of each kinase domain is controlled by layers of regulatory mechanisms involving different combinations of post-translational modifications, intramol. contacts, and intermol. interactions.  Ultimately, they all achieve their effect by favoring particular conformations that promote or prevent the kinase domain from catalyzing protein phosphorylation.  The central role of kinases in various diseases has encouraged extensive investigations of their biol. function and 3-dimensional structures, yielding a more detailed understanding of the mechanisms that regulate protein kinase activity by conformational changes.  Here, the authors discuss these regulatory mechanisms and show how conformational changes can be exploited for the design of specific inhibitors that lock protein kinases in inactive conformations.  In addn., the authors highlight recent developments to monitor ligand-induced structural changes in protein kinases and for screening and identifying inhibitors that stabilize enzymically incompetent kinase conformations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRChkP9MKuIbVg90H21EOLACvtfcHk0liN5JGCErD2UA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXjvFaku7s%253D&md5=0833f19b8565afc03c39bf5fb5a87175</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2Fardp.201000028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201000028%26sid%3Dliteratum%253Aachs%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRichters%26aufirst%3DA.%26aulast%3DTuckmantel%26aufirst%3DS.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DProteus%2520in%2520the%2520world%2520of%2520proteins%253A%2520conformational%2520changes%2520in%2520protein%2520kinases%26jtitle%3DArch.%2520Pharm.%26date%3D2010%26volume%3D343%26spage%3D193%26epage%3D206%26doi%3D10.1002%2Fardp.201000028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.1016/j.ccr.2006.12.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+H.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity&doi=10.1016%2Fj.ccr.2006.12.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lhq5QPwgk9iUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227%26doi%3D10.1016%2Fj.ccr.2006.12.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yusa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwata, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">2250</span>– <span class="NLM_lpage">2261</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2013.02.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmc.2013.02.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23490150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjvVOjur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=2250-2261&author=Y.+Kawakitaauthor=M.+Setoauthor=T.+Ohashiauthor=T.+Tamuraauthor=T.+Yusaauthor=H.+Mikiauthor=H.+Iwataauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=S.+Sogabeauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Design+and+synthesis+of+novel+pyrimido%5B4%2C5-b%5Dazepine+derivatives+as+HER2%2FEGFR+dual+inhibitors&doi=10.1016%2Fj.bmc.2013.02.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Design and synthesis of novel pyrimido[4,5-b]azepine derivatives as HER2/EGFR dual inhibitors</span></div><div class="casAuthors">Kawakita, Youichi; Seto, Masaki; Ohashi, Tomohiro; Tamura, Toshiya; Yusa, Tadashi; Miki, Hiroshi; Iwata, Hidehisa; Kamiguchi, Hidenori; Tanaka, Toshimasa; Sogabe, Satoshi; Ohta, Yoshikazu; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2250-2261</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A novel 7,6 fused bicyclic scaffold, pyrimido[4,5-b]azepine was designed to fit into the ATP binding site of the HER2/EGFR proteins.  The synthesis of this scaffold was accomplished by an intramol. Claisen-type condensation.  As the results of optimization lead us to 4-anilino and 6-functional groups, we discovered 6-substituted amide deriv. 19b, which has a 1-benzothiophen-4-yloxy group attached to the 4-anilino group.  An x-ray co-crystal structure of 19b with EGFR demonstrated that the N-1 and N-3 nitrogens of the pyrimido[4,5-b]azepine scaffold make hydrogen-bonding interactions with the main chain NH of Met793 and the side chain of Thr854 via a water-mediated hydrogen bond network, resp.  In addn., the NH proton at the 9-position makes an addnl. hydrogen bond with the carbonyl group of Met793, as we expected.  Compd. 19b revealed potent HER2/EGFR kinase (IC50: 24/36 nM) and BT474 cell growth (GI50: 18 nM) inhibitory activities based on its pseudo-irreversible (PI) profile.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgZnx0wBvJ2bVg90H21EOLACvtfcHk0lhq5QPwgk9iUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjvVOjur4%253D&md5=956974cbdbe39b00edb70587ca97af22</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2013.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2013.02.014%26sid%3Dliteratum%253Aachs%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DOhashi%26aufirst%3DT.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DYusa%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520pyrimido%255B4%252C5-b%255Dazepine%2520derivatives%2520as%2520HER2%252FEGFR%2520dual%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2013%26volume%3D21%26spage%3D2250%26epage%3D2261%26doi%3D10.1016%2Fj.bmc.2013.02.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gajiwala, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Feng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferre, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ryan, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brodsky, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weinrich, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kath, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stewart, A.</span></span> <span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">209</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1016/j.str.2012.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23273428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition&doi=10.1016%2Fj.str.2012.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0lhq5QPwgk9iUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219%26doi%3D10.1016%2Fj.str.2012.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sordella, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bell, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haber, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>305</i></span>,  <span class="NLM_fpage">1163</span>– <span class="NLM_lpage">1167</span>, <span class="refDoi"> DOI: 10.1126/science.1101637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscience.1101637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15284455" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=305&publication_year=2004&pages=1163-1167&author=R.+Sordellaauthor=D.+W.+Bellauthor=D.+A.+Haberauthor=J.+Settleman&title=Gefitinib-sensitizing+EGFR+mutations+in+lung+cancer+activate+anti-apoptotic+pathways&doi=10.1126%2Fscience.1101637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways</span></div><div class="casAuthors">Sordella, Raffaella; Bell, Daphne W.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">305</span>
        (<span class="NLM_cas:issue">5687</span>),
    <span class="NLM_cas:pages">1163-1167</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Gefitinib (Iressa, AstraZeneca Pharmaceuticals) is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) and induces dramatic clin. responses in nonsmall cell lung cancers (NSCLCs) with activating mutations within the EGFR kinase domain.  The authors report that these mutant EGFRs selectively activate Akt and signal transduction and activator of transcription (STAT) signaling pathways, which promote cell survival, but have no effect on extracellular signal-regulated kinase signaling, which induces proliferation.  NSCLC cells expressing mutant EGFRs underwent extensive apoptosis after small interfering RNA-mediated knockdown of the mutant EGFR or treatment with pharmacol. inhibitors of Akt and STAT signaling and were relatively resistant to apoptosis induced by conventional chemotherapeutic drugs.  Thus, mutant EGFRs selectively transduce survival signals on which NSCLCs become dependent; inhibition of those signals by gefitinib may contribute to the drug's efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrKHDqaSobm7Vg90H21EOLACvtfcHk0ljTsJNzyPiLug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXmslCmur8%253D&md5=e9742920d5e320357b774495746e6581</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1126%2Fscience.1101637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1101637%26sid%3Dliteratum%253Aachs%26aulast%3DSordella%26aufirst%3DR.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGefitinib-sensitizing%2520EGFR%2520mutations%2520in%2520lung%2520cancer%2520activate%2520anti-apoptotic%2520pathways%26jtitle%3DScience%26date%3D2004%26volume%3D305%26spage%3D1163%26epage%3D1167%26doi%3D10.1126%2Fscience.1101637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nafa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lau, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reva, B. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span> <span> </span><span class="NLM_article-title">EGFR exon 20 insertion mutations in lung adenocarcinomas: prevalence, molecular heterogeneity, and clinicopathologic characteristics</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">220</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-12-0620</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-12-0620" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23371856" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=220-229&author=M.+E.+Arcilaauthor=K.+Nafaauthor=J.+E.+Chaftauthor=N.+Rekhtmanauthor=C.+Lauauthor=B.+A.+Revaauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=M.+Ladanyi&title=EGFR+exon+20+insertion+mutations+in+lung+adenocarcinomas%3A+prevalence%2C+molecular+heterogeneity%2C+and+clinicopathologic+characteristics&doi=10.1158%2F1535-7163.MCT-12-0620"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics</span></div><div class="casAuthors">Arcila, Maria E.; Nafa, Khedoudja; Chaft, Jamie E.; Rekhtman, Natasha; Lau, Christopher; Reva, Boris A.; Zakowski, Maureen F.; Kris, Mark G.; Ladanyi, Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">220-229</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In contrast to other primary epidermal growth factor receptor (EGFR) mutations in lung adenocarcinomas, insertions in exon 20 of EGFR have been generally assocd. with resistance to EGFR-tyrosine kinase inhibitors.  Their mol. spectrum, clinicopathol. characteristics, and prevalence are not well established.  Tumors harboring EGFR exon 20 insertions were identified through an algorithmic screen of 1,500 lung adenocarcinomas.  Cases were first tested for common mutations in EGFR (exons 19 and 21) and KRAS (exon 2) and, if neg., further analyzed for EGFR exon 20 insertions.  All samples underwent extended genotyping for other driver mutations in EGFR, KRAS, BRAF, ERBB2/HER2, NRAS, PIK3CA, MEK1, and AKT by mass spectrometry; a subset was evaluated for ALK rearrangements.  We identified 33 EGFR exon 20 insertion cases [2.2%, 95% confidence interval (CI), 1.6-3.1], all mutually exclusive with mutations in the other genes tested (except PIK3CA).  They were more common among never-smokers (P < 0.0001).  There was no assocn. with age, sex, race, or stage.  Morphol., tumors were similar to those with common EGFR mutations but with frequent solid histol.  Insertions were highly variable in position and size, ranging from 3 to 12 bp, resulting in 13 different insertions, which, by mol. modeling, are predicted to have potentially different effects on erlotinib binding.  EGFR exon 20 insertion testing identifies a distinct subset of lung adenocarcinomas, accounting for at least 9% of all EGFR-mutated cases, representing the third most common type of EGFR mutation after exon 19 deletions and L858R.  Insertions are structurally heterogeneous with potential implications for response to EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqv1GpDUzx3KLVg90H21EOLACvtfcHk0ljTsJNzyPiLug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXitlWisrc%253D&md5=5f9c4df38f65a6948af8572c5dbfd222</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-12-0620&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-12-0620%26sid%3Dliteratum%253Aachs%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DNafa%26aufirst%3DK.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DLau%26aufirst%3DC.%26aulast%3DReva%26aufirst%3DB.%2BA.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DLadanyi%26aufirst%3DM.%26atitle%3DEGFR%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520adenocarcinomas%253A%2520prevalence%252C%2520molecular%2520heterogeneity%252C%2520and%2520clinicopathologic%2520characteristics%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D220%26epage%3D229%26doi%3D10.1158%2F1535-7163.MCT-12-0620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Leduc, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merlio, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Besse, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Debieuvre, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bringuier, P. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monnet, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rouquette, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fraboulet-Moreau, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemoine, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pouessel, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mosser, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vaylet, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Langlais, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Missy, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moro-Sibilot, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cadranel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barlesi, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beau-Faller, M.</span></span> <span> </span><span class="NLM_article-title">Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</span>. <i>Ann. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>28</i></span>,  <span class="NLM_fpage">2715</span>– <span class="NLM_lpage">2724</span>, <span class="refDoi"> DOI: 10.1093/annonc/mdx404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1093%2Fannonc%2Fmdx404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28945865" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1M%252FitV2rsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2017&pages=2715-2724&author=C.+Leducauthor=J.+P.+Merlioauthor=B.+Besseauthor=H.+Blonsauthor=D.+Debieuvreauthor=P.+P.+Bringuierauthor=I.+Monnetauthor=I.+Rouquetteauthor=S.+Fraboulet-Moreauauthor=A.+Lemoineauthor=D.+Pouesselauthor=J.+Mosserauthor=F.+Vayletauthor=A.+Langlaisauthor=P.+Missyauthor=F.+Morinauthor=D.+Moro-Sibilotauthor=J.+Cadranelauthor=F.+Barlesiauthor=M.+Beau-Faller&title=Clinical+and+molecular+characteristics+of+non-small-cell+lung+cancer+%28NSCLC%29+harboring+EGFR+mutation%3A+results+of+the+nationwide+French+Cooperative+Thoracic+Intergroup+%28IFCT%29+program&doi=10.1093%2Fannonc%2Fmdx404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program</span></div><div class="casAuthors">Leduc C; Merlio J P; Merlio J P; Besse B; Blons H; Blons H; Debieuvre D; Bringuier P P; Bringuier P P; Monnet I; Rouquette I; Fraboulet-Moreau S; Lemoine A; Lemoine A; Pouessel D; Mosser J; Vaylet F; Langlais A; Missy P; Morin F; Moro-Sibilot D; Cadranel J; Cadranel J; Barlesi F; Beau-Faller M; Beau-Faller M</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2715-2724</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Background:  EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI).  To better understand these features, we reviewed all cases of EGFR-mutated non-small-cell lung cancer collected in the Biomarkers France database.  Patients and methods:  Of 17 664 patients, 1837 (11%) with EGFR-mutated non-small-cell lung cancer were retrospectively analyzed for clinical and molecular characteristics.  Results were correlated with survival and treatment response for the 848 stage IV patients.  Results:  EGFR exon 18, 19, 20 and 21 mutations were found in 102 (5.5%), 931 (51%), 102 (5.5%) and 702 (38%) patients, respectively.  Over 50% of exon 18 and 20 mutated patients were smokers.  The median follow-up was 51.7 months.  EGFR mutation type was prognostic of overall survival (OS) versus wild-type {exon 19: hazard ratio (HR)=0.51 [95% confidence interval (CI): 0.41-0.64], P < 0.0001; exon 21: HR = 0.76 (95% CI: 0.61-0.95), P = 0.002; exon 20: HR = 1.56 (95% CI: 1.02-2.38), P = 0.004}.  EGFR mutation type was prognostic of progression-free survival versus wild-type [exon 19: HR = 0.62 (95% CI: 0.49-0.78), P < 0.0001; exon 20: HR = 1.46 (95% CI: 0.96-2.21), P = 0.07].  First-line treatment choice did not influence OS in multivariate analysis.  First-line TKI predicted improved progression-free survival versus chemotherapy [HR = 0.67 (95% CI: 0.53-0.85), P = 0.001].  OS was longer for del19 versus L858R, which was associated with better OS compared with other exon 21 mutations, including L861Q.  TKI improved survival in patients with exon 18 mutations, while chemotherapy was more beneficial for exon 20-mutated patients.  Conclusion:  EGFR mutation type can inform the most appropriate treatment.  Therapeutic schedule had no impact on OS in our study, although TKI should be prescribed in first-line considering the risk of missing the opportunity to use this treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSBxG_Z3jiSUcKL0FlyGHDofW6udTcc2eaqwwLmNpB1rbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1M%252FitV2rsw%253D%253D&md5=96f76c23b8d2b0ae5cc743f6fcce53a2</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx404%26sid%3Dliteratum%253Aachs%26aulast%3DLeduc%26aufirst%3DC.%26aulast%3DMerlio%26aufirst%3DJ.%2BP.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DBlons%26aufirst%3DH.%26aulast%3DDebieuvre%26aufirst%3DD.%26aulast%3DBringuier%26aufirst%3DP.%2BP.%26aulast%3DMonnet%26aufirst%3DI.%26aulast%3DRouquette%26aufirst%3DI.%26aulast%3DFraboulet-Moreau%26aufirst%3DS.%26aulast%3DLemoine%26aufirst%3DA.%26aulast%3DPouessel%26aufirst%3DD.%26aulast%3DMosser%26aufirst%3DJ.%26aulast%3DVaylet%26aufirst%3DF.%26aulast%3DLanglais%26aufirst%3DA.%26aulast%3DMissy%26aufirst%3DP.%26aulast%3DMorin%26aufirst%3DF.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DBarlesi%26aufirst%3DF.%26aulast%3DBeau-Faller%26aufirst%3DM.%26atitle%3DClinical%2520and%2520molecular%2520characteristics%2520of%2520non-small-cell%2520lung%2520cancer%2520%2528NSCLC%2529%2520harboring%2520EGFR%2520mutation%253A%2520results%2520of%2520the%2520nationwide%2520French%2520Cooperative%2520Thoracic%2520Intergroup%2520%2528IFCT%2529%2520program%26jtitle%3DAnn.%2520Oncol.%26date%3D2017%26volume%3D28%26spage%3D2715%26epage%3D2724%26doi%3D10.1093%2Fannonc%2Fmdx404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sarkaria, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Singh, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heelan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rusch, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fulton, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kupfer, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">EGF receptor gene mutations are common in lung cancers from ″never smokers″ and are associated with sensitivity of tumors to gefitinib and erlotinib</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>101</i></span>,  <span class="NLM_fpage">13306</span>– <span class="NLM_lpage">13311</span>, <span class="refDoi"> DOI: 10.1073/pnas.0405220101</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.0405220101" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15329413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=101&publication_year=2004&pages=13306-13311&author=W.+Paoauthor=V.+Millerauthor=M.+Zakowskiauthor=J.+Dohertyauthor=K.+Politiauthor=I.+Sarkariaauthor=B.+Singhauthor=R.+Heelanauthor=V.+Ruschauthor=L.+Fultonauthor=E.+Mardisauthor=D.+Kupferauthor=R.+Wilsonauthor=M.+Krisauthor=H.+Varmus&title=EGF+receptor+gene+mutations+are+common+in+lung+cancers+from+%E2%80%B3never+smokers%E2%80%B3+and+are+associated+with+sensitivity+of+tumors+to+gefitinib+and+erlotinib&doi=10.1073%2Fpnas.0405220101"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib</span></div><div class="casAuthors">Pao, William; Miller, Vincent; Zakowski, Maureen; Doherty, Jennifer; Politi, Katerina; Sarkaria, Inderpal; Singh, Bhuvanesh; Heelan, Robert; Rusch, Valerie; Fulton, Lucinda; Mardis, Elaine; Kupfer, Doris; Wilson, Richard; Kris, Mark; Varmus, Harold</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">101</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">13306-13311</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene are reportedly assocd. with sensitivity of lung cancers to gefitinib (Iressa), kinase inhibitor.  In-frame deletions occur in exon 19, whereas point mutations occur frequently in codon 858 (exon 21).  We found from sequencing the EGFR TK domain that 7 of 10 gefitinib-sensitive tumors had similar types of alterations; no mutations were found in eight gefitinib-refractory tumors (P = 0.004).  Five of seven tumors sensitive to erlotinib (Tarceva), a related kinase inhibitor for which the clin. relevant target is undocumented, had analogous somatic mutations, as opposed to none of 10 erlotinib-refractory tumors (P = 0.003).  Because most mutation-pos. tumors were adenocarcinomas from patients who smoked <100 cigarettes in a lifetime ("never smokers"), we screened EGFR exons 2-28 in 15 adenocarcinomas resected from untreated never smokers.  Seven tumors had TK domain mutations, in contrast to 4 of 81 non-small cell lung cancers resected from untreated former or current smokers (P = 0.0001).  Immunoblotting of lysates from cells transiently transfected with various EGFR constructs demonstrated that, compared to wild-type protein, an exon 19 deletion mutant induced diminished levels of phosphotyrosine, whereas the phosphorylation at tyrosine 1092 of an exon 21 point mutant was inhibited at 10-fold lower concns. of drug.  Collectively, these data show that adenocarcinomas from never smokers comprise a distinct subset of lung cancers, frequently contg. mutations within the TK domain of EGFR that are assocd. with gefitinib and erlotinib sensitivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovevWonTGqELVg90H21EOLACvtfcHk0lgbN1AcQqA4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFems70%253D&md5=38f491968552501b7463a688fa0e62ff</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0405220101&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0405220101%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DZakowski%26aufirst%3DM.%26aulast%3DDoherty%26aufirst%3DJ.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSarkaria%26aufirst%3DI.%26aulast%3DSingh%26aufirst%3DB.%26aulast%3DHeelan%26aufirst%3DR.%26aulast%3DRusch%26aufirst%3DV.%26aulast%3DFulton%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%26aulast%3DKupfer%26aufirst%3DD.%26aulast%3DWilson%26aufirst%3DR.%26aulast%3DKris%26aufirst%3DM.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DEGF%2520receptor%2520gene%2520mutations%2520are%2520common%2520in%2520lung%2520cancers%2520from%2520%25E2%2580%25B3never%2520smokers%25E2%2580%25B3%2520and%2520are%2520associated%2520with%2520sensitivity%2520of%2520tumors%2520to%2520gefitinib%2520and%2520erlotinib%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2004%26volume%3D101%26spage%3D13306%26epage%3D13311%26doi%3D10.1073%2Fpnas.0405220101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Paez, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tracy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gabriel, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kaye, F. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lindeman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boggon, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sasaki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujii, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, B. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span> <span> </span><span class="NLM_article-title">EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>304</i></span>,  <span class="NLM_fpage">1497</span>– <span class="NLM_lpage">1500</span>, <span class="refDoi"> DOI: 10.1126/science.1099314</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscience.1099314" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15118125" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=304&publication_year=2004&pages=1497-1500&author=J.+G.+Paezauthor=P.+A.+J%C3%A4nneauthor=J.+C.+Leeauthor=S.+Tracyauthor=H.+Greulichauthor=S.+Gabrielauthor=P.+Hermanauthor=F.+J.+Kayeauthor=N.+Lindemanauthor=T.+J.+Boggonauthor=K.+Naokiauthor=H.+Sasakiauthor=Y.+Fujiiauthor=M.+J.+Eckauthor=W.+R.+Sellersauthor=B.+E.+Johnsonauthor=M.+Meyerson&title=EGFR+mutations+in+lung+cancer%3A+correlation+with+clinical+response+to+gefitinib+therapy&doi=10.1126%2Fscience.1099314"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy</span></div><div class="casAuthors">Paez, J. Guillermo; Jaenne, Pasi A.; Lee, Jeffrey C.; Tracy, Sean; Greulich, Heidi; Gabriel, Stacey; Herman, Paula; Kaye, Frederic J.; Lindeman, Neal; Boggon, Titus J.; Naoki, Katsuhiko; Sasaki, Hidefumi; Fujii, Yoshitaka; Eck, Michael J.; Sellers, William R.; Johnson, Bruce E.; Meyerson, Matthew</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">304</span>
        (<span class="NLM_cas:issue">5676</span>),
    <span class="NLM_cas:pages">1497-1500</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinase genes were sequenced in non-small cell lung cancer (NSCLC) and matched normal tissue.  Somatic mutations of the epidermal growth factor receptor gene EGFR were found in 15 of 58 unselected tumors from Japan and 1 of 61 from the United States.  Treatment with the EGFR kinase inhibitor gefitinib (Iressa) causes tumor regression in some patients with NSCLC, more frequently in Japan.  EGFR mutations were found in addnl. lung cancer samples from U.S. patients who responded to gefitinib therapy and in a lung adenocarcinoma cell line that was hypersensitive to growth inhibition by gefitinib, but not in gefitinib-insensitive tumors or cell lines.  These results suggest that EGFR mutations may predict sensitivity to gefitinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGxLJH5f3Kb7Vg90H21EOLACvtfcHk0lgbN1AcQqA4WQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXksVGmsbs%253D&md5=6df1b11bf9b3c284fbe000e34c61ebac</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1126%2Fscience.1099314&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1099314%26sid%3Dliteratum%253Aachs%26aulast%3DPaez%26aufirst%3DJ.%2BG.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DTracy%26aufirst%3DS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHerman%26aufirst%3DP.%26aulast%3DKaye%26aufirst%3DF.%2BJ.%26aulast%3DLindeman%26aufirst%3DN.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DSasaki%26aufirst%3DH.%26aulast%3DFujii%26aufirst%3DY.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DMeyerson%26aufirst%3DM.%26atitle%3DEGFR%2520mutations%2520in%2520lung%2520cancer%253A%2520correlation%2520with%2520clinical%2520response%2520to%2520gefitinib%2520therapy%26jtitle%3DScience%26date%3D2004%26volume%3D304%26spage%3D1497%26epage%3D1500%26doi%3D10.1126%2Fscience.1099314" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wolle, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Augmented reality in scientific publications-taking the visualization of 3D structures to the next level</span>. <i>ACS Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">496</span>– <span class="NLM_lpage">499</span>, <span class="refDoi"> DOI: 10.1021/acschembio.8b00153</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acschembio.8b00153" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXktFOlu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2018&pages=496-499&author=P.+Wolleauthor=M.+P.+M%C3%BCllerauthor=D.+Rauh&title=Augmented+reality+in+scientific+publications-taking+the+visualization+of+3D+structures+to+the+next+level&doi=10.1021%2Facschembio.8b00153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Augmented Reality in Scientific Publications-Taking the Visualization of 3D Structures to the Next Level</span></div><div class="casAuthors">Wolle, Patrik; Mueller, Matthias P.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">496-499</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The examn. of three-dimensional structural models in scientific publications allows the reader to validate or invalidate conclusions drawn by the authors.  However, either due to a (temporary) lack of access to proper visualization software or a lack of proficiency, this information is not necessarily available to every reader.  As the digital revolution is quickly progressing, technologies have become widely available that overcome the limitations and offer to all the opportunity to appreciate models not only in 2D, but also in 3D.  Addnl., mobile devices such as smartphones and tablets allow access to this information almost anywhere, at any time.  Since access to such information has only recently become std. practice, we want to outline straightforward ways to incorporate 3D models in augmented reality into scientific publications, books, posters, and presentations and suggest that this should become general practice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrChR9HXFg1QrVg90H21EOLACvtfcHk0lhfNnole20cLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXktFOlu78%253D&md5=43b9e304629aea6e073f00a76e10f928</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facschembio.8b00153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facschembio.8b00153%26sid%3Dliteratum%253Aachs%26aulast%3DWolle%26aufirst%3DP.%26aulast%3DM%25C3%25BCller%26aufirst%3DM.%2BP.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DAugmented%2520reality%2520in%2520scientific%2520publications-taking%2520the%2520visualization%2520of%25203D%2520structures%2520to%2520the%2520next%2520level%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2018%26volume%3D13%26spage%3D496%26epage%3D499%26doi%3D10.1021%2Facschembio.8b00153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mengwasser, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Toms, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>105</i></span>,  <span class="NLM_fpage">2070</span>– <span class="NLM_lpage">2075</span>, <span class="refDoi"> DOI: 10.1073/pnas.0709662105</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+H.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP&doi=10.1073%2Fpnas.0709662105"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lhfNnole20cLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075%26doi%3D10.1073%2Fpnas.0709662105" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Foster, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whalen, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ozen, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wongchenko, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mayfield, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chmielecki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Song, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatzivassiliou, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eigenbrot, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manning, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skelton, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hymowitz, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span> <span> </span><span class="NLM_article-title">Activation mechanism of oncogenic deletion mutations in BRAF, EGFR, and HER2</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">477</span>– <span class="NLM_lpage">493</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2016.02.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ccell.2016.02.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=26996308" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2016&pages=477-493&author=S.+A.+Fosterauthor=D.+M.+Whalenauthor=A.+Ozenauthor=M.+J.+Wongchenkoauthor=J.+Yinauthor=I.+Yenauthor=G.+Schaeferauthor=J.+D.+Mayfieldauthor=J.+Chmieleckiauthor=P.+J.+Stephensauthor=L.+A.+Albackerauthor=Y.+Yanauthor=K.+Songauthor=G.+Hatzivassiliouauthor=C.+Eigenbrotauthor=C.+Yuauthor=A.+S.+Shawauthor=G.+Manningauthor=N.+J.+Skeltonauthor=S.+G.+Hymowitzauthor=S.+Malek&title=Activation+mechanism+of+oncogenic+deletion+mutations+in+BRAF%2C+EGFR%2C+and+HER2&doi=10.1016%2Fj.ccell.2016.02.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2</span></div><div class="casAuthors">Foster, Scott A.; Whalen, Daniel M.; Ozen, Aysegul; Wongchenko, Matthew J.; Yin, Jian Ping; Yen, Ivana; Schaefer, Gabriele; Mayfield, John D.; Chmielecki, Juliann; Stephens, Philip J.; Albacker, Lee A.; Yan, Yibing; Song, Kyung; Hatzivassiliou, Georgia; Eigenbrot, Charles; Yu, Christine; Shaw, Andrey S.; Manning, Gerard; Skelton, Nicholas J.; Hymowitz, Sarah G.; Malek, Shiva</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">477-493</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Activating mutations in protein kinases drive many cancers.  While how recurring point mutations affect kinase activity has been described, the effect of in-frame deletions is not well understood.  We show that oncogenic deletions within the β3-αC loop of HER2 and BRAF are analogous to the recurrent EGFR exon 19 deletions.  We identify pancreatic carcinomas with BRAF deletions mutually exclusive with KRAS mutations.  Crystal structures of BRAF deletions reveal the truncated loop restrains αC in an active "in" conformation, imparting resistance to inhibitors like vemurafenib that bind the αC "out" conformation.  Characterization of loop length explains the prevalence of five amino acid deletions in BRAF, EGFR, and HER2 and highlights the importance of this region for kinase activity and inhibitor efficacy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrObiwE2cwFlbVg90H21EOLACvtfcHk0lhfNnole20cLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XksVaisLw%253D&md5=7aad1cea6f17f2b74c42fbc3c1c9b0fd</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2016.02.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2016.02.010%26sid%3Dliteratum%253Aachs%26aulast%3DFoster%26aufirst%3DS.%2BA.%26aulast%3DWhalen%26aufirst%3DD.%2BM.%26aulast%3DOzen%26aufirst%3DA.%26aulast%3DWongchenko%26aufirst%3DM.%2BJ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DYen%26aufirst%3DI.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DMayfield%26aufirst%3DJ.%2BD.%26aulast%3DChmielecki%26aufirst%3DJ.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DAlbacker%26aufirst%3DL.%2BA.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DSong%26aufirst%3DK.%26aulast%3DHatzivassiliou%26aufirst%3DG.%26aulast%3DEigenbrot%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DC.%26aulast%3DShaw%26aufirst%3DA.%2BS.%26aulast%3DManning%26aufirst%3DG.%26aulast%3DSkelton%26aufirst%3DN.%2BJ.%26aulast%3DHymowitz%26aufirst%3DS.%2BG.%26aulast%3DMalek%26aufirst%3DS.%26atitle%3DActivation%2520mechanism%2520of%2520oncogenic%2520deletion%2520mutations%2520in%2520BRAF%252C%2520EGFR%252C%2520and%2520HER2%26jtitle%3DCancer%2520Cell%26date%3D2016%26volume%3D29%26spage%3D477%26epage%3D493%26doi%3D10.1016%2Fj.ccell.2016.02.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bose, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kavuri, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Searleman, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koboldt, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monsey, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aronson, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, C. X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mardis, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, M. J.</span></span> <span> </span><span class="NLM_article-title">Activating HER2 mutations in HER2 gene amplification negative breast cancer</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">224</span>– <span class="NLM_lpage">237</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0349</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-12-0349" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23220880" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=224-237&author=R.+Boseauthor=S.+M.+Kavuriauthor=A.+C.+Searlemanauthor=W.+Shenauthor=D.+Shenauthor=D.+C.+Koboldtauthor=J.+Monseyauthor=N.+Goelauthor=A.+B.+Aronsonauthor=S.+Liauthor=C.+X.+Maauthor=L.+Dingauthor=E.+R.+Mardisauthor=M.+J.+Ellis&title=Activating+HER2+mutations+in+HER2+gene+amplification+negative+breast+cancer&doi=10.1158%2F2159-8290.CD-12-0349"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer</span></div><div class="casAuthors">Bose, Ron; Kavuri, Shyam M.; Searleman, Adam C.; Shen, Wei; Shen, Dong; Koboldt, Daniel C.; Monsey, John; Goel, Nicholas; Aronson, Adam B.; Li, Shunqiang; Ma, Cynthia X.; Ding, Li; Mardis, Elaine R.; Ellis, Matthew J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">224-237</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Data from 8 breast cancer genome-sequencing projects identified 25 patients with HER2 somatic mutations in cancers lacking HER2 gene amplification.  To det. the phenotype of these mutations, we functionally characterized 13 HER2 mutations using in vitro kinase assays, protein structure anal., cell culture, and xenograft expts.  Seven of these mutations are activating mutations, including G309A, D769H, D769Y, V777L, P780ins, V842I, and R896C. HER2 in-frame deletion 755-759, which is homologous to EGF receptor (EGFR) exon 19 in-frame deletions, had a neomorphic phenotype with increased phosphorylation of EGFR or HER3.  L755S produced lapatinib resistance, but was not an activating mutation in our exptl. systems.  All of these mutations were sensitive to the irreversible kinase inhibitor, neratinib.  These findings show that HER2 somatic mutation is an alternative mechanism to activate HER2 in breast cancer and they validate HER2 somatic mutations as drug targets for breast cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqpInHiFiSDrrVg90H21EOLACvtfcHk0ljrFy3QRSnasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrg%253D&md5=4b271e961ad4a68862e4a3ba80e88972</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0349%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%26aulast%3DKavuri%26aufirst%3DS.%2BM.%26aulast%3DSearleman%26aufirst%3DA.%2BC.%26aulast%3DShen%26aufirst%3DW.%26aulast%3DShen%26aufirst%3DD.%26aulast%3DKoboldt%26aufirst%3DD.%2BC.%26aulast%3DMonsey%26aufirst%3DJ.%26aulast%3DGoel%26aufirst%3DN.%26aulast%3DAronson%26aufirst%3DA.%2BB.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMa%26aufirst%3DC.%2BX.%26aulast%3DDing%26aufirst%3DL.%26aulast%3DMardis%26aufirst%3DE.%2BR.%26aulast%3DEllis%26aufirst%3DM.%2BJ.%26atitle%3DActivating%2520HER2%2520mutations%2520in%2520HER2%2520gene%2520amplification%2520negative%2520breast%2520cancer%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D224%26epage%3D237%26doi%3D10.1158%2F2159-8290.CD-12-0349" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eastwood, M. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arkhipov, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dror, R. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jumper, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuriyan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, D. E.</span></span> <span> </span><span class="NLM_article-title">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">860</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2012.02.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.cell.2012.02.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22579287" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2012&pages=860-780&author=Y.+Shanauthor=M.+P.+Eastwoodauthor=X.+Zhangauthor=E.+T.+Kimauthor=A.+Arkhipovauthor=R.+O.+Drorauthor=J.+Jumperauthor=J.+Kuriyanauthor=D.+E.+Shaw&title=Oncogenic+mutations+counteract+intrinsic+disorder+in+the+EGFR+kinase+and+promote+receptor+dimerization&doi=10.1016%2Fj.cell.2012.02.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization</span></div><div class="casAuthors">Shan, Yibing; Eastwood, Michael P.; Zhang, Xuewu; Kim, Eric T.; Arkhipov, Anton; Dror, Ron O.; Jumper, John; Kuriyan, John; Shaw, David E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">860-870</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The mutation and overexpression of the epidermal growth factor receptor (EGFR) are assocd. with the development of a variety of cancers, making this prototypical dimerization-activated receptor tyrosine kinase a prominent target of cancer drugs.  Using long-timescale mol. dynamics simulations, we find that the N lobe dimerization interface of the wild-type EGFR kinase domain is intrinsically disordered and that it becomes ordered only upon dimerization.  Our simulations suggest, moreover, that some cancer-linked mutations distal to the dimerization interface, particularly the widespread L834R mutation (also referred to as L858R), facilitate EGFR dimerization by suppressing this local disorder.  Corroborating these findings, our biophys. expts. and kinase enzymic assays indicate that the L834R mutation causes abnormally high activity primarily by promoting EGFR dimerization rather than by allowing activation without dimerization.  We also find that phosphorylation of EGFR kinase domain at Tyr845 may suppress the intrinsic disorder, suggesting a mol. mechanism for autonomous EGFR signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZhEY912uUTrVg90H21EOLACvtfcHk0ljrFy3QRSnasw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFaju7k%253D&md5=8ab973e5a5626ac495d176322f30d2b7</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2012.02.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2012.02.063%26sid%3Dliteratum%253Aachs%26aulast%3DShan%26aufirst%3DY.%26aulast%3DEastwood%26aufirst%3DM.%2BP.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DKim%26aufirst%3DE.%2BT.%26aulast%3DArkhipov%26aufirst%3DA.%26aulast%3DDror%26aufirst%3DR.%2BO.%26aulast%3DJumper%26aufirst%3DJ.%26aulast%3DKuriyan%26aufirst%3DJ.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26atitle%3DOncogenic%2520mutations%2520counteract%2520intrinsic%2520disorder%2520in%2520the%2520EGFR%2520kinase%2520and%2520promote%2520receptor%2520dimerization%26jtitle%3DCell%26date%3D2012%26volume%3D149%26spage%3D860%26epage%3D780%26doi%3D10.1016%2Fj.cell.2012.02.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fassunke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Müller, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keul, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michels, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dammert, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmitt, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plenker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lategahn, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heydt, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bragelmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumbrink, H. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alber, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heimsoeth, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dahmen, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheffler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ihle, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Priesner, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheel, A. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagener, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kron, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frank, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garbert, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persigehl, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pusken, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Haneder, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaaf, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rodermann, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engel-Riedel, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smit, E. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merkelbach-Bruse, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reinhardt, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kast, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buttner, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">4655</span>, <span class="refDoi"> DOI: 10.1038/s41467-018-07078-0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fs41467-018-07078-0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30405134" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=4655&author=J.+Fassunkeauthor=F.+M%C3%BCllerauthor=M.+Keulauthor=S.+Michelsauthor=M.+A.+Dammertauthor=A.+Schmittauthor=D.+Plenkerauthor=J.+Lategahnauthor=C.+Heydtauthor=J.+Bragelmannauthor=H.+L.+Tumbrinkauthor=Y.+Alberauthor=S.+Kleinauthor=A.+Heimsoethauthor=I.+Dahmenauthor=R.+N.+Fischerauthor=M.+Schefflerauthor=M.+A.+Ihleauthor=V.+Priesnerauthor=A.+H.+Scheelauthor=S.+Wagenerauthor=A.+Kronauthor=K.+Frankauthor=K.+Garbertauthor=T.+Persigehlauthor=M.+Puskenauthor=S.+Hanederauthor=B.+Schaafauthor=E.+Rodermannauthor=W.+Engel-Riedelauthor=E.+Felipauthor=E.+F.+Smitauthor=S.+Merkelbach-Bruseauthor=H.+C.+Reinhardtauthor=S.+M.+Kastauthor=J.+Wolfauthor=D.+Rauhauthor=R.+Buttnerauthor=M.+L.+Sos&title=Overcoming+EGFR%28G724S%29-mediated+osimertinib+resistance+through+unique+binding+characteristics+of+second-generation+EGFR+inhibitors&doi=10.1038%2Fs41467-018-07078-0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(G724S)-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors</span></div><div class="casAuthors">Fassunke Jana; Heydt Carina; Klein Sebastian; Ihle Michaela A; Scheel Andreas H; Wagener Svenja; Merkelbach-Bruse Sabine; Buttner Reinhard; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Garbert Katia; Sos Martin L; Muller Fabienne; Dammert Marcel A; Plenker Dennis; Bragelmann Johannes; Tumbrink Hannah L; Klein Sebastian; Heimsoeth Alena; Dahmen Ilona; Garbert Katia; Buttner Reinhard; Sos Martin L; Keul Marina; Lategahn Jonas; Alber Yannic; Kast Stefan M; Rauh Daniel; Michels Sebastian; Fischer Rieke N; Scheffler Matthias; Priesner Vanessa; Kron Anna; Wolf Jurgen; Buttner Reinhard; Schmitt Anna; Reinhardt H Christian; Sos Martin L; Schmitt Anna; Reinhardt H Christian; Schmitt Anna; Reinhardt H Christian; Klein Sebastian; Frank Konrad; Persigehl Thorsten; Pusken Michael; Haneder Stefan; Schaaf Bernhard; Rodermann Ernst; Engel-Riedel Walburga; Felip Enriqueta; Smit Egbert F</div><div class="citationInfo"><span class="NLM_cas:title">Nature communications</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">4655</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The emergence of acquired resistance against targeted drugs remains a major clinical challenge in lung adenocarcinoma patients.  In a subgroup of these patients we identified an association between selection of EGFR(T790M)-negative but EGFR(G724S)-positive subclones and osimertinib resistance.  We demonstrate that EGFR(G724S) limits the activity of third-generation EGFR inhibitors both in vitro and in vivo.  Structural analyses and computational modeling indicate that EGFR(G724S) mutations may induce a conformation of the glycine-rich loop, which is incompatible with the binding of third-generation TKIs.  Systematic inhibitor screening and in-depth kinetic profiling validate these findings and show that second-generation EGFR inhibitors retain kinase affinity and overcome EGFR(G724S)-mediated resistance.  In the case of afatinib this profile translates into a robust reduction of colony formation and tumor growth of EGFR(G724S)-driven cells.  Our data provide a mechanistic basis for the osimertinib-induced selection of EGFR(G724S)-mutant clones and a rationale to treat these patients with clinically approved second-generation EGFR inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSbrRUzliurTsve_zCu79I8fW6udTcc2eYsYN5v6KBsELntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3cvnslShsQ%253D%253D&md5=a09a4c84fb50fd456dcab005d2d9366a</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1038%2Fs41467-018-07078-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41467-018-07078-0%26sid%3Dliteratum%253Aachs%26aulast%3DFassunke%26aufirst%3DJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DF.%26aulast%3DKeul%26aufirst%3DM.%26aulast%3DMichels%26aufirst%3DS.%26aulast%3DDammert%26aufirst%3DM.%2BA.%26aulast%3DSchmitt%26aufirst%3DA.%26aulast%3DPlenker%26aufirst%3DD.%26aulast%3DLategahn%26aufirst%3DJ.%26aulast%3DHeydt%26aufirst%3DC.%26aulast%3DBragelmann%26aufirst%3DJ.%26aulast%3DTumbrink%26aufirst%3DH.%2BL.%26aulast%3DAlber%26aufirst%3DY.%26aulast%3DKlein%26aufirst%3DS.%26aulast%3DHeimsoeth%26aufirst%3DA.%26aulast%3DDahmen%26aufirst%3DI.%26aulast%3DFischer%26aufirst%3DR.%2BN.%26aulast%3DScheffler%26aufirst%3DM.%26aulast%3DIhle%26aufirst%3DM.%2BA.%26aulast%3DPriesner%26aufirst%3DV.%26aulast%3DScheel%26aufirst%3DA.%2BH.%26aulast%3DWagener%26aufirst%3DS.%26aulast%3DKron%26aufirst%3DA.%26aulast%3DFrank%26aufirst%3DK.%26aulast%3DGarbert%26aufirst%3DK.%26aulast%3DPersigehl%26aufirst%3DT.%26aulast%3DPusken%26aufirst%3DM.%26aulast%3DHaneder%26aufirst%3DS.%26aulast%3DSchaaf%26aufirst%3DB.%26aulast%3DRodermann%26aufirst%3DE.%26aulast%3DEngel-Riedel%26aufirst%3DW.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DSmit%26aufirst%3DE.%2BF.%26aulast%3DMerkelbach-Bruse%26aufirst%3DS.%26aulast%3DReinhardt%26aufirst%3DH.%2BC.%26aulast%3DKast%26aufirst%3DS.%2BM.%26aulast%3DWolf%26aufirst%3DJ.%26aulast%3DRauh%26aufirst%3DD.%26aulast%3DButtner%26aufirst%3DR.%26aulast%3DSos%26aufirst%3DM.%2BL.%26atitle%3DOvercoming%2520EGFR%2528G724S%2529-mediated%2520osimertinib%2520resistance%2520through%2520unique%2520binding%2520characteristics%2520of%2520second-generation%2520EGFR%2520inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2018%26volume%3D9%26spage%3D4655%26doi%3D10.1038%2Fs41467-018-07078-0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manuia, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juarez, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lelais, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiDonato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bursulaya, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michellys, P. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Epple, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsilje, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNeill, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harris, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span> <span> </span><span class="NLM_article-title">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>534</i></span>,  <span class="NLM_fpage">129</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nature17960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature17960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27251290" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=534&publication_year=2016&pages=129-132&author=Y.+Jiaauthor=C.+H.+Yunauthor=E.+Parkauthor=D.+Ercanauthor=M.+Manuiaauthor=J.+Juarezauthor=C.+Xuauthor=K.+Rheeauthor=T.+Chenauthor=H.+Zhangauthor=S.+Palakurthiauthor=J.+Jangauthor=G.+Lelaisauthor=M.+DiDonatoauthor=B.+Bursulayaauthor=P.+Y.+Michellysauthor=R.+Eppleauthor=T.+H.+Marsiljeauthor=M.+McNeillauthor=W.+Luauthor=J.+Harrisauthor=S.+Benderauthor=K.+K.+Wongauthor=P.+A.+J%C3%A4nneauthor=M.+J.+Eck&title=Overcoming+EGFR%28T790M%29+and+EGFR%28C797S%29+resistance+with+mutant-selective+allosteric+inhibitors&doi=10.1038%2Fnature17960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors</span></div><div class="casAuthors">Jia, Yong; Yun, Cai-Hong; Park, Eunyoung; Ercan, Dalia; Manuia, Mari; Juarez, Jose; Xu, Chunxiao; Rhee, Kevin; Chen, Ting; Zhang, Haikuo; Palakurthi, Sangeetha; Jang, Jaebong; Lelais, Gerald; DiDonato, Michael; Bursulaya, Badry; Michellys, Pierre-Yves; Epple, Robert; Marsilje, Thomas H.; McNeill, Matthew; Lu, Wenshuo; Harris, Jennifer; Bender, Steven; Wong, Kwok-Kin; Janne, Pasi A.; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">534</span>
        (<span class="NLM_cas:issue">7605</span>),
    <span class="NLM_cas:pages">129-132</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR)-directed tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib and afatinib are approved treatments for non-small cell lung cancers harbouring activating mutations in the EGFR kinase, but resistance arises rapidly, most frequently owing to the secondary T790M mutation within the ATP site of the receptor.  Recently developed mutant-selective irreversible inhibitors are highly active against the T790M mutant, but their efficacy can be compromised by acquired mutation of C797, the cysteine residue with which they form a key covalent bond.  All current EGFR TKIs target the ATP-site of the kinase, highlighting the need for therapeutic agents with alternative mechanisms of action.  Here we describe the rational discovery of EAI045, an allosteric inhibitor that targets selected drug-resistant EGFR mutants but spares the wild-type receptor.  The crystal structure shows that the compd. binds an allosteric site created by the displacement of the regulatory C-helix in an inactive conformation of the kinase.  The compd. inhibits L858R/T790M-mutant EGFR with low-nanomolar potency in biochem. assays.  However, as a single agent it is not effective in blocking EGFR-driven proliferation in cells owing to differential potency on the two subunits of the dimeric receptor, which interact in an asym. manner in the active state.  We observe marked synergy of EAI045 with cetuximab, an antibody therapeutic that blocks EGFR dimerization, rendering the kinase uniformly susceptible to the allosteric agent.  EAI045 in combination with cetuximab is effective in mouse models of lung cancer driven by EGFR(L858R/T790M) and by EGFR(L858R/T790M/C797S), a mutant that is resistant to all currently available EGFR TKIs.  More generally, our findings illustrate the utility of purposefully targeting allosteric sites to obtain mutant-selective inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqQkr363w1dMLVg90H21EOLACvtfcHk0lgaSdoPwn3d0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosFWht7k%253D&md5=f4c2d2362eb900c64bad8550b9da0872</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1038%2Fnature17960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature17960%26sid%3Dliteratum%253Aachs%26aulast%3DJia%26aufirst%3DY.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DManuia%26aufirst%3DM.%26aulast%3DJuarez%26aufirst%3DJ.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DJang%26aufirst%3DJ.%26aulast%3DLelais%26aufirst%3DG.%26aulast%3DDiDonato%26aufirst%3DM.%26aulast%3DBursulaya%26aufirst%3DB.%26aulast%3DMichellys%26aufirst%3DP.%2BY.%26aulast%3DEpple%26aufirst%3DR.%26aulast%3DMarsilje%26aufirst%3DT.%2BH.%26aulast%3DMcNeill%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DHarris%26aufirst%3DJ.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DOvercoming%2520EGFR%2528T790M%2529%2520and%2520EGFR%2528C797S%2529%2520resistance%2520with%2520mutant-selective%2520allosteric%2520inhibitors%26jtitle%3DNature%26date%3D2016%26volume%3D534%26spage%3D129%26epage%3D132%26doi%3D10.1038%2Fnature17960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sng, N. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lucena-Araujo, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeo, W. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huberman, M. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cohen, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishioka, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamaguchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hanna, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lathan, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moran, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sequist, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chaft, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soo, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, S. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Costa, D. B.</span></span> <span> </span><span class="NLM_article-title">Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer</span>. <i>Sci. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">216ra177</span>, <span class="refDoi"> DOI: 10.1126/scitranslmed.3007205</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1126%2Fscitranslmed.3007205" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=24353160" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2013&pages=216ra177&author=H.+Yasudaauthor=E.+Parkauthor=C.+H.+Yunauthor=N.+J.+Sngauthor=A.+R.+Lucena-Araujoauthor=W.+L.+Yeoauthor=M.+S.+Hubermanauthor=D.+W.+Cohenauthor=S.+Nakayamaauthor=K.+Ishiokaauthor=N.+Yamaguchiauthor=M.+Hannaauthor=G.+R.+Oxnardauthor=C.+S.+Lathanauthor=T.+Moranauthor=L.+V.+Sequistauthor=J.+E.+Chaftauthor=G.+J.+Rielyauthor=M.+E.+Arcilaauthor=R.+A.+Sooauthor=M.+Meyersonauthor=M.+J.+Eckauthor=S.+S.+Kobayashiauthor=D.+B.+Costa&title=Structural%2C+biochemical%2C+and+clinical+characterization+of+epidermal+growth+factor+receptor+%28EGFR%29+exon+20+insertion+mutations+in+lung+cancer&doi=10.1126%2Fscitranslmed.3007205"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1126%2Fscitranslmed.3007205&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscitranslmed.3007205%26sid%3Dliteratum%253Aachs%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DSng%26aufirst%3DN.%2BJ.%26aulast%3DLucena-Araujo%26aufirst%3DA.%2BR.%26aulast%3DYeo%26aufirst%3DW.%2BL.%26aulast%3DHuberman%26aufirst%3DM.%2BS.%26aulast%3DCohen%26aufirst%3DD.%2BW.%26aulast%3DNakayama%26aufirst%3DS.%26aulast%3DIshioka%26aufirst%3DK.%26aulast%3DYamaguchi%26aufirst%3DN.%26aulast%3DHanna%26aufirst%3DM.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DLathan%26aufirst%3DC.%2BS.%26aulast%3DMoran%26aufirst%3DT.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DChaft%26aufirst%3DJ.%2BE.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DSoo%26aufirst%3DR.%2BA.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DKobayashi%26aufirst%3DS.%2BS.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26atitle%3DStructural%252C%2520biochemical%252C%2520and%2520clinical%2520characterization%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520exon%252020%2520insertion%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DSci.%2520Transl.%2520Med.%26date%3D2013%26volume%3D5%26spage%3D216ra177%26doi%3D10.1126%2Fscitranslmed.3007205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kosaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanizaki, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paranal, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endoh, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lydon, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Repellin, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogino, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calles, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahcall, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Response heterogeneity of EGFR and HER2 exon 20 insertions to covalent EGFR and HER2 inhibitors</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span>,  <span class="NLM_fpage">2712</span>– <span class="NLM_lpage">2721</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-3404</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-16-3404" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28363995" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXns1Skt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=2712-2721&author=T.+Kosakaauthor=J.+Tanizakiauthor=R.+M.+Paranalauthor=H.+Endohauthor=C.+Lydonauthor=M.+Capellettiauthor=C.+E.+Repellinauthor=J.+Choiauthor=A.+Oginoauthor=A.+Callesauthor=D.+Ercanauthor=A.+J.+Redigauthor=M.+Bahcallauthor=G.+R.+Oxnardauthor=M.+J.+Eckauthor=P.+A.+J%C3%A4nne&title=Response+heterogeneity+of+EGFR+and+HER2+exon+20+insertions+to+covalent+EGFR+and+HER2+inhibitors&doi=10.1158%2F0008-5472.CAN-16-3404"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors</span></div><div class="casAuthors">Kosaka, Takayuki; Tanizaki, Junko; Paranal, Raymond M.; Endoh, Hideki; Lydon, Christine; Capelletti, Marzia; Repellin, Claire E.; Choi, Jihyun; Ogino, Atsuko; Calles, Antonio; Ercan, Dalia; Redig, Amanda J.; Bahcall, Magda; Oxnard, Geoffrey R.; Eck, Michael J.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">2712-2721</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Insertion mutations in EGFR and HER2 both occur at analogous positions in exon 20.  Non-small cell lung cancer (NSCLC) patients with tumors harboring these mutations seldom achieve clin. responses to dacomitinib and afatinib, two covalent quinazoline-based inhibitors of EGFR or HER2, resp.  In this study, we investigated the effects of specific EGFR and HER2 exon 20 insertion mutations from NSCLC patients that had clin. achieved a partial response after dacomitinib treatment.  We identified Gly770 as a common feature among the drug-sensitive mutations.  Structural modeling suggested that this mutation may facilitate inhibitor binding to EGFR.  Introduction of Gly770 into two dacomitinib-resistant EGFR exon 20 insertion mutants restored sensitivity to dacomitinib.  Based on these findings, we used afatinib to treat an NSCLC patient whose tumor harbored the HER2 V777_G778insGSP mutation and achieved a durable partial response.  We further identified secondary mutations in EGFR (T790M or C797S) and HER2 (C805S) that mediated acquired drug resistance in drug-sensitive EGFR or HER2 exon 20 insertion models.  Overall, our findings identified a subset of EGFR and HER2 exon 20 insertion mutations that are sensitive to existing covalent quinazoline-based EGFR/HER2 inhibitors, with implications for current clin. treatment and next-generation small-mol. inhibitors.  Cancer Res; 77(10); 2712-21. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGon3qnueNbKabVg90H21EOLACvtfcHk0lhGnW3xxMjkTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXns1Skt74%253D&md5=fec24919ffcaef20ab9046f93727e81d</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-3404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-3404%26sid%3Dliteratum%253Aachs%26aulast%3DKosaka%26aufirst%3DT.%26aulast%3DTanizaki%26aufirst%3DJ.%26aulast%3DParanal%26aufirst%3DR.%2BM.%26aulast%3DEndoh%26aufirst%3DH.%26aulast%3DLydon%26aufirst%3DC.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DRepellin%26aufirst%3DC.%2BE.%26aulast%3DChoi%26aufirst%3DJ.%26aulast%3DOgino%26aufirst%3DA.%26aulast%3DCalles%26aufirst%3DA.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DBahcall%26aufirst%3DM.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DResponse%2520heterogeneity%2520of%2520EGFR%2520and%2520HER2%2520exon%252020%2520insertions%2520to%2520covalent%2520EGFR%2520and%2520HER2%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26spage%3D2712%26epage%3D2721%26doi%3D10.1158%2F0008-5472.CAN-16-3404" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fry, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bridges, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Denny, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doherty, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greis, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hook, K. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leopold, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loo, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McNamara, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nelson, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sherwood, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smaill, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Trumpp-Kallmeyer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dobrusin, E. M.</span></span> <span> </span><span class="NLM_article-title">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>95</i></span>,  <span class="NLM_fpage">12022</span>– <span class="NLM_lpage">12027</span>, <span class="refDoi"> DOI: 10.1073/pnas.95.20.12022</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1073%2Fpnas.95.20.12022" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9751783" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=95&publication_year=1998&pages=12022-12027&author=D.+W.+Fryauthor=A.+J.+Bridgesauthor=W.+A.+Dennyauthor=A.+Dohertyauthor=K.+D.+Greisauthor=J.+L.+Hicksauthor=K.+E.+Hookauthor=P.+R.+Kellerauthor=W.+R.+Leopoldauthor=J.+A.+Looauthor=D.+J.+McNamaraauthor=J.+M.+Nelsonauthor=V.+Sherwoodauthor=J.+B.+Smaillauthor=S.+Trumpp-Kallmeyerauthor=E.+M.+Dobrusin&title=Specific%2C+irreversible+inactivation+of+the+epidermal+growth+factor+receptor+and+erbB2%2C+by+a+new+class+of+tyrosine+kinase+inhibitor&doi=10.1073%2Fpnas.95.20.12022"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor</span></div><div class="casAuthors">Fry, David W.; Bridges, Alexander J.; Denny, William A.; Doherty, Annette; Greis, Kenneth D.; Hicks, James L.; Hook, Kenneth E.; Keller, Paul R.; Leopold, Wilbur R.; Loo, Joseph A.; McNamara, Dennis J.; Nelson, James M.; Sherwood, Veronika; Smaill, Jeff B.; Trumpp-Kallmeyer, Susanne; Dobrusin, Ellen M.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">95</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">12022-12027</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">A class of high-affinity inhibitors is disclosed that selectively target and irreversibly inactivate the epidermal growth factor receptor tyrosine kinase through specific, covalent modification of a cysteine residue present in the ATP binding pocket.  A series of expts. employing MS, mol. modeling, site-directed mutagenesis, and 14C-labeling studies in viable cells unequivocally demonstrate that these compds. selectively bind to the catalytic domain of the epidermal growth factor receptor with a 1:1 stoichiometry and alkylate Cys-773.  While the compds. are essentially non-reactive in soln., they are subject to rapid nucleophilic attack by this particular amino acid when bound in the ATP pocket.  The mol. orientation and positioning of the acrylamide group in these inhibitors in relation to Cys-773 entirely support these results as detd. from docking expts. in a homol.-built mol. model of the ATP site.  Evidence is also presented to indicate that the compds. interact in an analogous fashion with erbB2 but have no activity against the other receptor tyrosine kinases or intracellular tyrosine kinases that were tested in this study.  Finally, a direct comparison between 6-acrylamido-4-anilinoquinazoline and an equally potent but reversible analog shows that the irreversible inhibitor has far superior in vivo antitumor activity in a human epidermoid carcinoma xenograft model with no overt toxicity at therapeutically active doses.  The activity profile for this compd. is prototypical of a generation of tyrosine kinase inhibitors with great promise for therapeutic significance in the treatment of proliferative disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpibFpkhNyxDLVg90H21EOLACvtfcHk0lhGnW3xxMjkTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXmsV2ht7g%253D&md5=a89b0b8123511fb1bbb889c01a3f9df2</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.95.20.12022&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.95.20.12022%26sid%3Dliteratum%253Aachs%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DBridges%26aufirst%3DA.%2BJ.%26aulast%3DDenny%26aufirst%3DW.%2BA.%26aulast%3DDoherty%26aufirst%3DA.%26aulast%3DGreis%26aufirst%3DK.%2BD.%26aulast%3DHicks%26aufirst%3DJ.%2BL.%26aulast%3DHook%26aufirst%3DK.%2BE.%26aulast%3DKeller%26aufirst%3DP.%2BR.%26aulast%3DLeopold%26aufirst%3DW.%2BR.%26aulast%3DLoo%26aufirst%3DJ.%2BA.%26aulast%3DMcNamara%26aufirst%3DD.%2BJ.%26aulast%3DNelson%26aufirst%3DJ.%2BM.%26aulast%3DSherwood%26aufirst%3DV.%26aulast%3DSmaill%26aufirst%3DJ.%2BB.%26aulast%3DTrumpp-Kallmeyer%26aufirst%3DS.%26aulast%3DDobrusin%26aufirst%3DE.%2BM.%26atitle%3DSpecific%252C%2520irreversible%2520inactivation%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520and%2520erbB2%252C%2520by%2520a%2520new%2520class%2520of%2520tyrosine%2520kinase%2520inhibitor%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1998%26volume%3D95%26spage%3D12022%26epage%3D12027%26doi%3D10.1073%2Fpnas.95.20.12022" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carter, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poteete, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Estrada-Bernal, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Le, A. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Truini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brahmer, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doebele, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">646</span>, <span class="refDoi"> DOI: 10.1038/s41591-018-0007-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fs41591-018-0007-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29686424" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=638-646&author=J.+P.+Robichauxauthor=Y.+Y.+Elaminauthor=Z.+Tanauthor=B.+W.+Carterauthor=S.+Zhangauthor=S.+Liuauthor=S.+Liauthor=T.+Chenauthor=A.+Poteeteauthor=A.+Estrada-Bernalauthor=A.+T.+Leauthor=A.+Truiniauthor=M.+B.+Nilssonauthor=H.+Sunauthor=E.+Roartyauthor=S.+B.+Goldbergauthor=J.+R.+Brahmerauthor=M.+Altanauthor=C.+Luauthor=V.+Papadimitrakopoulouauthor=K.+Politiauthor=R.+C.+Doebeleauthor=K.+K.+Wongauthor=J.+V.+Heymach&title=Mechanisms+and+clinical+activity+of+an+EGFR+and+HER2+exon+20-selective+kinase+inhibitor+in+non-small+cell+lung+cancer&doi=10.1038%2Fs41591-018-0007-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer</span></div><div class="casAuthors">Robichaux, Jacqulyne P.; Elamin, Yasir Y.; Tan, Zhi; Carter, Brett W.; Zhang, Shuxing; Liu, Shengwu; Li, Shuai; Chen, Ting; Poteete, Alissa; Estrada-Bernal, Adriana; Le, Anh T.; Truini, Anna; Nilsson, Monique B.; Sun, Huiying; Roarty, Emily; Goldberg, Sarah B.; Brahmer, Julie R.; Altan, Mehmet; Lu, Charles; Papadimitrakopoulou, Vassiliki; Politi, Katerina; Doebele, Robert C.; Wong, Kwok-Kin; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">638-646</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Although most activating mutations of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancers (NSCLCs) are sensitive to available EGFR tyrosine kinase inhibitors (TKIs), a subset with alterations in exon 20 of EGFR and HER2 are intrinsically resistant and lack an effective therapy.  We used in silico, in vitro, and in vivo testing to model structural alterations induced by exon 20 mutations and to identify effective inhibitors. 3D modeling indicated alterations restricted the size of the drug-binding pocket, limiting the binding of large, rigid inhibitors.  We found that poziotinib, owing to its small size and flexibility, can circumvent these steric changes and is a potent inhibitor of the most common EGFR and HER2 exon 20 mutants.  Poziotinib demonstrated greater activity than approved EGFR TKIs in vitro and in patient-derived xenograft models of EGFR or HER2 exon 20 mutant NSCLC and in genetically engineered mouse models of NSCLC.  In a phase 2 trial, the first 11 patients with NSCLC with EGFR exon 20 mutations receiving poziotinib had a confirmed objective response rate of 64%.  These data identify poziotinib as a potent, clin. active inhibitor of EGFR and HER2 exon 20 mutations and illuminate the mol. features of TKIs that may circumvent steric changes induced by these mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk6UyVpv0h47Vg90H21EOLACvtfcHk0lg_cpj-OEnvgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXosVCnsLs%253D&md5=316a0a0765ebc9eec9b6460d27b28bb5</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1038%2Fs41591-018-0007-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41591-018-0007-9%26sid%3Dliteratum%253Aachs%26aulast%3DRobichaux%26aufirst%3DJ.%2BP.%26aulast%3DElamin%26aufirst%3DY.%2BY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DCarter%26aufirst%3DB.%2BW.%26aulast%3DZhang%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DPoteete%26aufirst%3DA.%26aulast%3DEstrada-Bernal%26aufirst%3DA.%26aulast%3DLe%26aufirst%3DA.%2BT.%26aulast%3DTruini%26aufirst%3DA.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DGoldberg%26aufirst%3DS.%2BB.%26aulast%3DBrahmer%26aufirst%3DJ.%2BR.%26aulast%3DAltan%26aufirst%3DM.%26aulast%3DLu%26aufirst%3DC.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DDoebele%26aufirst%3DR.%2BC.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DMechanisms%2520and%2520clinical%2520activity%2520of%2520an%2520EGFR%2520and%2520HER2%2520exon%252020-selective%2520kinase%2520inhibitor%2520in%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DNat.%2520Med.%26date%3D2018%26volume%3D24%26spage%3D638%26epage%3D646%26doi%3D10.1038%2Fs41591-018-0007-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yasuda, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamamoto, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nukaga, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Masuzawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawada, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naoki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niimi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mimasu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sakagami, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soejima, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betsuyaku, T.</span></span> <span> </span><span class="NLM_article-title">Pharmacological and structural characterizations of naquotinib, a novel third-generation EGFR tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">740</span>– <span class="NLM_lpage">750</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-17-1033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1535-7163.MCT-17-1033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29467275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXms1ejt7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=740-750&author=T.+Hiranoauthor=H.+Yasudaauthor=J.+Hamamotoauthor=S.+Nukagaauthor=K.+Masuzawaauthor=I.+Kawadaauthor=K.+Naokiauthor=T.+Niimiauthor=S.+Mimasuauthor=H.+Sakagamiauthor=K.+Soejimaauthor=T.+Betsuyaku&title=Pharmacological+and+structural+characterizations+of+naquotinib%2C+a+novel+third-generation+EGFR+tyrosine+kinase+inhibitor%2C+in+EGFR-mutated+non-small+cell+lung+cancer&doi=10.1158%2F1535-7163.MCT-17-1033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in EGFR-Mutated Non-Small Cell Lung Cancer</span></div><div class="casAuthors">Hirano, Toshiyuki; Yasuda, Hiroyuki; Hamamoto, Junko; Nukaga, Shigenari; Masuzawa, Keita; Kawada, Ichiro; Naoki, Katsuhiko; Niimi, Tatsuya; Mimasu, Shinya; Sakagami, Hideki; Soejima, Kenzo; Betsuyaku, Tomoko</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">740-750</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Multiple epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (EGFR-TKI) have been developed to effectively inhibit EGFR-derived signals in non-small cell lung cancer (NSCLC).  In this study, we assessed the efficacy of EGFR-TKIs, including a novel third-generation inhibitor naquotinib (ASP8273), in clin. relevant EGFR mutations, including L858R, exon 19 deletion, L858R+T790M, exon 19 deletion+T790M with or without a C797S mutation, and several exon 20 insertion mutations.  Using structural analyses, we also elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in EGFR exon 20 insertion mutations.  The efficacy of naquotinib in cells with L858R, exon 19 deletion and exon 19 deletion+T790M was comparable with that of osimertinib.  Interestingly, naquotinib was more potent than osimertinib for L858R+T790M.  Addnl., naquotinib and osimertinib had comparable efficacy and a wide therapeutic window for cells with EGFR exon 20 insertions.  Structural modeling partly elucidated the mechanism of activation and sensitivity/resistance to EGFR-TKIs in two EGFR exon 20 insertion mutants, A767_V769dupASV and Y764_V765insHH.  In summary, we have characterized the efficacy of EGFR-TKIs for NSCLC using in vitro and structural analyses and suggested the mechanism of activation and resistance to EGFR-TKIs of EGFR exon 20 insertion mutations.  Our findings should guide the selection of appropriate EGFR-TKIs for the treatment of NSCLC with EGFR mutations and help clarify the biol. of EGFR exon 20 insertion mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoM7fXCcishlLVg90H21EOLACvtfcHk0lg_cpj-OEnvgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXms1ejt7o%253D&md5=a654bd8355c631ecf63ecb51c13b8ac2</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-17-1033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-17-1033%26sid%3Dliteratum%253Aachs%26aulast%3DHirano%26aufirst%3DT.%26aulast%3DYasuda%26aufirst%3DH.%26aulast%3DHamamoto%26aufirst%3DJ.%26aulast%3DNukaga%26aufirst%3DS.%26aulast%3DMasuzawa%26aufirst%3DK.%26aulast%3DKawada%26aufirst%3DI.%26aulast%3DNaoki%26aufirst%3DK.%26aulast%3DNiimi%26aufirst%3DT.%26aulast%3DMimasu%26aufirst%3DS.%26aulast%3DSakagami%26aufirst%3DH.%26aulast%3DSoejima%26aufirst%3DK.%26aulast%3DBetsuyaku%26aufirst%3DT.%26atitle%3DPharmacological%2520and%2520structural%2520characterizations%2520of%2520naquotinib%252C%2520a%2520novel%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%252C%2520in%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26spage%3D740%26epage%3D750%26doi%3D10.1158%2F1535-7163.MCT-17-1033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Skene, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snell, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jennings, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwamoto, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirokawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span> <span> </span><span class="NLM_article-title">Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>286</i></span>,  <span class="NLM_fpage">18756</span>– <span class="NLM_lpage">18765</span>, <span class="refDoi"> DOI: 10.1074/jbc.M110.206193</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.M110.206193" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=21454582" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=286&publication_year=2011&pages=18756-18765&author=K.+Aertgeertsauthor=R.+Skeneauthor=J.+Yanoauthor=B.+C.+Sangauthor=H.+Zouauthor=G.+Snellauthor=A.+Jenningsauthor=K.+Iwamotoauthor=N.+Habukaauthor=A.+Hirokawaauthor=T.+Ishikawaauthor=T.+Tanakaauthor=H.+Mikiauthor=Y.+Ohtaauthor=S.+Sogabe&title=Structural+analysis+of+the+mechanism+of+inhibition+and+allosteric+activation+of+the+kinase+domain+of+HER2+protein&doi=10.1074%2Fjbc.M110.206193"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein</span></div><div class="casAuthors">Aertgeerts, Kathleen; Skene, Robert; Yano, Jason; Sang, Bi-Ching; Zou, Hua; Snell, Gyorgy; Jennings, Andy; Iwamoto, Keiji; Habuka, Noriyuki; Hirokawa, Aki; Ishikawa, Tomoyasu; Tanaka, Toshimasa; Miki, Hiroshi; Ohta, Yoshikazu; Sogabe, Satoshi</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">286</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">18756-18765</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Aberrant signaling of ErbB family members human epidermal growth factor 2 (HER2) and epidermal growth factor receptor (EGFR) is implicated in many human cancers, and HER2 expression is predictive of human disease recurrence and prognosis.  Small mol. kinase inhibitors of EGFR and of both HER2 and EGFR have received approval for the treatment of cancer.  We present the first high resoln. crystal structure of the kinase domain of HER2 in complex with a selective inhibitor to understand protein activation, inhibition, and function at the mol. level.  HER2 kinase domain crystallizes as a dimer and suggests evidence for an allosteric mechanism of activation comparable with previously reported activation mechanisms for EGFR and HER4.  A unique Gly-rich region in HER2 following the α-helix C is responsible for increased conformational flexibility within the active site and could explain the low intrinsic catalytic activity previously reported for HER2.  In addn., we solved the crystal structure of the kinase domain of EGFR in complex with a HER2/EGFR dual inhibitor (TAK-285).  Comparison with previously reported inactive and active EGFR kinase domain structures gave insight into the mechanism of HER2 and EGFR inhibition and may help guide the design and development of new cancer drugs with improved potency and selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomtAlJ0FGUX7Vg90H21EOLACvtfcHk0lg_cpj-OEnvgw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtlGltL0%253D&md5=c7897f5363d6452f7b60a8ced0f2bc30</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M110.206193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M110.206193%26sid%3Dliteratum%253Aachs%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DSkene%26aufirst%3DR.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DSang%26aufirst%3DB.%2BC.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DSnell%26aufirst%3DG.%26aulast%3DJennings%26aufirst%3DA.%26aulast%3DIwamoto%26aufirst%3DK.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DHirokawa%26aufirst%3DA.%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DSogabe%26aufirst%3DS.%26atitle%3DStructural%2520analysis%2520of%2520the%2520mechanism%2520of%2520inhibition%2520and%2520allosteric%2520activation%2520of%2520the%2520kinase%2520domain%2520of%2520HER2%2520protein%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2011%26volume%3D286%26spage%3D18756%26epage%3D18765%26doi%3D10.1074%2Fjbc.M110.206193" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ishikawa, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banno, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawakita, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oorui, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taniguchi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ohta, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakayama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Habuka, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sogabe, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yano, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aertgeerts, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kamiyama, K.</span></span> <span> </span><span class="NLM_article-title">Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">8030</span>– <span class="NLM_lpage">8050</span>, <span class="refDoi"> DOI: 10.1021/jm2008634</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2008634" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8030-8050&author=T.+Ishikawaauthor=M.+Setoauthor=H.+Bannoauthor=Y.+Kawakitaauthor=M.+Ooruiauthor=T.+Taniguchiauthor=Y.+Ohtaauthor=T.+Tamuraauthor=A.+Nakayamaauthor=H.+Mikiauthor=H.+Kamiguchiauthor=T.+Tanakaauthor=N.+Habukaauthor=S.+Sogabeauthor=J.+Yanoauthor=K.+Aertgeertsauthor=K.+Kamiyama&title=Design+and+synthesis+of+novel+human+epidermal+growth+factor+receptor+2+%28HER2%29%2Fepidermal+growth+factor+receptor+%28EGFR%29+dual+inhibitors+bearing+a+pyrrolo%5B3%2C2-d%5Dpyrimidine+scaffold&doi=10.1021%2Fjm2008634"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold</span></div><div class="casAuthors">Ishikawa, Tomoyasu; Seto, Masaki; Banno, Hiroshi; Kawakita, Youichi; Oorui, Mami; Taniguchi, Takahiko; Ohta, Yoshikazu; Tamura, Toshiya; Nakayama, Akiko; Miki, Hiroshi; Kamiguchi, Hidenori; Tanaka, Toshimasa; Habuka, Noriyuki; Sogabe, Satoshi; Yano, Jason; Aertgeerts, Kathleen; Kamiyama, Keiji</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">8030-8050</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Dual inhibitors of human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR) have been investigated for breast, lung, gastric, prostate, and other cancers; one, lapatinib, is currently approved for breast cancer.  To develop novel HER2/EGFR dual kinase inhibitors, we designed and synthesized pyrrolo[3,2-d]pyrimidine derivs., e.g. I, capable of fitting into the receptors' ATP binding site.  Among the prepd. compds., I showed potent HER2 and EGFR (HER1) inhibitory activities as well as tumor growth inhibitory activity.  The X-ray cocrystal structures of I with both HER2 and EGFR demonstrated that I interacts with the expected residues in their resp. ATP pockets.  Furthermore, reflecting its good oral bioavailability, I exhibited potent in vivo efficacy in HER2-overexpressing tumor xenograft models.  On the basis of these findings, we report I (TAK-285) as a promising candidate for clin. development as a novel HER2/EGFR dual kinase inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq9QtqAj6idYrVg90H21EOLACvtfcHk0ljeamqXmM6O4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlajur7M&md5=ce030ac133a1c0ff7cb78b269ff85987</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1021%2Fjm2008634&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2008634%26sid%3Dliteratum%253Aachs%26aulast%3DIshikawa%26aufirst%3DT.%26aulast%3DSeto%26aufirst%3DM.%26aulast%3DBanno%26aufirst%3DH.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DOorui%26aufirst%3DM.%26aulast%3DTaniguchi%26aufirst%3DT.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DTamura%26aufirst%3DT.%26aulast%3DNakayama%26aufirst%3DA.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DKamiguchi%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DHabuka%26aufirst%3DN.%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DYano%26aufirst%3DJ.%26aulast%3DAertgeerts%26aufirst%3DK.%26aulast%3DKamiyama%26aufirst%3DK.%26atitle%3DDesign%2520and%2520synthesis%2520of%2520novel%2520human%2520epidermal%2520growth%2520factor%2520receptor%25202%2520%2528HER2%2529%252Fepidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520dual%2520inhibitors%2520bearing%2520a%2520pyrrolo%255B3%252C2-d%255Dpyrimidine%2520scaffold%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8030%26epage%3D8050%26doi%3D10.1021%2Fjm2008634" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hemmer, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGlone, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsigelny, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, S. S.</span></span> <span> </span><span class="NLM_article-title">Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>272</i></span>,  <span class="NLM_fpage">16946</span>– <span class="NLM_lpage">16954</span>, <span class="refDoi"> DOI: 10.1074/jbc.272.27.16946</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fjbc.272.27.16946" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=9202006" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaK2sXksVemtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=272&publication_year=1997&pages=16946-16954&author=W.+Hemmerauthor=M.+McGloneauthor=I.+Tsigelnyauthor=S.+S.+Taylor&title=Role+of+the+glycine+triad+in+the+ATP-binding+site+of+cAMP-dependent+protein+kinase&doi=10.1074%2Fjbc.272.27.16946"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Role of the glycine triad in the ATP-binding site of cAMP-dependent protein kinase</span></div><div class="casAuthors">Hemmer, Wolfram; McGlones, Maria; Tsigelny, Igor; Taylor, Susan S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">272</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">16946-16954</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A Gly-rich loop in the ATP-binding site is one of the most highly conserved sequence motifs in protein kinases.  Each conserved Gly residue (Gly-50, Gly-52, and Gly-55) in the catalytic (C) subunit of cAMP-dependent protein kinase (protein kinase A; PKA) was replaced with Ser and/or Ala.  Active mutant proteins were expressed in Escherichia coli, purified to apparent homogeneity, sepd. into phosphoisoforms, and characterized.  Replacing Gly-55 had minimal effects on steady-state kinetic parameters, whereas replacement of either Gly-50 or Gly-52 had major effects on both Km and kcat values consistent with the prediction of the importance of the tip of the Gly-rich loop for catalysis.  Substitution of Gly-50 caused a 5-8 fold redn. in Km(ATP), an 8-12-fold increase in Km(peptide), and a 3-5-fold drop in the kcat.  The Km(ATP) and Km(peptide) values of the C(G52S) were increased 8- and 18-fold, resp., and the kcat was decreased 6-fold.  In contrast to catalytic efficiency, the ATPase rates of C(G50S) and C(G52S) were increased by more than an order of magnitude.  The thermostability of each mutant was slightly increased.  Unphosphorylated C(G52S) was characterized as well as several isoforms phosphorylated at a single site, Ser-338.  All of these phosphorylation-defective mutants displayed a substantial decrease in both enzymic activity and thermal stability that correlated with the missing phosphate at Thr-197.  These results were correlated with the crystal structure, models of the resp. mutant proteins, and conservation of the Gly residues within the protein kinase family.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNlWdiG-3RhrVg90H21EOLACvtfcHk0ljeamqXmM6O4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXksVemtr4%253D&md5=c443c26a926a5ccbfef213947186423d</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1074%2Fjbc.272.27.16946&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.272.27.16946%26sid%3Dliteratum%253Aachs%26aulast%3DHemmer%26aufirst%3DW.%26aulast%3DMcGlone%26aufirst%3DM.%26aulast%3DTsigelny%26aufirst%3DI.%26aulast%3DTaylor%26aufirst%3DS.%2BS.%26atitle%3DRole%2520of%2520the%2520glycine%2520triad%2520in%2520the%2520ATP-binding%2520site%2520of%2520cAMP-dependent%2520protein%2520kinase%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D1997%26volume%3D272%26spage%3D16946%26epage%3D16954%26doi%3D10.1074%2Fjbc.272.27.16946" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wulfert, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations</span>. <i>J. Am. Chem. Soc.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>132</i></span>,  <span class="NLM_fpage">4152</span>– <span class="NLM_lpage">4160</span>, <span class="refDoi"> DOI: 10.1021/ja908083e</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja908083e" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXislKit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=132&publication_year=2010&pages=4152-4160&author=J.+R.+Simardauthor=M.+Getlikauthor=C.+Gr%C3%BCtterauthor=R.+Schneiderauthor=S.+Wulfertauthor=D.+Rauh&title=Fluorophore+labeling+of+the+glycine-rich+loop+as+a+method+of+identifying+inhibitors+that+bind+to+active+and+inactive+kinase+conformations&doi=10.1021%2Fja908083e"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Fluorophore Labeling of the Glycine-Rich Loop as a Method of Identifying Inhibitors That Bind to Active and Inactive Kinase Conformations</span></div><div class="casAuthors">Simard, Jeffrey R.; Getlik, Matthaeus; Gruetter, Christian; Schneider, Ralf; Wulfert, Sabine; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of the American Chemical Society</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">132</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4152-4160</span>CODEN:
                <span class="NLM_cas:coden">JACSAT</span>;
        ISSN:<span class="NLM_cas:issn">0002-7863</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Targeting protein kinases with small org. mols. is a promising strategy to regulate unwanted kinase activity in both chem. biol. and medicinal chem. research.  Traditionally, kinase inhibitors are identified in activity-based screening assays using enzymically active kinase prepns. to measure the perturbation of substrate phosphorylation, often resulting in the enrichment of classical ATP competitive (Type I) inhibitors.  However, addressing enzymically incompetent kinase conformations offers new opportunities for targeted therapies and is moving to the forefront of kinase inhibitor research.  Here we report the development of a new FLiK (Fluorescent Labels in Kinases) binding assay to detect small mols. that induce changes in the conformation of the glycine-rich loop.  Due to cross-talk between the glycine-rich loop and the activation loop in kinases, this alternative labeling approach can also detect ligands that stabilize inactive kinase conformations, including slow-binding Type II and Type III kinase inhibitors.  Protein x-ray crystallog. validated the assay results and identified a novel DFG-out binding mode for a quinazoline-based inhibitor in p38α kinase.  We also detected the high-affinity binding of a clin. relevant and specific VEGFR2 inhibitor, and we provide structural details of its binding mode in p38α, in which it stabilizes the DFG-out conformation.  Last, we demonstrate the power of this new FLiK labeling strategy to detect the binding of Type I ligands that induce conformational changes in the glycine-rich loop as a means of gaining affinity for the target kinase.  This approach may be a useful alternative to develop direct binding assays for kinases that do not adopt the DFG-out conformation while also avoiding the use of expensive kits, detection reagents, or radioactivity frequently employed with activity-based assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPNWnX2gIfS7Vg90H21EOLACvtfcHk0ljeamqXmM6O4w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXislKit7c%253D&md5=ec40d16fa19b59beeb10ebbae6f4aaf1</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1021%2Fja908083e&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja908083e%26sid%3Dliteratum%253Aachs%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DWulfert%26aufirst%3DS.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DFluorophore%2520labeling%2520of%2520the%2520glycine-rich%2520loop%2520as%2520a%2520method%2520of%2520identifying%2520inhibitors%2520that%2520bind%2520to%2520active%2520and%2520inactive%2520kinase%2520conformations%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D2010%26volume%3D132%26spage%3D4152%26epage%3D4160%26doi%3D10.1021%2Fja908083e" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sellers, W. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, J. D.</span></span> <span> </span><span class="NLM_article-title">Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">8968</span>– <span class="NLM_lpage">8974</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-1829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-05-1829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16204070" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=8968-8974&author=J.+Jiangauthor=H.+Greulichauthor=P.+A.+J%C3%A4nneauthor=W.+R.+Sellersauthor=M.+Meyersonauthor=J.+D.+Griffin&title=Epidermal+growth+factor-independent+transformation+of+Ba%2FF3+cells+with+cancer-derived+epidermal+growth+factor+receptor+mutants+induces+gefitinib-sensitive+cell+cycle+progression&doi=10.1158%2F0008-5472.CAN-05-1829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces Gefitinib-sensitive cell cycle progression</span></div><div class="casAuthors">Jiang, Jingrui; Greulich, Heidi; Jaenne, Pasi A.; Sellers, William R.; Meyerson, Matthew; Griffin, James D.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">8968-8974</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Epidermal growth factor receptor (EGFR) plays crit. roles in many biol. processes and in tumorigenesis.  Here, we show that two mutated EGFRs found in lung and other malignancies, EGFR-G719S and EGFR-L858R, could transform Ba/F3 cells to interleukin-3 (IL-3)-independent growth, in a ligand-independent manner, an activity assocd. with the transforming function of other mutated tyrosine kinases.  The mutated receptors are autophosphorylated in the absence of IL-3 without EGF stimulation, and their expression led to the constitutive activation of signal transducers and activators of transcription 5, extracellular signal-regulated kinase 1/2 (ERK1/2), ERK5, and Akt.  In wild-type EGFR-expressing Ba/F3 cells, the major EGF-mediated signaling pathways were still intact.  Gefitinib inhibited the growth of mutant EGFR-transformed Ba/F3 cells.  Strikingly, the gefitinib sensitivity of cells expressing the L858R mutant was significantly greater than that of cells expressing the G719S mutant form, suggesting that distinct EGFR mutations may be differentially sensitive to small-mol. inhibitors.  Furthermore, our data showed an antiproliferative effect of gefitinib on the EGFR-transformed Ba/F3 cells.  Our results provide a model system to study the function of mutated EGFR and the differential effects of pharmacol. EGFR inhibition on the distinct mutant forms of this tyrosine kinase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHpgPE3k7sNbVg90H21EOLACvtfcHk0lh0fv06zhE8dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVKiu7rO&md5=d0f02ce379ff724245967f833e39507f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-1829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-1829%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DJ.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DSellers%26aufirst%3DW.%2BR.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DGriffin%26aufirst%3DJ.%2BD.%26atitle%3DEpidermal%2520growth%2520factor-independent%2520transformation%2520of%2520Ba%252FF3%2520cells%2520with%2520cancer-derived%2520epidermal%2520growth%2520factor%2520receptor%2520mutants%2520induces%2520gefitinib-sensitive%2520cell%2520cycle%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D8968%26epage%3D8974%26doi%3D10.1158%2F0008-5472.CAN-05-1829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chan, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gullick, W. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hill, M. E.</span></span> <span> </span><span class="NLM_article-title">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy</span>. <i>Eur. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">23</span>, <span class="refDoi"> DOI: 10.1016/j.ejca.2005.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.ejca.2005.07.031" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16364841" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2006&pages=17-23&author=S.+K.+Chanauthor=W.+J.+Gullickauthor=M.+E.+Hill&title=Mutations+of+the+epidermal+growth+factor+receptor+in+non-small+cell+lung+cancer+-+search+and+destroy&doi=10.1016%2Fj.ejca.2005.07.031"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy</span></div><div class="casAuthors">Chan, S. K.; Gullick, W. J.; Hill, M. E.</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-23</span>CODEN:
                <span class="NLM_cas:coden">EJCAEL</span>;
        ISSN:<span class="NLM_cas:issn">0959-8049</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  The targeting of the ATP binding pocket of the epidermal growth factor receptor (EGFR) tyrosine kinase, by the small mol. drugs gefitinib and erlotinib, represents a promising new therapeutic strategy in non-small cell lung cancer.  However, it is now apparent that only a subset of patients responds to such treatment.  Two publications in early 2004 reported the presence of activating mutations in the EGFR tyrosine kinase gene conferring exquisite sensitivity to these drugs.  Several publications have since reported prospective data consistent with this finding.  This brief review summarizes the mutation data from 15 such studies in terms of mutation frequency by clinicopathol. features and correlation with response to tyrosine kinase inhibition.  A new paradigm for the routine detection of such mutations is needed to facilitate patient selection for treatment and further studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo2iKbYyg0gqbVg90H21EOLACvtfcHk0lh0fv06zhE8dA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtlCktLzL&md5=01e38085f3beed6636d5e3979d4b9c5a</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1016%2Fj.ejca.2005.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejca.2005.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DChan%26aufirst%3DS.%2BK.%26aulast%3DGullick%26aufirst%3DW.%2BJ.%26aulast%3DHill%26aufirst%3DM.%2BE.%26atitle%3DMutations%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520in%2520non-small%2520cell%2520lung%2520cancer%2520-%2520search%2520and%2520destroy%26jtitle%3DEur.%2520J.%2520Cancer%26date%3D2006%26volume%3D42%26spage%3D17%26epage%3D23%26doi%3D10.1016%2Fj.ejca.2005.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shigematsu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gazdar, A. F.</span></span> <span> </span><span class="NLM_article-title">Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers</span>. <i>Int. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">262</span>, <span class="refDoi"> DOI: 10.1002/ijc.21496</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fijc.21496" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16231326" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD2Mngs1Ojug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2006&pages=257-262&author=H.+Shigematsuauthor=A.+F.+Gazdar&title=Somatic+mutations+of+epidermal+growth+factor+receptor+signaling+pathway+in+lung+cancers&doi=10.1002%2Fijc.21496"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers</span></div><div class="casAuthors">Shigematsu Hisayuki; Gazdar Adi F</div><div class="citationInfo"><span class="NLM_cas:title">International journal of cancer</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-62</span>
        ISSN:<span class="NLM_cas:issn">0020-7136</span>.
    </div><div class="casAbstract">Somatic mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR) gene in lung cancers have generated enormous interest, because they predict for sensitivity to TK inhibitors (TKIs).  While mutational status is of great importance in determining response to TKIs, it is not the sole factor, and evidence is accumulating that EGFR gene amplification, other members of the EGFR family (HER2, HER3) and genes downstream of EGFR signaling (KRAS, BRAF), may be involved in cancer pathogenesis and the response of TKIs.  EGFR mutations occur in highly selected subpopulations of lung cancer patients: adenocarcinoma histology, never-smoker status, East Asian ethnicity and female gender.  The recent finding of "a resistance associated" mutation for TKIs also provides new insights into this complicated mechanism.  Thus, molecular-based studies to analyze the biological functions and to assess TKI sensitivity depending on the type of mutations are required.  Epidemiological studies to identify possible carcinogenic factor(s) affecting different subpopulations are also of interest.  In addition, for optimal therapeutic approach a comprehensive understanding of the genes related to EGFR signaling pathway, including RAS/RAF/MAPK and PI3K-AKT pathways, are required.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSSKJs50Ui3ehWfpMXQLRstfW6udTcc2ebYo9IZJhguh7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2Mngs1Ojug%253D%253D&md5=14c1c3ef842ca5817275870c9667ec10</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1002%2Fijc.21496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fijc.21496%26sid%3Dliteratum%253Aachs%26aulast%3DShigematsu%26aufirst%3DH.%26aulast%3DGazdar%26aufirst%3DA.%2BF.%26atitle%3DSomatic%2520mutations%2520of%2520epidermal%2520growth%2520factor%2520receptor%2520signaling%2520pathway%2520in%2520lung%2520cancers%26jtitle%3DInt.%2520J.%2520Cancer%26date%3D2006%26volume%3D118%26spage%3D257%26epage%3D262%26doi%3D10.1002%2Fijc.21496" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yoshikawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kukimoto-Niino, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Handa, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terada, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fujimoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terazawa, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wakiyama, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sato, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kobayashi, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tanaka, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shirouzu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kawa, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Semba, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamamoto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yokoyama, S.</span></span> <span> </span><span class="NLM_article-title">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>32</i></span>,  <span class="NLM_fpage">27</span>– <span class="NLM_lpage">38</span>, <span class="refDoi"> DOI: 10.1038/onc.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fonc.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=22349823" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXnvFKl" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2013&pages=27-38&author=S.+Yoshikawaauthor=M.+Kukimoto-Niinoauthor=L.+Parkerauthor=N.+Handaauthor=T.+Teradaauthor=T.+Fujimotoauthor=Y.+Terazawaauthor=M.+Wakiyamaauthor=M.+Satoauthor=S.+Sanoauthor=T.+Kobayashiauthor=T.+Tanakaauthor=L.+Chenauthor=Z.+J.+Liuauthor=B.+C.+Wangauthor=M.+Shirouzuauthor=S.+Kawaauthor=K.+Sembaauthor=T.+Yamamotoauthor=S.+Yokoyama&title=Structural+basis+for+the+altered+drug+sensitivities+of+non-small+cell+lung+cancer-associated+mutants+of+human+epidermal+growth+factor+receptor&doi=10.1038%2Fonc.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Structural basis for the altered drug sensitivities of non-small cell lung cancer-associated mutants of human epidermal growth factor receptor</span></div><div class="casAuthors">Yoshikawa, S.; Kukimoto-Niino, M.; Parker, L.; Handa, N.; Terada, T.; Fujimoto, T.; Terazawa, Y.; Wakiyama, M.; Sato, M.; Sano, S.; Kobayashi, T.; Tanaka, T.; Chen, L.; Liu, Z.-J.; Wang, B.-C.; Shirouzu, M.; Kawa, S.; Semba, K.; Yamamoto, T.; Yokoyama, S.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">27-38</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) has an essential role in multiple signaling pathways, including cell proliferation and migration, through extracellular ligand binding and subsequent activation of its intracellular tyrosine kinase (TK) domain.  The non-small cell lung cancer (NSCLC)-assocd. EGFR mutants, L858R and G719S, are constitutively active and oncogenic.  They display sensitivity to TK inhibitors, including gefitinib and erlotinib.  In contrast, the secondary mutation of the gatekeeper residue, T790M, reportedly confers inhibitor resistance on the oncogenic EGFR mutants.  In this study, our biochem. analyses revealed that the introduction of the T790M mutation confers gefitinib resistance on the G719S mutant.  The G719S/T790M double mutant has enhanced activity and retains high gefitinib-binding affinity.  The T790M mutation increases the ATP affinity of the G719S mutant, explaining the acquired drug resistance of the double mutant.  Structural analyses of the G719S/T790M double mutant, as well as the wild type and the G719S and L858R mutants, revealed that the T790M mutation stabilizes the hydrophobic spine of the active EGFR-TK conformation.  The Met790 side chain of the G719S/T790M double mutant, in the apo form and gefitinib- and AMPPNP-bound forms, adopts different conformations that explain the accommodation of these ligands.  In the L858R mutant structure, the active-site cleft is expanded by the repositioning of Phe723 within the P-loop.  Notably, the introduction of the F723A mutation greatly enhanced the gefitinib sensitivity of the wild-type EGFR in vivo, supporting our hypothesis that the expansion of the active-site cleft results in enhanced gefitinib sensitivity.  Taken together, our results provide a structural basis for the altered drug sensitivities caused by distinct NSCLC-assocd. EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqr7hEqvdS5i7Vg90H21EOLACvtfcHk0liCH40RCwFmlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXnvFKl&md5=f9b29aac7bcb52cc0605f157f7f14809</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fonc.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DYoshikawa%26aufirst%3DS.%26aulast%3DKukimoto-Niino%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DL.%26aulast%3DHanda%26aufirst%3DN.%26aulast%3DTerada%26aufirst%3DT.%26aulast%3DFujimoto%26aufirst%3DT.%26aulast%3DTerazawa%26aufirst%3DY.%26aulast%3DWakiyama%26aufirst%3DM.%26aulast%3DSato%26aufirst%3DM.%26aulast%3DSano%26aufirst%3DS.%26aulast%3DKobayashi%26aufirst%3DT.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%2BJ.%26aulast%3DWang%26aufirst%3DB.%2BC.%26aulast%3DShirouzu%26aufirst%3DM.%26aulast%3DKawa%26aufirst%3DS.%26aulast%3DSemba%26aufirst%3DK.%26aulast%3DYamamoto%26aufirst%3DT.%26aulast%3DYokoyama%26aufirst%3DS.%26atitle%3DStructural%2520basis%2520for%2520the%2520altered%2520drug%2520sensitivities%2520of%2520non-small%2520cell%2520lung%2520cancer-associated%2520mutants%2520of%2520human%2520epidermal%2520growth%2520factor%2520receptor%26jtitle%3DOncogene%26date%3D2013%26volume%3D32%26spage%3D27%26epage%3D38%26doi%3D10.1038%2Fonc.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tong, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, C.</span></span> <span> </span><span class="NLM_article-title">Investigating novel resistance mechanisms to third-generation EGFR tyrosine kinase inhibitor osimertinib in non-small cell lung cancer patients</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3097</span>– <span class="NLM_lpage">3107</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-17-2310</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-17-2310" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29506987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=3097-3107&author=Z.+Yangauthor=N.+Yangauthor=Q.+Ouauthor=Y.+Xiangauthor=T.+Jiangauthor=X.+Wuauthor=H.+Baoauthor=X.+Tongauthor=X.+Wangauthor=Y.+W.+Shaoauthor=Y.+Liuauthor=Y.+Wangauthor=C.+Zhou&title=Investigating+novel+resistance+mechanisms+to+third-generation+EGFR+tyrosine+kinase+inhibitor+osimertinib+in+non-small+cell+lung+cancer+patients&doi=10.1158%2F1078-0432.CCR-17-2310"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients</span></div><div class="casAuthors">Yang, Zhe; Yang, Nong; Ou, Qiuxiang; Xiang, Yi; Jiang, Tao; Wu, Xue; Bao, Hua; Tong, Xiaoling; Wang, Xiaonan; Shao, Yang W.; Liu, Yunpeng; Wang, Yan; Zhou, Caicun</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3097-3107</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The third-generation EGFR tyrosine kinase inhibitor osimertinib is approved to treat patients with EGFR T790M-pos. non-small cell lung cancer (NSCLC) who have developed resistance to earlier-generation drugs.  Acquired EGFR C797S mutation has been reported to mediate osimertinib resistance in some patients.  However, the remaining resistance mechanisms are largely unknown.  Exptl. Design: We performed mutation profiling using targeted next-generation sequencing (NGS) for 416 cancer-relevant genes on 93 osimertinib-resistant lung cancer patients' samples, mainly cell-free DNAs (cfDNAs), and matched pretreatment samples of 12 patients.  In vitro expts. were conducted to functionally study the secondary EGFR mutations identified.  Results: EGFR G796/C797, L792, and L718/G719 mutations were identified in 24.7%, 10.8%, and 9.7% of the cases, resp., with certain mutations coexisting in one patient with different prevalence.  L792 and L718 mutants markedly increased the half inhibitory concn. (IC50) of osimertinib in vitro, among which the L718Q mutation conferred the greatest resistance to osimertinib, as well as gefitinib resistance when not coexisting with T790M.  Further anal. of the 12 matched pretreatment samples confirmed that these EGFR mutations were acquired during osimertinib treatment.  Alterations in parallel or downstream oncogenes such as MET, KRAS, and PIK3CA were also discovered, potentially contributing to the osimertinib-resistance in patients without EGFR secondary mutations.  Conclusions: We present comprehensive mutation profiles of a large cohort of osimertinib-resistance lung cancer patients using mainly cfDNA.  Besides C797 mutations, novel secondary mutations of EGFR L718 and L792 residues confer osimertinib resistance, both in vitro and in vivo, and are of great clin. and pharmaceutical relevance.  Clin Cancer Res; 24(13); 3097-107. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNVy8b5kjUl7Vg90H21EOLACvtfcHk0liCH40RCwFmlA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1alurvK&md5=434ecc4e1a150078fe88cdaf786165b2</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DYang%26aufirst%3DN.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DXiang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DT.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DBao%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DC.%26atitle%3DInvestigating%2520novel%2520resistance%2520mechanisms%2520to%2520third-generation%2520EGFR%2520tyrosine%2520kinase%2520inhibitor%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520patients%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D3097%26epage%3D3107%26doi%3D10.1158%2F1078-0432.CCR-17-2310" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, Y. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ying, J.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>118</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">5</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2018.01.015</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2018.01.015" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29571986" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktlyrtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=118&publication_year=2018&pages=1-5&author=Y.+Liuauthor=Y.+Liauthor=Q.+Ouauthor=X.+Wuauthor=X.+Wangauthor=Y.+W.+Shaoauthor=J.+Ying&title=Acquired+EGFR+L718V+mutation+mediates+resistance+to+osimertinib+in+non-small+cell+lung+cancer+but+retains+sensitivity+to+afatinib&doi=10.1016%2Fj.lungcan.2018.01.015"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib</span></div><div class="casAuthors">Liu Yutao; Li Yan; Ou Qiuxiang; Wu Xue; Wang Xiaonan; Shao Yang W; Ying Jianming</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">118</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-5</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVES:  Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are promising targeted therapies for EGFR-mutated non-small-cell lung cancer (NSCLC) patients.  However, acquired resistance inevitably develops.  Comprehensive and dynamic companion genomic diagnosis can gain insights into underlying resistance mechanisms, thereby help oncologists and patients to make informed decision on the potential benefit of the treatment.  MATERIALS AND METHODS:  A 67-year-old male who was initially diagnosed of EGFR L858R-mediated NSCLC received multiple lines of chemotherapy and EGFR TKI therapies after surgery.  The EGFR mutational status of individual metastatic lesion was determined by genetic testing of the tumor tissue biopsies using next generation sequencing (NGS) throughout the patient's clinical course.  An acquired potentially drug-resistant EGFR mutation was functionally validated in vitro and its sensitivity to different EGFR TKIs was assessed simultaneously.  RESULTS:  We have identified distinct resistance mechanisms to EGFR blockade in different metastatic lung lesions.  Acquired EGFR T790M was first detected that leads to the resistance to the gefitinib treatment.  Consequently, osimertinib was administrated and the response lasted until disease progressed.  We identified a newly acquired EGFR L718V mutation in one lesion in conjunction with L858R, but not T790M, which showed stable disease on the following erlotinib treatment, while EGFR C797S together with L858R/T790M was detected in the other lesion that continuously progressed.  In vitro functional studies demonstrated that EGFR-L858R/L718V confers resistance to osimertinib, but retains sensitivity to the second generation TKI afatinib.  CONCLUSION:  We reported that distinct resistance mechanisms could arise in different metastases within the same patient in response to EGFR blockade.  We also demonstrated in vitro that EGFR L718V mutation mediates resistance to osimertinib, but retains sensitivity to afatinib.  We evidenced that dynamic companion genomic diagnosis offers valuable information to help define the mechanisms of drug resistance and to guide the selection of subsequent treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQgt4Gd6-WlAL5XHngOXiV_fW6udTcc2eavxrfyFAP7Krntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktlyrtQ%253D%253D&md5=d4501279f5b5faa7d8a099e608e17e47</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2018.01.015&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2018.01.015%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DOu%26aufirst%3DQ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DShao%26aufirst%3DY.%2BW.%26aulast%3DYing%26aufirst%3DJ.%26atitle%3DAcquired%2520EGFR%2520L718V%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%2520in%2520non-small%2520cell%2520lung%2520cancer%2520but%2520retains%2520sensitivity%2520to%2520afatinib%26jtitle%3DLung%2520Cancer%26date%3D2018%26volume%3D118%26spage%3D1%26epage%3D5%26doi%3D10.1016%2Fj.lungcan.2018.01.015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ma, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, X. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span> <span> </span><span class="NLM_article-title">Structural insights into drug development strategy targeting EGFR T790M/C797S</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">13652</span>– <span class="NLM_lpage">13665</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.24113</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.18632%2Foncotarget.24113" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29568384" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=13652-13665&author=S.+J.+Zhuauthor=P.+Zhaoauthor=J.+Yangauthor=R.+Maauthor=X.+E.+Yanauthor=S.+Y.+Yangauthor=J.+W.+Yangauthor=C.+H.+Yun&title=Structural+insights+into+drug+development+strategy+targeting+EGFR+T790M%2FC797S&doi=10.18632%2Foncotarget.24113"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into drug development strategy targeting EGFR T790M/C797S</span></div><div class="casAuthors">Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Zhu Su-Jie; Zhao Peng; Ma Rui; Yan Xiao-E; Yun Cai-Hong; Yang Jiao; Yang Sheng-Yong; Yang Jing-Wen</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">13652-13665</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Treatment of non-small-cell lung cancers (NSCLCs) harboring primary EGFR oncogenic mutations such as L858R and exon 19 deletion delE746_A750 (Del-19) using gefitinib/erlotinib ultimately fails due to the emergence of T790M mutation.  Though WZ4002/CO-1686/AZD9291 are effective in overcoming EGFR T790M by targeting Cys797 via covalent bonding, their efficacy is again limited due to the emergence of C797S mutation.  New agents effectively inhibiting EGFR T790M without covalent linkage through Cys 797 may solve this problem.  We presented here crystal structures of EGFR activating/drug-resistant mutants in complex with a panel of reversible inhibitors along with mutagenesis and enzyme kinetic data.  These data revealed a previously un-described hydrophobic clamp structure in the EGFR kinase which may be exploited to facilitate development of next generation drugs targeting EGFR T790M with or without concomitant C797S.  Interestingly, mutations in the hydrophobic clamp that hinder drug binding often also weaken ATP binding and/or abolish kinase activity, thus do not readily result in resistance to the drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRatiF0vPAX33ELvajU9pjPfW6udTcc2ebkhaAuoyPltLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MnktVaqug%253D%253D&md5=7502a50efce99f712a54003680a95bde</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.24113&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.24113%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DS.%2BJ.%26aulast%3DZhao%26aufirst%3DP.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DMa%26aufirst%3DR.%26aulast%3DYan%26aufirst%3DX.%2BE.%26aulast%3DYang%26aufirst%3DS.%2BY.%26aulast%3DYang%26aufirst%3DJ.%2BW.%26aulast%3DYun%26aufirst%3DC.%2BH.%26atitle%3DStructural%2520insights%2520into%2520drug%2520development%2520strategy%2520targeting%2520EGFR%2520T790M%252FC797S%26jtitle%3DOncotarget%26date%3D2018%26volume%3D9%26spage%3D13652%26epage%3D13665%26doi%3D10.18632%2Foncotarget.24113" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oztan, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Erlich, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raez, L. E.</span></span> <span> </span><span class="NLM_article-title">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">84</span>– <span class="NLM_lpage">87</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.07.002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2017.07.002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28838405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2017&pages=84-87&author=A.+Oztanauthor=S.+Fischerauthor=A.+B.+Schrockauthor=R.+L.+Erlichauthor=C.+M.+Lovlyauthor=P.+J.+Stephensauthor=J.+S.+Rossauthor=V.+Millerauthor=S.+M.+Aliauthor=S.+I.+Ouauthor=L.+E.+Raez&title=Emergence+of+EGFR+G724S+mutation+in+EGFR-mutant+lung+adenocarcinoma+post+progression+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.07.002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib</span></div><div class="casAuthors">Oztan A; Fischer S; Schrock A B; Erlich R L; Stephens P J; Ross J S; Miller V; Ali S M; Lovly C M; Ou S-H I; Raez L E</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">84-87</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mutations in the epidermal growth factor receptor (EGFR) are drivers for a subset of lung cancers.  Osimertinib is a third-generation tyrosine kinase inhibitor (TKI) recently approved for the treatment of T790M-positive non-small cell lung cancer (NSCLC); however, acquired resistance to osimertinib is evident and resistance mechanisms remain incompletely defined.  The EGFR G724S mutation was detected using hybrid-capture based comprehensive genomic profiling (CGP) and a hybrid-capture based circulating tumor DNA (ctDNA) assays in two cases of EGFR-driven lung adenocarcinoma in patients who had progressed on osimertinib treatment.  This study demonstrates the importance of both tissue and blood based hybrid-capture based genomic profiling at disease progression to identifying novel resistance mechanisms in the clinic.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTsycCvNkMcjjToTC3aBaesfW6udTcc2ebkhaAuoyPltLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cbhtl2jsg%253D%253D&md5=c7173dc6b94f44f48532bebb352e345f</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.07.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.07.002%26sid%3Dliteratum%253Aachs%26aulast%3DOztan%26aufirst%3DA.%26aulast%3DFischer%26aufirst%3DS.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DErlich%26aufirst%3DR.%2BL.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DRaez%26aufirst%3DL.%2BE.%26atitle%3DEmergence%2520of%2520EGFR%2520G724S%2520mutation%2520in%2520EGFR-mutant%2520lung%2520adenocarcinoma%2520post%2520progression%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D111%26spage%3D84%26epage%3D87%26doi%3D10.1016%2Fj.lungcan.2017.07.002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span> <span> </span><span class="NLM_article-title">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">51</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.2147/OTT.S188612</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2147%2FOTT.S188612" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30588029" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=51-56&author=Y.+Zhangauthor=B.+Heauthor=D.+Zhouauthor=M.+Liauthor=C.+Hu&title=Newly+emergent+acquired+EGFR+exon+18+G724S+mutation+after+resistance+of+a+T790M+specific+EGFR+inhibitor+osimertinib+in+non-small-cell+lung+cancer%3A+a+case+report&doi=10.2147%2FOTT.S188612"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">Newly emergent acquired EGFR exon 18 G724S mutation after resistance of a T790M specific EGFR inhibitor osimertinib in non-small-cell lung cancer: a case report</span></div><div class="casAuthors">Zhang, Yan; He, Bixiu; Zhou, Dongbo; Li, Min; Hu, Chengping</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">51-56</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: T790M mutation is well known as the most common mechanism for resistance to the first- and second-generation tyrosine kinase inhibitors (TKIs) for EGFR mutation in non-small-cell lung cancer.  Several third-generation EGFR TKIs, such as osimertinib, have been explored and approved for conquering this resistance; however, acquired resistance to osimertinib is evident and the resistance mechanisms remain complex and incompletely explored.  Case presentation: A non-smoking 58-yr-old female patient was initially diagnosed with lung adenocarcinoma harboring EGFR exon 19 deletion and clin. responded to initial gefitinib treatment.  The patient progressed on gefitinib after > 1 yr and a T790M mutation was detected in tissue biopsy by next-generation sequencing (NGS).  Osimertinib treatment was administrated for several months and an acquired rare EGFR G724S mutation was detected via NGS blood sample after osimertinib resistance.  Conclusion: The specific mechanisms of acquiring drug resistance for EGFR-TKIs have not been fully explored.  EGFR G724S mutation might be assocd. with osimertinib resistance but more studies about the mechanism should be explored.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGCPcRDGUQb7Vg90H21EOLACvtfcHk0liKOBAlTBy0pA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlKms73K&md5=87e7c138506ba5973a82cf7715aacff5</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FOTT.S188612&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S188612%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DHe%26aufirst%3DB.%26aulast%3DZhou%26aufirst%3DD.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DHu%26aufirst%3DC.%26atitle%3DNewly%2520emergent%2520acquired%2520EGFR%2520exon%252018%2520G724S%2520mutation%2520after%2520resistance%2520of%2520a%2520T790M%2520specific%2520EGFR%2520inhibitor%2520osimertinib%2520in%2520non-small-cell%2520lung%2520cancer%253A%2520a%2520case%2520report%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D51%26epage%3D56%26doi%3D10.2147%2FOTT.S188612" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Brown, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ross, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bazhenova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meiler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovly, C. M.</span></span> <span> </span><span class="NLM_article-title">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">3341</span>– <span class="NLM_lpage">3351</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3829</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-18-3829" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30796031" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=3341-3351&author=B.+P.+Brownauthor=Y.+K.+Zhangauthor=D.+Westoverauthor=Y.+Yanauthor=H.+Qiaoauthor=V.+Huangauthor=Z.+Duauthor=J.+A.+Smithauthor=J.+S.+Rossauthor=V.+A.+Millerauthor=S.+Aliauthor=L.+Bazhenovaauthor=A.+B.+Schrockauthor=J.+Meilerauthor=C.+M.+Lovly&title=On-target+resistance+to+the+mutant-selective+EGFR+inhibitor+osimertinib+can+develop+in+an+allele-specific+manner+dependent+on+the+original+EGFR-activating+mutation&doi=10.1158%2F1078-0432.CCR-18-3829"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">On-target resistance to the mutant-selective EGFR inhibitor osimertinib can develop in an allele-specific manner dependent on the original EGFR-activating mutation</span></div><div class="casAuthors">Brown, Benjamin P.; Zhang, Yun-Kai; Westover, David; Yan, Yingjun; Qiao, Huan; Huang, Vincent; Du, Zhenfang; Smith, Jarrod A.; Ross, Jeffrey S.; Miller, Vincent A.; Ali, Siraj; Bazhenova, Lyudmila; Schrock, Alexa B.; Meiler, Jens; Lovly, Christine M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3341-3351</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The third-generation EGFR inhibitor, osimertinib, is the first mutant-selective inhibitor that has received regulatory approval for the treatment of patients with EGFR-mutant lung cancer.  Here, we investigate how G724S confers resistance to osimertinib.  We combine structure-based predictive modeling of G724S in combination with the 2 most common EGFR-activating mutations, exon 19 deletion (Ex19Del) and L858R, with in vitro drug-response models and patient genomic profiling.  Our simulations suggest that the G724S mutation selectively reduces osimertinib-binding affinity in the context of Ex19Del.  Consistent with our simulations, cell lines transduced with Ex19Del/G724S demonstrate resistance to osimertinib, whereas cells transduced with L858R/G724S are sensitive to osimertinib.  Subsequent clin. genomic profiling data further suggest G724S occurs with Ex19Del but not L858R.  Furthermore, we demonstrate that Ex19Del/G724S retains sensitivity to afatinib, but not to erlotinib, suggesting a possible therapy for patients at the time of disease relapse.  Altogether, these data suggest that G724S is an allele-specific resistance mutation emerging in the context of Ex19Del but not L858R.  Our results fundamentally reframe the problem of targeted therapy resistance from one focused on the drug-resistance mutation pair to one focused on activating mutation-drug-resistance mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKneM5OFx3BrVg90H21EOLACvtfcHk0ljKXM392WQ5Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXhsFSktLvO&md5=5ea6914733351fabdf1c59c19a66e49e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3829&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3829%26sid%3Dliteratum%253Aachs%26aulast%3DBrown%26aufirst%3DB.%2BP.%26aulast%3DZhang%26aufirst%3DY.%2BK.%26aulast%3DWestover%26aufirst%3DD.%26aulast%3DYan%26aufirst%3DY.%26aulast%3DQiao%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DV.%26aulast%3DDu%26aufirst%3DZ.%26aulast%3DSmith%26aufirst%3DJ.%2BA.%26aulast%3DRoss%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBazhenova%26aufirst%3DL.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DMeiler%26aufirst%3DJ.%26aulast%3DLovly%26aufirst%3DC.%2BM.%26atitle%3DOn-target%2520resistance%2520to%2520the%2520mutant-selective%2520EGFR%2520inhibitor%2520osimertinib%2520can%2520develop%2520in%2520an%2520allele-specific%2520manner%2520dependent%2520on%2520the%2520original%2520EGFR-activating%2520mutation%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26spage%3D3341%26epage%3D3351%26doi%3D10.1158%2F1078-0432.CCR-18-3829" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somwar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Varmus, H.</span></span> <span> </span><span class="NLM_article-title">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span>. <i>PLoS Med.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">e73</span>, <span class="refDoi"> DOI: 10.1371/journal.pmed.0020073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1371%2Fjournal.pmed.0020073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=15737014" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=e73&author=W.+Paoauthor=V.+A.+Millerauthor=K.+A.+Politiauthor=G.+J.+Rielyauthor=R.+Somwarauthor=M.+F.+Zakowskiauthor=M.+G.+Krisauthor=H.+Varmus&title=Acquired+resistance+of+lung+adenocarcinomas+to+gefitinib+or+erlotinib+is+associated+with+a+second+mutation+in+the+EGFR+kinase+domain&doi=10.1371%2Fjournal.pmed.0020073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain</span></div><div class="casAuthors">Pao William; Miller Vincent A; Politi Katerina A; Riely Gregory J; Somwar Romel; Zakowski Maureen F; Kris Mark G; Varmus Harold</div><div class="citationInfo"><span class="NLM_cas:title">PLoS medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">e73</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Lung adenocarcinomas from patients who respond to the tyrosine kinase inhibitors gefitinib (Iressa) or erlotinib (Tarceva) usually harbor somatic gain-of-function mutations in exons encoding the kinase domain of the epidermal growth factor receptor (EGFR).  Despite initial responses, patients eventually progress by unknown mechanisms of "acquired" resistance.  METHODS AND FINDINGS:  We show that in two of five patients with acquired resistance to gefitinib or erlotinib, progressing tumors contain, in addition to a primary drug-sensitive mutation in EGFR, a secondary mutation in exon 20, which leads to substitution of methionine for threonine at position 790 (T790M) in the kinase domain.  Tumor cells from a sixth patient with a drug-sensitive EGFR mutation whose tumor progressed on adjuvant gefitinib after complete resection also contained the T790M mutation.  This mutation was not detected in untreated tumor samples.  Moreover, no tumors with acquired resistance had KRAS mutations, which have been associated with primary resistance to these drugs.  Biochemical analyses of transfected cells and growth inhibition studies with lung cancer cell lines demonstrate that the T790M mutation confers resistance to EGFR mutants usually sensitive to either gefitinib or erlotinib.  Interestingly, a mutation analogous to T790M has been observed in other kinases with acquired resistance to another kinase inhibitor, imatinib (Gleevec).  CONCLUSION:  In patients with tumors bearing gefitinib- or erlotinib-sensitive EGFR mutations, resistant subclones containing an additional EGFR mutation emerge in the presence of drug.  This observation should help guide the search for more effective therapy against a specific subset of lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcREkXMV3u1nwwMthz5_Rx5rfW6udTcc2eYEnuTR0LpSkrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2MzjtVehsw%253D%253D&md5=3e626105e0dea2a38997156ae513f56b</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1371%2Fjournal.pmed.0020073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1371%252Fjournal.pmed.0020073%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DPoliti%26aufirst%3DK.%2BA.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DSomwar%26aufirst%3DR.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DVarmus%26aufirst%3DH.%26atitle%3DAcquired%2520resistance%2520of%2520lung%2520adenocarcinomas%2520to%2520gefitinib%2520or%2520erlotinib%2520is%2520associated%2520with%2520a%2520second%2520mutation%2520in%2520the%2520EGFR%2520kinase%2520domain%26jtitle%3DPLoS%2520Med.%26date%3D2005%26volume%3D2%26spage%3De73%26doi%3D10.1371%2Fjournal.pmed.0020073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yu, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arcila, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rekhtman, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sima, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zakowski, M. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pao, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kris, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ladanyi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riely, G. J.</span></span> <span> </span><span class="NLM_article-title">Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">2240</span>– <span class="NLM_lpage">2247</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-2246</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-12-2246" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23470965" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=2240-2247&author=H.+A.+Yuauthor=M.+E.+Arcilaauthor=N.+Rekhtmanauthor=C.+S.+Simaauthor=M.+F.+Zakowskiauthor=W.+Paoauthor=M.+G.+Krisauthor=V.+A.+Millerauthor=M.+Ladanyiauthor=G.+J.+Riely&title=Analysis+of+tumor+specimens+at+the+time+of+acquired+resistance+to+EGFR-TKI+therapy+in+155+patients+with+EGFR-mutant+lung+cancers&doi=10.1158%2F1078-0432.CCR-12-2246"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers</span></div><div class="casAuthors">Yu, Helena A.; Arcila, Maria E.; Rekhtman, Natasha; Sima, Camelia S.; Zakowski, Maureen F.; Pao, William; Kris, Mark G.; Miller, Vincent A.; Ladanyi, Marc; Riely, Gregory J.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">2240-2247</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">All patients with EGF receptor (EGFR)-mutant lung cancers eventually develop acquired resistance to EGFR tyrosine kinase inhibitors (TKI).  Smaller series have identified various mechanisms of resistance, but systematic evaluation of a large no. of patients to definitively establish the frequency of various mechanisms has not been conducted.  Patients with lung adenocarcinomas and acquired resistance to erlotinib or gefitinib enrolled onto a prospective biopsy protocol and underwent a rebiopsy after the development of acquired resistance.  Histol. was reviewed.  Samples underwent genotyping for mutations in EGFR, AKT1, BRAF, ERBB2, KRAS, MEK1, NRAS and PIK3CA, and FISH for MET and HER2.  Adequate tumor samples for mol. anal. were obtained in 155 patients.  Ninety-eight had second-site EGFR T790M mutations [63%; 95% confidence interval (CI), 55%-70%] and four had small cell transformation (3%, 95% CI, 0%-6%).  MET amplification was seen in 4 of 75 (5%; 95% CI, 1%-13%).  HER2 amplification was seen in 3 of 24 (13%; 95% CI, 3%-32%).  We did not detect any acquired mutations in PIK3CA, AKT1, BRAF, ERBB2, KRAS, MEK1, or NRAS (0 of 88, 0%; 95% CI, 0%-4%).  Overlap among mechanisms of acquired resistance was seen in 4%.  This is the largest series reporting mechanisms of acquired resistance to EGFR-TKI therapy.  We identified EGFR T790M as the most common mechanism of acquired resistance, whereas MET amplification, HER2 amplification, and small cell histol. transformation occur less frequently.  More comprehensive methods to characterize mol. alterations in this setting are needed to improve our understanding of acquired resistance to EGFR-TKIs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb7zbRcb1jUrVg90H21EOLACvtfcHk0ljKXM392WQ5Og"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXlvFyjtrw%253D&md5=132122dd72bb1facaf81985674510941</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-2246&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-2246%26sid%3Dliteratum%253Aachs%26aulast%3DYu%26aufirst%3DH.%2BA.%26aulast%3DArcila%26aufirst%3DM.%2BE.%26aulast%3DRekhtman%26aufirst%3DN.%26aulast%3DSima%26aufirst%3DC.%2BS.%26aulast%3DZakowski%26aufirst%3DM.%2BF.%26aulast%3DPao%26aufirst%3DW.%26aulast%3DKris%26aufirst%3DM.%2BG.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26atitle%3DAnalysis%2520of%2520tumor%2520specimens%2520at%2520the%2520time%2520of%2520acquired%2520resistance%2520to%2520EGFR-TKI%2520therapy%2520in%2520155%2520patients%2520with%2520EGFR-mutant%2520lung%2520cancers%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D2240%26epage%3D2247%26doi%3D10.1158%2F1078-0432.CCR-12-2246" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Michalczyk, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grütter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">3482</span>– <span class="NLM_lpage">3488</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2008.02.053</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmc.2008.02.053" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18316192" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2008&pages=3482-3488&author=A.+Michalczykauthor=S.+Kl%C3%BCterauthor=H.+B.+Rodeauthor=J.+R.+Simardauthor=C.+Gr%C3%BCtterauthor=M.+Rabillerauthor=D.+Rauh&title=Structural+insights+into+how+irreversible+inhibitors+can+overcome+drug+resistance+in+EGFR&doi=10.1016%2Fj.bmc.2008.02.053"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into how irreversible inhibitors can overcome drug resistance in EGFR</span></div><div class="casAuthors">Michalczyk, Anja; Klueter, Sabine; Rode, Haridas B.; Simard, Jeffrey R.; Gruetter, Christian; Rabiller, Matthias; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">3482-3488</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Resistance to kinase-targeted cancer drugs has recently been linked to a single point mutation in the ATP binding site of the kinase.  In EGFR, the crucial Thr790 gatekeeper residue is mutated to a Met and prevents reversible ATP competitive inhibitors from binding.  Irreversible 4-(phenylamino)quinazolines have been shown to overcome this drug resistance and are currently in clin. trials.  In order to obtain a detailed structural understanding of how irreversible inhibitors overcome drug resistance, the authors used Src kinase as a model system for drug resistant EGFR-T790M.  The authors report the first crystal structure of a drug resistant kinase in complex with an irreversible inhibitor.  This 4-(phenylamino)quinazoline inhibits wild type and drug resistant EGFR in vitro at low nM concns.  The cocrystal structure of drug resistant cSrc-T338M kinase domain provides the structural basis of this activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp52JtORqsX7Vg90H21EOLACvtfcHk0ljDnOY0GCqPzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXks1Gruro%253D&md5=b9fc704067e495279bad4913e9c703ab</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2008.02.053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2008.02.053%26sid%3Dliteratum%253Aachs%26aulast%3DMichalczyk%26aufirst%3DA.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGr%25C3%25BCtter%26aufirst%3DC.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DStructural%2520insights%2520into%2520how%2520irreversible%2520inhibitors%2520can%2520overcome%2520drug%2520resistance%2520in%2520EGFR%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2008%26volume%3D16%26spage%3D3482%26epage%3D3488%26doi%3D10.1016%2Fj.bmc.2008.02.053" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sos, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rode, H. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heynck, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peifer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klüter, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pawar, V. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reuter, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heuckmann, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weiss, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruddigkeit, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rabiller, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Koker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Getlik, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuza, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greulich, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, R. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rauh, D.</span></span> <span> </span><span class="NLM_article-title">Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>70</i></span>,  <span class="NLM_fpage">868</span>– <span class="NLM_lpage">874</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-3106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F0008-5472.CAN-09-3106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20103621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=868-874&author=M.+L.+Sosauthor=H.+B.+Rodeauthor=S.+Heynckauthor=M.+Peiferauthor=F.+Fischerauthor=S.+Kl%C3%BCterauthor=V.+G.+Pawarauthor=C.+Reuterauthor=J.+M.+Heuckmannauthor=J.+Weissauthor=L.+Ruddigkeitauthor=M.+Rabillerauthor=M.+Kokerauthor=J.+R.+Simardauthor=M.+Getlikauthor=Y.+Yuzaauthor=T.+H.+Chenauthor=H.+Greulichauthor=R.+K.+Thomasauthor=D.+Rauh&title=Chemogenomic+profiling+provides+insights+into+the+limited+activity+of+irreversible+EGFR+Inhibitors+in+tumor+cells+expressing+the+T790M+EGFR+resistance+mutation&doi=10.1158%2F0008-5472.CAN-09-3106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Chemogenomic Profiling Provides Insights into the Limited Activity of Irreversible EGFR Inhibitors in Tumor Cells Expressing the T790M EGFR Resistance Mutation</span></div><div class="casAuthors">Sos, Martin L.; Rode, Haridas B.; Heynck, Stefanie; Peifer, Martin; Fischer, Florian; Klueter, Sabine; Pawar, Vijaykumar G.; Reuter, Cecile; Heuckmann, Johannes M.; Weiss, Jonathan; Ruddigkeit, Lars; Rabiller, Matthias; Koker, Mirjam; Simard, Jeffrey R.; Getlik, Matthaeus; Yuza, Yuki; Chen, Tzu-Hsiu; Greulich, Heidi; Thomas, Roman K.; Rauh, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">868-874</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Reversible epidermal growth factor receptor (EGFR) inhibitors are the first class of small mols. to improve progression-free survival of patients with EGFR-mutated lung cancers.  Second-generation EGFR inhibitors introduced to overcome acquired resistance by the T790M resistance mutation of EGFR have thus far shown limited clin. activity in patients with T790M-mutant tumors.  In this study, we systematically analyzed the determinants of the activity and selectivity of the second-generation EGFR inhibitors.  A focused library of irreversible as well as structurally corresponding reversible EGFR-inhibitors was synthesized for chemogenomic profiling involving over 79 genetically defined NSCLC and 19 EGFR-dependent cell lines.  Overall, our results show that the growth-inhibitory potency of all irreversible inhibitors against the EGFRT790M resistance mutation was limited by reduced target inhibition, linked to decreased binding velocity to the mutant kinase.  Combined treatment of T790M-mutant tumor cells with BIBW-2992 and the phosphoinositide-3-kinase/mammalian target of rapamycin inhibitor PI-103 led to synergistic induction of apoptosis.  Our findings offer a mechanistic explanation for the limited efficacy of irreversible EGFR inhibitors in EGFRT790M gatekeeper-mutant tumors, and they prompt combination treatment strategies involving inhibitors that target signaling downstream of the EGFR.  Cancer Res; 70(3); 868-74.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoNjzYq32JnJ7Vg90H21EOLACvtfcHk0ljDnOY0GCqPzw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12ru7Y%253D&md5=db40fb75245450e8f79fca7e37bad588</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-3106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-3106%26sid%3Dliteratum%253Aachs%26aulast%3DSos%26aufirst%3DM.%2BL.%26aulast%3DRode%26aufirst%3DH.%2BB.%26aulast%3DHeynck%26aufirst%3DS.%26aulast%3DPeifer%26aufirst%3DM.%26aulast%3DFischer%26aufirst%3DF.%26aulast%3DKl%25C3%25BCter%26aufirst%3DS.%26aulast%3DPawar%26aufirst%3DV.%2BG.%26aulast%3DReuter%26aufirst%3DC.%26aulast%3DHeuckmann%26aufirst%3DJ.%2BM.%26aulast%3DWeiss%26aufirst%3DJ.%26aulast%3DRuddigkeit%26aufirst%3DL.%26aulast%3DRabiller%26aufirst%3DM.%26aulast%3DKoker%26aufirst%3DM.%26aulast%3DSimard%26aufirst%3DJ.%2BR.%26aulast%3DGetlik%26aufirst%3DM.%26aulast%3DYuza%26aufirst%3DY.%26aulast%3DChen%26aufirst%3DT.%2BH.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DThomas%26aufirst%3DR.%2BK.%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DChemogenomic%2520profiling%2520provides%2520insights%2520into%2520the%2520limited%2520activity%2520of%2520irreversible%2520EGFR%2520Inhibitors%2520in%2520tumor%2520cells%2520expressing%2520the%2520T790M%2520EGFR%2520resistance%2520mutation%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D868%26epage%3D874%26doi%3D10.1158%2F0008-5472.CAN-09-3106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sholl, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Redig, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pillai, R. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacroix, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Planchard, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Soria, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Mechanisms of acquired resistance to AZD9291 in EGFR T790M positive lung cancer</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">Suppl. 2</span>),  <span class="NLM_fpage">ORAL17.07</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=ORAL17.07&issue=Suppl.+2&author=G.+R.+Oxnardauthor=K.+Thressauthor=C.+Paweletzauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=E.+Felipauthor=A.+Vivancosauthor=Y.+Kuangauthor=L.+Shollauthor=A.+J.+Redigauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=R.+N.+Pillaiauthor=B.+C.+Choauthor=L.+Lacroixauthor=D.+Planchardauthor=J.+C.+Soriaauthor=P.+A.+J%C3%A4nne&title=Mechanisms+of+acquired+resistance+to+AZD9291+in+EGFR+T790M+positive+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26aulast%3DThress%26aufirst%3DK.%26aulast%3DPaweletz%26aufirst%3DC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DSholl%26aufirst%3DL.%26aulast%3DRedig%26aufirst%3DA.%2BJ.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DPillai%26aufirst%3DR.%2BN.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DLacroix%26aufirst%3DL.%26aulast%3DPlanchard%26aufirst%3DD.%26aulast%3DSoria%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DMechanisms%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR%2520T790M%2520positive%2520lung%2520cancer%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2015%26volume%3D10%26issue%3DSuppl.%25202%26spage%3DORAL17.07" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thress, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paweletz, C. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felip, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, B. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stetson, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dougherty, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Markovets, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vivancos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matthews, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cantarini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oxnard, G. R.</span></span> <span> </span><span class="NLM_article-title">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span>. <i>Nat. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">560</span>– <span class="NLM_lpage">562</span>, <span class="refDoi"> DOI: 10.1038/nm.3854</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnm.3854" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=25939061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=560-562&author=K.+S.+Thressauthor=C.+P.+Paweletzauthor=E.+Felipauthor=B.+C.+Choauthor=D.+Stetsonauthor=B.+Doughertyauthor=Z.+Laiauthor=A.+Markovetsauthor=A.+Vivancosauthor=Y.+Kuangauthor=D.+Ercanauthor=S.+E.+Matthewsauthor=M.+Cantariniauthor=J.+C.+Barrettauthor=P.+A.+J%C3%A4nneauthor=G.+R.+Oxnard&title=Acquired+EGFR+C797S+mutation+mediates+resistance+to+AZD9291+in+non-small+cell+lung+cancer+harboring+EGFR+T790M&doi=10.1038%2Fnm.3854"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M</span></div><div class="casAuthors">Thress, Kenneth S.; Paweletz, Cloud P.; Felip, Enriqueta; Cho, Byoung Chul; Stetson, Daniel; Dougherty, Brian; Lai, Zhongwu; Markovets, Aleksandra; Vivancos, Ana; Kuang, Yanan; Ercan, Dalia; Matthews, Sarah E.; Cantarini, Mireille; Barrett, J. Carl; Janne, Pasi A.; Oxnard, Geoffrey R.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Medicine (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">560-562</span>CODEN:
                <span class="NLM_cas:coden">NAMEFI</span>;
        ISSN:<span class="NLM_cas:issn">1078-8956</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here we studied cell-free plasma DNA (cfDNA) collected from subjects with advanced lung cancer whose tumors had developed resistance to the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) AZD9291.  We first performed next-generation sequencing of cfDNA from seven subjects and detected an acquired EGFR C797S mutation in one; expression of this mutant EGFR construct in a cell line rendered it resistant to AZD9291.  We then performed droplet digital PCR on serial cfDNA specimens collected from 15 AZD9291-treated subjects.  All were pos. for the T790M mutation before treatment, but upon developing AZD9291 resistance three mol. subtypes emerged: six cases acquired the C797S mutation, five cases maintained the T790M mutation but did not acquire the C797S mutation and four cases lost the T790M mutation despite the presence of the underlying EGFR activating mutation.  Our findings provide insight into the diversity of mechanisms through which tumors acquire resistance to AZD9291 and highlight the need for therapies that are able to overcome resistance mediated by the EGFR C797S mutation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTggAW5fpGrbVg90H21EOLACvtfcHk0lgJErG_FMDwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtFemsbfJ&md5=adac4cb6c7057855aff61fd62890d010</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.1038%2Fnm.3854&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnm.3854%26sid%3Dliteratum%253Aachs%26aulast%3DThress%26aufirst%3DK.%2BS.%26aulast%3DPaweletz%26aufirst%3DC.%2BP.%26aulast%3DFelip%26aufirst%3DE.%26aulast%3DCho%26aufirst%3DB.%2BC.%26aulast%3DStetson%26aufirst%3DD.%26aulast%3DDougherty%26aufirst%3DB.%26aulast%3DLai%26aufirst%3DZ.%26aulast%3DMarkovets%26aufirst%3DA.%26aulast%3DVivancos%26aufirst%3DA.%26aulast%3DKuang%26aufirst%3DY.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DMatthews%26aufirst%3DS.%2BE.%26aulast%3DCantarini%26aufirst%3DM.%26aulast%3DBarrett%26aufirst%3DJ.%2BC.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DOxnard%26aufirst%3DG.%2BR.%26atitle%3DAcquired%2520EGFR%2520C797S%2520mutation%2520mediates%2520resistance%2520to%2520AZD9291%2520in%2520non-small%2520cell%2520lung%2520cancer%2520harboring%2520EGFR%2520T790M%26jtitle%3DNat.%2520Med.%26date%3D2015%26volume%3D21%26spage%3D560%26epage%3D562%26doi%3D10.1038%2Fnm.3854" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yun, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cortot, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chirieac, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iacob, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Padera, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Engen, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eck, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span> <span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>462</i></span>,  <span class="NLM_fpage">1070</span>– <span class="NLM_lpage">1074</span>, <span class="refDoi"> DOI: 10.1038/nature08622</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+H.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+J%C3%A4nne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M&doi=10.1038%2Fnature08622"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lgJErG_FMDwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%2BH.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074%26doi%3D10.1038%2Fnature08622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ercan, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jänne, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Discovery of selective irreversible inhibitors for EGFR-T790M</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">638</span>– <span class="NLM_lpage">643</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2010.12.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bmcl.2010.12.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=21208802" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2011&pages=638-643&author=W.+Zhouauthor=D.+Ercanauthor=P.+A.+J%C3%A4nneauthor=N.+S.+Gray&title=Discovery+of+selective+irreversible+inhibitors+for+EGFR-T790M&doi=10.1016%2Fj.bmcl.2010.12.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of selective irreversible inhibitors for EGFR-T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Jaenne, Pasi A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">638-643</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Targeting the epidermal growth factor receptor kinase (EGFR) with ATP-competitive kinase inhibitors results in dramatic but short-lived responses in patients with EGFR mutant non small cell lung cancer.  A series of novel covalent EGFR kinase inhibitors with selectivity for the clin. relevant T790M gatekeeper' resistance mutation relative to wild-type EGFR were discovered by library screening.  A representative compd. 3i (I) was obtained through a systematic SAR study guided by mutant EGFR-dependent cellular proliferation assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqB2Qq3f78-wLVg90H21EOLACvtfcHk0lgJErG_FMDwnA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVKrtA%253D%253D&md5=c19f3f288ab99aaaab0a23bcf5273daf</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2010.12.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2010.12.036%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDiscovery%2520of%2520selective%2520irreversible%2520inhibitors%2520for%2520EGFR-T790M%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D21%26spage%3D638%26epage%3D643%26doi%3D10.1016%2Fj.bmcl.2010.12.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Omura, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iwai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakagawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Awaya, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsuchiya, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takahashi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asuma, R.</span></span> <span> </span><span class="NLM_article-title">A new alkaloid AM-2282 of streptomyces origin. taxonomy, fermentation, isolation and preliminary characterization</span>. <i>J. Antibiot.</i> <span class="NLM_year" style="font-weight: bold;">1977</span>,  <span class="NLM_volume"><i>30</i></span>,  <span class="NLM_fpage">275</span>– <span class="NLM_lpage">282</span>, <span class="refDoi"> DOI: 10.7164/antibiotics.30.275</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.7164%2Fantibiotics.30.275" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=612708" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1977&pages=275-282&author=S.+Omuraauthor=Y.+Iwaiauthor=A.+Hiranoauthor=A.+Nakagawaauthor=J.+Awayaauthor=H.+Tsuchiyaauthor=Y.+Takahashiauthor=R.+Asuma&title=A+new+alkaloid+AM-2282+of+streptomyces+origin.+taxonomy%2C+fermentation%2C+isolation+and+preliminary+characterization&doi=10.7164%2Fantibiotics.30.275"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">A new alkaloid AM-2282 of Streptomyces origin.  Taxonomy, fermentation, isolation and preliminary characterization</span></div><div class="casAuthors">Omura, Satoshi; Iwai, Yuzuru; Hirano, Atsushi; Nakagawa, Akira; Awaya, Juichi; Tsuchiya, Hisae; Takahashi, Yoko; Masuma, Rokurou</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Antibiotics</span>
        (<span class="NLM_cas:date">1977</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">275-82</span>CODEN:
                <span class="NLM_cas:coden">JANTAJ</span>;
        ISSN:<span class="NLM_cas:issn">0021-8820</span>.
    </div><div class="casAbstract">A novel alkaloid, AM-2282 [62996-74-1], with high hypotensive activity, was isolated from Streptomyces strain AM-2282, for which the name S. staurosporens is proposed.  The substance was active against fungi and yeast but had no activity against bacteria.  The mol. formula is C28H26N4O3, and the i.p. LD50 of its hydrochloride in mice was 6.6 mg/kg.  Taxonomic features of the strain AM-2282, together with the fermn. isolation, and physicochem. and biol. properties of the new alkaloid are presented.  UV, IR, and 1H-NMR spectra are also given.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqjO4pjDwMWLrVg90H21EOLACvtfcHk0lgKbEMSP0QFmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaE2sXkt1Smsbs%253D&md5=4f52ee08da1cba35345c971c313c7fc6</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.7164%2Fantibiotics.30.275&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7164%252Fantibiotics.30.275%26sid%3Dliteratum%253Aachs%26aulast%3DOmura%26aufirst%3DS.%26aulast%3DIwai%26aufirst%3DY.%26aulast%3DHirano%26aufirst%3DA.%26aulast%3DNakagawa%26aufirst%3DA.%26aulast%3DAwaya%26aufirst%3DJ.%26aulast%3DTsuchiya%26aufirst%3DH.%26aulast%3DTakahashi%26aufirst%3DY.%26aulast%3DAsuma%26aufirst%3DR.%26atitle%3DA%2520new%2520alkaloid%2520AM-2282%2520of%2520streptomyces%2520origin.%2520taxonomy%252C%2520fermentation%252C%2520isolation%2520and%2520preliminary%2520characterization%26jtitle%3DJ.%2520Antibiot.%26date%3D1977%26volume%3D30%26spage%3D275%26epage%3D282%26doi%3D10.7164%2Fantibiotics.30.275" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Karaman, M. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herrgard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Treiber, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallant, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Atteridge, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Campbell, B. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, K. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciceri, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davis, M. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edeen, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Faraoni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Floyd, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hunt, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milanov, Z. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morrison, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pallares, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pritchard, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wodicka, L. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zarrinkar, P. P.</span></span> <span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span>. <i>Nat. Biotechnol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>26</i></span>,  <span class="NLM_fpage">127</span>– <span class="NLM_lpage">132</span>, <span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0lgKbEMSP0QFmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schaefer, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heffron, T. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ye, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sideris, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chan, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merchant, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">La, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ubhayakar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yauch, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pirazzoli, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Politi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Settleman, J.</span></span> <span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">168</span>– <span class="NLM_lpage">181</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-12-0357</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F2159-8290.CD-12-0357" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23229345" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+J.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M&doi=10.1158%2F2159-8290.CD-12-0357"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">Noncovalent Wild-type-Sparing Inhibitors of EGFR T790M</span></div><div class="casAuthors">Lee, Ho-June; Schaefer, Gabriele; Heffron, Timothy P.; Shao, Lily; Ye, Xiaofen; Sideris, Steve; Malek, Shiva; Chan, Emily; Merchant, Mark; La, Hank; Ubhayakar, Savita; Yauch, Robert L.; Pirazzoli, Valentina; Politi, Katerina; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">168-181</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Approx. half of EGFR-mutant non-small cell lung cancer (NSCLC) patients treated with small-mol. EGFR kinase inhibitors develop drug resistance assocd. with the EGF receptor (EGFR)T790M "gatekeeper" substitution, prompting efforts to develop covalent EGFR inhibitors, which can effectively suppress EGFR T790M in preclin. models.  However, these inhibitors have yet to prove clin. efficacious, and their toxicity in skin, reflecting activity against wild-type EGFR, may limit dosing required to effectively suppress EGFR T790M in vivo.  While profiling sensitivity to various kinase inhibi.tors across a large cancer cell line panel, we identified indolocarbazole compds., including a clin. well-tolerated FLTB inhibitor, as potent and reversible inhibitors of EGFR T790M that spare wild-type EGFR.  These findings show the use of broad cancer cell profiling of kinase inhibitor efficacy to identify unanticipated novel applications, and they identify indolocarbazole compds. as potentially effective EGFR inhibitors in the context of T790M-mediated drug resistance in N5CLC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZ5m_cmYkDYrVg90H21EOLACvtfcHk0lgKbEMSP0QFmA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXis1Wktrw%253D&md5=fe34e9532c254baa0e834a801fd361bd</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-12-0357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-12-0357%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181%26doi%3D10.1158%2F2159-8290.CD-12-0357" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Goldberg, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, V. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albacker, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span> <span> </span><span class="NLM_article-title">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span>. <i>Lung Cancer</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">228</span>– <span class="NLM_lpage">231</span>, <span class="refDoi"> DOI: 10.1016/j.lungcan.2017.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.lungcan.2017.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28625641" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2017&pages=228-231&author=S.+I.+Ouauthor=J.+Cuiauthor=A.+B.+Schrockauthor=M.+E.+Goldbergauthor=V.+W.+Zhuauthor=L.+Albackerauthor=P.+J.+Stephensauthor=V.+A.+Millerauthor=S.+M.+Ali&title=Emergence+of+novel+and+dominant+acquired+EGFR+solvent-front+mutations+at+Gly796+%28G796S%2FR%29+together+with+C797S%2FR+and+L792F%2FH+mutations+in+one+EGFR+%28L858R%2FT790M%29+NSCLC+patient+who+progressed+on+osimertinib&doi=10.1016%2Fj.lungcan.2017.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib</span></div><div class="casAuthors">Ou Sai-Hong Ignatius; Cui Jean; Schrock Alexa B; Goldberg Michael E; Albacker Lee; Stephens Philip J; Miller Vincent A; Ali Siraj M; Zhu Viola W</div><div class="citationInfo"><span class="NLM_cas:title">Lung cancer (Amsterdam, Netherlands)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">108</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">228-231</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Acquired epidermal growth factor receptor (EGFR) resistance mutations to osimertinib are common, including the EGFR C797S that abolishes the covalent binding of osimertinib to EGFR.  Here we report the emergence of novel EGFR solvent front mutations at Gly796 (G796S/R) in addition to a hinge pocket L792F/H mutations, and C797S/G all in cis with T790M in a single patient on progression on osimertinib as detected by plasma circulating tumor DNA (ctDNA) assay in the course of clinical care.  A 69-year-old Caucasian female former light-smoker presented with stage IV EGFR L858R positive adenocarcinoma who developed EGFR T790M mutation after 8 month treatment of erlotinib.  The patient was initiated on osimertinib with disease shrinkage after 2 months, but tumor regrowth was observed after 5 months of osimertinib treatment.  Assay of plasma ctDNA at this time revealed these different secondary resistance mutations all in trans with each other including distinct mutations at the same codon producing different amino acid changes: G796S/R (mutant allele frequency [MAF]; 14.4%), C797S/G (MAF: 2.26%), L792F/H (MAF: 0.36%), and V802F (MAF: 0.40%), in addition to the pre-existing L858R (MAF:17.9%) and T790M (MAF:18.2%) but all in cis with T790M.  The G796S/R mutations are homologous with known reported solvent front mutations in ALK G1202R, ROS1 G2032R, TrkA G595R and TrkC G623R, all of which are associated with acquired resistance to type I TKIs.  In silico modeling revealed mutation at G796 interferes with osimertinib binding to the EGFR kinase domain at the phenyl aromatic ring position as this residue forms a narrow "hydrophobic sandwich" with L718, while L792F/H mutation interferes with osimertinib binding at the methoxyl group on the phenyl ring.  Multiple resistance mutations at differing allele frequencies including novel EGFR solvent front mutations can emerge in a single patient with progression on osimertinib potentially due to tumor hetereogeneity and definitely present a significant therapeutic and drug development challenge.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTk4Muekmj_ccAKB7Fa-xrUfW6udTcc2ebSJzK39NL6brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnptlyjsg%253D%253D&md5=f2cedb07d65360f42885e5cd46220f57</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.lungcan.2017.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.lungcan.2017.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26aulast%3DCui%26aufirst%3DJ.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DGoldberg%26aufirst%3DM.%2BE.%26aulast%3DZhu%26aufirst%3DV.%2BW.%26aulast%3DAlbacker%26aufirst%3DL.%26aulast%3DStephens%26aufirst%3DP.%2BJ.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DAli%26aufirst%3DS.%2BM.%26atitle%3DEmergence%2520of%2520novel%2520and%2520dominant%2520acquired%2520EGFR%2520solvent-front%2520mutations%2520at%2520Gly796%2520%2528G796S%252FR%2529%2520together%2520with%2520C797S%252FR%2520and%2520L792F%252FH%2520mutations%2520in%2520one%2520EGFR%2520%2528L858R%252FT790M%2529%2520NSCLC%2520patient%2520who%2520progressed%2520on%2520osimertinib%26jtitle%3DLung%2520Cancer%26date%3D2017%26volume%3D108%26spage%3D228%26epage%3D231%26doi%3D10.1016%2Fj.lungcan.2017.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J.</span></span> <span> </span><span class="NLM_article-title">EGFR G796D mutation mediates resistance to osimertinib</span>. <i>Oncotarget</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">49671</span>– <span class="NLM_lpage">49679</span>, <span class="refDoi"> DOI: 10.18632/oncotarget.17913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.18632%2Foncotarget.17913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28572531" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=49671-49679&author=D.+Zhengauthor=M.+Huauthor=Y.+Baiauthor=X.+Zhuauthor=X.+Luauthor=C.+Wuauthor=J.+Wangauthor=L.+Liuauthor=Z.+Wangauthor=J.+Niauthor=Z.+Yangauthor=J.+Xu&title=EGFR+G796D+mutation+mediates+resistance+to+osimertinib&doi=10.18632%2Foncotarget.17913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR G796D mutation mediates resistance to osimertinib</span></div><div class="casAuthors">Zheng Di; Wang Jiying; Liu Li; Ni Jian; Xu Jianfang; Hu Min; Bai Yu; Zhu Xuehua; Yang Zhenfan; Lu Xuesong; Wang Zheng; Wu Chunyan</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">49671-49679</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osimertinib is an effective third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) approved in multiple countries and regions for patients with EGFR T790M mutation-positive non-small cell lung cancer (NSCLC).  Despite impressive initial tumor responses, development of drug resistance ultimately limits the benefit of this compound.  Mechanisms of resistance to osimertinib are just beginning to emerge, such as EGFR C797S and L718Q mutations, BRAF V600E and PIK3CA E545K mutations, as well as ERBB2 and MET amplification.  However, a comprehensive view is still missing.  In this study, we presented the first case of Chinese NSCLC patient who developed resistance to osimertinib, and discovered de novo EGFR G796D mutation as a potential mechanism.  Our findings provided insights into mechanisms of resistance to osimertinib and highlighted tumor heterogeneity and clonal evolution during the development of drug resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRJ_SCYdyBBVPEeosoOnpOLfW6udTcc2ebSJzK39NL6brntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1cnktVOrsQ%253D%253D&md5=9a871c015caf328b0af6d6412efae5c3</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.17913%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DD.%26aulast%3DHu%26aufirst%3DM.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DZ.%26aulast%3DNi%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DJ.%26atitle%3DEGFR%2520G796D%2520mutation%2520mediates%2520resistance%2520to%2520osimertinib%26jtitle%3DOncotarget%26date%3D2017%26volume%3D8%26spage%3D49671%26epage%3D49679%26doi%3D10.18632%2Foncotarget.17913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Klempner, S. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mehta, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schrock, A. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ou, S. I.</span></span> <span> </span><span class="NLM_article-title">Cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature</span>. <i>Lung Cancer: Targets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">241</span>– <span class="NLM_lpage">247</span>, <span class="refDoi"> DOI: 10.2147/LCTT.S147129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2147%2FLCTT.S147129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvFKmtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=241-247&author=S.+J.+Klempnerauthor=P.+Mehtaauthor=A.+B.+Schrockauthor=S.+M.+Aliauthor=S.+I.+Ou&title=Cis-oriented+solvent-front+EGFR+G796S+mutation+in+tissue+and+ctDNA+in+a+patient+progressing+on+osimertinib%3A+a+case+report+and+review+of+the+literature&doi=10.2147%2FLCTT.S147129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">cis-oriented solvent-front EGFR G796S mutation in tissue and ctDNA in a patient progressing on osimertinib: a case report and review of the literature</span></div><div class="casAuthors">Klempner, Samuel J.; Mehta, Pareen; Schrock, Alexa B.; Ali, Siraj M.; Ou, Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Lung Cancer: Targets and Therapy</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">241-247</span>CODEN:
                <span class="NLM_cas:coden">LCTTBI</span>;
        ISSN:<span class="NLM_cas:issn">1179-2728</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Acquired resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) is a universal event and limits clin. efficacy.  The third-generation EGFR inhibitor osimertinib is active in EGFR-mutant/T790M pos. non-small-cell lung cancer.  Mechanisms of acquired resistance are emerging, and here we describe a cis-oriented solvent-front EGFR G796S mutation as the resistance mechanism obsd. in a progression biopsy and circulating tumor DNA (ctDNA) from a patient with initial response followed by progression on osimertinib.  This is one of the earliest reports of a sole solvent-front tertiary EGFR mutation as a resistance mechanism to osimertinib.  Our case suggests a monoclonal resistance mechanism.  We review the importance of the solvent-front residues across TKIs and describe known osimertinib resistance mechanisms.  We observe that nearly all clin. osimertinib-resistant tertiary EGFR mutations are oriented in cis with EGFR T790M.  This case highlights the importance of mutations affecting EGFR kinase domains and supports the feasibility of broad panel ctDNA assays for detection of novel acquired resistance and tumor heterogeneity in routine clin. care.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqm4B6qa-qgibVg90H21EOLACvtfcHk0li8BiGpxw5FNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvFKmtrg%253D&md5=5115bf357ae144230739b72520908815</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.2147%2FLCTT.S147129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FLCTT.S147129%26sid%3Dliteratum%253Aachs%26aulast%3DKlempner%26aufirst%3DS.%2BJ.%26aulast%3DMehta%26aufirst%3DP.%26aulast%3DSchrock%26aufirst%3DA.%2BB.%26aulast%3DAli%26aufirst%3DS.%2BM.%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DCis-oriented%2520solvent-front%2520EGFR%2520G796S%2520mutation%2520in%2520tissue%2520and%2520ctDNA%2520in%2520a%2520patient%2520progressing%2520on%2520osimertinib%253A%2520a%2520case%2520report%2520and%2520review%2520of%2520the%2520literature%26jtitle%3DLung%2520Cancer%253A%2520Targets%2520Ther.%26date%3D2017%26volume%3D8%26spage%3D241%26epage%3D247%26doi%3D10.2147%2FLCTT.S147129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bersanelli, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Minari, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bordi, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gnetti, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bozzetti, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Squadrilli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lagrasta, C. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bottarelli, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osipova, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletto, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tiseo, M.</span></span> <span> </span><span class="NLM_article-title">L718Q mutation as new mechanism of acquired resistance to AZD9291 in EGFR-mutated NSCLC</span>. <i>J. Thorac. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">e121</span>– <span class="NLM_lpage">e123</span>, <span class="refDoi"> DOI: 10.1016/j.jtho.2016.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.jtho.2016.05.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27257132" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=e121-e123&author=M.+Bersanelliauthor=R.+Minariauthor=P.+Bordiauthor=L.+Gnettiauthor=C.+Bozzettiauthor=A.+Squadrilliauthor=C.+A.+Lagrastaauthor=L.+Bottarelliauthor=G.+Osipovaauthor=E.+Capellettoauthor=M.+Morauthor=M.+Tiseo&title=L718Q+mutation+as+new+mechanism+of+acquired+resistance+to+AZD9291+in+EGFR-mutated+NSCLC&doi=10.1016%2Fj.jtho.2016.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1016%2Fj.jtho.2016.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jtho.2016.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DBersanelli%26aufirst%3DM.%26aulast%3DMinari%26aufirst%3DR.%26aulast%3DBordi%26aufirst%3DP.%26aulast%3DGnetti%26aufirst%3DL.%26aulast%3DBozzetti%26aufirst%3DC.%26aulast%3DSquadrilli%26aufirst%3DA.%26aulast%3DLagrasta%26aufirst%3DC.%2BA.%26aulast%3DBottarelli%26aufirst%3DL.%26aulast%3DOsipova%26aufirst%3DG.%26aulast%3DCapelletto%26aufirst%3DE.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DTiseo%26aufirst%3DM.%26atitle%3DL718Q%2520mutation%2520as%2520new%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520AZD9291%2520in%2520EGFR-mutated%2520NSCLC%26jtitle%3DJ.%2520Thorac.%2520Oncol.%26date%3D2016%26volume%3D11%26spage%3De121%26epage%3De123%26doi%3D10.1016%2Fj.jtho.2016.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Le, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Puri, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Negrao, M. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nilsson, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Robichaux, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boyle, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hicks, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lovinger, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roarty, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rinsurongkawong, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elamin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lacerda, L. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Swisher, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, W. N.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glisson, B. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadimitrakopoulou, V. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heymach, J. V.</span></span> <span> </span><span class="NLM_article-title">Landscape of EGFR-dependent and -independent resistance mechanisms to osimertinib and continuation therapy beyond progression in EGFR-Mutant NSCLC</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6203</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-1542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1158%2F1078-0432.CCR-18-1542" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=30228210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BB3czgtV2qtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2018&pages=6195-6203&author=X.+Leauthor=S.+Puriauthor=M.+V.+Negraoauthor=M.+B.+Nilssonauthor=J.+Robichauxauthor=T.+Boyleauthor=J.+K.+Hicksauthor=K.+L.+Lovingerauthor=E.+Roartyauthor=W.+Rinsurongkawongauthor=M.+Tangauthor=H.+Sunauthor=Y.+Elaminauthor=L.+C.+Lacerdaauthor=J.+Lewisauthor=J.+A.+Rothauthor=S.+G.+Swisherauthor=J.+J.+Leeauthor=W.+N.+Williamauthor=B.+S.+Glissonauthor=J.+Zhangauthor=V.+A.+Papadimitrakopoulouauthor=J.+E.+Grayauthor=J.+V.+Heymach&title=Landscape+of+EGFR-dependent+and+-independent+resistance+mechanisms+to+osimertinib+and+continuation+therapy+beyond+progression+in+EGFR-Mutant+NSCLC&doi=10.1158%2F1078-0432.CCR-18-1542"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC</span></div><div class="casAuthors">Le Xiuning; Negrao Marcelo V; Nilsson Monique B; Robichaux Jacqulyne; Roarty Emily; Rinsurongkawong Waree; Tang Ming; Sun Huiying; Elamin Yasir; Lacerda Lara C; William William N Jr; Glisson Bonnie S; Zhang Jianjun; Papadimitrakopoulou Vassiliki A; Heymach John V; Puri Sonam; Gray Jhanelle E; Boyle Theresa; Hicks J Kevin; Lovinger Katherine L; Lewis Jeff; Lee J Jack; Roth Jack A; Swisher Stephen G</div><div class="citationInfo"><span class="NLM_cas:title">Clinical cancer research : an official journal of the American Association for Cancer Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">6195-6203</span>
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    </div><div class="casAbstract">PURPOSE:  Osimertinib was initially approved for T790M-positive non-small cell lung cancer (NSCLC) and, more recently, for first-line treatment of EGFR-mutant NSCLC.  However, resistance mechanisms to osimertinib have been incompletely described.  EXPERIMENTAL DESIGN:  Using cohorts from The University of Texas MD Anderson Lung Cancer Moonshot GEMINI and Moffitt Cancer Center lung cancer databases, we collected clinical data for patients treated with osimertinib.  Molecular profiling analysis was performed at the time of progression in a subset of the patients.  RESULTS:  In the 118 patients treated with osimertinib, 42 had molecular profiling at progression.  T790M was preserved in 21 (50%) patients and lost in 21 (50%).  EGFR C797 and L792 (26%) mutations were the most common resistance mechanism and were observed exclusively in T790M-preserved cases.  MET amplification was the second most common alteration (14%).  Recurrent alterations were observed in 22 genes/pathways, including PIK3CA, FGFR, and RET.  Preclinical studies confirmed MET, PIK3CA, and epithelial-to-mesenchymal transition as potential resistance drivers.  Alterations of cell-cycle genes were associated with shorter median progression-free survival (PFS, 4.4 vs. 8.8 months, P = 0.01).  In 76 patients with progression, osimertinib was continued in 47 cases with a median second PFS (PFS2) of 12.6 months; 21 patients received local consolidation radiation with a median PFS of 15.5 months.  Continuation of osimertinib beyond progression was associated with a longer overall survival compared with discontinuation (11.2 vs. 6.1 months, P = 0.02).  CONCLUSIONS:  Osimertinib resistance is associated with diverse, predominantly EGFR-independent genomic alterations.  Continuation of osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected patients.See related commentary by Devarakonda and Govindan, p. 6112.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdipwLPXO73z69zv1FsJFMfW6udTcc2eZf0o24HjL9nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3czgtV2qtw%253D%253D&md5=7228ac68946b3d2f0a26ec4158c71655</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-1542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-1542%26sid%3Dliteratum%253Aachs%26aulast%3DLe%26aufirst%3DX.%26aulast%3DPuri%26aufirst%3DS.%26aulast%3DNegrao%26aufirst%3DM.%2BV.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DRobichaux%26aufirst%3DJ.%26aulast%3DBoyle%26aufirst%3DT.%26aulast%3DHicks%26aufirst%3DJ.%2BK.%26aulast%3DLovinger%26aufirst%3DK.%2BL.%26aulast%3DRoarty%26aufirst%3DE.%26aulast%3DRinsurongkawong%26aufirst%3DW.%26aulast%3DTang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DElamin%26aufirst%3DY.%26aulast%3DLacerda%26aufirst%3DL.%2BC.%26aulast%3DLewis%26aufirst%3DJ.%26aulast%3DRoth%26aufirst%3DJ.%2BA.%26aulast%3DSwisher%26aufirst%3DS.%2BG.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DWilliam%26aufirst%3DW.%2BN.%26aulast%3DGlisson%26aufirst%3DB.%2BS.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DPapadimitrakopoulou%26aufirst%3DV.%2BA.%26aulast%3DGray%26aufirst%3DJ.%2BE.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DLandscape%2520of%2520EGFR-dependent%2520and%2520-independent%2520resistance%2520mechanisms%2520to%2520osimertinib%2520and%2520continuation%2520therapy%2520beyond%2520progression%2520in%2520EGFR-Mutant%2520NSCLC%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2018%26volume%3D24%26spage%3D6195%26epage%3D6203%26doi%3D10.1158%2F1078-0432.CCR-18-1542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shim, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ahn, M. J.</span></span> <span> </span><span class="NLM_article-title">Rare mechanism of acquired resistance to osimertinib in Korean patients with EGFR-mutated non-small cell lung cancer</span>. <i>Cancer Res. Treat.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span>,  <span class="NLM_fpage">408</span>– <span class="NLM_lpage">412</span>, <span class="refDoi"> DOI: 10.4143/crt.2018.138</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.4143%2Fcrt.2018.138" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=29807405" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A280%3ADC%252BC1MfnvVehtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=408-412&author=J.+Leeauthor=J.+H.+Shimauthor=W.+Y.+Parkauthor=H.+K.+Kimauthor=J.+M.+Sunauthor=S.+H.+Leeauthor=J.+S.+Ahnauthor=K.+Parkauthor=M.+J.+Ahn&title=Rare+mechanism+of+acquired+resistance+to+osimertinib+in+Korean+patients+with+EGFR-mutated+non-small+cell+lung+cancer&doi=10.4143%2Fcrt.2018.138"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer</span></div><div class="casAuthors">Lee Jiyun; Kim Hee Kyung; Sun Jong-Mu; Lee Se-Hoon; Ahn Jin Seok; Park Keunchil; Ahn Myung-Ju; Shim Joon Ho; Park Woong-Yang; Shim Joon Ho; Park Woong-Yang; Park Woong-Yang</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research and treatment : official journal of Korean Cancer Association</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">408-412</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are effective clinical therapeutics for EGFR-mutant non-small cell lung cancer (NSCLC).  Osimertinib, a thirdgeneration EGFR TKI, has proven effective against T790M mutations.  However, the vast majority of patients acquire resistance following successful treatment.  A 59-year-old female patient with metastatic NSCLC developed resistance after 43 weeks of osimertinib.  CancerSCAN of the metastatic liver lesion revealed a EGFR C797G mutation at an allele frequency of 72%, a preexisting T790M mutation (73%) in cis and an exon 19 deletion (87%).  Another 53-year-old female patient developed systemic progression after 10 months of osimertinib.  CancerSCAN of the lung biopsy identified an EGFR L718Q mutation at an allele frequency of 7%, concomitant PIK3CA E545K (12.90%) and preexisting EGFR L858R (38%), but loss of the T790M mutation.  The heterogeneity of osimertinib resistance mechanisms warrants further investigation into novel or combination agents to overcome the rare acquired resistances.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTkG4XPud7IksKL0FlyGHDofW6udTcc2eZf0o24HjL9nLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC1MfnvVehtw%253D%253D&md5=c5c21a7076c96e86592fc2b7f93cddfc</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.4143%2Fcrt.2018.138&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4143%252Fcrt.2018.138%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DJ.%26aulast%3DShim%26aufirst%3DJ.%2BH.%26aulast%3DPark%26aufirst%3DW.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BK.%26aulast%3DSun%26aufirst%3DJ.%2BM.%26aulast%3DLee%26aufirst%3DS.%2BH.%26aulast%3DAhn%26aufirst%3DJ.%2BS.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26atitle%3DRare%2520mechanism%2520of%2520acquired%2520resistance%2520to%2520osimertinib%2520in%2520Korean%2520patients%2520with%2520EGFR-mutated%2520non-small%2520cell%2520lung%2520cancer%26jtitle%3DCancer%2520Res.%2520Treat.%26date%3D2019%26volume%3D51%26spage%3D408%26epage%3D412%26doi%3D10.4143%2Fcrt.2018.138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Parker, M. W.</span></span> <span> </span><span class="NLM_article-title">Protein structure from x-ray diffraction</span>. <i>J. Biol. Phys.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">341</span>– <span class="NLM_lpage">362</span>, <span class="refDoi"> DOI: 10.1023/A:1027310719146</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1023%2FA%3A1027310719146" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23345855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD3sXos1amtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2003&pages=341-362&author=M.+W.+Parker&title=Protein+structure+from+x-ray+diffraction&doi=10.1023%2FA%3A1027310719146"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Protein Structure from X-Ray Diffraction</span></div><div class="casAuthors">Parker, M. W.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Physics</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">341-362</span>CODEN:
                <span class="NLM_cas:coden">JBPHBZ</span>;
        ISSN:<span class="NLM_cas:issn">0092-0606</span>.
    
            (<span class="NLM_cas:orgname">Kluwer Academic Publishers</span>)
        </div><div class="casAbstract">A review.  Protein crystallog. is the study of the three-dimensional structures of proteins at near at. resoln.  It has provided a tremendous insight into the workings of numerous biol. processes over the last few decades.  The field has undergone a massive worldwide expansion over the last ten years, not only in academic labs., but also in the pharmaceutical industry.  The main driving force for this expansion has been the promise of using three-dimensional at. structures of proteins and other macromols. to design lead drugs and to improve the action of existing drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGol2Lb4Niz6zbVg90H21EOLACvtfcHk0ljpzkg0Yn2tAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXos1amtrw%253D&md5=7edbffbbd98d19a2967bb4bd6c4ae3d1</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1023%2FA%3A1027310719146&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1027310719146%26sid%3Dliteratum%253Aachs%26aulast%3DParker%26aufirst%3DM.%2BW.%26atitle%3DProtein%2520structure%2520from%2520x-ray%2520diffraction%26jtitle%3DJ.%2520Biol.%2520Phys.%26date%3D2003%26volume%3D29%26spage%3D341%26epage%3D362%26doi%3D10.1023%2FA%3A1027310719146" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sayers, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Avsar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cholak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karmous, I.</span></span> <span> </span><span class="NLM_article-title">Application of advanced X-ray methods in life sciences</span>. <i>Biochim. Biophys. Acta, Gen. Subj.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>1861</i></span>,  <span class="NLM_fpage">3671</span>– <span class="NLM_lpage">3685</span>, <span class="refDoi"> DOI: 10.1016/j.bbagen.2016.05.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.bbagen.2016.05.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=27156488" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC28XnslansL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1861&publication_year=2017&pages=3671-3685&author=Z.+Sayersauthor=B.+Avsarauthor=E.+Cholakauthor=I.+Karmous&title=Application+of+advanced+X-ray+methods+in+life+sciences&doi=10.1016%2Fj.bbagen.2016.05.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Application of advanced X-ray methods in life sciences</span></div><div class="casAuthors">Sayers, Zehra; Avsar, Bihter; Cholak, Ersoy; Karmous, Ines</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, General Subjects</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">1861</span>
        (<span class="NLM_cas:issue">1_Part_B</span>),
    <span class="NLM_cas:pages">3671-3685</span>CODEN:
                <span class="NLM_cas:coden">BBGSB3</span>;
        ISSN:<span class="NLM_cas:issn">0304-4165</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Synchrotron radiation (SR) sources provide diverse X-ray methods for the investigation of structure-function relationships in biol. macromols.  Recent developments in SR sources and in the X-ray tools they offer for life sciences are reviewed.  Specifically, advances in macromol. crystallog., small angle X-ray soln. scattering, X-ray absorption and fluorescence spectroscopy, and imaging are discussed with examples.  SR sources offer a range of X-ray techniques that can be used in a complementary fashion in studies of biol. systems at a wide range of resolns. from at. to cellular scale.  Emerging applications of X-ray techniques include the characterization of disordered proteins, noncryst. and nonequil. systems, elemental imaging of tissues, cells and organs, and detection of time-resolved changes in mol. structures.  X-ray techniques are in the center of hybrid approaches that are used to gain insight into complex problems relating to biomol. mechanisms, disease and possible therapeutic solns.  This article is part of a Special Issue entitled "Science for Life". Guest Editors: Dr. Austen Angell, Dr. Salvatore Magaz´u and Dr. Federica Migliardo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOzYI_kZg_NrVg90H21EOLACvtfcHk0ljpzkg0Yn2tAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnslansL0%253D&md5=8edd9f24140c85d7b2b0f0d0499e97e6</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bbagen.2016.05.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbagen.2016.05.008%26sid%3Dliteratum%253Aachs%26aulast%3DSayers%26aufirst%3DZ.%26aulast%3DAvsar%26aufirst%3DB.%26aulast%3DCholak%26aufirst%3DE.%26aulast%3DKarmous%26aufirst%3DI.%26atitle%3DApplication%2520of%2520advanced%2520X-ray%2520methods%2520in%2520life%2520sciences%26jtitle%3DBiochim.%2520Biophys.%2520Acta%252C%2520Gen.%2520Subj.%26date%3D2017%26volume%3D1861%26spage%3D3671%26epage%3D3685%26doi%3D10.1016%2Fj.bbagen.2016.05.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Venien-Bryan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vuillard, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boutin, J. A.</span></span> <span> </span><span class="NLM_article-title">Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery</span>. <i>Acta Crystallogr., Sect. F: Struct. Biol. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>73</i></span>,  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">183</span>, <span class="refDoi"> DOI: 10.1107/S2053230X17003740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1107%2FS2053230X17003740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28368275" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlsFSiu78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2017&pages=174-183&author=C.+Venien-Bryanauthor=Z.+Liauthor=L.+Vuillardauthor=J.+A.+Boutin&title=Cryo-electron+microscopy+and+X-ray+crystallography%3A+complementary+approaches+to+structural+biology+and+drug+discovery&doi=10.1107%2FS2053230X17003740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-electron microscopy and X-ray crystallography: complementary approaches to structural biology and drug discovery</span></div><div class="casAuthors">Venien-Bryan, Catherine; Li, Zhuolun; Vuillard, Laurent; Boutin, Jean Albert</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section F: Structural Biology Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">73</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">174-183</span>CODEN:
                <span class="NLM_cas:coden">ACSFEN</span>;
        ISSN:<span class="NLM_cas:issn">2053-230X</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The invention of the electron microscope has greatly enhanced the view scientists have of small structural details.  Since its implementation, this technol. has undergone considerable evolution and the resoln. that can be obtained for biol. objects has been extended.  In addn., the latest generation of cryo-electron microscopes equipped with direct electron detectors and software for the automated collection of images, in combination with the use of advanced image-anal. methods, has dramatically improved the performance of this technique in terms of resoln.  While calcg. a sub-10 Å resoln. structure was an accomplishment less than a decade ago, it is now common to generate structures at sub-5 Å resoln. and even better.  It is becoming possible to relatively quickly obtain high-resoln. structures of biol. mols., in particular large ones (>500 kDa) which, in some cases, have resisted more conventional methods such as X-ray crystallog. or NMR (NMR).  Such newly resolved structures may, for the first time, shed light on the precise mechanisms that are essential for cellular physiol. processes.  The ability to attain at. resoln. may support the development of new drugs that target these proteins, allowing medicinal chemists to understand the intimacy of the relationship between their mols. and targets.  In addn., recent developments in cryo-electron microscopy combined with image anal. can provide unique information on the conformational variability of macromol. complexes.  Conformational flexibility of macromol. complexes can be investigated using cryo-electron microscopy and multiconformation reconstruction methods.  However, the biochem. quality of the sample remains the major bottleneck to routine cryo-electron microscopy-based detn. of structures at very high resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwIUueQxXP1bVg90H21EOLACvtfcHk0ljpzkg0Yn2tAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlsFSiu78%253D&md5=38ce13849f7695231022821f5bcea946</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1107%2FS2053230X17003740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS2053230X17003740%26sid%3Dliteratum%253Aachs%26aulast%3DVenien-Bryan%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DVuillard%26aufirst%3DL.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26atitle%3DCryo-electron%2520microscopy%2520and%2520X-ray%2520crystallography%253A%2520complementary%2520approaches%2520to%2520structural%2520biology%2520and%2520drug%2520discovery%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520F%253A%2520Struct.%2520Biol.%2520Commun.%26date%3D2017%26volume%3D73%26spage%3D174%26epage%3D183%26doi%3D10.1107%2FS2053230X17003740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glazer, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Radmer, R. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altman, R. B.</span></span> <span> </span><span class="NLM_article-title">Improving structure-based function prediction using molecular dynamics</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">919</span>– <span class="NLM_lpage">929</span>, <span class="refDoi"> DOI: 10.1016/j.str.2009.05.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1016%2Fj.str.2009.05.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=19604472" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD1MXosV2gsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2009&pages=919-929&author=D.+S.+Glazerauthor=R.+J.+Radmerauthor=R.+B.+Altman&title=Improving+structure-based+function+prediction+using+molecular+dynamics&doi=10.1016%2Fj.str.2009.05.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Improving Structure-Based Function Prediction Using Molecular Dynamics</span></div><div class="casAuthors">Glazer, Dariya S.; Radmer, Randall J.; Altman, Russ B.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">919-929</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The no. of mols. with solved three-dimensional structure but unknown function is increasing rapidly.  Particularly problematic are novel folds with little detectable similarity to mols. of known function.  Exptl. assays can det. the functions of such mols., but are time-consuming and expensive.  Computational approaches can identify potential functional sites; however, these approaches generally rely on single static structures and do not use information about dynamics.  In fact, structural dynamics can enhance function prediction: the authors coupled mol. dynamics simulations with structure-based function prediction algorithms that identify Ca2+ binding sites.  When applied to 11 challenging proteins, both methods showed substantial improvement in performance, revealing 22 more sites in one case and 12 more in the other, with a modest increase in apparent false positives.  Thus, the authors show that treating mols. as dynamic entities improves the performance of structure-based function prediction methods.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpX8TYjzyrgD7Vg90H21EOLACvtfcHk0ljpzkg0Yn2tAQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXosV2gsrw%253D&md5=f3bc60f2400bf2ec4d2d7634ef6a6663</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2009.05.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2009.05.010%26sid%3Dliteratum%253Aachs%26aulast%3DGlazer%26aufirst%3DD.%2BS.%26aulast%3DRadmer%26aufirst%3DR.%2BJ.%26aulast%3DAltman%26aufirst%3DR.%2BB.%26atitle%3DImproving%2520structure-based%2520function%2520prediction%2520using%2520molecular%2520dynamics%26jtitle%3DStructure%26date%3D2009%26volume%3D17%26spage%3D919%26epage%3D929%26doi%3D10.1016%2Fj.str.2009.05.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Faraggi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dunker, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sussman, J. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kloczkowski, A.</span></span> <span> </span><span class="NLM_article-title">Comparing NMR and X-ray protein structure: Lindemann-like parameters and NMR disorder</span>. <i>J. Biomol. Struct. Dyn.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">2331</span>– <span class="NLM_lpage">2341</span>, <span class="refDoi"> DOI: 10.1080/07391102.2017.1352539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1080%2F07391102.2017.1352539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=28714803" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXht12ltL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=2331-2341&author=E.+Faraggiauthor=A.+K.+Dunkerauthor=J.+L.+Sussmanauthor=A.+Kloczkowski&title=Comparing+NMR+and+X-ray+protein+structure%3A+Lindemann-like+parameters+and+NMR+disorder&doi=10.1080%2F07391102.2017.1352539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Comparing NMR and X-ray protein structure: Lindemann-like parameters and NMR disorder</span></div><div class="casAuthors">Faraggi, Eshel; Dunker, A. Keith; Sussman, Joel L.; Kloczkowski, Andrzej</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biomolecular Structure and Dynamics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2331-2341</span>CODEN:
                <span class="NLM_cas:coden">JBSDD6</span>;
        ISSN:<span class="NLM_cas:issn">0739-1102</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis Ltd.</span>)
        </div><div class="casAbstract">Disordered protein chains and segments are fast becoming a major pathway for our understanding of biol. function, esp. in more evolved species.  However, the std. definition of disordered residues: the inability to constrain them in X-ray derived structures, is not easily applied to NMR derived structures.  We carry out a statistical comparison between proteins whose structure was resolved using NMR and using X-ray protocols.  We start by establishing a connection between these two protocols for obtaining protein structure.  We find a close statistical correspondence between NMR and X-ray structures if fluctuations inherent to the NMR protocol are taken into account.  Intuitively this tends to lend support to the validity of both NMR and X-ray protocols in deriving biomol. models that correspond to in vivo conditions.  We then establish Lindemann-like parameters for NMR derived structures and examine what order/disorder cutoffs for these parameters are most consistent with X-ray data and how consistent are they.  Finally, we find crit. value of for the best correspondence between X-ray and NMR derived order/disorder assignment, judged by maximizing the Matthews correlation, and a crit. value if a balance between false pos. and false neg. prediction is sought.  We examine a few non-conforming cases, and examine the origin of the structure derived in X-ray.  This study could help in assigning meaningful disorder from NMR expts.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGql_4jZYodT4bVg90H21EOLACvtfcHk0ljZtMfhFLus4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXht12ltL3M&md5=a9d1aba4bc60bd89c19d03a980eeef5f</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1080%2F07391102.2017.1352539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F07391102.2017.1352539%26sid%3Dliteratum%253Aachs%26aulast%3DFaraggi%26aufirst%3DE.%26aulast%3DDunker%26aufirst%3DA.%2BK.%26aulast%3DSussman%26aufirst%3DJ.%2BL.%26aulast%3DKloczkowski%26aufirst%3DA.%26atitle%3DComparing%2520NMR%2520and%2520X-ray%2520protein%2520structure%253A%2520Lindemann-like%2520parameters%2520and%2520NMR%2520disorder%26jtitle%3DJ.%2520Biomol.%2520Struct.%2520Dyn.%26date%3D2018%26volume%3D36%26spage%3D2331%26epage%3D2341%26doi%3D10.1080%2F07391102.2017.1352539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marion, D.</span></span> <span> </span><span class="NLM_article-title">An introduction to biological NMR spectroscopy</span>. <i>Mol. Cell. Proteomics</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">3006</span>– <span class="NLM_lpage">3025</span>, <span class="refDoi"> DOI: 10.1074/mcp.O113.030239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1074%2Fmcp.O113.030239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=23831612" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3006-3025&author=D.+Marion&title=An+introduction+to+biological+NMR+spectroscopy&doi=10.1074%2Fmcp.O113.030239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">An Introduction to Biological NMR Spectroscopy</span></div><div class="casAuthors">Marion, Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Molecular & Cellular Proteomics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3006-3025</span>CODEN:
                <span class="NLM_cas:coden">MCPOBS</span>;
        ISSN:<span class="NLM_cas:issn">1535-9484</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">A review.  NMR spectroscopy is a powerful tool for biologists interested in the structure, dynamics, and interactions of biol. macromols.  This review aims at presenting in an accessible manner the requirements and limitations of this technique.  As an introduction, the history of NMR will highlight how the method evolved from physics to chem. and finally to biol. over several decades.  We then introduce the NMR spectral parameters used in structural biol., namely the chem. shift, the J-coupling, nuclear Overhauser effects, and residual dipolar couplings.  Resonance assignment, the required step for any further NMR study, bears a resemblance to jigsaw puzzle strategy.  The NMR spectral parameters are then converted into angle and distances and used as input using restrained mol. dynamics to compute a bundle of structures.  When interpreting a NMR-derived structure, the biologist has to judge its quality on the basis of the statistics provided.  When the 3D structure is a priori known by other means, the mol. interaction with a partner can be mapped by NMR: information on the binding interface as well as on kinetic and thermodn. consts. can be gathered.  NMR is suitable to monitor, over a wide range of frequencies, protein fluctuations that play a crucial role in their biol. function.  In the last section of this review, intrinsically disordered proteins, which have escaped the attention of classical structural biol., are discussed in the perspective of NMR, one of the rare available techniques able to describe structural ensembles.  This Tutorial is part of the International Proteomics Tutorial Program (IPTP 16 MCP).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2WDfR3dKc4bVg90H21EOLACvtfcHk0ljZtMfhFLus4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslWgsrrJ&md5=2825e9c538ac6d594f853a0895fd7207</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fmcp.O113.030239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fmcp.O113.030239%26sid%3Dliteratum%253Aachs%26aulast%3DMarion%26aufirst%3DD.%26atitle%3DAn%2520introduction%2520to%2520biological%2520NMR%2520spectroscopy%26jtitle%3DMol.%2520Cell.%2520Proteomics%26date%3D2013%26volume%3D12%26spage%3D3006%26epage%3D3025%26doi%3D10.1074%2Fmcp.O113.030239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mainz, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Religa, T. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprangers, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linser, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kay, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reif, B.</span></span> <span> </span><span class="NLM_article-title">NMR spectroscopy of soluble protein complexes at one mega-dalton and beyond</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>52</i></span>,  <span class="NLM_fpage">8746</span>– <span class="NLM_lpage">8751</span>, <span class="refDoi"> DOI: 10.1002/anie.201301215</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201301215" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL%252FN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2013&pages=8746-8751&author=A.+Mainzauthor=T.+L.+Religaauthor=R.+Sprangersauthor=R.+Linserauthor=L.+E.+Kayauthor=B.+Reif&title=NMR+spectroscopy+of+soluble+protein+complexes+at+one+mega-dalton+and+beyond&doi=10.1002%2Fanie.201301215"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">NMR Spectroscopy of Soluble Protein Complexes at One Mega-Dalton and Beyond</span></div><div class="casAuthors">Mainz, Andi; Religa, Tomasz L.; Sprangers, Remco; Linser, Rasmus; Kay, Lewis E.; Reif, Bernd</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">8746-8751</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Sequential backbone assignments are obtained by NMR spectroscopy for a 1 MDa proteasome complex.  The method relies on immobilization of a sol. protein complex by magic-angle spinning.  Deuteration and proton detection of exchangeable sites and paramagnetic relaxation enhancement enables exploration of structural and dynamic properties of supramol. assemblies at at. resoln.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqPETi3UNlWr7Vg90H21EOLACvtfcHk0ljZtMfhFLus4Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCktL%252FN&md5=e40812180583d71b01a05439ab1be1a8</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1002%2Fanie.201301215&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201301215%26sid%3Dliteratum%253Aachs%26aulast%3DMainz%26aufirst%3DA.%26aulast%3DReliga%26aufirst%3DT.%2BL.%26aulast%3DSprangers%26aufirst%3DR.%26aulast%3DLinser%26aufirst%3DR.%26aulast%3DKay%26aufirst%3DL.%2BE.%26aulast%3DReif%26aufirst%3DB.%26atitle%3DNMR%2520spectroscopy%2520of%2520soluble%2520protein%2520complexes%2520at%2520one%2520mega-dalton%2520and%2520beyond%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2013%26volume%3D52%26spage%3D8746%26epage%3D8751%26doi%3D10.1002%2Fanie.201301215" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Xiang, Z.</span></span> <span> </span><span class="NLM_article-title">Advances in homology protein structure modeling</span>. <i>Curr. Protein Pept. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">217</span>– <span class="NLM_lpage">227</span>, <span class="refDoi"> DOI: 10.2174/138920306777452312</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.2174%2F138920306777452312" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=16787261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BD28Xmt1emtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2006&pages=217-227&author=Z.+Xiang&title=Advances+in+homology+protein+structure+modeling&doi=10.2174%2F138920306777452312"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Advances in homology protein structure modeling</span></div><div class="casAuthors">Xiang, Zhexin</div><div class="citationInfo"><span class="NLM_cas:title">Current Protein and Peptide Science</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CPPSCM</span>;
        ISSN:<span class="NLM_cas:issn">1389-2037</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Homol. modeling plays a central role in detg. protein structure in the structural genomics project.  The importance of homol. modeling has been steadily increasing because of the large gap that exists between the overwhelming no. of available protein sequences and exptl. solved protein structures, and also, more importantly, because of the increasing reliability and accuracy of the method.  In fact, a protein sequence with over 30% identity to a known structure can often be predicted with an accuracy equiv. to a low-resoln. x-ray structure.  The recent advances in homol. modeling, esp. in detecting distant homologs, aligning sequences with template structures, modeling of loops and side chains, as well as detecting errors in a model, have contributed to reliable prediction of protein structure, which was not possible even several years ago.  The ongoing efforts in solving protein structures, which can be time-consuming and often difficult, will continue to spur the development of a host of new computational methods that can fill in the gap and further contribute to understanding the relationship between protein structure and function.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqdQdunnMscg7Vg90H21EOLACvtfcHk0ljpbfBPSN25_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xmt1emtLc%253D&md5=46bb5be04bc0e85cebbfb71b0a3040a1</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.2174%2F138920306777452312&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138920306777452312%26sid%3Dliteratum%253Aachs%26aulast%3DXiang%26aufirst%3DZ.%26atitle%3DAdvances%2520in%2520homology%2520protein%2520structure%2520modeling%26jtitle%3DCurr.%2520Protein%2520Pept.%2520Sci.%26date%3D2006%26volume%3D7%26spage%3D217%26epage%3D227%26doi%3D10.2174%2F138920306777452312" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Raunser, S.</span></span> <span> </span><span class="NLM_article-title">Cryo-EM revolutionizes the structure determination of biomolecules</span>. <i>Angew. Chem., Int. Ed.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>56</i></span>,  <span class="NLM_fpage">16450</span>– <span class="NLM_lpage">16452</span>, <span class="refDoi"> DOI: 10.1002/anie.201710679</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=10.1002%2Fanie.201710679" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvFegt7nJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2017&pages=16450-16452&author=S.+Raunser&title=Cryo-EM+revolutionizes+the+structure+determination+of+biomolecules&doi=10.1002%2Fanie.201710679"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Cryo-EM Revolutionizes the Structure Determination of Biomolecules</span></div><div class="casAuthors">Raunser, Stefan</div><div class="citationInfo"><span class="NLM_cas:title">Angewandte Chemie, International Edition</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">52</span>),
    <span class="NLM_cas:pages">16450-16452</span>CODEN:
                <span class="NLM_cas:coden">ACIEF5</span>;
        ISSN:<span class="NLM_cas:issn">1433-7851</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review, discussing cryo-electron microscopy, which has now become a major technique in structural biol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKkYhmLo9aQLVg90H21EOLACvtfcHk0ljpbfBPSN25_w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvFegt7nJ&md5=032af61f396e08f9e835df5818d24e2d</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1002%2Fanie.201710679&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fanie.201710679%26sid%3Dliteratum%253Aachs%26aulast%3DRaunser%26aufirst%3DS.%26atitle%3DCryo-EM%2520revolutionizes%2520the%2520structure%2520determination%2520of%2520biomolecules%26jtitle%3DAngew.%2520Chem.%252C%2520Int.%2520Ed.%26date%3D2017%26volume%3D56%26spage%3D16450%26epage%3D16452%26doi%3D10.1002%2Fanie.201710679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1XKK','PDB','1XKK'); return false;">PDB: 1XKK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1M17','PDB','1M17'); return false;">PDB: 1M17</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITT','PDB','2ITT'); return false;">PDB: 2ITT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIV','PDB','2JIV'); return false;">PDB: 2JIV</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LRM','PDB','4LRM'); return false;">PDB: 4LRM</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PP0" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3PP0','PDB','3PP0'); return false;">PDB: 3PP0</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITO" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITO','PDB','2ITO'); return false;">PDB: 2ITO</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4G5J','PDB','4G5J'); return false;">PDB: 4G5J</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UG1" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3UG1','PDB','3UG1'); return false;">PDB: 3UG1</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X2K" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5X2K','PDB','5X2K'); return false;">PDB: 5X2K</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XGN','PDB','5XGN'); return false;">PDB: 5XGN</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=3IKA','PDB','3IKA'); return false;">PDB: 3IKA</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5XDK','PDB','5XDK'); return false;">PDB: 5XDK</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-4"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i11"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00964">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_21248"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00964">10.1021/acs.jmedchem.9b00964</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Chemical structures of representative examples of the three TKI-generations of EGFR (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00964/suppl_file/jm9b00964_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00964/suppl_file/jm9b00964_si_001.pdf">jm9b00964_si_001.pdf (46.32 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00964&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00964%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-1%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00964" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6798fdc0ca1932c1","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
